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Abstract	  
Membrane	   transporters	   are	   increasingly	   recognised	   as	   being	   important	   in	  
determining	  drug	  pharmacokinetics	  at	  whole	  body,	  organ,	  and	  cellular	  levels.	  At	  the	  
blood-­‐brain	  barrier	  (BBB),	  membrane	  transporters	  determine	  the	  passage	  of	  drugs	  
into	  and	  out	  of	  the	  brain.	  About	  30	  %	  of	  all	  patients	  are	  classed	  as	  non-­‐responders	  
for	   both	   epilepsy	   and	   schizophrenia.	   Drug	   transporters	   from	   the	   adenosine	   5'-­‐
triphosphate	   (ATP)-­‐binding	   cassette	   (ABC)	   transporter	   family	   or	   from	   the	   solute	  
carrier	   (SLC)	   superfamily	   may	   contribute	   to	   these	   drug	   resistant	   phenotypes	   but	  
most	  have	  received	  limited	  attention.	  
Treatment	   response	   to	   carbamazepine	   (CBZ)	   has	   been	   associated	   with	  
genetic	   polymorphisms	   in	  ABCC2,	   particularly	   -­‐24C>T,	   c.1249G>A,	   and	   c.3972C>T.	  
However,	  the	  results	  have	  been	  conflicting	  and	  inconclusive	  amongst	  the	  different	  
studies.	  A	  functional	  and	  clinical	  analysis	  was	  undertaken	  to	  investigate	  the	  impact	  
of	  ABCC2	  on	  CBZ	   treatment	   response.	   In	   vitro,	   no	  ABCC2-­‐mediated	  CBZ	   transport	  
could	  be	  observed	  in	  efflux	  assays	  with	  an	  ABCC2-­‐transfected	  human	  fibrosarcoma	  
cell	   line	   (Rht14-­‐10)	   and	   a	   dog	   kidney	   cell	   line	   (MDCKII).	   In	   addition,	   uptake	   into	  
inside-­‐out	  vesicles	  derived	  from	  the	  Rht14-­‐10	  cell	  line	  was	  negative.	  Clinical	  analysis	  
of	  patients	  from	  the	  SANAD	  (Standard	  and	  New	  Antiepileptic	  Drugs)	  trial	  (assessing	  
the	   clinical	   end-­‐points	   time	   to	   first	   seizure	   (n	   =	   229)	   and	   time	   to	   12-­‐month	  
remission	   (n	   =	   134))	   did	   not	   show	   any	   significant	   associations	   between	   the	   three	  
ABCC2	  gene	  polymorphisms,	  -­‐24C>T,	  c.1249G>A,	  c.3972C>T,	  and	  clinical	  outcomes.	  
In	  an	  attempt	  to	  identify	  currently	  unrecognised	  human	  drug	  transporters	  
with	   potential	   relevance	   to	   epilepsy	   and	   schizophrenia,	   screening	   of	   transport	   of	  
CBZ,	  lamotrigine	  (LTG),	  topiramate	  (TPM),	  levetiracetam,	  valproate,	  phenytoin,	  and	  
clozapine	  (CLP)	  was	  undertaken	  using	  an	  immortalised	  human	  brain	  endothelial	  cell	  
line	   (hCMEC/D3)	   as	   an	   in	   vitro	   model	   of	   the	   BBB.	   Accumulation	   of	   TPM	   was	  
significantly	   enhanced	   by	   44-­‐53	   %	   in	   the	   presence	   of	   the	   typical	   ABCC	   efflux	  
transporter	   inhibitors	   MK571	   and	   montelukast.	   Furthermore,	   CLP	   uptake	   was	  
significantly	  reduced	  by	  94	  %	  and	  83	  %	  in	  the	  presence	  of	  the	  typical	  organic	  cation	  
transporter	   inhibitors	   prazosin	   and	   verapamil,	   respectively.	   CLP	   uptake	   into	   the	  
hCMEC/D3	   cell	   line	   followed	   classical	   Michaelis-­‐Menten	   kinetics	   with	   Vmax	   of	  	  
3288	  (pmol/million	  cells)/min	  and	  Km	  of	  35.93	  µM.	  To	  identify	  the	  exact	  underlying	  
transporters	   involved	   in	   TPM	   efflux	   and	   CLP	   uptake,	   both	   functional	   siRNA	  
screening	  was	  undertaken	  and	  transport	  was	   investigated	   in	  transfected	  cell	   lines.	  
None	  of	  the	  known	  functional	  ABCC	  transporters	  were	  shown	  to	  transport	  TPM.	  In	  
addition,	   none	   of	   the	   expressed	   and	   functionally	   characterised	   organic	   cation	  
transporters	   from	   the	   SLC22A	   family,	   as	   well	   as	   transporters	   from	   the	   SLC6A,	  
SLC28A,	  and	  SLC29A	  families,	  had	  an	  effect	  on	  CLP	  accumulation.	  
LTG	   has	   recently	   been	   identified	   as	   a	   substrate	   for	   SLC22A1	   (OCT1).	  
Interaction	   with	   the	   human	   immunodeficiency	   virus	   protease	   inhibitors	  
lopinavir/ritonavir	   and	   the	   antipsychotic	   CLP	   was	   therefore	   investigated.	   At	  
clinically	   relevant	   concentrations,	   lopinavir	   was	   found	   to	   significantly	   reduce	  
SLC22A1-­‐mediated	  uptake	  of	  LTG	  by	  39	  %.	  In	  addition,	  CLP	  was	  a	  potent	  inhibitor	  of	  
SLC22A1-­‐mediated	  LTG	  uptake	  yielding	  an	   IC50	  of	  1.8	  µM.	  Similarly	   low	  IC50	  values	  
were	  obtained	  with	  primary	  human	  hepatocytes	   from	  two	  patients	   (IC50	  =	  7.9	  µM	  
and	   IC50	   =	   3.9	   µM,	   respectively)	   and	   the	   hCMEC/D3	   cell	   line	   (IC50	   =	   2.0	   µM).	   The	  
	   v	  
clinical	   consequences	   of	   these	   observations	   will	   require	   further	   in	   vivo	  
pharmacokinetic	  and	  epidemiological	  research.	  
In	   conclusion,	   the	   results	   presented	   in	   this	   thesis	   demonstrate	   that	  
membrane	  transporters	  can	  be	  involved	  in	  the	  passage	  of	  AEDs	  and	  antipsychotics	  
across	  the	  BBB	  and	  other	  membrane	  barriers.	  However,	  currently	  available	  in	  vitro	  
methods	   proved	   to	   be	   insufficient	   to	   identify	   and	   characterise	   the	   underlying	  
transporters	  involved	  and	  to	  further	  evaluate	  the	  impact	  on	  treatment	  efficacy.	  The	  
development	  of	  large-­‐scale	  functional	  screening	  methodologies	  will	  be	  crucial	  for	  a	  
more	   systematic	   and	   comprehensive	   understanding	   of	   drug	   transport	   processes	  
involved	  in	  determining	  access	  of	  drugs	  to	  the	  central	  nervous	  system.	  This	  will	  help	  
in	   improving	   drug	   efficacy	   and	   drug	   safety,	   allow	   prediction	   of	   drug-­‐drug	  
interactions,	  and	  eventually	  allowed	  a	  more	  personalised	  approach	  to	  prescribing	  in	  
diseases	  such	  as	  epilepsy	  and	  schizophrenia.	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1.1. The	  blood-­‐brain	  barrier	  
1.1.1. Structure	  and	  function	  
The	  central	  nervous	  system	  (CNS)	  is	  of	  fundamental	  importance	  for	  the	  control	  and	  
regulation	  of	  physiological	  processes.	  It	  is	  an	  extremely	  sensitive	  microenvironment	  
and	   thus	   strict	   homeostatic	   regulation	   is	   essential	   in	   order	   to	  maintain	   neuronal	  
signalling.	  A	  key	  aspect	  in	  regulation	  is	  the	  physical	  separation	  of	  the	  CNS	  from	  the	  
rest	  of	  the	  body	  by	  means	  of	  CNS	  barriers.	  CNS	  barriers	  restrict	  the	  access,	  but	  also	  
the	   exit,	   of	  molecules	   into	   and	   from	   the	   brain	   and	   thereby	   provide	   control	   over	  
concentration	   and	   composition	   of	   ions,	   neurotransmitters,	   macromolecules,	  
neurotoxins,	  and	  nutrients	  (Abbott	  et	  al.	  2010).	  	  
In	  humans,	  three	  CNS	  barriers	  are	  known	  to	  exist:	  the	  blood-­‐cerebrospinal	  
fluid	  barrier	  (BCSFB),	  the	  avascular	  arachnoid	  epithelium	  (AAE),	  and	  the	  blood-­‐brain	  
barrier	  (BBB)	  (Abbott	  et	  al.	  2010).	  The	  BCSFB	  is	  the	  outer	  epithelial	  cell	  layer	  of	  the	  
choroid	   plexus,	   located	   in	   the	   lateral	   ventricles	   (third	   and	   fourth)	   of	   the	   brain,	  
separating	   the	   cerebrospinal	   fluid	   (CSF)	   from	   blood.	   The	   choroid	   plexus	   is	   a	  
branched	   structure	   with	   various	   villi	   reaching	   into	   the	   ventricles,	   composed	   of	  
connective	  tissue	  and	  fenestrated	  “leaky”	  blood	  capillaries.	  It	  is	  the	  main	  source	  of	  
CSF	   that	   is	   produced	   by	   blood	   “leaking”	   through	   the	   capillaries	   and	   then	   being	  
filtered	   by	   the	   overlying	   BCSFB	   (Brown	   et	   al.	   2004).	   The	  AAE	   is	   an	   avascular	   CNS	  
barrier	  and,	  as	  part	  of	  the	  meninges,	  completely	  surrounds	  the	  brain	  (Abbott	  et	  al.	  
2010).	  The	  meninges	  consist	  of	  three	  layers,	  the	  outer	  one	  being	  referred	  to	  as	  dura	  
mater,	   the	   middle	   layer	   as	   AAE	   or	   arachnoid	   mater,	   and	   the	   inner	   layer	   as	   pia	  
mater.	  AAE	  and	  pia	  mater	  are	  separated	  by	  the	  sub-­‐arachnoid	  space,	  a	  sponge-­‐like	  
structure	   that	   is	   connected	   to	   the	   ventricles	   and	   filled	   with	   CSF.	   The	   AAE	   itself	  
consists	   of	   several	   epithelial	   cell	   layers	  with	   the	  middle	   layer	   forming	   the	   barrier	  
(Abbott	   et	   al.	   2010).	   The	  BBB	   is	   the	  endothelial	   cell	   layer	   forming	   the	  walls	  of	   all	  
capillaries	  in	  the	  brain	  and	  represents	  the	  third	  and	  largest	  CNS	  barrier	  with	  regards	  
to	  surface	  area.	  In	  contrast	  to	  the	  other	  two	  barriers,	  the	  BBB	  directly	  separates	  the	  
blood	   from	   the	   extracellular	   fluid	   of	   CNS	   neuronal	   tissue	   and	   hence	   is	   in	   close	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proximity	   to	  neurons	   (Abbott	  et	  al.	  2010).	  These	   features	  make	  the	  BBB	  the	  most	  
important	  CNS	  barrier	  in	  pharmacology.	  
1.1.1.1. Tight	  junctions	  
The	  key	  attribute	  of	  all	  three	  discussed	  CNS	  barriers	  is	  the	  presence	  of	  intercellular	  
tight	   junctions	   (zonula	   occludens)	   (Abbott	   et	   al.	   2010).	   Tight	   junctions	   form	   an	  
intercellular	   “seal”	   and	   highly	   restrict	   any	   paracellular	   diffusion	   of	   molecules	  
through	   a	   cell	   monolayer.	   They	   are	   part	   of	   the	   junctional	   complex	   generally	  
involved	   in	   cell	   adhesion	   (Farquhar	   et	   al.	   1963).	   The	   junctional	   complex	   also	  
includes	   adherence	   junctions,	   important	   structural	   proteins	   such	   as	   the	   cadherin-­‐
catenin	   complex,	   that	   attach	   endothelial	   or	   epithelial	   cells	   and	   are	   essential	   to	  
build-­‐up	  tight	  junctions	  (Abbott	  et	  al.	  2010,	  Kurita	  et	  al.	  2013).	  Adherens	  junctions	  
are	   located	  underneath	  tight	   junctions	  which	  are	   found	  at	   the	  most	  apical	  part	  of	  
the	   junctional	   complex	   between	   the	   apical	   and	   the	   basolateral	   cell	   membrane	  
(Forster	  2008).	  Tight	  junctions	  consist	  of	  several	  transmembrane	  proteins	  that	  span	  
the	   intercellular	   cleft	   and	   thereby	   constitute	   a	   physical	   barrier.	   The	   primary	  
components	   of	   tight	   junctions	   are	   the	   claudins	   and	   occludins	   but	   also	   junctional	  
adhesion	  molecules	  (JAMs),	  with	  the	  latter	  proposed	  to	  be	  involved	  in	  leukocyte	  cell	  
adhesion	   (Abbott	   et	   al.	   2010,	  Weber	   et	   al.	   2007).	   In	   addition,	   there	   are	   scaffold	  
proteins	  such	  as	  zonula	  occludens	  1	  (ZO-­‐1),	  ZO-­‐2,	  and	  ZO-­‐3	  clustering	  the	  spanning	  
proteins	   and	   connecting	   them	   to	   the	   actin/myosin	   cytoskeleton	   (Niessen	   2007).	  
Tight	   junctions	   not	   only	   form	   intercellular	   barriers	   but	   also	   restrict	   membrane	  
trafficking	   within	   one	   cell,	   thereby	   separating	   the	   apical	   from	   the	   basolateral	  
membrane	  domain	  (Forster	  2008).	  Figure	  1.1	   illustrates	  the	  basic	  composition	  and	  
arrangement	  of	  tight	  junctions	  and	  adherens	  junctions	  at	  the	  BBB.	  
1.1.1.2. Neurovascular	  unit	  
The	   BBB	   constitutes	   the	   main	   physical	   barrier	   between	   the	   CNS	   and	   the	  
bloodstream.	   Many	   other	   cell	   types	   and	   structures,	   however,	   are	   important	   for	  
maintaining	   and	   regulating	   the	   BBB	   and	   together	   they	   are	   referred	   to	   as	   the	  
neurovascular	   unit	   (Hawkins	   et	   al.	   2005).	   Neurons,	   astrocytes,	   pericytes,	   and	  
microglia	  are	  recognised	  as	  particularly	  important	  cells	  within	  this	  network	  but	  also	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structures	  such	  as	  the	  basal	   lamina	  and	  endothelial	  glycocalyx	  (Abbott	  et	  al.	  2012,	  
Neuwelt	   et	   al.	   2011).	  Anatomically,	   the	  endothelial	   cell	   layer	   is	   closely	   associated	  
with	   pericytes	   and	   the	   end-­‐feet	   of	   astrocytes,	   both	   increasingly	   recognised	   to	   be	  
involved	  in	  regulating	  BBB	  induction,	  maintenance,	  and	  permeability	  (Abbott	  2013,	  
Abbott	  et	  al.	  2006,	  Alvarez	  et	  al.	  2011,	  Armulik	  et	  al.	  2010).	  In	  addition,	  astrocytes	  
provide	   a	   cellular	   link	   between	   the	   endothelial	   cell	   layer	   and	   neurons	   with	  
important	   cell-­‐signalling	   properties	   (Abbott	   et	   al.	   2006).	   Microglia	   are	   resident	  
macrophages	   derived	   from	   erythromyeloid	   precursor	   cells	   and	   are	   particularly	  
important	  for	  an	   immune	  response	  within	  the	  brain	  (Ginhoux	  et	  al.	  2010,	  Kierdorf	  
et	   al.	   2013).	   The	  basal	  membrane	   is	   a	   structure	   composed	  of	   extracellular	  matrix	  
proteins	   such	   as	   collagen	   type	   IV	   and	   laminin	   and	   surrounds	   the	   endothelial	   cell	  
layer	  and	  pericytes	  (Hawkins	  et	  al.	  2005,	  Neuwelt	  et	  al.	  2011).	  The	  term	  glycocalyx	  
refers	   to	   the	   collective	   extracellular	   sugar	   layer	   derived	   from	   endothelial	   cell-­‐
membrane	   glycoproteins.	   It	   seems	   to	   be	   involved	   in	   regulation	   of	   membrane	  












Figure	  1.1:	  Model	  of	  blood-­‐brain	  barrier	  tight	  junctions	  and	  adherens	  junctions	  
Simplified	   model	   illustrating	   tight	   junction	   and	   adherens	   junction	   composition	   and	   arrangement.	  
Junctional	   adhesion	   molecules	   (JAMs),	   claudin	   3/5,	   and	   occludin	   are	   important	   tight	   junction	  
proteins	  with	  the	  claudins	  and	  occludins	  spanning	  and	  “sealing”	  the	  intercellular	  cleft	  between	  brain	  
endothelial	   cells.	   Zonula	   occludens	   (ZO)	   scaffolding	   proteins	   cluster	   and	   connect	   tight	   junction	  
proteins	   to	   the	   actin/myosin	   cytoskeleton.	   VE-­‐cadherin	   proteins	   are	   adhesive	   junction	   proteins	  
important	  for	  structural	  integrity	  and	  tight	  junction	  formation.	  They	  are	  linked	  to	  the	  cytoskeleton	  by	  
means	  of	  the	  catenin	  scaffolding	  proteins.	  Model	  adapted	  from	  Abbott	  et	  al.,	  2010	  
1.1.2. Principles	  of	  blood-­‐brain	  barrier	  transport	  
The	  key	  feature	  of	  the	  BBB	  is	  a	  tight	  restriction	  of	  paracellular	  diffusion	  by	  means	  of	  
tight	   junctions.	   This	   makes	   other	   mechanisms	   crucial	   to	   allow	  molecules	   to	   pass	  
through	   this	   barrier	   in	   order	   to	   supply	   the	   brain	   with	   nutrients	   and	   remove	  
metabolic	   waste	   products.	   In	   addition,	   drug	   delivery	   and	   extrusion	   is	   of	  
fundamental	   interest	   in	   pharmacology,	   particularly	   in	   CNS	   diseases	   where	   drugs	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usually	   target	   receptors	   in	   the	   brain	   and	   have	   to	   cross	   the	   BBB	   at	   substantial	  
concentrations	   (Pardridge	  2005).	   Figure	  1.2	   illustrates	   important	  pathways	  of	  BBB	  
drug	  transit.	  	  
The	   simplest	   mechanism	   is	   the	   passive	   transcellular	   lipophilic	   pathway	  
(Figure	   1.2	  A),	   also	   referred	   to	   as	   “passive	   diffusion”.	   Passive	   diffusion	   requires	   a	  
molecule	   to	   have	   certain	   physicochemical	   properties	   to	   allow	   entry	   into	   the	   lipid	  
bilayer	   of	   the	   endothelial	   cells.	   It	   has	   played	   a	   decisive	   role	   in	   drug	  development	  
with	  regards	  to	  CNS	  drug	  efficacy	  and	  toxicity.	  The	  lipophilicity	  of	  drugs	  is	  generally	  
accepted	  to	  be	  an	  important	  determinant	  for	  passive	  diffusion,	  both	  in	  vitro	  and	  in	  
vivo,	  but	  correlation	  becomes	  poor	   for	  highly	   lipophilic	  drugs,	  possibly	  because	  of	  
preferential	   accumulation	   in	   the	   membrane	   as	   the	   surrounding	   aqueous	  
environment	  is	  energetically	  not	  favourable	  for	  a	  molecule	  to	  exit	  (Summerfield	  et	  
al.	  2007).	  Other	  important	  characteristics	  for	  drugs	  to	  passively	  diffuse	  through	  the	  
BBB	   include	   the	  molecular	   size	   and	   total	   hydrogen	   bond	   strengths	   (Sugano	   et	   al.	  
2010).	   Passive	   diffusion	   follows	   a	   concentration	   gradient	   and	   is	   usually	   a	   non-­‐
saturating	  and	  non-­‐inhibitable	  process	  (Sugano	  et	  al.	  2010).	  	  
Figure	   1.2	   B	   illustrates	   the	   transcytosis	   pathways,	   either	   receptor-­‐
mediated	   or	   adsorptive-­‐mediated	   (Abbott	   et	   al.	   2010).	   Transcytosis	   pathways,	  
particularly	   receptor-­‐mediated,	   have	   garnered	   interest	   in	   recent	   years	   as	   a	   drug	  
delivery	   strategy	   into	   the	   brain.	   Various	   macromolecules,	   such	   as	   peptides	   and	  
proteins,	   are	   known	   to	   cross	   the	   BBB	   via	   transcytosis,	   and	   biologics,	   such	   as	  
monoclonal	   antibodies,	   could	   possibly	   be	   modified	   to	   overcome	   BBB	   restrictions	  
(Watts	   et	   al.	   2013).	   Finally,	   the	   membrane	   transporter	   pathway	   is	   indicated	   in	  
Figure	   1.2	   C+D	   by	   the	   solute	   carrier	   (SLC)	   superfamily	   and	   adenosine	   5'-­‐
triphosphate	   (ATP)-­‐binding	   cassette	   (ABC)	   family,	   both	   of	   which	   are	   described	   in	  




Figure	  1.2:	  Model	  of	  blood-­‐brain	  barrier	  transport	  	  
Simplified	   model	   illustrating	   important	   drug	   transport	   mechanisms	   across	   brain	   endothelial	   cell	  
layers;	   A)	   Passive	   diffusion;	   B)	   Adsorptive-­‐mediated	   and	   receptor-­‐mediated	   transcytosis;	   C)	   ABC	  
transporter	  efflux;	  D)	  SLC	  transport;	  Model	  adapted	  from	  Abbott	  et	  al.,	  2010	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1.2. Membrane	  transporters	  
Membrane	   transporters	   are	   increasingly	   recognised	   as	   important	   mediators	   for	  
drug	   transport	   across	   biological	   barriers	   such	   as	   the	   BBB,	   but	   also	   intestinal	  
epithelial	   cells,	   hepatocytes,	   and	   renal	   tubule	   epithelial	   cells,	   all	   of	   which	   are	  
characterised	  by	  the	  presence	  of	  tight	  junctions.	  Each	  of	  these	  barriers	  expresses	  a	  
unique	   and	   adjustable	   transportome,	   owing	   to	   the	   distinct	   role	   of	   the	   respective	  
organ	  with	  specific	  permeability	  requirements.	  	  
Mechanistically,	  membrane	  transporters	  can	  be	  classified	  as	  facilitative	  or	  
active	   transporters	   (Hediger	  et	  al.	  2013).	  Facilitative	   transporters	  passively	  shuttle	  
substrates	   down	   their	   electrochemical	   concentration	   gradient	   with	   no	   additional	  
energy	  source	  required.	  Active	  transporters,	  in	  contrast,	  utilise	  an	  energy	  source	  to	  
pump	   substrates	   against	   their	   electrochemical	   concentration	   gradient	   and	   are	  
classified	   as	   primary-­‐active	   or	   secondary-­‐active	   transporters.	   Primary-­‐active	  
transporters	   hydrolyse	   ATP	   as	   an	   energy	   source	   whereas	   secondary-­‐active	  
transporters	   utilise	   the	   electrochemical	   gradients	   generated	   by	   primary-­‐active	  
transporters	  in	  the	  form	  of	  symporters	  or	  antiporters	  (Hediger	  et	  al.	  2013).	  Primary-­‐
active	  transporters	  include	  ion	  pumps	  (ATPases)	  such	  as	  the	  abundantly	  expressed	  
Na+/K+	   ATPase	   (Sandtner	   et	   al.	   2011)	   and	   ABC	   transporters	   (Hediger	   et	   al.	   2013)	  
(1.2.2).	   Secondary-­‐active	   and	   facilitative	   transporters	   often	   belong	   to	   the	  
superfamily	  of	   SLC	   transporters	  as	  described	   in	   section	  1.2.1	   (He	   et	  al.	   2009).	   For	  
example,	   membrane	   transporters	   from	   the	   SLC6	   family	   utilise	   a	   Na+	   gradient	   as	  
energy	  source	  for	  substrate	  translocation	  (1.2.1.1).	  
Membrane	  transporters,	  such	  as	  the	  SLC	  superfamily	  and	  ABC	  family,	  are	  
referred	  to	  as	  carriers	  and	  can	  be	   functionally	  distinguished	   from	  another	  class	  of	  
transport	   proteins	   known	   as	   channels.	   The	   fundamental	   difference	   between	  
carriers	  and	  channels	   is	  that	  carriers	  undergo	  a	  conformational	  change	  to	  catalyse	  
the	   translocation	   of	   substrates	   either	   downhill	   or	   uphill	   of	   an	   electrochemical	  
gradient.	  A	  carrier	   is	  only	  accessible	   from	  one	  side	  of	   the	  membrane	  at	  any	  given	  
time	   whereas	   the	   pore	   of	   a	   channel	   may	   be	   fully	   open,	   allowing	   substrates	   to	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rapidly	   diffuse	   through	   the	   pore	   exclusively	   down	   their	   electrochemical	   gradient	  
(Gadsby	   2009,	   Shi	   2013).	   Consequently,	   the	   turnover	   rate	   of	   a	   channel	   can	   be	  
orders	  of	  magnitude	  higher	  than	  that	  of	  a	  carrier	  (Shi	  2013).	  Two	  noteworthy	  types	  
of	   channels	   are	   the	   water	   and	   ion	   channels	   with	   the	   latter	   being	   particularly	  
important	  in	  neuronal	  signalling	  and	  acting	  as	  targets	  for	  antiepileptic	  drugs	  (1.3.3).	  
The	   mechanistic	   differences	   between	   carrier-­‐mediated	   and	   channel-­‐mediated	  
transport	  is	  illustrated	  in	  Figure	  1.3.	  
SLC	   (1.2.1)	   and	  ABC	   (1.2.2)	   transporters	   are	  playing	   an	  emerging	   role	   in	  
the	   field	   of	   pharmacokinetics	   due	   to	   the	   increasing	   number	   of	   drugs	   known	   to	  
interact	  with	  members	  of	  these	  families.	  Absorption,	  distribution,	  metabolism,	  and	  
excretion	  (ADME)	  are	  key	  variables	  that	  determine	  the	  efficacy	  or	  toxicity	  of	  drugs.	  
Drug	   transporters	   are	   increasingly	   recognised	   as	   critical	   components	   within	   this	  
network.	   As	   for	   other	   proteins	   involved	   in	   ADME,	   drug	   transporters	   have	   the	  
potential	  to	  account	  for	  critical	  drug	  interactions	  if	  the	  transport	  efficiency	  of	  a	  drug	  
is	   affected	   by	   another	   compound.	   In	   2010,	   the	   International	   Transporter	  
Consortium	   (ITC)	   published	   a	   white	   paper	   with	   recommendations	   for	   important	  
drug	   transporters	   to	   be	   considered	   in	   drug	   development	   and	   a	   list	   of	   additional	  
emerging	  transporters	  was	  released	  in	  2013	  (Giacomini	  et	  al.	  2013,	  Giacomini	  et	  al.	  
2010).	  In	  2012,	  the	  United	  States	  (US)	  Food	  and	  Drug	  Administration	  (FDA)	  issued	  a	  
draft	   industry	   guideline	   for	   drug	   interaction	   studies	   in	   drug	   development	   that	  
included	   transporters	   based	   on	   the	   2010	   white	   paper	   recommendations	   (United	  
States	   Food	   and	   Drug	   Administration	   2012).	   Transporters	   currently	   included	   are	  
ABCB1	   (MDR1,	   Pgp)	   (1.2.2.1),	   ABCG2	   (BCRP)	   (1.2.2.3),	   SLCO1B1	   (OATP1B1),	  
SLCO1B3	   (OATP1B3)	   (1.2.1.2),	   SLC22A2	   (OCT2),	   SLC22A6	   (OAT1),	   and	   SLC22A8	  
(OAT3)	   (1.2.1.3).	   This	   list,	   however,	   is	   likely	   to	   be	   expanded	   soon	   based	   on	   new	  
recommendations	  from	  the	  ITC	  (Giacomini	  et	  al.	  2013).	  
Chapter	  1	  
11	  
Figure	  1.3:	  Mechanistic	  model	  illustrating	  the	  transport	  principles	  of	  transporters	  and	  channels	  	  
Transporters	   (carriers)	   catalyse	   the	   translocation	   of	   substrates	   either	   downhill	   or	   uphill	   of	   an	  
electrochemical	  gradient.	  A	  conformational	  change	  of	  the	  protein	  exposes	  the	  binding	  site	  either	  to	  
the	   outside	   or	   to	   the	   inside.	   Channels,	   in	   contrast,	   may	   be	   open	   to	   both	   sides	   simultaneously,	  
allowing	   rapid	   diffusion	   of	   substrates	   exclusively	   down	   their	   electrochemical	   gradient.	   Model	  
adapted	  from	  Shi,	  2013	  
1.2.1. Solute	  carriers	  
SLCs	   represent	   the	   largest	   superfamily	   of	  membrane	   transporters	   and	   the	   official	  
list	   currently	   consists	   of	   390	   SLC	   transporter	   encoding	   genes	   (excluding	  
pseudogenes)	  within	  52	  families	  (SLC1-­‐SLC52)	  and	  is	  available	  as	  a	  Human	  Genome	  
Organisation	   Gene	   Nomenclature	   Committee	   at	   the	   European	   Bioinformatics	  
Institute	   (HGNC)	   approved	   source	   at	   http://slc.bioparadigms.org.	  A	   corresponding	  
review	  article	  for	  each	  family	  has	  recently	  been	  published	  in	  the	  “Molecular	  Aspects	  
of	  Medicine”	   journal	   and	   some	   selected	   families	   are	  highlighted	   in	  more	  detail	   in	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this	   section.	   SLC	   genes	   are	   allocated	   to	   a	   family	   with	   other	   genes	   if	   the	   coded	  
proteins	   share	   at	   least	   20	   %	   of	   the	   amino	   acid	   sequence	   and	   they	   may	   also	   be	  
further	  divided	  into	  subfamilies	  (Hediger	  et	  al.	  2013).	  The	  official	  nomenclature	  for	  
each	   gene	  begins	  with	  SLC	   to	   indicate	   the	   corresponding	   gene	   superfamily	   and	   is	  
followed	  by	  the	  family	  number	  and	  subfamily	  letter.	  Finally,	  each	  gene	  is	  allocated	  a	  
unique	  number	  (Hediger	  et	  al.	  2013).	  The	  SLC	  superfamily	  comprises	  a	  diverse	  set	  of	  
transporters	   involved	   in	   the	   absorption	   and	   excretion	   of	   a	   broad	   spectrum	   of	  
physiologically	   important	  endogenous	  molecules/ions	  but	  also	  xenobiotics	  such	  as	  
drugs.	   For	   example,	   members	   of	   the	   SLC2A	   family	   are	   essential	   for	   an	   adequate	  
sugar	  supply	  to	  the	  brain	  and	  other	  organs	  (Mueckler	  et	  al.	  2013)	  while	  the	  SLC39A	  
family	  is	  essential	  for	  metal	  ion	  homeostasis,	  particularly	  zinc	  (Jeong	  et	  al.	  2013).	  
1.2.1.1. SLC6	  family	  
The	  SLC6	  family	  of	  membrane	  transporters	  currently	  comprises	  20	  genes	  (excluding	  
two	  putative	  pseudogenes)	  and	  is	  one	  of	  the	  most	  clinically	  relevant	  groups	  in	  the	  
field	  of	  neurology.	  All	  genes	  belong	  to	  the	  SLC6A	  subfamily	  and	  are	  further	  divided	  
into	   subgroups	   based	   on	   sequence	   similarities	   and	   functions	   (Kristensen	   et	   al.	  
2011).	   The	   genes	   that	   have	   gained	   most	   interest	   code	   for	   neurotransmitter	  
transporters	  (NTTs)	  that	  play	  a	  critical	  role	  in	  neuronal	  signalling.	  Among	  them	  are	  
inhibitory	   amino	   acid	   neurotransmitter	   transporters	   such	   as	   the	   glycine	   (SLC6A5,	  
SLC6A9)	   or	   gamma-­‐aminobutyric	   acid	   (GABA,	   SLC6A1,	   SLC6A11-­‐13)	   transporters,	  
and	   the	   monoamine	   neurotransmitter	   transporters	   SLC6A2	   (NET),	   SLC6A3	   (DAT),	  
and	   SLC6A4	   (SERT),	   recognising	   the	   substrates	   norepinephrine,	   dopamine,	   and	  
serotonin,	  respectively	  (Pramod	  et	  al.	  2013).	  
SLC6	  transporters	  are	  secondary-­‐active	  symporters	  utilising	  a	  Na+	  gradient	  
as	  energy	  source.	   In	  addition,	  some	  of	  these	  transporters	  co-­‐transport	  Cl-­‐	  (Pramod	  
et	   al.	   2013).	   The	   principal	   function	   of	  NTTs	   is	   the	   re-­‐uptake	   of	   neurotransmitters	  
from	  the	  synaptic	  cleft	   into	  the	  pre-­‐synapsis,	   in	  order	  to	  terminate	  synaptic	  signal	  
transmission	   and	   to	   recycle	   the	   neurotransmitters	   for	   further	   stimuli.	  
Neurotransmitter	   homoeostasis	   is	   a	   critical	   component	   for	   proper	   neuronal	  
signalling	   and	   imbalances	   are	   associated	   with	   various	   neurological	   diseases,	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including	  mood	  disorders	  such	  as	  depression,	  but	  also	  epilepsy,	  schizophrenia,	  and	  
attention	  deficit	  hyperactivity	  disorder.	  Accordingly,	  NTTs	  are	  of	  marked	  interest	  as	  
targets	   for	   pharmacotherapy	   with	   more	   than	   30	   predominantly	   inhibitory	   drugs	  
currently	  approved	  for	  different	  conditions	  (Kristensen	  et	  al.	  2011).	  
NTT	   inhibition	   is	   usually	   characterised	   by	   prolonged	   neurotransmitter	  
activity	  at	  post-­‐synaptic	  receptors	  and	  the	  majority	  of	  these	  drugs	  are	  indicated	  for	  
the	   treatment	   of	   mood	   disorders	   and	   target	   the	   monoamine	   neurotransmitter	  
transporters	  SLC6A2,	  SLC6A3,	  and	  SLC6A4.	  Targeting	  drugs	  belong	  to	  the	  classes	  of	  
tricyclic	   antidepressants,	   selective	   serotonin/norepinephrine/dopamine	   re-­‐uptake	  
inhibitors,	  and	  non-­‐selective	  re-­‐uptake	   inhibitors.	  An	  exception	   is	   tiagabine,	  which	  
specifically	  targets	  the	  GABA	  re-­‐uptake	  transporter	  SLC6A1	  and	  is	  indicated	  for	  the	  
treatment	  of	  epilepsy	  (Kristensen	  et	  al.	  2011).	  SLC6A2,	  SLC6A3,	  and	  SLC6A4	  are	  also	  
known	   to	   interact	   with	   drugs	   of	   abuse	   such	   as	   cocaine,	   amphetamine,	  
methamphetamine,	   and	   3,4-­‐methylenedioxymethamphetamine	   (“ecstasy”)	   and	  
hence	  play	  an	  important	  role	  in	  addiction	  (Kristensen	  et	  al.	  2011).	  
A	   breakthrough	   in	   understanding	   the	   structure	   and	   function	   of	   SLC6	  
transporters	  was	  achieved	  by	  resolving	  the	  X-­‐ray	  crystal	  structure	  of	  the	  prokaryotic	  
leucine	   transporter	   (LeuT)	   in	   2005,	   a	   homologue	   to	   human	   SLC6	   transporters	  
(Yamashita	  et	  al.	  2005).	  The	  three-­‐dimensional	  structure	  revealed	  an	  unknown	  but	  
common	   structural	   motif	   for	   many	   transporters	   referred	   to	   as	   the	   5+5	   inverted	  
repeat	  fold	  (Pramod	  et	  al.	  2013).	  It	   is	  characterised	  by	  a	  five	  transmembrane	  helix	  
(TMH)	   bundle	   that	   is	   repeated	   in	   a	   similar	   form	   following	   a	   pseudo	   two-­‐fold	  
rotation	  that	  is	  not	  obvious	  from	  the	  amino	  acid	  sequence	  (Yamashita	  et	  al.	  2005).	  
This	  motif	  has	   subsequently	  been	   found	   in	  many	  other	  prokaryotic	   transporter	  X-­‐
ray	   crystal	   structures	  with	   “snapshots”	  of	  different	   stages	  of	  a	   common	   transport	  
mechanism	  referred	  to	  as	  the	  alternate	  access	  model	  (Kristensen	  et	  al.	  2011).	  In	  this	  
model,	   the	   transporter	   alternates	   between	   different	   conformational	   states,	   the	  
outward-­‐facing	   open	   state,	   the	   outward-­‐facing	   occluded	   state,	   and	   the	   inward-­‐
facing	  open	   state.	   The	  outward-­‐facing	  open	   state	   is	   characterised	  by	   a	   substrate-­‐
binding	  site	  accessible	  from	  the	  extracellular	  environment.	  Upon	  substrate	  binding,	  
the	   transporter	   undergoes	   a	   conformational	   change	   that	   leads	   to	   the	   outward-­‐
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facing	   occluded	   state	   and	   finally	   the	   inward-­‐facing	   open	   state	  with	   the	   substrate	  
being	  released	  (Kristensen	  et	  al.	  2011).	  
Interestingly,	  an	  X-­‐ray	  crystal	  structure	  of	  LeuT	  binding	  to	  the	  competitive	  
inhibitor	  tryptophan	  revealed	  a	  molecular	  basis	   for	  the	  mechanism	  of	  competitive	  
inhibition	   as	   seen	   with	   many	   NTT-­‐targeting	   drugs.	   In	   this	   structure,	   tryptophan	  
stabilises	  the	  open	  outward-­‐facing	  confirmation	  by	  binding	  to	  the	  substrate-­‐binding	  
site	   and	   therefore	   sterically	   hinders	   the	   transporter	   to	   undergo	   conformational	  
changes	  (Singh	  et	  al.	  2008).	  The	  basic	  mechanistic	  principles	  of	  substrate	  transport	  
and	  drug	  inhibition	  derived	  from	  LeuT	  and	  other	  prokaryotic	  transporters	  with	  the	  
5+5	   inverted	   repeat	  motif	   have	   recently	   been	   confirmed	  with	   the	   first	   eukaryotic	  
Slc6a3	   (Dat)	   transporter	   X-­‐ray	   crystal	   structure	   derived	   from	   Drosophila	  
melanogaster	   that	   is	   binding	   to	   the	   competitive	   inhibitor	   nortriptyline,	   a	   tricyclic	  
antidepressant	  (Penmatsa	  et	  al.	  2013).	  	  
1.2.1.2. SLCO	  superfamily	  
The	   SLCO	   superfamily	   of	   membrane	   transporter	   genes	   encodes	   for	   the	   organic	  
anion	   transporting	   polypeptides	   (OATPs)	   and	   are	   recognised	   as	   being	   particularly	  
important	   for	   drug	   transport	   across	   biological	   barriers.	   The	   SLCO	   genes	   were	  
formerly	  assigned	  to	  family	  SLC21	  within	  the	  SLC	  gene	  nomenclature	  system	  (1.2.1).	  
About	  a	  decade	  ago,	  however,	  a	  re-­‐classification	  was	   introduced	  and	  approved	  by	  
the	  HGNC	  due	  to	  major	  name	  inconsistencies	  for	  newly	  discovered	  genes/proteins	  
and	  a	  cross-­‐species	  phylogenetic	  correlation	  that	  revealed	  the	  presence	  of	  a	  distinct	  
and	   species-­‐independent	   gene	   superfamily	   (Hagenbuch	   et	   al.	   2004).	   This	  
superfamily	  has	  subsequently	  been	  termed	  SLCO	  to	  highlight	  the	  relationship	  to	  SLC	  
transporters,	   but	   still	   allows	   a	   species-­‐independent	   sub-­‐classification	   into	   families	  
and	  subfamilies.	  Usually,	  genes	  are	  assigned	  to	  a	  SLCO	  family	  and	  subfamily	  if	  they	  
show	  ≥	  40	  %	  and	  ≥	  60	  %	  amino	  acid	  sequence	  identity,	  respectively	  (Hagenbuch	  et	  
al.	  2004).	  	  
The	   first	   human	   SLCO	   gene,	   SLCO1A2,	   was	   cloned	   in	   1995,	   based	   on	   a	  
previously	  cloned	  rat	  homologue	  (Jacquemin	  et	  al.	  1994,	  Kullak-­‐Ublick	  et	  al.	  1995).	  
Currently,	   11	   human	   SLCO	   genes	   are	   assigned	   to	   6	   families,	   namely	   SLCO1A2,	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SLCO1B1,	   SLCO1B3,	   SLCO1C1,	   SLCO2A1,	   SLCO2B1,	   SLCO3A1,	   SLCO4A1,	   SLCO4C1,	  
SLCO5A1,	  and	  SLCO6A1	  (Hagenbuch	  et	  al.	  2013).	  No	  crystal	  structure	  from	  any	  SLCO	  
protein	   (any	   species)	   has	   been	   published	   so	   far	   but	   biochemical	   data	   from	   rat	  
Slco1a1	   (Oatp1a1),	   hydrophobicity	   plots,	   and	   homology	   modelling	   suggest	   that	  
SLCOs	   consist	   of	   12	   TMHs	   (Hagenbuch	   et	   al.	   2013,	   Roth	   et	   al.	   2011,	  Wang	   et	   al.	  
2008).	  
As	   can	   be	   seen	   from	   the	   name,	   SLCO	   proteins	   (OATPs)	   predominantly	  
mediate	   the	   transport,	  particularly	  uptake,	  of	  endogenous	  and	  exogenous	  organic	  
anions	  (Obaidat	  et	  al.	  2012).	  While	  the	  exact	  transport	  mechanism	  remains	  unclear,	  
data	  from	  several	  studies	   indicate	  a	  possible	  anion	  exchange	  process	  and,	  at	   least	  
for	  some	  SLCOs,	  the	  transport	  of	  selected	  substrates	  was	  stimulated	  by	  a	  lower	  pH,	  
possibly	   coupled	   to	   a	   secondary-­‐active	   bicarbonate	   exchange	   (Hagenbuch	   et	   al.	  
2013,	   Kobayashi	   et	   al.	   2003,	   Leuthold	   et	   al.	   2009,	   Satlin	   et	   al.	   1997).	   In	   addition,	  
reduced	   glutathione	   (GSH)	   and	   GSH-­‐conjugates	   were	   demonstrated	   to	   act	   as	  
counter-­‐ions	  for	  selected	  transporters	  and	  substrates	  (Hagenbuch	  et	  al.	  2013,	  Li	  et	  
al.	  1998,	  Li	  et	  al.	  2000).	  
While	   the	   whole	   SLCO	   gene	   superfamily	   seems	   to	   be	   important	   in	   the	  
disposition	   of	   endogenous	   and	   exogenous	   substrates,	   most	   attention	   has	   been	  
drawn	  on	  the	  SLCO1B1	  (OATP1B1)	  and	  SLCO1B3	  (OATP1B3)	  proteins	  as	  both	  were	  
found	   to	   be	   strongly	   expressed	   at	   the	   basolateral	   (sinusoidal)	   membrane	   of	  
hepatocytes	  (Abe	  et	  al.	  1999,	  Abe	  et	  al.	  2001,	  Hsiang	  et	  al.	  1999,	  Konig	  et	  al.	  2000a,	  
b).	   SLCO1B1	   and	   SLCO1B3	   mediate	   the	   hepatic	   uptake	   of	   various	   endogenous	  
substrates,	   including	   conjugated	   and	   unconjugated	   bile	   acids,	   conjugated	   and	  
unconjugated	   bilirubin	   and	   thyroid	   hormones,	   as	   well	   as	   many	   important	   drugs	  
(Hagenbuch	   et	   al.	   2013,	   Roth	   et	   al.	   2011).	   Among	   drugs,	   examples	   of	   identified	  
substrates	   include	   statins,	   such	   as	   rosuvastatin	   (Ho	   et	   al.	   2006),	   human	  
immunodeficiency	  virus	  (HIV)	  protease	  inhibitors,	  such	  as	  lopinavir	  (Hartkoorn	  et	  al.	  
2010),	  and	  the	  antineoplastic	  agent	  methotrexate	  (Abe	  et	  al.	  2001).	  Interestingly,	  a	  
large	   and	   prospective	   genome-­‐wide	   association	   study	   (GWAS)	   found	   SLCO1B1	  
polymorphisms	   to	   be	   associated	   with	   statin-­‐induced	   myopathy,	   particularly	   at	  
higher	  doses	  (Link	  et	  al.	  2008).	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SLCO1B1	  and	  SLCO1B3	  are	  not	  expressed	  at	   the	  BBB	   (Roth	   et	   al.	   2011).	  
Instead,	   SLCO1A2	   (OATP1A2)	   and	   SLCO2B1	   (OATP2B1)	   may	   be	   of	   particular	  
importance	   for	   the	   uptake	   of	   drugs	   into	   the	   CNS.	   Both	   transporters	   have	   been	  
shown	  to	  be	  expressed	  in	  brain	  endothelial	  cells,	  localised	  to	  the	  apical	  membrane	  
(Bronger	   et	   al.	   2005,	   Lee	   et	   al.	   2005),	   and	   are	   known	   to	   recognise	   numerous	  
substrates.	  Endogenous	  substrates	  of	  SLCO1A2	  are	  similar	  to	  SLCO1B1	  and	  SLCO1B3	  
and	   include	   conjugated	   and	   unconjugated	   bile	   acids,	   unconjugated	   bilirubin,	   and	  
thyroid	   hormones	   (Hagenbuch	   et	   al.	   2013,	   Roth	   et	   al.	   2011).	   Accordingly,	   many	  
drugs	  that	  have	  been	  identified	  as	  substrates	  for	  SLCO1B1	  and/or	  SLCO1B3	  are	  also	  
known	   to	   be	   transported	   by	   SLCO1A2	   (Roth	   et	   al.	   2011)	   including	   rosuvastatin,	  
lopinavir,	  and	  methotrexate	  (Badagnani	  et	  al.	  2006,	  Hartkoorn	  et	  al.	  2010,	  Ho	  et	  al.	  
2006).	   For	   SLCO2B1	   (OATP2B1)	   the	   list	   of	   currently	   known	   substrates	   is	  
considerably	  shorter	  (Hagenbuch	  et	  al.	  2013,	  Roth	  et	  al.	  2011).	  However,	  this	  seems	  
to	  be	  primarily	  a	   result	  of	   less	  extensive	   research	  carried	  out	   so	   far	  and	  does	  not	  
necessarily	   imply	   a	   less	   important	   role	   for	   SLCO2B1.	   Important	   endogenous	  
substrates	   identified	   include	  the	  thyroid	  hormone	  thyroxine	   (T4)	  and	  the	  bile	  acid	  
taurocholate	   (Leuthold	   et	   al.	   2009,	   Nozawa	   et	   al.	   2004).	   Several	   drugs	   have	   also	  
been	  reported	  to	  be	  substrates	  of	  SLCO2B1,	  particularly	   from	  the	  group	  of	  statins	  
such	  as	  rosuvastatin	  (Ho	  et	  al.	  2006,	  Roth	  et	  al.	  2011).	  Despite	  SLCO1A2,	  SLCO1B1,	  
SLCO1B3,	  and	  SLCO2B1,	  the	  other	  7	  currently	  known	  human	  SLCO	  transporter	  genes	  
might	  also	  be	  of	  importance	  for	  drug	  disposition,	  but	  their	  role	  is	  less	  clear.	  
1.2.1.3. SLC22	  family	  
The	  human	  SLC22	   family	  of	  membrane	  transporter	  genes	   is	  recognised	  as	  another	  
particularly	  important	  family	  encoding	  for	  transporters	  involved	  in	  drug	  disposition.	  
The	  SLC22	  family	  currently	  comprises	  23	  genes,	  all	  assigned	  to	  subfamily	  A.	  Within	  
the	  SLC22A	   subfamily,	  13	  proteins	  have	  been	   functionally	   characterised	  and	  were	  
further	  assigned	  to	  three	  subgroups,	  based	  on	  primary	  protein	  structure	  similarities	  
(Koepsell	   2013).	   Transporters	   within	   these	   groups	   often	   have	   a	   similar	   transport	  
mechanism	  with	  overlapping,	  but	  still	  distinct,	  substrate/inhibitor	  specificities.	  They	  
are	   referred	   to	   as	   organic	   cation	   transporters	   (OCTs),	   organic	   zwitterion/cation	  
transporters	   (OCTNs),	   and	  organic	   anion	   transporters	   (OATs)	   (Koepsell	   2013).	   The	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first	   group	   comprises	   SLC22A1-­‐3	   (OCT1-­‐3),	   the	   second	   group	   SLC22A4-­‐5	   plus	  
SLC22A16	   (OCTN1-­‐2	  plus	  OCT6),	   and	   the	   third	  group	  SLC22A6-­‐9	  and	  SLC22A11-­‐13	  
(OAT1-­‐3,	   OAT7,	   OAT4,	   URAT1,	   OAT10).	   Table	   1.1	   summarises	   these	   functionally	  
characterised	   transporters	   from	   the	   SLC22A	   subfamily	   with	   examples	   for	  
endogenous	  and	  exogenous	  substrates.	  
All	   SLC22	   proteins	   have	   a	   similar	   predicted	   topology	   of	   12	   TMHs	   with	  
intracellular	   and	   extracellular	   large	   loops	   (Koepsell	   2013).	   The	   large	   extracellular	  
loop	  contains	  several	  glycosylation	  sites.	  Results	  from	  in	  vitro	  experiments	  with	  rat	  
Slc22a1	   (Oct1),	  human	  SLC22A2	   (OCT2),	   and	  human	  SLC22A6	   (OAT1)	   suggest	   that	  
these	   loops	  mediate	   the	  homo-­‐oligomerisation	  of	   the	   respective	   transporters	  and	  
are	  crucial	   for	  proper	  plasma	  membrane	   trafficking	   (Brast	   et	  al.	   2012,	  Duan	   et	  al.	  
2011,	  Keller	  et	  al.	  2011).	  The	  intracellular	  loop	  is	  characterised	  by	  several	  putative	  
phosphorylation	   sites	   involved	   in	   posttranscriptional	   transporter	   regulation	  
(Koepsell	  2013,	  Koepsell	  et	  al.	  2007).	  
So	   far,	   no	   X-­‐ray	   crystal	   structure	   has	   been	   published	   for	   any	   SLC22	  
transporter,	   which	   would	   be	   important	   to	   understand	   the	   exact	   transport	  
mechanism.	  However,	  extensive	  mutagenesis	  experiments	  have	  been	  carried	  out	  in	  
addition	  to	  homology	  modelling	  with	  rat	  Slc22a1	  based	  on	  prokaryotic	  X-­‐ray	  crystal	  
structures	   derived	   from	   transporters	   of	   the	   same	   superfamily,	   particularly	  
Escherichia	  coli	  lactose	  permease	  (LacY)	  (Koepsell	  2013).	  Results	  from	  these	  studies	  
suggest	  a	  similar	  basic	  transport	  mechanism	  as	  described	  for	  the	  prokaryotic	  LeuT	  
and	  Drosophila	  melanogaster	   Slc6a3	   (Dat)	   transporter	   (1.2.1.1)	   with	   an	   outward-­‐
facing	  open	  confirmation,	  outward-­‐facing	  occluded	  confirmation,	  and	  inward-­‐facing	  
open	   confirmation,	   also	   known	   as	   the	   alternate	   access	   model	   (Abramson	   et	   al.	  
2003,	   Popp	   et	   al.	   2005,	   Volk	   et	   al.	   2009).	   Interestingly,	  whereas	   LeuT	   and	   Slc6a3	  
exhibit	  a	  5+5	  inverted	  repeat	  structural	  motif	  (1.2.1.1),	  LacY	  was	  found	  to	  contain	  a	  
motif	  with	   2x6	   transmembrane	  bundles	   related	   to	   each	  other	   by	   an	   approximate	  
two-­‐fold	   symmetry	   (Abramson	   et	   al.	   2003).	   The	   large	   substrate-­‐binding	   cavity	   is	  
located	  between	  these	  domains	  that	  were	  suggested	  to	  undergo	  a	  relative	  rotation	  
to	   switch	   between	   the	   outward-­‐facing	   and	   the	   inward-­‐facing	   conformation	  
(Abramson	   et	   al.	   2003).	   Low-­‐	   and	  high-­‐affinity	   substrate	   and/or	   inhibitor	  binding-­‐
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sites	  that	  may	  interact	  by	  an	  allosteric	  or	  inhibitory	  mechanism	  have	  been	  identified	  
in	   the	   large	   cavity	   of	   rat	   Slc22a1	   and	   Slc22a2	   (Oct2)	   for	   selected	   compounds	  
utilising	   site-­‐directed	  mutagenesis	   (Egenberger	   et	  al.	   2012,	  Gorboulev	   et	  al.	   2005,	  
Gorboulev	   et	  al.	   1999,	  Gorbunov	   et	  al.	   2008,	  Nies	   et	  al.	   2011b,	  Popp	   et	  al.	   2005,	  
Volk	  et	  al.	  2009).	  The	  presence	  of	  high-­‐	  and	  low-­‐affinity	  binding	  sites	  has	  also	  been	  
suggested	   for	  human	  SLC22A1-­‐3	   in	  experiments	  utilising	   transfected	  cell	   lines	  and	  
the	  HIV	  nucleoside	  reverse	  transcriptase	  inhibitor	  (NRTI)	  lamivudine	  as	  inhibitor	  for	  
1-­‐methyl-­‐4-­‐phenylpyridinium	   (MPP+)	  uptake,	  an	  OCT	  model	   substrate	   (Minuesa	   et	  
al.	  2009).	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Carnitine	   Bleomycin-­‐A5	  
(Aouida	  et	  al.	  2010,	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Urate	   -­‐	   (Bahn	  et	  al.	  2008)	  
Cyclo(his-­‐pro)	   =	   Histidyl-­‐proline	   diketopiperazine,	   DHEAS	   =	   Dehydroepiandrostone	   sulfate,	  	  
E3S	  =	  Estrone-­‐3-­‐sulfate,	  5-­‐FU	  =	  5-­‐Fluorouracil,	  MTX	  =	  Methotrexate,	  PGE2	  =	  Prostaglandin	  E2	  
SLC22A1	  (OCT1),	  SLC22A2	  (OCT2),	  and	  SLC22A3	  (OCT3)	  constitute	  the	  first	  
subgroup	   of	   functionally	   characterised	   transporters	   from	   the	   SLC22A	   family.	   In	  
1994,	   the	   first	  member,	  Slc22a1,	  was	  cloned	  from	  a	  rat	  cDNA	   library	  by	  means	  of	  
functional	  expression	  cloning.	  This	  was	  followed	  by	  cloning	  of	  the	  human	  SLC22A1	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gene	   in	  1997	  (Gorboulev	  et	  al.	  1997,	  Grundemann	  et	  al.	  1994,	  Zhang	  et	  al.	  1997).	  
Corresponding	   to	   their	   name,	   OCTs	   predominantly	   recognise	   organic	   cations	   or	  
weakly	  alkaline	  molecules	  that	  are	  positively	  charged	  at	  physiological	  pH	  (Nies	  et	  al.	  
2011b).	  40	  %	  of	  all	  orally	  administered	  drugs	  exhibit	  these	  properties	  (Neuhoff	  et	  al.	  
2003)	  and	  accordingly,	  a	   large	  number	  of	  compounds	  have	  been	  found	  to	  interact	  
with	   SLC22A1-­‐3,	   particularly	   as	   inhibitors,	   with	   broadly	   overlapping	   but	   still	  
distinctive	  specificities	  (Nies	  et	  al.	  2011b).	  	  
The	  translocation	  of	  substrates	  follows	  a	  passive	  facilitated,	  bi-­‐directional	  
mechanism	   down	   the	   electrochemical	   gradient	   (Nies	   et	   al.	   2011b).	   The	   large	  
number	   of	   identified	   inhibitors	   makes	   substrates	   susceptible	   to	   many	   potential	  
drug-­‐drug	   interactions.	   Drug	   library	   screenings	   with	   SLC22A1	   and	   SLC22A2	   have	  
revealed	   some	   common	   physicochemical	   features	   of	   potent	   inhibitors	   such	   as	   a	  
positive	  net	  charge	  and	  high	  lipophilicity	  (Ahlin	  et	  al.	  2008,	  Kido	  et	  al.	  2011).	  	  
On	  the	  mRNA	  level,	  SLC22A1	  is	  most	  abundantly	  expressed	  in	  the	  liver	  but	  
also	  detectable	  in	  the	  intestine,	  kidney,	  brain,	  and	  other	  organs	  (Nies	  et	  al.	  2011b).	  
The	   protein	   has	   been	   localised	   to	   the	   basolateral	   (sinusoidal)	   membrane	   of	  
hepatocytes	   (Nies	   et	   al.	   2008),	   apical	   membrane	   of	   renal	   tubule	   epithelial	   cells	  
(Tzvetkov	  et	  al.	  2009),	  apical	  membrane	  of	  brain	  endothelial	  cells	  (Lin	  et	  al.	  2010),	  
and	   apical	   membrane	   of	   enterocytes	   (Han	   et	   al.	   2013),	   mediating	   the	   uptake	   of	  
substrates	  from	  the	  blood	  into	  liver	  and	  brain,	  and	  from	  the	  lumen	  of	  the	  intestine	  
and	   kidney	   into	   the	   blood.	   SLC22A2	  mRNA	   is	  most	   significantly	   detectable	   in	   the	  
kidney	  but	  also	  present	  in	  the	  brain,	  intestine	  and	  other	  tissues	  (Nies	  et	  al.	  2011b).	  
The	  protein	  is	  localised	  in	  the	  basolateral	  membrane	  of	  renal	  tubule	  epithelial	  cells	  
(Motohashi	  et	  al.	  2002)	  and	  the	  apical	  membrane	  of	  brain	  endothelial	  cells	  (Lin	  et	  
al.	  2010),	  mediating	  the	  uptake	  of	  substrates	   from	  the	  blood.	  SLC22A3	   transcripts	  
are	   detectable	   in	   various	   tissues	   including	   the	   liver,	   kidney,	   brain,	   and	   intestine	  
(Nies	   et	   al.	   2011b).	   As	   for	   SLC22A1,	   the	   SLC22A3	   protein	   is	   expressed	   at	   the	  
basolateral	  (sinusoidal)	  membrane	  of	  hepatocytes	  (Nies	  et	  al.	  2009)	  and	  the	  apical	  
membrane	  of	  enterocytes	  (Muller	  et	  al.	  2005).	  Protein	  expression	  has	  recently	  also	  
been	   shown	   in	   isolated	   human	   brain	  microvessels	   but	   the	   subcellular	   localisation	  
remains	  to	  be	  determined	  (Geier	  et	  al.	  2013).	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SLC22A4	  (OCTN1),	  SLC22A5	  (OCTN2),	  and	  SLC22A16	  (OCT6)	  represent	  the	  
second	   subgroup	   of	   functionally	   characterised	   SLC22A	   transporters.	   The	   first	  
members,	  SLC22A4	  and	  SLC22A5,	  were	  cloned	  shortly	  after	  SLC22A1	   in	  1997/1998	  
and	   the	   proteins	   named	   OCTN1/OCTN2	   due	   to	   a	   unique	   nucleotide	   binding	  
sequence	  motif	  that	  is	  not	  present	  in	  the	  other	  OCTs	  (Tamai	  et	  al.	  1998,	  Tamai	  et	  al.	  
1997).	   Transporters	   within	   this	   group	   principally	   mediate	   the	   bi-­‐directional	  
membrane	   translocation	   of	   organic	   cations	   and	   zwitterions	   (Koepsell	   2013).	   For	  
some	   substrates	   and	   transporters,	   a	  Na+-­‐or	  H+-­‐dependency	   suggests	   a	   secondary-­‐
active	   ion	   exchange	   as	   the	   driving-­‐force	   (Ohashi	   et	   al.	   1999,	   Tamai	   et	   al.	   1998,	  
Tamai	  et	  al.	  1997).	  
SLC22A4	  and	  SLC22A5	  are	  expressed	  at	  the	  mRNA	  level	  in	  brain,	  intestine,	  
and	  kidneys,	  but	  only	  SLC22A5	  mRNA	  was	  detected	  in	  the	  adult	  liver	  (Koepsell	  2013,	  
Meier	   et	   al.	   2007,	   Tamai	   et	   al.	   1998,	   Tamai	   et	   al.	   1997).	   SLC22A16	   mRNA	   was	  
predominantly	   found	   in	  the	  testis	  but	  not	  detected	   in	  brain,	   liver,	  kidney,	  and	  the	  
small	  intestine	  (Enomoto	  et	  al.	  2002b,	  Gong	  et	  al.	  2002).	  
SLC22A6-­‐9	   and	   SLC22A11-­‐13	   (OAT1-­‐3,	   OAT7,	   OAT4,	   URAT1,	   OAT10)	  
proteins	  belong	  to	  the	  third	  and	  largest	  subgroup	  of	  membrane	  transporters	  from	  
the	  SLC22A	  family.	  They	  mediate	  the	  transport	  of	  organic	  anions	  in	  either	  direction	  
and	   are	   particularly	   important	   in	   the	   first	   step	   of	   renal	   excretion	   (Rizwan	   et	   al.	  
2007).	   Most,	   if	   not	   all,	   are	   secondary-­‐active	   organic	   anion	   exchangers	   utilising	  
counter-­‐ions	   such	  as	  α-­‐ketoglutarate,	   lactate,	   and	  nicotinate	   (Rizwan	   et	  al.	   2007).	  
So	   far,	   all	   transporters	   have	   been	   functionally	   characterised	   (Koepsell	   2013),	  
although	  it	  remains	  unclear	  if	  any	  of	  them	  is	  involved	  in	  human	  BBB	  transport.	  
SLC22A11	  mRNA	  (coding	  OAT4)	  was	  abundantly	  present	  in	  the	  kidney	  but	  
not	  detectable	   in	  brain,	   liver,	   and	   the	   intestine	   (Burckhardt	   et	  al.	   2011).	  A	   similar	  
expression	  profile	  was	  observed	  for	  SLC22A12	   (coding	  URAT1)	  but	  with	  conflicting	  
data	   for	   the	   brain	   (Bleasby	   et	   al.	   2006,	   Burckhardt	   et	   al.	   2011,	   Nishimura	   et	   al.	  
2005).	  SLC22A9	   (coding	  OAT7)	  has	  been	  described	  as	  exclusively	  expressed	   in	   the	  
liver	  (Shin	  et	  al.	  2007).	  The	  remaining	  four	  transporters,	  SLC22A6-­‐8	  (coding	  OAT1-­‐3)	  
and	  SLC22A13	   (coding	  OAT10),	  were	  found	  to	  be	  strongly	  expressed	   in	  the	  kidney	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but	  mRNA	  was	  also	  detectable	   in	  the	  brain	  and	  other	  organs	  (Bleasby	  et	  al.	  2006,	  
Burckhardt	  et	  al.	  2011,	  Nishimura	  et	  al.	  2005).	  A	  quantitative	  absolute	  proteomics	  
study	   with	   isolated	   human	   brain	   microvessels	   has	   attempted	   to	   analyse	   the	  
expression	  of	  transporters	  from	  this	  group	  at	  the	  human	  BBB	  (Uchida	  et	  al.	  2011).	  
None	  of	  the	  transporters	  was	  above	  the	  limit	  of	  quantification.	  However,	  the	  same	  
negative	  results	  were	  obtained	  for	  the	  entire	  SLC22A	  family	  and	  all	  11	  human	  SLCO	  
(OATP)	  transporters	   (Uchida	  et	  al.	  2011).	  Therefore,	  caution	   is	  warranted	  as	  there	  
may	   be	   issues	  with	   the	   sensitivity	   of	   the	  method.	   In	   sharp	   contrast,	   recent	  work	  
that	   analysed	   the	   mRNA	   expression	   of	   most	   SLC	   transporters	   in	   isolated	   human	  
brain	  microvessels	  found	  the	  majority	  of	  the	  SLC22A	  genes	  to	  be	  expressed	  (Geier	  
et	  al.	  2013).	  While	  involvement	  at	  the	  BBB	  remains	  questionable,	  most	  transporters	  
from	  this	  group	  are	  highly	  expressed	   in	  the	  kidney	  where	  they	  mediate	   important	  
transport	   processes.	   SLC22A6-­‐8	   (OAT1-­‐3)	   have	   been	   localised	   to	   the	   basolateral	  
membrane	  and	  SLC22A11	  (OAT4),	  SLC22A12	  (URAT1),	  and	  SLC22A13	  (OAT10)	  to	  the	  
apical	  membrane	  of	  renal	  tubule	  epithelial	  cells	  (Burckhardt	  et	  al.	  2011).	  Together,	  
these	   transporters	   constitute	   a	   unit	   that	   is	   involved	   in	   organic	   anion	   transport	  
across	  the	  tubule	  epithelial	  barrier	  as	  the	  first	  step	  in	  renal	  excretion	  (Burckhardt	  et	  
al.	  2011).	  
1.2.1.4. SLC28	  and	  SLC29	  families	  
Genes	  assigned	   to	   families	  SLC28	   and	  SLC29	   encode	   the	   concentrative	  nucleoside	  
transporters	   (CNTs)	   and	   the	   equilibrative	   nucleoside	   transporters	   (ENTs),	  
respectively.	   SLC28	   consists	   of	   three	   human	   genes	   all	   assigned	   to	   subfamily	   A	  
(SLC28A1-­‐3).	   Similarly,	   a	   total	   of	   four	   genes	   belong	   to	   the	   SLC29	   subfamily	   A	  
(SLC29A1-­‐4).	   SLC28A1	   and	   SLC29A1	   were	   the	   first	   genes	   to	   be	   cloned	   and	   the	  
corresponding	  proteins	   functionally	  characterised	  from	  each	  family	   (Griffiths	  et	  al.	  
1997,	  Kwong	  et	  al.	  1988,	  Ritzel	  et	  al.	  1997).	  	  
CNTs	  act	  as	  secondary-­‐active	  symporters	  and	  mediate	  the	  cellular	  uptake	  
of	   substrates	   against	   their	   electrochemical	   gradients.	   For	   SLC28A1	   (CNT1)	   and	  
SLC28A2	   (CNT2),	   a	   co-­‐transport	   of	   Na+	   ions	   down	   their	   electrochemical	   gradient	  
with	   a	   1:1	   stoichiometry	   has	   been	   identified	   as	   the	   driving-­‐force	   for	   substrate	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translocation	   (Ritzel	   et	   al.	   1997,	   Ritzel	   et	   al.	   1998,	   Smith	   et	   al.	   2004,	   Smith	   et	   al.	  
2007).	   The	   driving-­‐force	   for	   SLC28A3	   (CNT3)	   substrate	   translocation	   is	   more	  
complex	  and	  varies	  between	  Na+	  co-­‐transport	  with	  a	  substrate/Na+	  stoichiometry	  of	  
1:2	   and	   H+	   co-­‐transport	   with	   a	   substrate/H+	   stoichiometry	   of	   1:1,	   or	   may	   be	   a	  
mixture	   (Ritzel	   et	   al.	   2001,	   Smith	   et	   al.	   2007,	   Smith	   et	   al.	   2005).	   Interestingly,	  
SLC28A3	   displays	   different	   transport	   characteristics	   depending	   on	   the	   co-­‐
transported	  cation	  (Smith	  et	  al.	  2005).	  
Currently,	  no	  X-­‐ray	  crystal	  structure	  is	  available	  for	  any	  human	  CNT,	  but	  a	  
prokaryotic	  homologue	  to	  SLC28A3	  from	  Vibrio	  cholerae	  (vcCNT)	  has	  recently	  been	  
published	   (39	   %	   sequence	   identity)	   and	   the	   transport	   mechanism	   described	  
(Johnson	  et	  al.	  2012).	  The	  transporter	  was	  found	  to	  form	  homo-­‐trimers	  with	  each	  
protomer	  consisting	  of	  eight	  TMHs,	  two	  re-­‐entrant	  hairpin	  structures	  arranged	  in	  an	  
opposite	  direction	  within	  the	  membrane,	  and	  three	   interfacial	  helices	  collateral	  to	  
the	  membrane	  (Johnson	  et	  al.	  2012).	  These	  components	  build	  two	  subdomains,	  an	  
outer	  scaffolding	  domain	  that	  is	  assumed	  to	  be	  important	  for	  the	  overall	  structure	  
of	   the	   transporter,	   and	   an	   inner	   transporter	   domain	   with	   conserved	   amino	   acid	  
residues	  that	  are	  important	  for	  substrate	  recognition	  and	  the	  transport	  process.	  The	  
transport	   domain	   contains	   two	   related	   elements	   arranged	   in	   a	   pseudo	   two-­‐fold	  
symmetry	  that	  is	  not	  obvious	  from	  the	  amino	  acid	  sequence.	  The	  substrate-­‐binding	  
pocket	   is	   located	   in	   the	   centre	  of	   this	   symmetric	  unit	   in	   a	  deep	   cleft	   close	   to	   the	  
hairpin	  structures	  on	  both	  sides.	  A	  TMH	  was	  identified	  as	  a	  critical	  component	  that	  
is	   forming	  a	  hydrophobic	  barrier	  and	  blocking	  substrate	  access	  to	  the	   intracellular	  
compartment.	   The	   authors	   proposed	   an	   alternate	   access	   transport	   mechanism	  
where	  a	   “rigid-­‐body	  motion”	  moves	   the	   substrate	  binding-­‐pocket	  across	   the	  TMH	  
barrier	   and	  exposes	   it	   to	   the	  opposite	   side	   (Johnson	   et	  al.	   2012).	  Whereas	   vcCNT	  
contains	  eight	  TMHs,	  the	  human	  CNTs	  have	  a	  topology	  of	  12	  TMHs	  as	  predicated	  by	  
TMHMM	   server	   version	   2.0	   (http://www.cbs.dtu.dk/services/TMHMM-­‐2.0).	  
Homology	   modelling	   with	   SLC28A2,	   however,	   suggested	   that	   the	   human	  
transporters	   exhibit	   the	   same	   principal	   structure	   and	   transport	   mechanism	   as	  
vcCNT	   and	   that	   the	   additional	   TMHs	   are	   not	   critically	   involved	   in	   the	   transport	  
process	  (Young	  et	  al.	  2013).	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Not	  much	  is	  known	  about	  the	  tissue	  expression	  of	  human	  CNTs.	  Initially,	  
SLC28A1	  and	  SLC28A2	  mRNA	  was	  detected	  in	  the	  intestine	  and	  kidney	  (Ritzel	  et	  al.	  
1998).	  In	  the	  liver,	  however,	  only	  SLC28A1	  mRNA	  was	  detectable	  and	  no	  data	  were	  
presented	  for	  the	  brain	  (Ritzel	  et	  al.	  1998).	  SLC28A3	  mRNA	  expression,	  in	  contrast,	  
was	  studied	  in	  more	  detail	  and	  found	  in	  different	  brain	  regions,	  the	  intestine,	  liver,	  
and	  kidney	  (Ritzel	  et	  al.	  2001).	  Subsequent	  studies	  analysing	  the	  gene	  expression	  of	  
various	   SLC	   and	  ABC	   transporters	   in	   different	   human	   tissues	   reported	   conflicting	  
results	   and	   a	   quantitative	   absolute	   proteomics	   study	   with	   isolated	   human	   brain	  
microvessels	  failed	  to	  find	  any	  proteins	  expressed	  above	  the	  limit	  of	  quantification	  
(see	  1.2.1.3	  for	  discussion)	  (Bleasby	  et	  al.	  2006,	  Nishimura	  et	  al.	  2005,	  Uchida	  et	  al.	  
2011).	   Immunofluorescence	   studies	   reported	   a	   predominantly	   apical	   membrane	  
localisation	   for	  SLC28A1	   in	  enterocytes	  and	   renal	   tubule	  epithelial	   cells,	  while	   the	  
transporter	   was	   mainly	   expressed	   at	   the	   basolateral	   (sinusoidal)	   membrane	   of	  
hepatocytes	   (Govindarajan	   et	   al.	   2007,	   Govindarajan	   et	   al.	   2008).	   SLC28A2	   was	  
expressed	   on	   both	   sides	   of	   the	   membrane	   in	   hepatocytes	   and	   renal	   tubule	  
epithelial	   cells	   but	   predominantly	   in	   the	   apical	   membrane	   of	   enterocytes	  
(Govindarajan	  et	  al.	  2007,	  Govindarajan	  et	  al.	  2008).	  SLC28A3	  was	   localised	   in	  the	  
apical	   membrane	   of	   renal	   tubule	   epithelial	   cells	   (Damaraju	   et	   al.	   2007).	  
Interestingly,	   an	   alternative	   splice-­‐variant	   lacking	   the	   first	   N-­‐terminal	   69	   amino	  
acids	  (CNT3ins)	  was	  found	  to	  be	  retained	  within	  the	  endoplasmic	  reticulum	  where	  it	  
showed	  typical	  transporter	  function	  (Errasti-­‐Murugarren	  et	  al.	  2009).	  
SLC29A1	  (ENT1)	  and	  SLC29A2	  (ENT2)	  are	  passive	   facilitative	   transporters	  
and	   substrates	   are	   translocated	   down	   their	   electrochemical	   gradient	   in	   both	  
directions	  (Young	  et	  al.	  2013).	  In	  contrast,	  SLC29A3	  (ENT3)	  was	  found	  to	  display	  pH-­‐
dependency	  with	  a	  maximum	  activity	  at	  pH	  5.5	  and	  no	  activity	  at	  pH	  8.0	  or	  higher	  
(Baldwin	   et	   al.	   2005).	   Correspondingly,	   SLC29A3	   is	   predominantly	   localised	   to	  
intracellular	   compartments,	   probably	  mitochondria	   and/or	   lysosomes	   (Baldwin	   et	  
al.	   2005,	   Govindarajan	   et	   al.	   2009).	   The	   last	   member	   of	   this	   subfamily,	   SLC29A4	  
(ENT4),	   is	   also	   known	   as	   a	   pH-­‐dependent	   and	   membrane-­‐potential	   sensitive	  
transporter	   (Barnes	   et	   al.	   2006,	   Itagaki	   et	   al.	   2012).	   In	   contrast	   to	   SLC29A3,	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however,	   SLC29A4	   is	   expressed	   predominantly	   at	   the	   plasma	  membrane	   of	   cells	  
(Engel	  et	  al.	  2004).	  
As	   for	   the	  CNTs,	  no	  X-­‐ray	   crystal	   structure	  has	   yet	  been	  determined	   for	  
ENT	   transporters.	   In	   addition,	   no	   structure	   from	   a	   homologue	   prokaryotic	  
transporter	   is	   currently	   available	   but	   based	   on	   site-­‐directed	   mutagenesis	  
experiments,	  structural	  similarities	  to	  LacY	  (1.2.1.3)	  have	  been	  proposed	  (Parkinson	  
et	   al.	   2011).	   The	   predicted	   number	   of	   ENT	   TMHs	   is	   10-­‐11	   as	   determined	   by	  
TMHMM	  server	  version	  2.0	  (http://www.cbs.dtu.dk/services/TMHMM-­‐2.0).	  
On	   the	   mRNA	   level,	   all	   SLC29A	   genes	   are	   widely	   expressed	   in	   various	  
human	   tissues,	   including	   the	   brain,	   liver,	   kidney,	   and	   intestine	   (Anderson	   et	   al.	  
1999,	   Bleasby	   et	   al.	   2006,	   Crawford	   et	   al.	   1998,	   Engel	   et	   al.	   2004,	   Jennings	   et	   al.	  
2001,	   Nishimura	   et	   al.	   2005).	   Proteomic	   analysis	   of	   isolated	   human	   brain	  
microvessels	  showed	  SLC29A1	  to	  be	  the	  only	  protein	  expressed	  above	  the	   limit	  of	  
quantification	  (Uchida	  et	  al.	  2011).	  Immunofluorescence	  studies	  with	  SLC29A1	  and	  
SLC29A2	   indicated	  a	  predominantly	  basolateral	   (sinusoidal	  membrane)	   expression	  
in	  hepatocytes	  and	  both	  sides	  of	  the	  membrane	  in	  enterocytes	  (Govindarajan	  et	  al.	  
2007,	  Govindarajan	  et	  al.	  2008).	  In	  addition,	  SLC29A1	  was	  predominantly	  detected	  
in	   either	   the	   apical	   or	   the	   basolateral	   membrane	   of	   renal	   tubule	   epithelial	   cells,	  
depending	  on	   the	  exact	   tubular	   region	   (Damaraju	   et	   al.	   2007,	  Govindarajan	   et	   al.	  
2007).	  
As	  indicated	  by	  the	  protein	  names,	  CNT	  and	  ENT	  transporters	  mediate	  the	  
transport	   of	   pyrimidine	   and	   purine	   nucleosides	   across	   biological	   barriers	   with	  
distinct	   transport	   and	   inhibitor	   characteristics	   (Parkinson	   et	  al.	   2011).	   In	   addition,	  
some	  ENT	  transporters,	  but	  not	  CNTs,	  can	  also	  translocate	  nucleobases	  (Young	  et	  al.	  
2013).	   Due	   to	   their	   hydrophilic	   nature,	   nucleosides	   and	   derivatives	   rely	   on	  
membrane	  transporters	  to	  cross	  biological	  barriers	  and	  to	  enter/exit	  cells.	  CNT	  and	  
ENT	  transporters	  are	  key	  components	  in	  this	  essential	  process	  (Young	  et	  al.	  2013).	  
SLC29A4	   is	   an	   exception,	   as	   this	   transporter	   only	   recognises	   the	   nucleoside	  
adenosine	   at	   acidic	   pH	   (Barnes	   et	   al.	   2006,	   Engel	   et	   al.	   2004).	   Instead,	   SLC29A4	  
displays	   similar	   substrate	   and	   inhibitor	   characteristics	   as	   the	   organic	   cation	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transporters	   (1.2.1.3)	   (Engel	   et	   al.	   2005).	   Corresponding	   to	   their	   physiological	  
function,	  several	  CNT	  and	  ENT	  transporters	  have	  been	  characterised	  as	  nucleoside	  
drug	  transporters	  interacting	  with	  many	  antiviral	  and	  anticancer	  drugs	  (Parkinson	  et	  
al.	   2011).	   For	   example,	   the	   guanosine	   analogue	   ribavirin,	   indicated	   for	   the	  
treatment	  of	  hepatitis	  C,	  has	  been	  identified	  as	  a	  substrate	  for	  SLC28A2,	  SLC28A3,	  
SLC29A1,	  and	  SLC29A2	  (Yamamoto	  et	  al.	  2007).	  
	  
	  
Figure	  1.4:	  Subcellular	  localisation	  of	  selected	  SLC	  transporters	  at	  the	  blood-­‐brain	  barrier	  
Selected	  human	  SLC	  transporters	  at	  the	  blood-­‐brain	  barrier	  as	  introduced	  in	  this	  thesis	  chapter	  with	  
confirmed	  subcellular	  localisation	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1.2.2. ATP-­‐binding	  cassette	  transporters	  
The	   family	   of	   ABC	   transporter	   genes	   currently	   comprises	   48	   genes	   (excluding	  
pseudogenes).	   The	   official	   list	   is	   available	   on	   the	   HGNC	   website	  
(http://www.genenames.org/genefamilies/ABC).	   The	  ABC	   family	   is	   further	   divided	  
into	  seven	  subfamilies	  with	  designated	  letters	  A-­‐G	  and	  each	  gene	  assigned	  a	  unique	  
number	  following	  the	  family	  root	  ABC	  and	  the	  subfamily	  letter,	  e.g.	  ABCB1	  (1.2.2.1).	  
All	   ABC	   transporters,	   corresponding	   to	   their	   name,	   are	   characterised	   by	   the	  
presence	  of	   two	  ATP-­‐binding	   cassettes,	   also	   referred	   to	  as	   the	  nucleotide-­‐binding	  
domains	   (NBDs).	  NBDs	  bind	  to	  ATP	  and	  the	  energy	  derived	   from	  ATP	  hydrolysis	   is	  
utilised	   as	   the	   driving-­‐force	   for	   active	   substrate	   translocation	   against	   an	  
electrochemical	  gradient.	  NBDs	  typically	  consist	  of	  two	  highly	  conserved	  nucleotide-­‐
binding	   motifs	   referred	   to	   as	   Walker	   A	   and	   Walker	   B,	   linked	   by	   another	   highly	  
conserved	  motif,	  the	  ABC	  Signature	  or	  C	  motif	  (Dean	  et	  al.	  2001,	  Hyde	  et	  al.	  1990,	  
Walker	  et	  al.	  1982).	  In	  addition	  to	  the	  NBDs,	  ABC	  transporters	  further	  comprise	  two	  
transmembrane	   domains	   (TMDs)	   with	   varying	   numbers	   of	   TMHs	   (Deeley	   et	   al.	  
2006).	  While	   a	   functional	   transporter	   consists	   of	   the	   core	   structure	   of	   two	   TMDs	  
and	  two	  NBDs,	  the	  corresponding	  gene	  may	  only	  encode	  for	  a	  half-­‐transporter	  with	  
one	  TMD	  and	  one	  NBD	  and	  subsequent	  homo-­‐dimerisation	  or	  hetero-­‐dimerisation	  
at	  the	  protein	  level	  (Dean	  et	  al.	  2001,	  Hyde	  et	  al.	  1990).	  
Functionally,	   ABC	   transporters	   are	   involved	   in	   the	   unidirectional,	   active	  
extrusion	   of	   xenobiotics	   and	   endogenous	   substances,	   such	   as	  metabolic	   products	  
and	   lipids,	   and	   thus	   important	   cell	   detoxification	   systems	   (Fletcher	   et	   al.	   2010).	  
Along	  with	   this	   function,	  many	  ABC	  transporters	  are	  recognised	  as	  mediators	  of	  a	  
multidrug-­‐resistance	   phenotype,	   particularly	   for	   cytotoxic	   anticancer	   drugs.	  Many	  
drugs,	   including	  anticancer	  drugs,	  have	  been	  characterised	  as	  being	  substrates	   for	  
ABC	   transporters.	   Some	  of	   the	  most	   important	  ABC	   transporters	  and	  examples	  of	  




The	  ABCB1	  gene	  was	  the	  first	  member	  of	  the	  ABCB	  subfamily	  of	  efflux	  transporter	  
genes	   to	  be	  described	  and	   is	   the	  best-­‐characterised	   transporter	  of	   the	  entire	  ABC	  
family.	   The	   ABCB1	   protein	   is	   also	   referred	   to	   as	   multidrug	   resistance	   protein	   1	  
(MDR1)	  or	  P-­‐glycoprotein	  (Pgp).	  It	  was	  initially	  described	  in	  1976	  as	  a	  glycoprotein	  
expressed	  at	  the	  surface	  of	  drug	  resistant	  Chinese	  hamster	  ovary	  cells	  (Juliano	  et	  al.	  
1976).	   It	   took	  another	  10	  years	  before	  the	  gene	  was	  subsequently	  cloned	  and	  the	  
sequence	  obtained	  (Chen	  et	  al.	  1986).	  ABCB1	  has	  been	  studied	  for	  decades	  and	  is	  
one	   of	   the	   main	   drug	   efflux	   transporters	   that	   is	   critically	   involved	   in	   the	  
bioavailability	   of	   a	   large	   number	   of	   drugs	   (Borst	   et	   al.	   2013).	   This	   function	   turns	  
ABCB1	  into	  a	  double-­‐edged	  sword	  with	  a	  tissue-­‐protecting	  effect	  on	  the	  one	  hand	  
and	   a	   mediator	   for	   drug	   resistance	   on	   the	   other,	   particularly	   for	   many	   highly	  
cytotoxic	  anticancer	  agents	  (Gottesman	  et	  al.	  2002).	  
In	   2009,	   a	   high-­‐resolution	   X-­‐ray	   crystal	   structure	   of	  mouse	   Abcb1a	  was	  
published.	  It	  displays	  87	  %	  sequence	  identity	  with	  human	  ABCB1	  and	  confirms	  the	  
basic	   structural	   assumptions	   that	   have	   been	   made	   before	   (Aller	   et	   al.	   2009).	  
Because	  all	  ABC	  transporters	  have	  the	  same	  basic	  core	  structure	  of	  two	  TMDs	  and	  
two	  NBDs,	   the	  mechanistic	   insights	   gained	   from	   this	   crystal	   structure	   are	   of	   high	  
value	   for	   the	   whole	   family.	   Abcb1a	   was	   crystallised	   in	   the	   inward-­‐facing	  
confirmation	  (Figure	  1.5)	  and	  the	  two	  TMDs	  display	  a	  pseudo	  two-­‐fold	  symmetry	  to	  
each	   other	   forming	   a	   large	   portal	   with	   many	   hydrophobic	   amino	   acid	   residues	  
localised	   in	   the	   membrane,	   the	   assumed	   substrate	   binding-­‐pocket	   (Aller	   et	   al.	  
2009).	   Consistent	   with	   the	   predicted	   ABCB1	   topology,	   each	   domain	   displays	   a	  
bundle	  of	  six	  TMHs	  (Aller	  et	  al.	  2009).	  Mechanistically,	  the	  inward-­‐facing	  structure	  
does	  not	  allow	  substrates	  to	  access	  the	  binding-­‐pocket	   from	  the	  outer	  membrane	  
layer	  or	  the	  extracellular	  space.	  Instead,	  it	  has	  been	  suggested	  that	  substrates	  enter	  
the	  binding-­‐pocket	  from	  within	  the	  inner	  membrane	  layer,	  which	  further	  stimulates	  
ATP	  binding	  to	  the	  NBDs	  and	   is	   followed	  by	  a	  conformational	  change	  of	  ABCB1	  to	  
the	  outward-­‐facing	  state	  (Aller	  et	  al.	  2009).	  ATP	  hydrolysis	  has	  been	  suggested	  to	  be	  
a	   likely	   mechanism	   to	   disrupt	   the	   dimerisation	   of	   both	   NBDs,	   and	   to	   allow	   the	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transporter	   to	   flip	   back	   into	   the	   inward-­‐facing	   confirmation	   (Aller	   et	   al.	   2009,	  
Tombline	  et	  al.	  2005).	  
	  
	  
Figure	  1.5:	  Crystal	  structure	  of	  mouse	  Abcb1a	  
Cartoon	   ribbon	   models	   derived	   from	   the	   mouse	   Abcb1a	   crystal	   structure	   in	   the	   inward-­‐facing	  
conformation;	   A)	   Hydrophobicity	   model	   with	   green	   indicating	   hydrophobic	   amino	   acid	   residues;	  
B)	  Segment	  model	  indicating	  the	  N-­‐terminal	  half	  of	  the	  protein	  (grey)	  and	  the	  C-­‐terminal	  half	  (blue),	  
respectively.	   Each	   half	   consists	   of	   the	   typical	   ABC	   transporter	   core	   structure	   of	   one	   nucleotide-­‐
binding	   domain	   (NBD)	   and	   one	   transmembrane	   domain;	   Models	   derived	   from	   MacPyMOL	   1.3	  
(www.pymol.org)	  based	  on	  Aller	  et	  al.,	  2009	  
ABCB1	   is	   expressed	   in	   many	   human	   tissues,	   including	   barriers	   such	   as	  
brain	   endothelial	   cells,	   intestinal	   epithelial	   cells,	   kidney	   epithelial	   cells,	   and	  
hepatocytes,	  all	  of	  which	  display	  an	  apical	  membrane	  localisation	  of	  the	  transporter	  
consistent	  with	   its	   role	   in	   the	   efflux/elimination	   of	   substrates	   (Cascorbi	   2011).	   In	  
accordance	  with	   the	   proposed	  mechanism	   of	   ABCB1	   transport,	   ABCB1	   substrates	  
are	   usually	   hydrophobic	  molecules	   (Giacomini	   et	   al.	   2010),	   and	   the	   analysis	   of	   a	  
diverse	   set	  of	   known	  ABCB1	   substrates	   further	   indicated	   that	   substrate-­‐binding	   is	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positively	  associated	  with	  the	  total	  hydrogen-­‐bond	  acceptor	  strength	  (Seelig	  1998).	  
Examples	   of	   ABCB1	   substrates	   include	   the	   anticancer	   drugs	   doxorubicin	   and	  
paclitaxel,	   the	   cardiac	   drug	   digoxin,	   and	   the	   antihistamine	   fexofenadine	   (Cascorbi	  
2011,	  Giacomini	  et	  al.	  2010).	  
The	   ABCB1	   gene	   is	   located	   on	   chromosome	   7.	   Numerous	   studies	  
investigated	  the	  effect	  of	  ABCB1	  genetic	  variants	  on	  drug	  response.	  In	  epilepsy,	  an	  
association	  between	   impaired	   treatment	   response	   to	   different	   antiepileptic	   drugs	  
(AEDs)	   and	   the	   synonymous	   polymorphism	   c.3435C>T	   (rs1045642)	   was	   reported	  
(Siddiqui	  et	  al.	  2003).	  Several	  subsequent	  studies,	  however,	  failed	  to	  confirm	  these	  
results	   and	   its	   likely	   role	   in	   determining	   AED	   efficacy	   remains	   controversial	  
(Leschziner	  et	  al.	  2006,	  Leschziner	  et	  al.	  2007,	  Sills	  et	  al.	  2005).	  
1.2.2.2. ABCC	  subfamily	  
Twelve	   genes	   (excluding	   one	   pseudogene)	   are	   assigned	   to	   the	  ABCC	   subfamily	   of	  
membrane	   transporters	   designated	   as	   ABCC1-­‐ABCC12.	   Based	   on	   their	   functional	  
roles,	   the	   encoded	   proteins	   are	   further	   divided	   into	   three	   classes,	   namely	   the	  
multidrug-­‐resistance	  associated	  proteins	  (MRPs),	  the	  sulfonylurea	  receptors	  (SURs),	  
and	  the	  cystic	  fibrosis	  transmembrane	  conductance	  regulator	  (CFTR).	  ABCC1-­‐ABCC6	  
and	  ABCC10-­‐ABCC12	  encode	  MRP1-­‐9	  while	  ABCC7	  encodes	  CFTR	  and	  ABCC8-­‐9	   the	  
SUR	   proteins,	   respectively.	   MRP	   transporters,	   as	   a	   general	   rule,	   translocate	  
amphiphilic	   organic	   anions	   while	   CFTR	   and	   the	   SUR	   proteins	   are	   involved	   in	  
inorganic	  ion	  transport	  and	  regulation	  (Bryan	  et	  al.	  2007,	  Egan	  et	  al.	  1992,	  Keppler	  
2011).	   Depending	   on	   the	   specific	   substrate	   and	   transporter,	   the	   transport	  
mechanism	   of	  MRPs	   can	   be	   either	   GSH-­‐independent	   or	   GSH-­‐dependent	   and	  GSH	  
may	  either	  be	  co-­‐transported	  with	  the	  substrate	  or	  it	  may	  act	  as	  a	  stimulant	  (Cole	  
2013).	  
Besides	   the	   core	   structure	   of	   two	   TMDs	   and	   two	   NBDs,	   many	   ABCC	  
proteins	  have	  a	  predicted	  third,	  N-­‐terminal	  TMD	  that	  is	  possibly	  involved	  in	  protein	  
dimerisation	  and/or	  membrane	  trafficking	  (Deeley	  et	  al.	  2006,	  Westlake	  et	  al.	  2005,	  
Yang	   et	   al.	   2010).	   The	   predicated	  ABCC	  protein	   core	   structures	   and	   examples	   for	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selected	   important	   endogenous	   and	   exogenous	   substrates	   are	   summarised	   in	  
Table	  1.2.	  
















E217βG,	  LTC4,	  MGB	  
Vincristine	  
(Jedlitschky	  et	  al.	  1996,	  
Jedlitschky	  et	  al.	  1994,	  Leier	  et	  
al.	  1994,	  Loe	  et	  al.	  1996,	  Loe	  et	  
al.	  1998,	  Rigato	  et	  al.	  2004,	  









(Cui	  et	  al.	  1999,	  Deeley	  et	  al.	  
2006,	  Kamisako	  et	  al.	  1999,	  








(Deeley	  et	  al.	  2006,	  Lee	  et	  al.	  






LTC4,	  PGE1,	  PGE2,	  	  
MTX,	  Tenofovir	  
(Chen	  et	  al.	  2001,	  Deeley	  et	  al.	  
2006,	   Imaoka	   et	   al.	   2007,	   Reid	  
et	   al.	   2003,	   Rius	   et	   al.	   2008,	  











(Deeley	   et	  al.	   2006,	   Jedlitschky	  
et	   al.	   2000,	   Pratt	   et	   al.	   2005,	  
Wielinga	   et	   al.	   2005,	   Wielinga	  








(Belinsky	  et	  al.	  2002,	  Deeley	  et	  
al.	  2006,	  Ilias	  et	  al.	  2002)	  
ABCC7	  
(CFTR)	  
No	   Cl-­‐	   -­‐	  




No	   -­‐	   -­‐	  

















No	   -­‐	   -­‐	  




Yes	   E217βG,	  LTC4	  	  
Paclitaxel,	  
Tenofovir	  
(Chen	   et	   al.	   2003a,	   Hopper-­‐
Borge	   et	   al.	   2004,	   Kruh	   et	   al.	  










(Chen	   et	   al.	   2005,	   Guo	   et	   al.	  




No	   -­‐	   -­‐	  
(Keppler	   2011,	   Kruh	   et	   al.	  
2007)	  
BGB	  =	  Bisglucuronosyl	  bilirubin,	  cAMP	  =	  Cyclic	  adenosine	  monophosphate,	  cGMP	  =	  Cyclic	  guanosine	  
monophosphate,	  E217βG	  =	  Estradiol-­‐17β-­‐D-­‐glucuronide,	  5-­‐FU	  =	  5-­‐Fluorouracil,	  LTC4	  =	  Leukotriene	  C4,	  
MGB	  =	  Monoglucuronosyl	  bilirubin,	  MTX	  =	  Methotrexate	  
ABCC1	   was	   the	   first	   human	   gene	   cloned	   and	   functionally	   characterised	  
from	   the	   ABCC	   subfamily	   in	   1992	   and	   1994,	   respectively	   (Cole	   et	   al.	   1994,	  
Jedlitschky	   et	   al.	   1994,	   Leier	   et	   al.	   1994).	   In	   the	   initial	   study,	   ABCC1	   mRNA	   was	  
detectable	  in	  several	  human	  tissues	  including	  the	  lung	  and	  testis	  but	  not	  the	  brain,	  
kidneys,	   and	   liver	   (Cole	   et	   al.	   1992).	   Subsequent	   studies,	   however,	   reported	  
different	  results	  and	  detected	  ABCC1	  mRNA	  or	  the	  corresponding	  protein	   in	  many	  
human	  tissues	  including	  the	  brain,	  kidneys,	  liver,	  and	  intestine	  (Bleasby	  et	  al.	  2006,	  
Flens	   et	   al.	   1996,	   Nies	   et	   al.	   2004,	   Nishimura	   et	   al.	   2005).	   Proteomic	   analysis	   of	  
isolated	  human	  brain	  microvessels	   (see	  1.2.1.3)	   failed	  to	  detect	  the	  protein	  above	  
the	   limit	   of	   quantification,	   but	   an	   immunolocalisation	   study	   reported	   weak	   BBB	  
expression	   in	   the	   apical	   membrane	   (Nies	   et	   al.	   2004,	   Uchida	   et	   al.	   2011).	   In	  
addition,	   other	   studies	   also	   confirmed	  mRNA	   expression	   in	   isolated	   human	   brain	  
microvessels	  (Geier	  et	  al.	  2013,	  Warren	  et	  al.	  2009).	  
Human	   and	   rat	   ABCC2	  were	   first	   cloned	   in	   1996	   (Buchler	   et	   al.	   1996,	  
Paulusma	   et	   al.	   1996,	   Taniguchi	   et	   al.	   1996)	   following	   extensive	   functional	   work	  
with	  different	  rat	  mutant	  strains	  that	  displayed	  a	  hepatocellular	  apical	  (canalicular)	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transport	   defect	   resulting	   in	   conjugated	   hyperbilirubinemia	   (Jemnitz	   et	   al.	   2010,	  
Nies	   et	   al.	   2007).	   The	   first	   rat	   strain,	   referred	   to	   as	   transport-­‐deficient	   rat	   strain	  	  
(TR-­‐),	  was	  described	  in	  1985.	  The	  authors	  noted	  that	  the	  phenotype	  was	  similar	  to	  
that	  seen	  with	  Dubin-­‐Johnson	  syndrome,	  a	  disease	  also	  characterised	  by	  conjugated	  
hyperbilirubinema	  (Dubin	  et	  al.	  1954,	  Jansen	  et	  al.	  1985).	  These	  observations	  were	  
later	  confirmed	  to	  be	  a	  direct	  result	  of	  mutations	  in	  the	  ABCC2	  gene	  with	  impaired	  
ABCC2	  (MRP2)	  transport	  of	  conjugated	  bilirubin	  from	  the	  hepatocytes	  into	  the	  bile	  
(Buchler	  et	  al.	  1996,	  Paulusma	  et	  al.	  1996,	  Paulusma	  et	  al.	  1997).	  ABCC2	   is	  now	  a	  
well-­‐characterised	   transporter	  with	   a	   dominant	   function	   in	   the	   hepatic	   and	   renal	  
excretion	   of	   conjugated	   substrates.	   The	   expression	   of	   ABCC2	   mRNA	   and	   ABCC2	  
protein	  is	  particularly	  strong	  in	  liver	  and	  kidney,	  but	  also	  detectable	  in	  the	  intestine.	  
In	   the	  brain,	  however,	  no	  significant	  expression	  has	  been	  observed	   (Bleasby	  et	  al.	  
2006,	  Geier	  et	  al.	  2013,	  Nies	  et	  al.	  2004,	  Sandusky	  et	  al.	  2002,	  Taniguchi	  et	  al.	  1996,	  
Uchida	   et	   al.	   2011,	   Warren	   et	   al.	   2009).	   The	   ABCC2	   protein	   principally	   displays	  
apical	  membrane	   localisation	   in	  hepatocytes	   (canalicular	  membrane),	   renal	   tubule	  
epithelial	  cells,	  and	  enterocytes	  (Fromm	  et	  al.	  2000,	  Paulusma	  et	  al.	  1997,	  Schaub	  et	  
al.	   1999).	   Although	   membrane	   localisation	   and	   amino	   acid	   sequence	   differs	  
considerably	  from	  ABCC1	  (MRP1),	  the	  substrate	  specificity	  seems	  to	  be	  quite	  similar	  
(see	  Table	  1.2).	  
ABCC3	   gene	   expression	   is	   similar	   to	   that	   of	  ABCC2	   and	  mRNA	  has	   been	  
detected	   in	   liver,	   kidney,	   and	   intestine,	   but	   there	   is	   only	   borderline	   expression	   in	  
the	  brain	  (Bleasby	  et	  al.	  2006,	  Kiuchi	  et	  al.	  1998,	  Konig	  et	  al.	  1999,	  Kool	  et	  al.	  1997,	  
Nies	  et	  al.	  2004).	   In	  studies	  utilising	  isolated	  human	  brain	  microvessels,	  conflicting	  
results	  have	  been	  reported	  with	  mRNA	  detectable	  in	  two	  studies	  but	  no	  protein	  in	  
the	  quantitative	  proteomic	  study	  (Geier	  et	  al.	  2013,	  Uchida	  et	  al.	  2011,	  Warren	  et	  
al.	  2009).	  Membrane	   localisation	  of	   the	  ABCC3	   (MRP3)	  protein	   is	  opposed	  to	   that	  
seen	  with	   ABCC2	   in	   the	   basolateral	  membranes	   of	   hepatocytes	   and	   renal	   tubule	  
epithelial	  cells,	  respectively	  (Konig	  et	  al.	  1999,	  Scheffer	  et	  al.	  2002b).	  Interestingly,	  
in	  patients	  with	  Dubin-­‐Johnson	  syndrome	  hepatic	  up-­‐regulation	  of	  ABCC3	  seems	  to	  
compensate	   for	   impaired	   ABCC2	   transport	   into	   the	   bile	   duct,	   and	  might	   act	   as	   a	  
protective	  mechanism	  to	  avoid	   liver	   toxicity	   (Konig	  et	  al.	  1999).	  Because	  ABCC3	   is	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localised	   to	   the	   basolateral	   rather	   than	   the	   apical	   membrane,	   ABCC3-­‐mediated	  
hepatic	  elimination	  of	  bilirubin	  conjugates	  is	  facilitated	  into	  the	  blood	  and	  provides	  
an	  explanation	  for	  the	  observed	  phenotype.	  ABCC3	  has	  also	  been	  suggested	  to	  play	  
an	   important	   role	   in	   bile	   acid	   transport,	   particularly	   in	   the	   intestine	   and	   liver	  
(Deeley	  et	  al.	  2006).	  
Tissue	  expression	  of	  ABCC4	  mRNA	  has	   consistently	  been	   reported	   to	  be	  
relatively	  strong	  in	  the	  intestine	  but	  conflicting	  results	  have	  been	  obtained	  for	  the	  
liver,	  kidneys,	  and	  brain.	  Expression	  in	  these	  tissues	  was	  either	  relatively	  low	  or	  not	  
detectable,	  depending	  on	  the	  study	  (Bleasby	  et	  al.	  2006,	  Kool	  et	  al.	  1997,	  Lee	  et	  al.	  
1998,	  Nies	  et	  al.	  2004,	  Nishimura	  et	  al.	  2005).	  Immunolocalisation	  studies,	  however,	  
revealed	  basolateral	  membrane	  localisation	  in	  hepatocytes	  (sinusoidal	  membrane),	  
dominant	  apical	  expression	  in	  the	  colon-­‐derived	  tumour	  cell	   lines	  HT29-­‐CL19A	  and	  
T84,	  and	  an	  apical	  expression	   in	  brain	  endothelial	  cells	  and	  renal	   tubule	  epithelial	  
cells	  (Li	  et	  al.	  2007,	  Nies	  et	  al.	  2004,	  Rius	  et	  al.	  2003,	  van	  Aubel	  et	  al.	  2002).	  While	  
most	   ABC	   and	   SLC	   transporters	   were	   below	   the	   limit	   of	   quantification,	   ABCC4	  
(MRP4)	  was	  one	  of	  the	  few	  proteins	  found	  to	  be	  expressed	  in	  isolated	  human	  brain	  
microvessels	   (Uchida	   et	   al.	   2011).	   In	   agreement	  with	   these	   results,	  ABCC4	  mRNA	  
was	  also	  detectable	  in	  two	  other	  studies	  utilising	  isolated	  human	  brain	  microvessels	  
(Geier	  et	  al.	  2013,	  Warren	  et	  al.	  2009).	  ABCC4	  displays	  overlapping	  but	  also	  quite	  
distinct	   transport	   characteristics	   within	   the	   ABCC	   subfamily.	   It	   is	   particularly	  
involved	  in	  the	  translocation	  of	  cyclic	  nucleotides,	  prostaglandins,	  and	  bile	  acids.	  
ABCC5	  is	  widely	  expressed	  in	  many	  human	  tissues	  with	  high	  mRNA	  levels	  
in	   the	   brain	   and	   rather	   weak	  mRNA	   levels	   detectable	   in	   the	   liver	   (Bleasby	   et	   al.	  
2006,	   Kool	   et	   al.	   1997,	   McAleer	   et	   al.	   1999,	   Nishimura	   et	   al.	   2005).	   No	   protein	  
expression	  was	  found	  in	  isolated	  human	  brain	  microvessels	  (Uchida	  et	  al.	  2011),	  but	  
an	   immunolocalisation	   study	   revealed	   ABCC5	   (MRP5)	   protein	   expression	   on	   the	  
apical	  side	  of	  brain	  endothelial	  cells	  (Nies	  et	  al.	  2004).	  In	  addition,	  mRNA	  has	  been	  
detected	   in	   isolated	   human	   brain	   microvessels	   (Geier	   et	   al.	   2013,	   Warren	   et	   al.	  
2009).	   The	   substrate	   profile	   appears	   to	   have	   distinct	   overlaps	   with	   ABCC4,	  
particularly	  with	  regards	  to	  nucleotides	  (see	  Table	  1.2).	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At	   the	  mRNA	   level,	  ABCC6	   is	   strongly	   expressed	   in	   liver	   and	   kidney	   but	  
also	  detectable	   in	  the	   intestine.	  Brain	  expression,	  on	  the	  other	  hand,	  seems	  to	  be	  
absent	  or	  very	  weak	  with	  potential	  expression	  in	  neurons	  (Beck	  et	  al.	  2005,	  Bleasby	  
et	   al.	   2006,	   Kool	   et	   al.	   1999,	   Nies	   et	   al.	   2004,	   Nishimura	   et	   al.	   2005).	  
Immunolocalisation	  studies	  found	  the	  ABCC6	  (MRP6)	  protein	  to	  be	  expressed	  in	  the	  
basolateral	  membrane	   of	   renal	   tubule	   epithelial	   cells	   and	   hepatocytes	   (sinusoidal	  
membrane),	   but	   no	   BBB	   staining	   was	   observed	   (Nies	   et	   al.	   2004,	   Scheffer	   et	   al.	  
2002a).	   In	   studies	   with	   isolated	   human	   brain	   microvessels,	   ABCC6	   mRNA	   was	  
detectable	   in	   two	   studies	   while	   proteomic	   analysis	   failed	   to	   detect	   any	   ABCC6	  
protein	   (Geier	   et	   al.	   2013,	   Uchida	   et	   al.	   2011,	  Warren	   et	   al.	   2009).	   Interestingly,	  
mutations	   in	   the	   ABCC6	   gene	   have	   been	   linked	   to	   the	   heritable	   disease	  
pseudoxanthoma	   elasticum,	   a	   condition	   characterised	   by	   defects	   in	   connective	  
tissue	   with	   clinical	   manifestations	   in	   the	   cardiovascular	   system,	   skin,	   and	   eyes	  
(Bergen	  et	  al.	  2000,	  Ringpfeil	  et	  al.	  2000,	  Struk	  et	  al.	  2000).	  The	  pathophysiological	  
role	  of	  ABCC6	  is	  still	  unclear,	  but	  evidence	  suggests	  that	  impaired	  cellular	  excretion	  
of	   nucleoside	   triphosphates	   into	   the	   circulatory	   system	  might	   be	   involved	   in	   the	  
development	  of	  this	  metabolic	  disorder	  (Jansen	  et	  al.	  2013).	  
ABCC7	   (CFTR)	   is	   a	   cAMP-­‐dependent	   Cl-­‐	   channel	   and	   regulator	   of	   many	  
other	  transport	  proteins	  such	  as	  aquaporins	  (Guggino	  et	  al.	  2006).	  Mutations	  in	  the	  
ABCC7	  gene	  cause	  cystic	  fibrosis,	  a	  lethal	  disease	  characterised	  by	  abnormally	  thick	  
mucous	  due	  to	  impaired	  epithelial	  Cl-­‐	  transport	  (Riordan	  et	  al.	  1989,	  Rommens	  et	  al.	  
1989).	  ABCC8	  and	  ABCC9	  (SUR1	  and	  SUR2)	  proteins	  are	  involved	  in	  the	  regulation	  of	  
K+	  channels	  and	  form	  hetero-­‐octamers	  with	  four	  channel-­‐forming	  proteins	  from	  the	  
KIR6.x	   subfamily	   (Bryan	   et	   al.	   2007).	   These	   complexes	   are	   important	   regulators	  of	  
cell	   excitability	   and	   stabilise	   the	   membrane	   resting-­‐potential	   (Nichols	   2006).	  
Complexes	  with	  ABCC8	  are	  particularly	  recognised	  as	  being	  involved	  in	  the	  release	  
of	   insulin	   from	   pancreatic	   ß-­‐cells	   (Bryan	   et	   al.	   2007).	   Sulfonylureas	   are	   a	   class	   of	  
antidiabetic	  drugs	  that	  target	  ABCC8	  and	  thereby	  stimulate	  the	  release	  of	  insulin	  in	  
type	  2	  diabetes	  (Proks	  et	  al.	  2002).	  None	  of	  these	  three	  ABCC	  transporters	  has	  been	  
linked	  to	  drug	  transport	  so	  far.	  The	  predicted	  core	  structure	  of	  two	  TMDs	  and	  two	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NBDs,	  however,	  is	  the	  same	  as	  for	  the	  other	  ABCC	  (MRP)	  transporters	  (Deeley	  et	  al.	  
2006).	  
ABCC10	  mRNA	   is	  widely	  expressed	   in	  human	  tissues	   including	   the	  brain,	  
kidneys,	   liver,	  and	   intestine,	  but	   the	  protein	  membrane	   localisation	   is	  unknown	   in	  
these	  organs	  (Bleasby	  et	  al.	  2006,	  Hopper	  et	  al.	  2001,	  Nishimura	  et	  al.	  2005).	  Data	  
on	   BBB	   expression	   utilising	   isolated	   human	   brain	   microvessels	   are	   contradictory	  
(Geier	   et	   al.	   2013,	  Uchida	   et	   al.	   2011,	  Warren	   et	   al.	   2009).	   Interestingly,	   ABCC10	  
(MRP7)	   substrates	   include	   the	   HIV	   nucleotide	   analogue	   reverse	   transcriptase	  
inhibitor	  tenofovir	  (see	  Table	  1.2)	  and	  a	  genetic	  polymorphism	  in	  the	  ABCC10	  gene	  
has	   recently	   been	   associated	   with	   tenofovir-­‐induced	   kidney	   tubular	   dysfunction	  
(Pushpakom	  et	  al.	  2011).	  
ABCC11	  mRNA	  expression	  was	  studied	  by	  different	  groups	  using	  a	  panel	  
of	   human	   tissues.	   The	   results,	   however,	   were	   partially	   inconsistent.	   While	   liver	  
expression	  was	   confirmed	   in	   five	   out	   of	   five	   studies,	   expression	   in	   the	   brain	   and	  
intestine	  was	  reported	   in	   four	  out	  of	   five	  studies	  and	  expression	   in	   the	  kidneys	   in	  
three	  out	  of	   five	  studies	  (Bera	  et	  al.	  2001,	  Bleasby	  et	  al.	  2006,	  Martin	  et	  al.	  2010,	  
Nishimura	   et	   al.	   2005,	   Tammur	   et	   al.	   2001,	   Yabuuchi	   et	   al.	   2001).	   BBB	   protein	  
expression	  is	  below	  the	  limit	  of	  quantification	  (Uchida	  et	  al.	  2011).	  Very	  weak	  mRNA	  
expression	   has	   been	   reported	   by	   a	   different	   group	   (Warren	   et	   al.	   2009).	  
Interestingly,	   the	  non-­‐synonymous	  genetic	  polymorphism	  538G>A	  (rs17822931)	   in	  
the	  ABCC11	  gene	  seems	  to	  determine	  the	  human	  earwax	  type	  as	  either	  being	  wet	  
(GG	   or	   GA	   genotype)	   or	   dry	   (AA	   genotype)	   (Yoshiura	   et	   al.	   2006).	   The	   allele	  
frequency	   is	   highly	   population-­‐specific	   with	   the	   G	   allele	   being	   dominant	   in	  
Europeans	  and	  African	  Americans	  and	  the	  variant	  in	  Asian	  populations	  such	  as	  the	  
Japanese,	  Chinese,	  and	  Koreans	  (Yoshiura	  et	  al.	  2006).	   In	  addition	  to	  earwax	  type,	  
the	   same	   polymorphism	   has	   been	   associated	   with	   a	   lower	   frequency	   of	   axillary	  
osmidrosis	  in	  a	  Japanese	  study	  (Nakano	  et	  al.	  2009).	  A	  subsequent	  analytical	  study	  
confirmed	   that	   homozygotic	   carriers	   of	   the	   variant	   (AA	   genotype,	   dry-­‐earwax)	  
display	  an	  altered	  axillary	  sweat	  composition	  lacking	  certain	  amino	  acid	  conjugates	  
(Martin	  et	  al.	  2010).	  The	  authors	  speculated	  that	  these	  sweat	  compounds	  might	  be	  
substrates	  for	  ABCC11	  (MRP8)	  with	  impaired	  transport	  in	  the	  AA	  genotype.	  A	  strong	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selection-­‐pressure	   could	   have	   resulted	   in	   the	   dominant	   AA	   genotype	   observed	   in	  
Asians	   due	   to	   mating	   advantages	   for	   carriers	   of	   the	   AA	   genotype	   (Martin	   et	   al.	  
2010).	  
ABCC12	  mRNA	  expression	  studies	  have	  been	  contradictory,	  ranging	  from	  
strong	   expression	   to	   no	   expression	   (Bleasby	   et	   al.	   2006,	   Nishimura	   et	   al.	   2005,	  
Tammur	  et	  al.	  2001,	  Yabuuchi	  et	  al.	  2001).	  ABCC12	  (MRP9)	  BBB	  protein	  expression	  
is	  below	  the	  limit	  of	  quantification	  in	  isolated	  human	  brain	  microvessels	  (Uchida	  et	  
al.	  2011),	  but	  mRNA	  has	  been	  detected	  (Geier	  et	  al.	  2013).	  The	  transporter	  has	  so	  
far	  not	  been	  functionally	  characterised	  (Keppler	  2011,	  Kruh	  et	  al.	  2007).	  
1.2.2.3. ABCG2	  
ABCG2	  is	  the	  dominant	  gene	  associated	  with	  drug	  efflux	  and	  multidrug-­‐resistance	  in	  
the	   human	   ABCG	   subfamily.	   It	   was	   initially	   cloned	   by	   three	   research	   groups	   in	  
parallel	   from	   a	   drug-­‐resistant	   breast	   cancer	   cell	   line,	   a	   drug-­‐resistant	   colon	  
carcinoma	  cell	  line,	  and	  placenta	  (Allikmets	  et	  al.	  1998,	  Doyle	  et	  al.	  1998,	  Miyake	  et	  
al.	   1999).	   The	   protein	   is	   also	   commonly	   referred	   to	   as	   breast	   cancer	   resistance	  
protein	  (BCRP).	  
The	   mRNA	   expression	   profile	   has	   revealed	   that	   ABCG2	   is	   expressed	   in	  
many	  human	  organs	  including	  the	  brain,	   liver,	   intestine	  and	  kidneys,	  although	  two	  
of	   the	   original	   studies	   failed	   to	   detect	   mRNA	   in	   some	   of	   these	   organs	   using	  
Northern	  blotting	  (Allikmets	  et	  al.	  1998,	  Bleasby	  et	  al.	  2006,	  Doyle	  et	  al.	  1998,	  Huls	  
et	   al.	   2008,	   Nishimura	   et	   al.	   2005).	   ABCG2	   displays	   the	   same	   apical	   membrane	  
localisation	  as	  ABCB1	  (1.2.2.1),	  and	   immunolocalisation	  studies	  have	  confirmed	   its	  
presence	   in	   brain	   endothelial	   cells,	   renal	   tubule	   epithelial	   cells,	   hepatocytes	  
(canalicular	  membrane),	  and	  enterocytes	   (Aronica	   et	  al.	   2005,	  Cooray	   et	  al.	   2002,	  
Huls	   et	   al.	   2008,	   Maliepaard	   et	   al.	   2001).	   ABCG2	   has	   also	   been	   detected	   by	  
proteomic	  analysis	  (Uchida	  et	  al.	  2011).	  
Together	   with	   ABCB1,	   ABCG2	   is	   particularly	   recognised	   as	  mediator	   for	  
multidrug-­‐resistance	   in	   cancer	  with	   an	   overlapping	   and	   complementary	   substrate	  
profile	   to	   ABCB1	   (Fletcher	   et	   al.	   2010).	   Unlike	   ABCB1	   and	   the	   other	   ABC	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transporters	  discussed	  so	  far,	  the	  ABCG2	  gene	  only	  encodes	  for	  one	  NBD	  and	  one	  
TMD.	   Protein	   oligomerisation	   seems	   to	   be	   crucial	   to	   produce	   a	   functional	  
transporter	  (Xu	  et	  al.	  2004).	  Endogenous	  substrates	  of	  ABCG2	  include	  E217βG	  and	  
urate,	  while	  examples	  for	  exogenous	  substrates	  include	  rosuvastatin,	  the	  HIV	  NRTI	  
lamivudine,	  and	  the	  anticancer	  drug	  methotrexate	  including	  some	  polyglutamylated	  
metabolites	  (Chen	  et	  al.	  2003b,	  Huang	  et	  al.	  2006,	  Kim	  et	  al.	  2007,	  Woodward	  et	  al.	  
2009).	   Interestingly,	   a	   non-­‐synonymous	   genetic	   polymorphism	   in	   the	   nucleotide-­‐
binding	   domain	   of	   the	  ABCG2	   gene	   has	   repeatedly	   displayed	   strong	   associations	  
with	  elevated	  serum	  urate	  levels,	  which	  leads	  to	  gout.	  The	  variant	  protein	  has	  been	  
shown	  to	  abolish	  urate	  transport	  in	  transfected	  cells	   in	  vitro	  (Dehghan	  et	  al.	  2008,	  
Kottgen	  et	  al.	  2013,	  Woodward	  et	  al.	  2009).	  
	  
	  
Figure	  1.6:	  Subcellular	  localisation	  of	  selected	  ABC	  transporters	  at	  the	  blood-­‐brain	  barrier	  
Selected	  human	  ABC	  transporters	  at	  the	  blood-­‐brain	  barrier	  as	  introduced	  in	  this	  thesis	  chapter	  with	  
confirmed	  subcellular	  localisation	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1.3. 	  Epilepsy	  
1.3.1. General	  
Epilepsy	   is	   a	   chronic	   neurological	   disease	   affecting	   around	   50	   million	   people	  
worldwide	  (World	  Health	  Organisation	  2009).	  It	  is	  characterised	  by	  an	  excessive	  and	  
synchronised	   neuronal	   discharge	   in	   the	   brain	   that	   leads	   to	   recurrent	   seizures	  
(Brodie	   et	   al.	   2010,	  World	   Health	   Organisation	   2009).	   Seizures	   can	   have	   a	   broad	  
range	   of	   clinical	   characteristics	   and	  may	   impair	   a	   patient´s	   consciousness	   and/or	  
lead	  to	  motor,	  sensory,	  autonomic,	  or	  psychological	  events	  (Brodie	  et	  al.	  2010).	  As	  a	  
result,	  seizures	  can	  severely	   interfere	  with	  a	  patient´s	  quality	  of	   life	  and	  are	  often	  
accompanied	   by	   secondary	   events	   such	   as	   injuries.	   In	   addition,	   mortality	   is	  
increased	   by	   a	   factor	   of	   about	   2-­‐3	   when	   compared	   with	   the	   general	   population	  
(Brodie	  et	  al.	  2010).	  
1.3.2. Classification	  
Classification	   of	   epilepsy	   is	   challenging	   and	   an	   on-­‐going	   matter	   of	   discussion.	   In	  
2010,	   the	   International	   League	   Against	   Epilepsy	   updated	   its	   recommended	  
classification	   and	   terminology	   that	   is	   based	   on	   proposals	   from	   1981	   and	   1989,	  
respectively	  (Berg	  et	  al.	  2010,	  Commission	  on	  Classification	  and	  Terminology	  of	  the	  
International	  League	  Against	  Epilepsy	  1989,	  1981).	  Epilepsy	  is	  classified	  according	  to	  
a	  specific	  electroclinical	  syndrome	  in	  a	  patient.	  Electroclinical	  syndromes	  consists	  of	  
groups	   of	   clinical	   features	   that	   can	   be	   reliably	   identified	   by	   means	   of	   diagnostic	  
measurements	   including	   the	   age	   at	   seizure	   onset,	   underlying	   genetics,	   seizure	  
types,	  and	  neurological	  abnormalities	  (Brodie	  et	  al.	  2010).	  Epilepsies	  that	  cannot	  be	  
classified	   by	   an	   electroclinical	   syndrome	   but	   still	   have	   distinctive	   clinical	  
characteristics	   are	   referred	   to	   as	   constellations.	   Less	   distinctive	   forms	   of	   epilepsy	  
are	  classified	  as	  epilepsy	  secondary	  to	  metabolic/structural	  lesions	  or	  as	  epilepsy	  of	  
unknown	  cause	  (Berg	  et	  al.	  2010).	  
The	  most	  important	  symptom	  of	  epilepsy	  is	  a	  seizure.	  The	  type	  of	  seizure	  
strongly	  influences	  the	  classification	  of	  epilepsy	  and	  the	  prognosis	  and	  treatment	  of	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a	  patient.	  Seizures	  are	  essentially	  classified	  by	  their	  region	  of	  origin	  and	  are	  referred	  
to	  as	  generalised	  seizures	  or	  focal	  seizures.	  Generalised	  seizures	  commonly	  involve	  
both	   brain	   hemispheres	   and	   usually	   impair	   consciousness.	   Focal	   seizures,	   by	  
contrast,	   originate	   locally	   in	   one	   hemisphere	   and	   can	   or	   cannot	   involve	   impaired	  
consciousness.	   Focal	   onset	   seizures	   can,	   however,	   rapidly	   develop	   into	   secondary	  
generalised	   seizures	   (Brodie	   et	   al.	   2010).	  Generalised	   seizures	   are	   further	   divided	  
into	   subtypes,	   namely	   tonic-­‐clonic,	   absence,	   myoclonic,	   clonic,	   tonic,	   and	   atonic	  
seizures,	  depending	  on	  the	  exact	  symptoms	  (Berg	  et	  al.	  2010).	  The	  onset	  of	  tonic-­‐
clonic	  seizures	  is	  characterised	  by	  a	  sudden	  contraction	  of	  muscles	  accompanied	  by	  
loss	  of	  consciousness	  that	  will	  cause	  a	  patient	  to	  fall	  to	  the	  ground.	  This	  tonic	  phase	  
is	   then	   followed	   by	   the	   clonic	   phase	   with	   convulsive	   muscle	   movements	   (The	  
Epilepsy	  Foundation	  of	  America	  2013).	  
1.3.3. Pharmacological	  treatment	  
Pharmacological	   treatment	   is	   the	   most	   important	   medical	   strategy	   to	   control	  
seizures	  in	  epilepsy.	  The	  primary	  goal	  is	  to	  achieve	  seizure	  freedom	  with	  a	  minimum	  
of	  side	  effects	  in	  order	  to	  enhance	  a	  patient´s	  quality	  of	  life	  to	  a	  level	  as	  normal	  as	  
possible	  (Brodie	  et	  al.	  2010).	  A	  large	  panel	  of	  AEDs	  are	  available	  for	  treatment,	  but	  
the	  exact	  regimen	  and	  dosing	  requires	  a	  careful	  and	  patient-­‐specific	  management.	  
Not	   all	   AEDs	   are	   indicated	   for	   the	   full	   seizure	   spectrum	   and	   some	   can	   even	  
exacerbate	  the	  condition	  if	  given	  for	  the	  wrong	  seizure	  type	  (National	  Institute	  for	  
Health	  and	  Clinical	  Excellence	  2012).	   In	  addition	  to	  efficacy,	  adverse	  reactions	  and	  
drug	  interactions	  are	  considerably	  different	  between	  AEDs	  and	  hence	  certain	  drugs	  
are	   favoured	   as	   first-­‐line	   treatments	   or	   in	   conditions	   such	   as	   pregnancy.	  
Furthermore,	   cost	   effectiveness	   is	   an	   increasingly	   important	   factor.	   In	   general,	  
modern	  AEDs	  tend	  to	  have	  a	  better	  tolerability	  when	  compared	  to	  established	  AEDs	  
(Brodie	  et	  al.	  2010).	  
Country-­‐specific	  guidelines	  are	  available	  and	  recommend	  how	  to	   initiate	  
treatment	  for	  different	  seizure	  types	  and	  how	  to	  handle	  insufficient	  drug	  response	  
or	   adverse	   reactions.	   In	   the	   UK,	   patients	   with	   epilepsy	   should	   be	   started	   on	  
appropriate	   monotherapy,	   if	   possible	   (National	   Institute	   for	   Health	   and	   Clinical	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Excellence	  2012).	  About	  50	  %	  of	  all	  patients	  will	  achieve	  remission	  and	  tolerate	  the	  
drug	   (Brodie	  et	  al.	  2010).	  The	  remaining	  patients	  should	  be	  offered	  an	  alternative	  
AED	  monotherapy	  before	  adjunctive	   treatment	   is	   considered	  due	   to	  an	   increased	  
risk	   for	   adverse	   reactions	   and	  drug	   interactions	   (National	   Institute	   for	  Health	   and	  
Clinical	  Excellence	  2012).	  About	  70	  %	  of	  newly	  diagnosed	  patients	  with	  epilepsy	  will	  
achieve	  full	  seizure	  control	  with	  AEDs	  (World	  Health	  Organisation	  2009)	  and	  30	  %	  
will	  remain	  refractory	  (1.3.4).	  
Three	  established	  AEDs,	  namely	  carbamazepine	  (CBZ),	  valproic	  acid	  (VPA),	  
and	   phenytoin	   (PHT),	   plus	   three	   modern	   AEDs,	   namely	   lamotrigine	   (LTG),	  
topiramate	   (TPM),	   and	   levetiracetam	   (LEV)	   were	   studied	   in	   this	   work	   and	   their	  
pharmacological	  properties	  are	  described	  in	  more	  detail	  based	  on	  the	  official	  FDA-­‐
approved	  prescribing	  information.	  
1.3.3.1. Carbamazepine	  
CBZ	   is	   a	   widely	   used	   anticonvulsant	   drug	   for	   the	   treatment	   of	   focal,	   generalised	  
tonic-­‐clonic,	  and	  mixed	  type	  seizures.	  In	  addition,	  it	  is	  effective	  in	  the	  symptomatic	  
treatment	  of	  pain	  derived	  from	  trigeminal	  neuralgia	  and	  may	  also	  be	  used	  for	  the	  
treatment	  of	  bipolar	  disorder	  (Novartis	  Pharmaceuticals	  Corporation	  2013,	  Validus	  
Pharmaceuticals	  LLC	  2009).	  In	  1968,	  CBZ	  was	  initially	  approved	  by	  the	  FDA	  and	  still	  
remains	  an	  important	  drug	  for	  the	  treatment	  of	  epilepsy.	  Along	  with	  LTG	  (1.3.3.2)	  it	  
is	   recommended	   as	   first-­‐line	   treatment	   for	   focal	   seizures	   in	   the	   UK	   (National	  
Institute	   for	   Health	   and	   Clinical	   Excellence	   2012).	   CBZ	   seems	   to	   exhibit	   its	  
anticonvulsant	   activity	   by	   blocking	   voltage-­‐gated	   sodium	   channels	   leading	   to	  
reduced	  repetitive	  firing	  of	  neurons	  (Brodie	  et	  al.	  2010).	  76	  %	  of	  the	  drug	  is	  bound	  
to	   plasma	   proteins	   (Novartis	   Pharmaceuticals	   Corporation	   2013)	   and	   the	   target	  
serum	  concentration	  is	  between	  17-­‐50	  µM	  (Brodie	  et	  al.	  2010).	  
CBZ	   undergoes	   extensive	   and	   self-­‐induced	  metabolism	  with	   only	   3	  %	  of	  
unchanged	   parental	   drug	   excreted	   into	   the	   urine	   (Novartis	   Pharmaceuticals	  
Corporation	  2013).	  The	  primary	  route	  of	  hepatic	  CBZ	  biotransformation	  in	  humans	  
is	   by	   oxidation	   of	   CBZ	   into	   the	   active	   metabolite	   CBZ-­‐10,11-­‐epoxide	   with	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subsequent	   hydrolysis	   to	   trans-­‐10,11-­‐dihydrodiol-­‐CBZ	   by	   microsomal	   epoxide	  
hydrolase	   (Frigerio	   et	   al.	   1972,	   Lertratanangkoon	   et	   al.	   1982,	   Pirmohamed	   et	   al.	  
1992).	   The	   major	   enzyme	   involved	   in	   the	   first	   step	   of	   this	   process	   has	   been	  
identified	   as	   cytochrome	   P450	   (CYP)	   3A4	   with	   some	   minor	   contributions	   from	  
CYP2C8	   (Kerr	   et	   al.	   1994).	   Hydroxylated	   CBZ	   metabolites	   undergo	   further	  
glucuronidation	  and	  are	  finally	  excreted	  in	  the	  urine	  (Maggs	  et	  al.	  1997).	  CBZ	  is	  an	  
inducer	  of	  its	  own	  major	  metabolising	  enzyme	  CYP3A4.	  Drug	  therapy	  is	  initiated	  at	  
low	  and	  slowly	  increasing	  doses	  (Bertilsson	  et	  al.	  1997,	  Brodie	  et	  al.	  2010,	  Pichard	  et	  
al.	   1990).	   About	   50	   %	   of	   all	   clinically	   used	   drugs	   are	   known	   to	   be	   substrates	   of	  
CYP3A4/5	   (Bachmann	  2009).	   Therefore,	  CBZ	   is	   at	   a	  high	   risk	   for	   clinically	   relevant	  
drug-­‐drug	  interactions	  (Spina	  et	  al.	  1996).	  
CBZ-­‐induced	  CYP3A4	  seems,	  at	  least	  partly,	  to	  be	  regulated	  by	  the	  nuclear	  
receptor	  pregnane	  X	  (PXR),	  as	  first	  observed	  in	  primary	  human	  hepatocytes	  and	  the	  
hepatocellular	   carcinoma	   cell	   line	   HepG2	   (Lehmann	   et	   al.	   1998,	   Luo	   et	   al.	   2002).	  
Other	  nuclear	  receptors	  might	  also	  be	  involved,	  for	  example	  CBZ-­‐induced	  mRNA	  up-­‐
regulation	  of	  the	  constitutive	  androstane	  receptor	  (CAR)	  has	  been	  demonstrated	  in	  
liver	   specimens	   derived	   from	   two	   epilepsy	   patients	   (Oscarson	   et	   al.	   2006).	  
Interestingly,	   CBZ-­‐mediated	   PXR	   activation	   not	   only	   seems	   to	   induce	   CYP3A4	   but	  
also	  the	  expression	  of	  drug	  efflux	  transporters,	  particularly	  ABCB1	  (MDR1,	  Pgp)	  and	  
ABCC2	  (MRP2)	  (Geick	  et	  al.	  2001,	  Giessmann	  et	  al.	  2004,	  Owen	  et	  al.	  2006).	  
Several	   other	  membrane	   transporters	  were	   also	   differentially	   expressed	  
at	   the	   mRNA	   level	   in	   liver	   samples	   derived	   from	   patients	   treated	   with	   CBZ	   as	  
compared	   to	   control	   samples	   (Oscarson	   et	   al.	   2006).	   So	   far,	   however,	   direct	  
evidence	   that	   CBZ	   is	   a	   substrate	   for	   any	   human	  ABC	   transporter,	   namely	   ABCB1,	  
ABCC1	   (MRP1),	  ABCC2,	  ABCC5	   (MRP5),	  and	  ABCG2	   (BCRP),	   is	   lacking	   (Baltes	   et	  al.	  
2007b,	   Cerveny	   et	   al.	   2006,	   Crowe	   et	   al.	   2006,	   Dickens	   et	   al.	   2013b,	   Feng	   et	   al.	  
2008,	   Luna-­‐Tortos	   et	   al.	   2010,	   2008,	   Owen	   et	   al.	   2001,	   Zhang	   et	   al.	   2011).	   In	  
addition,	  SLC	  transporters	  have	  rarely	  been	  studied	  and	  SLC22A1	  (OCT1)	  is	  the	  only	  
transporter	   where	   direct	   CBZ	   transport	   has	   been	   assessed	   but	   with	   negative	  
outcome	  (Dickens	  et	  al.	  2012).	  Consistent	  with	   these	   in	  vitro	  observations,	   results	  
from	   animal	   studies	   comparing	   CBZ	   brain	   concentrations	   in	   wildtype	   (WT)	   and	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knockout	   rodents	   were	   also	   largely	   negative	   (Doran	   et	   al.	   2005,	   Nakanishi	   et	   al.	  
2013,	  Owen	  et	  al.	  2001,	  Potschka	  et	  al.	  2003,	  Rizzi	  et	  al.	  2002,	  Sills	  et	  al.	  2002).	  To	  
date,	   results	   from	   animal	   studies	   utilising	   knockout	   models	   are	   limited	   to	   the	  
Abcb1a,	   Abcb1b,	   and	   Abcg2	   transporters	   in	   mice	   and	   a	   mutant	   rat	   strain	   (TR-­‐)	  
lacking	  functional	  Abcc2	  protein	  expression.	  Human	  ABCB1	  has	  two	  corresponding	  
isoforms	  in	  mice,	  Abcb1a	  and	  Abcb1b,	  and	  both	  transporters	  have	  been	  suggested	  
to	  combine	  the	  functions	  of	  ABCB1	  (Schinkel	  et	  al.	  1996).	  Based	  on	  these	  studies	  it	  
seems	  unlikely	  that	  CBZ	   is	  a	  substrate	  for	  ABCB1,	  but	  there	   is	  some	  evidence	  that	  
the	  main	  CBZ	  metabolite,	  CBZ-­‐10,11-­‐epoxide,	  could	  be	  a	  substrate	  instead	  (Schinkel	  
et	  al.	  1996,	  Zhang	  et	  al.	  2011).	  
The	   most	   severe	   adverse	   reactions	   associated	   with	   CBZ	   treatment	   are	  
serious	  dermatologic	   reactions.	   These	   reactions	   can	  be	   fatal	   and	   include	   Stevens-­‐
Johnson	   syndrome	   (SJS)	   and	   toxic	   epidermal	   necrolysis	   (TEN).	   There	   is	   growing	  
evidence	  that	  these	  reactions	  are	  principally	  immune-­‐mediated	  by	  T-­‐cells	  (Wu	  et	  al.	  
2007,	   Yip	   et	   al.	   2012).	   Over	   the	   last	   decade,	   genetic	   markers	   in	   the	   human	  
leukocyte	   antigen	   (HLA)	   region,	   involved	   in	   peptide	   presentation	   to	   T-­‐cells,	   have	  
been	   associated	   with	   severe	   skin	   reactions.	   First,	   it	   was	   demonstrated	   that	   Han	  
Chinese	  patients	  carrying	  the	  HLA-­‐B*1502	  allele	  are	  at	  a	  substantially	  higher	  risk	  for	  
developing	   SJS	  and	  TEN	   (Chung	   et	  al.	   2004,	  Hung	   et	  al.	   2006).	   Later,	  HLA-­‐A*3101	  
has	   been	   identified	   to	   be	   strongly	   associated	   with	   CBZ-­‐induced	   hypersensitivity	  
reactions	   in	   the	   Northern	   European	   and	   Japanese	   populations	   (Kashiwagi	   et	   al.	  
2008,	   McCormack	   et	   al.	   2011,	   Ozeki	   et	   al.	   2011).	   In	   addition	   to	   severe	   skin	  
reactions,	   CBZ	   carries	   boxed	   warnings	   for	   aplastic	   anemia	   and	   agranulocytosis	  
(Novartis	  Pharmaceuticals	  Corporation	  2013).	  	  
1.3.3.2. Lamotrigine	  
LTG	   is	   a	   relatively	  modern	   antiepileptic	   drug	   indicated	   for	   the	   treatment	   of	   focal	  
seizures,	  primary	  generalised	   tonic-­‐clonic	   seizures,	  and	  Lennox-­‐Gastaut	   syndrome.	  
In	   addition,	   it	   is	   licensed	   for	   the	   maintenance	   treatment	   of	   bipolar	   I	   disorder	  
(GlaxoSmithKline	   Inc.	   2012a).	   LTG	   received	   FDA	   approval	   in	   1994	   and,	   along	  with	  
CBZ,	  is	  the	  recommended	  first-­‐line	  treatment	  for	  focal	  seizures	  in	  the	  UK	  (National	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Institute	   for	   Health	   and	   Clinical	   Excellence	   2012).	   The	   proposed	   mechanism	   of	  
action	   is	   similar	   to	   that	   of	   CBZ	   and	   involves	   blocking	   of	   voltage-­‐gated	   sodium	  
channels	   leading	   to	   reduced	  synaptic	   release	  of	  excitatory	  neurotransmitters	  such	  
as	   glutamate	   (Brodie	   et	   al.	   2010).	   Peak	   plasma	   concentrations	   vary	   between	  	  
2-­‐18	  µM	  following	  single	  LTG	  doses	  of	  50	  –	  400	  mg,	  and	  about	  55	  %	  of	  the	  drug	  is	  
plasma	  protein	  bound	  (GlaxoSmithKline	  Inc.	  2012b).	  
LTG	  is	  metabolised	  by	  glucuronic	  acid	  conjugation,	  the	  main	  metabolite	  is	  
the	   inactive	   2-­‐N-­‐glucuronide	   conjugate	   catalysed	   predominantly	   by	   uridine	   5'-­‐
diphospho-­‐glucuronosyltransferase	  (UGT)	  isoform	  1A4	  (Cohen	  et	  al.	  1987,	  Rowland	  
et	   al.	   2006,	   Sinz	   et	   al.	   1991).	   No	   significant	   interactions	   with	   CYP	   enzymes	   have	  
been	  observed,	  but	   LTG	   steady-­‐state	   concentrations	   are	   known	   to	  be	  affected	  by	  
co-­‐administration	  of	  CBZ,	  VPA,	  PHT	  (and	  other	  drugs),	  likely	  through	  an	  induction	  or	  
inhibition	  of	  UGTs	   (GlaxoSmithKline	   Inc.	  2012a).	   In	  addition,	  LTG	   is	  known	  to	  self-­‐
induce	   its	   metabolism	   when	   administered	   as	   monotherapy	   (Cohen	   et	   al.	   1987,	  
GlaxoSmithKline	   Inc.	   2012a).	   About	   10	   %	   parental	   drug	   and	   76	   %	   of	   the	   2-­‐N-­‐
glucuronide	   were	   found	   to	   be	   eliminated	   in	   the	   urine	   of	   healthy	   volunteers	  
(GlaxoSmithKline	  Inc.	  2012a).	  
LTG	   has	   recently	   been	   described	   as	   a	   substrate	   for	   human	   SLC22A1	  
(Dickens	  et	  al.	  2012)	  and	  represents	  the	  only	  SLC	  transporter	  studied	  so	  far.	  As	  with	  
CBZ,	  most	   studies	   investigating	  direct	   LTG	   transport	   have	   focused	  on	  human	  ABC	  
transporters.	   In	  vitro	   studies	  assessing	   the	   transport	  by	  ABCB1	  were	  negative	   in	  3	  
out	  of	   4	   studies	   (Crowe	   et	   al.	   2006,	  Dickens	   et	   al.	   2013b,	   Feng	   et	   al.	   2008,	   Luna-­‐
Tortos	   et	   al.	   2008).	   In	   addition,	   no	  direct	   LTG	   transport	  was	  observed	   for	  ABCC1,	  
ABCC2,	  ABCC5,	  and	  ABCG2	  (Cerveny	  et	  al.	  2006,	  Luna-­‐Tortos	  et	  al.	  2010).	  Similarly	  
to	  these	  largely	  negative	  in	  vitro	  results,	  animal	  studies	  with	  WT	  and	  knockout	  mice	  
did	  not	  find	  any	  support	  for	  a	  role	  of	  Abcb1a,	  Abcb1b,	  and	  Abcg2	  (Doran	  et	  al.	  2005,	  
Nakanishi	  et	  al.	  2013,	  Sills	  et	  al.	  2002).	   In	  addition,	  LTG	  brain	  concentrations	  were	  




LTG	   treatment	   is	   associated	   with	   potentially	   severe	   dermatologic	  
reactions	  including	  SJS	  and	  TEN.	  Interestingly,	  the	  HLA-­‐A*3101	  allele	  as	  a	  predictor	  
for	   CBZ-­‐induced	   hypersensitivity	   reactions	   in	   Europeans	   was	   not	   found	   to	   be	  
associated	  with	  LTG-­‐induced	  cutaneous	  adverse	  drug	   reactions	   (McCormack	   et	  al.	  
2012).	  
1.3.3.3. Topiramate	  
TPM	  received	  FDA	  marketing	  authorisation	  in	  1996.	  It	  is	  licensed	  for	  the	  treatment	  
of	  focal	  seizures,	  primary	  generalised	  tonic-­‐clonic	  seizures,	  and	  seizures	  that	  derive	  
from	   Lennox-­‐Gastaut	   syndrome.	   In	   addition,	   it	   may	   be	   used	   as	   a	   prophylactic	  
treatment	   for	   migraine	   (Janssen	   Pharmaceuticals	   Inc.	   2012).	   Chemically,	   TPM	   is	  
notably	   different	   to	   other	   AEDs	   and	   is	   a	   sulfamate-­‐substituted,	   fructose-­‐based	  
monosaccharide	  (Maryanoff	  et	  al.	  1987,	  Shank	  et	  al.	  1994).	  The	  precise	  mechanism	  
of	   action	   is	   unknown	   but	   involves	   multiple	   synaptic	   targets	   such	   as	   blocking	   of	  
voltage-­‐gated	   sodium	   channels,	   enhancing	   the	   inhibitory	   effects	   on	   a	   subset	   of	  
GABA	   receptors,	   and	   antagonising	   subtypes	   of	   the	   glutamate	   receptor	   (Janssen	  
Pharmaceuticals	   Inc.	   2012).	   TPM	   peak	   plasma	   concentrations	   ranged	   from	   5	   to	  	  
85	  µM	  in	  a	  singe-­‐dose	  study	  with	  healthy	  volunteers	  that	  received	  100	  –	  1,200	  mg	  
TPM	   (Doose	   et	   al.	   1996).	   About	   15-­‐41	   %	   of	   the	   drug	   is	   plasma	   protein	   bound,	  
depending	  on	  the	  blood	  concentration	  (Janssen	  Pharmaceuticals	  Inc.	  2012).	  
TPM	  is	  not	  extensively	  metabolised	  and	  about	  70	  %	  of	  unchanged	  drug	  is	  
eliminated	  in	  the	  urine	  (Janssen	  Pharmaceuticals	  Inc.	  2012).	  Interestingly,	  in	  a	  study	  
with	   primary	   human	   hepatocytes	   TPM	  was	   found	   to	   activate	   PXR,	   particularly	   at	  
higher	   doses.	   Consistent	   with	   these	   observations,	   the	   expression	   and	   activity	   of	  
CYP3A4	   was	   elevated	   (Nallani	   et	   al.	   2003).	   In	   addition	   to	   the	   mild	   induction	   of	  
CYP3A4,	  TPM	  is	  a	  mild	  inhibitor	  of	  CYP2C19	  (Janssen	  Pharmaceuticals	  Inc.	  2012).	  
So	  far,	  TPM	  has	  not	  been	  extensively	  studied	  as	  a	  potential	  substrate	  for	  
drug	   transporters.	  One	   in	   vitro	   study	   found	  TPM	   to	  be	   transported	  by	  ABCB1	  but	  
not	  ABCC1,	  ABCC2,	  and	  ABCC5	  (Luna-­‐Tortos	  et	  al.	  2009).	  Another	  study,	  however,	  
reported	  negative	  results	  for	  ABCB1	  (Crowe	  et	  al.	  2006)	  and	  no	  TPM	  transport	  was	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observed	   for	   SLC22A1	   (Dickens	   et	   al.	   2012).	   Interestingly,	   data	   from	   two	   studies	  
treating	  knockout	  animal	  models	  with	  TPM	  found	  increased	  brain	  concentrations	  in	  
Abcb1a(-­‐/-­‐)	  and	  Abcb1a/1b(-­‐/-­‐)	  mice	  as	  compared	  to	  WT	  animals	   (Nakanishi	  et	  al.	  
2013,	  Sills	  et	  al.	  2002).	  A	  triple	  knockout	  mouse	  model,	  Abcb1a/Abcb1b/Abcg2(-­‐/-­‐),	  
exhibited	  no	  further	  elevated	  TPM	  brain	  to	  plasma	  concentration	  ratio	  as	  compared	  
to	  the	  double	  knockout	  mouse	  model	  Abcb1a/Abcb1b(-­‐/-­‐)	  (Nakanishi	  et	  al.	  2013).	  
TPM	  treatment	  has	  been	  associated	  with	  severe	  skin	   reactions	   including	  
SJS	  and	  TEN	  (Janssen	  Pharmaceuticals	  Inc.	  2012).	  
1.3.3.4. Levetiracetam	  
LEV	   is	  a	   relatively	  new	  AED	  and	  received	  FDA	  marketing	  authorisation	   in	  1999	   for	  
the	   treatment	   of	   focal	   seizures,	   primary	   generalised	   tonic-­‐clonic	   seizures,	   and	  
myoclonic	   seizures	   (UCB	   Inc.	   2013).	   The	   exact	  mechanism	  by	  which	   LEV	   prevents	  
seizures	  is	  not	  fully	  understood	  but	  it	  seems	  to	  be	  distinctive	  to	  other	  AEDs.	  In	  vitro	  
studies	   did	   not	   find	   LEV	   to	   block	   voltage-­‐gates	   sodium	   channels	   or	   to	   directly	  
interact	  with	  inhibitory	  GABAergic	  neurotransmission	  (UCB	  Inc.	  2013).	  Instead,	  data	  
from	   in	  vitro	  and	  animal	  models	  demonstrated	  that	  LEV	  binds	  the	  synaptic	  vesicle	  
glycoprotein	   SV2A	   (Lynch	   et	   al.	   2004).	   Although	   the	   exact	   molecular	   function	   of	  
SV2A	   is	   still	   unknown,	   there	   is	   some	   evidence	   that	   proteins	   from	   the	   SV2	   family	  
could	   be	   involved	   in	   the	   regulation	   of	   pre-­‐synaptic	   calcium	   signalling	   triggering	  
vesicle	   exocytosis	   (Wan	   et	   al.	   2010).	   LEV	   peak	   plasma	   concentrations	   reached	  	  
182	  µM	  following	  a	  1000	  mg	  single-­‐dose	  and	  253	  µM	  following	  twice-­‐daily	  1000	  mg	  
repeated	  doses	  (Patsalos	  2000).	  
LEV	  is	  not	  metabolised	  in	  the	  liver	  and	  <	  10	  %	  is	  bound	  to	  plasma	  proteins	  
(UCB	  Inc.	  2013).	  66	  %	  of	  the	  dose	  is	  eliminated	  in	  the	  urine	  as	  unchanged	  drug	  with	  
the	  major	  metabolite	  being	   a	  pharmacologically	   inactive	   acidic	   hydrolysis	   product	  
(24	  %	  of	  a	  dose)	  produced	  in	  the	  blood	  (Patsalos	  2000,	  UCB	  Inc.	  2013).	  No	  clinically	  
relevant	   interactions	   with	   the	   major	   drug	   metabolising	   enzymes	   have	   been	  
observed	  in	  vitro	  for	  both	  LEV	  and	  its	  main	  metabolite	  (UCB	  Inc.	  2013).	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Not	  much	  information	   is	  available	  about	  LEV	  as	  a	  potential	  substrate	  for	  
drug	  transporters.	  Only	  one	  research	  group	  investigated	  direct	  transport	  by	  ABCB1,	  
ABCC1,	   ABCC2,	   and	   ABCC5	   in	   two	   in	   vitro	   studies	   and	   found	   LEV	   not	   to	   be	   a	  
substrate	   for	   the	   three	   ABCC	   transporters.	   Conflicting	   results,	   however,	   were	  
obtained	  for	  ABCB1	  (Baltes	  et	  al.	  2007b,	  Luna-­‐Tortos	  et	  al.	  2010,	  2008).	  In	  addition	  
to	  ABC	  transporters,	  LEV	  is	  not	  transported	  by	  SLC22A1	  (Dickens	  et	  al.	  2012).	  
Adverse	  events	  that	  are	  associated	  with	  LEV	  treatment	  include	  psychiatric	  
symptoms	   and	   serious	   dermatological	   reactions	   such	   as	   SJS	   and	   TEN	   (UCB	   Inc.	  
2013).	  
1.3.3.5. Valproic	  acid	  
VPA	  received	  initial	  FDA	  approval	  in	  1978	  and	  is	  indicated	  for	  the	  treatment	  of	  the	  
full	   seizure	   spectrum,	   thereby	   being	   particularly	   important	   for	   the	   treatment	   of	  
generalised	  seizures	  (AbbVie	  Inc.	  2013a,	  b,	  Brodie	  et	  al.	  2010).	  VPA	  is	  also	  indicated	  
for	   the	   treatment	  of	  manic	   episodes	   associated	  with	  bipolar	   disorder	   and	   for	   the	  
prophylaxis	   of	  migraine	   (AbbVie	   Inc.	   2013b).	   In	   the	  UK,	  VPA	   is	   the	   recommended	  
first-­‐line	   treatment	   for	  newly	  diagnosed	  generalised	   tonic-­‐clonic	  seizures,	  absence	  
seizures,	  myoclonic	  seizures,	   tonic	  seizures,	  and	  atonic	  seizures	   (National	   Institute	  
for	  Health	  and	  Clinical	  Excellence	  2012).	  The	  precise	  mechanism	  of	  how	  VPA	  exerts	  
its	   antiepileptic	  properties	   is	  unknown	  but	   seems	   to	   involve	   facilitated	  GABAergic	  
neurotransmission	   by	   increasing	   the	   brain	   GABA	   concentrations	   (AbbVie	   Inc.	  
2013a).	  The	  target	  serum	  concentration	  is	  between	  350	  and	  700	  µM	  (Brodie	  et	  al.	  
2010).	  
About	  90	  %	  of	  the	  drug	  is	  plasma	  protein	  bound	  but	  decreases	  at	  higher	  
VPA	   concentrations	   (81.5	   %	   at	   902	   µM)	   (AbbVie	   Inc.	   2013a).	   VPA	   is	   extensively	  
metabolised	   in	   the	   liver	  with	  only	   3	  %	  of	   an	   administered	  dose	  eliminated	   in	   the	  
urine.	   30-­‐50	   %	   undergoes	   glucuronidation	   by	   various	   UGT	   enzymes	   and	   another	  	  
40	   %	   undergoes	   mitochondrial	   ß-­‐oxidation.	   Oxidation	   by	   CYP	   enzymes	   only	  
accounts	  for	  about	  10	  %	  (Ghodke-­‐Puranik	  et	  al.	  2013).	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There	  is	  some	  evidence	  that	  VPA	  can	  induce	  the	  expression	  of	  ABCB1	  and	  
CYP3A4	  at	   the	  mRNA	   level	  by	  means	  of	  CAR	  and/or	  PXR	  activation	  (Cerveny	  et	  al.	  
2007).	  Also,	  VPA	  has	  been	  demonstrated	  to	  induce	  ABCB1	  expression	  at	  the	  protein	  
level	   in	   different	   human	   tumour	   cell	   lines	   (Eyal	   et	   al.	   2006).	   Direct	   evidence	   for	  
active	  VPA	  transport,	  however,	  is	  lacking	  and	  results	  from	  in	  vitro	  studies	  assessing	  
the	   direct	   transport	   by	   ABCB1,	   ABCC1,	   ABCC2,	   ABCC5,	   and	   ABCG2	  were	   negative	  
(Baltes	  et	  al.	  2007a,	  Cerveny	  et	  al.	  2006,	  Luna-­‐Tortos	  et	  al.	  2010).	  In	  addition,	  VPA	  
was	  found	  not	  to	  be	  transported	  by	  SLC22A1	  (Dickens	  et	  al.	  2012).	  Consistent	  with	  
these	   observations,	   no	   difference	   in	   the	   VPA	   brain	   to	   plasma	   concentration	   ratio	  
was	   observed	   in	   triple	   knockout	   mice	   as	   compared	   to	   WT	   controls	   for	  
Abcb1a/Abcb1b/Abcg2(-­‐/-­‐)	  animals	   (Nakanishi	  et	  al.	  2013).	  Likewise,	  no	  difference	  
was	  observed	  between	  WT	  and	  Abcc2-­‐deficient	  TR-­‐	  rat	  strains	  (Baltes	  et	  al.	  2007a).	  
Potentially	  life-­‐threatening	  side	  effects	  of	  VPA	  include	  hepatotoxicity	  and	  
pancreatitis.	   In	   addition,	   VPA	   is	   a	   teratogenic	   drug	   that	   is	   contraindicated	   in	  
pregnant	  women	  unless	  medically	  essential	  (AbbVie	  Inc.	  2013a).	  
1.3.3.6. Phenytoin	  
PHT	   is	   one	   of	   the	   oldest	   AEDs	   and	   received	   initial	   FDA	   approval	   in	   1953.	   It	   is	  
indicated	  for	  the	  treatment	  of	  generalised	  tonic-­‐clonic	  and	  focal	  seizures	  as	  well	  as	  
for	   the	   prevention	   and	   the	   treatment	   of	   seizures	   during/following	   neurosurgery	  
(Pfizer	   Inc.	   2012).	   PHT	   seems	   to	   exhibit	   its	   antiepileptic	   properties	   by	   inhibiting	  
voltage-­‐gated	  sodium	  channels	  and	  thereby	  preventing	  excessive	  repetitive	  firing	  of	  
neurons	   (Pfizer	   Inc.	   2012,	   Thorn	   et	   al.	   2012).	   The	   target	   serum	   concentration	   for	  
PHT	  is	  between	  40-­‐80	  µM	  with	  90-­‐93	  %	  of	  the	  drug	  serum	  protein	  bound	  (Brodie	  et	  
al.	  2010).	  
PHT	  is	  extensively	  metabolised	  in	  the	  liver.	  The	  main	  metabolic	  pathway	  is	  
the	   initial	   oxidation	   to	   the	   pharmacologically	   inactive	   hydroxyphenytoin	   via	   a	  
reactive	  arene	  oxide.	  This	  reaction	  is	  essentially	  mediated	  by	  CYP2C9	  and	  CYP2C19.	  
Hydroxyphenytoin	   is	   subsequently	   glucuronidated	   by	   various	   UGTs	   and	   finally	  
excreted	   in	   the	  urine.	   (Thorn	  et	  al.	  2012).	  PHT	   is	  a	  known	   inducer	  of	  various	  drug	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metabolising	  enzymes	  and	  hence	  susceptible	  to	  many	  drug-­‐drug	  interactions	  (Pfizer	  
Inc.	  2012).	   In	  vitro	  reporter	  gene	  assays	  with	  human	  hepatocytes	  and	  studies	  with	  
knockout	  mice	  indicated	  that	  PHT	  mediates	  enzyme	  induction	  through	  activation	  of	  
CAR	  but	  not	  PXR	  (Wang	  et	  al.	  2004).	  
Various	   groups	   have	   undertaken	   in	   vitro	   studies	   to	   assess	   the	   direct	  
transport	   of	   PHT	  by	   human	  ABC	   (1.2.2)	   transporters,	   particularly	  ABCB1	   (1.2.2.1).	  
PHT	   is	   the	   only	   AED	   that	   has	   repeatedly	   been	   found	   to	   be	   a	   weak	   substrate	   of	  
ABCB1	  by	  independent	  groups	  (Luna-­‐Tortos	  et	  al.	  2008,	  Schinkel	  et	  al.	  1996,	  Tishler	  
et	  al.	  1995,	  Zhang	  et	  al.	  2010),	  but	  some	  studies	  were	  also	  negative	  or	  inconclusive	  
(Baltes	   et	   al.	   2007b,	   Crowe	   et	   al.	   2006,	   Dickens	   et	   al.	   2013b,	   Feng	   et	   al.	   2008).	  
Results	   from	   studies	   with	   ABCC1,	   ABCC2,	   ABCC5	   (1.2.2.2),	   ABCG2,	   and	   SLC22A1	  
transfected	   cell	   lines	   were	   negative	   (Baltes	   et	   al.	   2007b,	   Cerveny	   et	   al.	   2006,	  
Dickens	   et	   al.	   2012,	   Luna-­‐Tortos	   et	   al.	   2010).	  Data	   derived	   from	  knockout	  mouse	  
models	   also	   suggest	   that	   PHT	   could	  be	   a	   substrate	  of	  Abcb1a/1b	  but	   not	  Abcb1a	  
alone	  (Doran	  et	  al.	  2005,	  Nakanishi	  et	  al.	  2013,	  Rizzi	  et	  al.	  2002,	  Schinkel	  et	  al.	  1996,	  
Sills	  et	  al.	  2002).	  In	  contrast	  to	  the	   in	  vitro	  results	  obtained	  for	  human	  ABCC2,	  one	  
study	  also	  reported	  higher	  PHT	  brain	  concentrations	  in	  the	  Abcc2-­‐deficient	  TR-­‐	  rat	  
strain	   as	   compared	   to	   WT	   animals,	   concluding	   that	   PHT	   is	   a	   substrate	   of	   Abcc2	  
(Potschka	  et	  al.	  2001).	  
PHT	   is	   a	   known	   teratogen	   and	   can	   induce	   severe	   hypersensitivity	  
reactions	  including	  SJS	  and	  TEN	  (Pfizer	  Inc.	  2012).	  
1.3.4. Refractory	  epilepsy	  
The	  majority	  of	  epilepsy	  patients	  achieve	  proper	  seizure	  control	  when	  treated	  with	  
AEDs.	   However,	   a	   substantial	   number,	   about	   30	   %,	   remain	   refractory	   to	   AED	  
treatment	  (World	  Health	  Organisation	  2009).	  Refractory	  epilepsy	  is	  a	  major	  health	  
problem	   and	   accompanied	   by	   increased	   morbidity	   and	   mortality	   that	   severely	  
affects	  a	  patient´s	  quality	  of	  life	  (Devinsky	  1999).	  In	  an	  attempt	  to	  define	  epilepsy	  as	  
pharmacologically	   refractory,	   a	   commission	  on	  behalf	  of	  The	   International	   League	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Against	   Epilepsy	   suggested	   that	   non-­‐response	   to	   two	   tolerated	   AEDs,	   either	   as	  
monotherapy	  or	  in	  combination,	  can	  be	  considered	  refractory	  (Kwan	  et	  al.	  2010).	  
Non-­‐response	   was	   defined	   as	   not	   achieving	   sustained	   seizure	   freedom.	  
Mesial	   temporal	   lobe	   epilepsy	   (MTLE)	   is	   a	   form	   of	   epilepsy	   that	   is	   classified	   as	   a	  
constellation	   (1.3.2).	   It	   is	   characterised	   by	   a	   distinctive	   pathology	   of	   hippocampal	  
sclerosis	   (HS)	  usually	  seen	  by	  magnetic	   resonance	   imaging	   (MRI).	  MTLE	  with	  HS	   is	  
one	  of	   the	   commonest	   causes	  of	   refractory	  epilepsy	   (Brodie	   et	   al.	   2010).	   Surgical	  
intervention	  is	  a	  possible	  alternative	  for	  treatment.	  Superiority	  to	  pharmacological	  
treatment	  has	  been	  demonstrated	   in	  a	   randomised	  controlled	  study	   (Wiebe	  et	  al.	  
2001)	   and	   long-­‐term	   (5	   years)	   seizure-­‐freedom	   has	   been	   achieved	   for	   >	   50	   %	   of	  
patients	  who	  underwent	  surgery	  for	  MTLE	  with	  HS	  (McIntosh	  et	  al.	  2004).	  
Brain	  specimens	  collected	   from	  surgery	  provide	  a	  unique	  opportunity	   to	  
study	  the	  underlying	  cause	  for	  refractoriness.	  Several	  independent	  research	  groups	  
found	   elevated	   expression	   of	   ABC	   transporters	   (1.2.2)	   in	   these	   specimens	   as	  
compared	   to	   controls,	   particularly	   ABCB1	   (MDR1,	   Pgp)	   (1.2.2.1)	   but	   also	   ABCC1	  
(MRP1),	   ABCC2	   (MRP2),	   and	   ABCC5	   (MRP5)	   (1.2.2.2)	   (Aronica	   et	   al.	   2004,	  
Dombrowski	   et	   al.	   2001,	   Kubota	   et	   al.	   2006,	   Liu	   et	   al.	   2012,	   Sisodiya	   et	   al.	   2002,	  
Tishler	  et	  al.	  1995).	  In	  addition,	  a	  recent	  in	  vivo	  positron	  emission	  tomography	  (PET)	  
study	  confirmed	  significantly	  higher	  transporter	  activity	  in	  refractory	  patients	  versus	  
controls	   utilising	   (R)-­‐[11C]verapamil	   as	   a	   PET	   tracer	   and	   tariquidar	   as	   an	   ABCB1	  
inhibitor	   (Feldmann	   et	   al.	   2013).	   Based	   on	   these	   cumulative	   findings,	  it	   has	   been	  
hypothesised	   that	   enhanced	   drug	   efflux	   at	   the	   BBB	  might	   contribute	   to	   the	   drug	  
resistant	  phenotype	  by	  lowering	  the	  drug	  concentration	  in	  the	  brain,	  particularly	  at	  
the	   seizure	   focus.	   While	   this	   is	   an	   elegant	   and	   plausible	   explanation,	   the	   drug	  
transporter	  hypothesis	  would	  require	  the	  majority	  of	  all	  AEDs	  to	  be	  substrates	  for	  
human	  drug	  efflux	  transporters.	  Published	  transporter	  data,	  however,	  have	  largely	  
been	  negative	  or	  conflicting	  so	  far	  (Cascorbi	  2010,	  Marchi	  et	  al.	  2010).	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1.4. Research	  aims	  
Membrane	   transporters	   are	   increasingly	   recognised	   as	   important	   mediators	   for	  
drug	   delivery	   across	   biological	   barriers.	   The	   concentration	   of	   a	   drug	   and	   its	  
potential	   metabolites	   is	   a	   key	   factor	   that	   will	   determine	   a	   drug’s	   effectiveness	  
and/or	   toxicity.	  Membrane	   transporters	   can	   be	   crucial	   factors	   within	   this	   system	  
and	   may	   affect	   the	   concentration	   of	   a	   drug	   in	   a	   particular	   organ	   or	   the	   whole	  
circulatory	   system.	   The	   CNS	   is	   a	   highly	   sensitive	   microenvironment	   with	   access	  
restricted	  by	  CNS	  barriers,	  particularly	  the	  BBB.	   In	  epilepsy	  and	  other	  neurological	  
diseases,	   pharmacological	   targets	   are	   usually	   located	   within	   the	   CNS	   and	   drugs	  
therefore	  have	  to	  cross	  the	  BBB	  in	  order	  to	  become	  effective.	  
Pharmacological	  management	   in	  epilepsy	   is	   ineffective	   in	  about	  30	  %	  of	  
all	   patients.	   The	   underlying	   reason,	   however,	   remains	   unknown.	   A	   few	   drug	  
transporters	   from	   the	   ABC	   family	   have	   been	   reported	   to	   be	   overexpressed	   in	  
patients	   with	   a	   common	   form	   of	   refractory	   epilepsy,	   MTLE	   with	   HS.	   This	  
observation	  has	   led	   to	   the	  drug	   transporter	  hypothesis,	   suggesting	   that	  enhanced	  
AED	  efflux	  at	  the	  BBB	  is	  leading	  to	  inefficient	  drug	  delivery	  to	  the	  seizure	  focus.	  This	  
hypothesis	  would,	  however,	  require	  all	  or	  most	  AEDs	  to	  be	  substrates	  of	  drug	  efflux	  
transporters	   but	   in	   vitro	   studies	   with	   human	   ABC	   transporters	   have	   largely	   been	  
negative	  or	  conflicting	  so	  far.	  Table	  1.3	  summarises	  the	  in	  vitro	  results	  for	  six	  major	  
AEDs	   from	   studies	   that	   assessed	   direct	   transport	   by	   human	   ABC	   and	   SLC	  
transporters,	   respectively.	   Although	   these	   results	   do	   not	   support	   the	   transporter	  
hypothesis	  as	  an	  exclusive	  explanation	  for	  refractory	  epilepsy,	  drug	  transport	  could	  
still	  be	  one	  out	  of	  many	  factors	   inducing	  the	  refractory	  phenotype	  for	  a	  subset	  of	  
treatments	  and/or	  patients.	   In	  addition,	   the	   large	  SLC	  transporter	  superfamily	  has	  
rarely	   been	   studied	   but	   is	   important	   to	   consider,	   particularly	   regarding	   brain	  
uptake.	   A	   concerted	   effect	   of	   various	   drug	   influx	   and	   efflux	   transporters	   with	   a	  
unique	   combination	   for	   every	   AED	   may	   also	   be	   the	   basis	   for	   an	   extended	   drug	  
transporter	   hypothesis.	   Besides	   drug	   efficacy,	   toxicity	   and	   drug-­‐drug	   interactions	  
are	  of	  particular	   importance	  and	  could	  be	  a	  direct	   result	  of	  altered	  AED	  transport	  
Chapter	  1	  
52	  
processes.	  Therefore,	   it	   is	  of	  fundamental	   importance	  to	  understand	  the	  transport	  
processes	  potentially	  involved	  in	  AED	  ADME.	  
The	   aims	   of	   this	   research	   project	   were	   (a)	   to	   assess	   whether	   CBZ	   is	   a	  
substrate	   of	   ABCC2	   (MRP2)	   in	   vitro	   and	   if	   previously	   reported	   genetic	  
polymorphisms	  in	  the	  ABCC2	  gene	  contribute	  to	  a	  drug	  resistant	  phenotype	  (b)	  to	  
identify	   and	   characterise	   new	  potential	   transport	   processes	   for	   six	  major	  AEDs	   in	  
vitro	   utilising	   a	  BBB	  model	   cell	   line	   (c)	   to	   assess	  potential	   clinically	   relevant	  drug-­‐
drug	  interactions	  in	  vitro	  with	  LTG	  as	  a	  substrate	  of	  SLC22A1	  (OCT1).	  
Table	  1.3:	  Summary	  of	  in	  vitro	  studies	  that	  directly	  assessed	  the	  transport	  of	  carbamazepine	  (CBZ),	  
lamotrigine	  (LTG),	  topiramate	  (TPM),	  levetiracetam	  (LEV),	  valproate	  (VPA),	  and	  phenytoin	  (PHT)	  by	  
human	  drug	  transporters	  
Drug	   Not	  a	  substrate	   Substrate	   References	  
CBZ	   ABCB1	   	   (Owen	  et	  al.	  2001)	  
	   ABCG2	   	   (Cerveny	  et	  al.	  2006)	  
	   ABCB1	   	   (Crowe	  et	  al.	  2006)	  
	   ABCB1,	  ABCC2	   	   (Baltes	  et	  al.	  2007b)	  
	   ABCB1	   	   (Feng	  et	  al.	  2008)	  
	   ABCB1	   	   (Luna-­‐Tortos	  et	  al.	  2008)	  
	   ABCC1,	  ABCC2,	  ABCC5	   	   (Luna-­‐Tortos	  et	  al.	  2010)	  
	   ABCB1	   	   (Zhang	  et	  al.	  2011)	  
	   SLC22A1	  (OCT1)	   	   (Dickens	  et	  al.	  2012)	  
	   ABCB1	   	   (Dickens	  et	  al.	  2013b)	  
	   	   	   	  
LTG	   ABCG2	   	   (Cerveny	  et	  al.	  2006)	  
	   ABCB1	   	   (Crowe	  et	  al.	  2006)	  
	   ABCB1	   	   (Feng	  et	  al.	  2008)	  
	   	   ABCB1	   (Luna-­‐Tortos	  et	  al.	  2008)	  
	   ABCC1,	  ABCC2,	  ABCC5	   	   (Luna-­‐Tortos	  et	  al.	  2010)	  
	   	   SLC22A1	  (OCT1)	   (Dickens	  et	  al.	  2012)	  
	   ABCB1	   	   (Dickens	  et	  al.	  2013b)	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Drug	   Not	  a	  substrate	   Substrate	   References	  
TPM	   ABCB1	   	   (Crowe	  et	  al.	  2006)	  
	   ABCC1,	  ABCC2,	  ABCC5	   ABCB1	   (Luna-­‐Tortos	  et	  al.	  2009)	  
	   SLC22A1	  (OCT1)	   	   (Dickens	  et	  al.	  2012)	  
LEV	   ABCB1,	  ABCC2	   	   (Baltes	  et	  al.	  2007b)	  
	   	   ABCB1	   (Luna-­‐Tortos	  et	  al.	  2008)	  
	   ABCC1,	  ABCC2,	  ABCC5	   	   (Luna-­‐Tortos	  et	  al.	  2010)	  
	   SLC22A1	  (OCT1)	   	   (Dickens	  et	  al.	  2012)	  
	   	   	   	  
VPA	   ABCG2	   	   (Cerveny	  et	  al.	  2006)	  
	   ABCB1,	  ABCC1,	  ABCC2	   	   (Baltes	  et	  al.	  2007a)	  
	   ABCC1,	  ABCC2,	  ABCC5	   	   (Luna-­‐Tortos	  et	  al.	  2010)	  
	   SLC22A1	  (OCT1)	   	   (Dickens	  et	  al.	  2012)	  
	   	   	   	  
PHT	   	   ABCB1	   (Tishler	  et	  al.	  1995)	  
	   	   ABCB1	   (Schinkel	  et	  al.	  1996)	  
	   ABCG2	   	   (Cerveny	  et	  al.	  2006)	  
	   ABCB1	   	   (Crowe	  et	  al.	  2006)	  
	   ABCB1,	  ABCC2	   	   (Baltes	  et	  al.	  2007b)	  
	   ABCB1	   	   (Feng	  et	  al.	  2008)	  
	   	   ABCB1	   (Luna-­‐Tortos	  et	  al.	  2008)	  
	   ABCC1,	  ABCC2,	  ABCC5	   	   (Luna-­‐Tortos	  et	  al.	  2010)	  
	   	   ABCB1	   (Zhang	  et	  al.	  2010)	  
	   SLC22A1	  (OCT1)	   	   (Dickens	  et	  al.	  2012)	  
	   ABCB1	   (ABCB1)*	   (Dickens	  et	  al.	  2013b)	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2.1. Introduction	  
Note:	   Substantial	   parts	   of	   this	   research	   chapter	   have	   been	   published	   in	   the	   The	  
Pharmacogenomics	  Journal	  (Radisch	  et	  al.	  2014).	  
At	   the	  BBB,	   overexpression	  of	  ABCC2	   (MRP2)	  has	  been	   suggested	   to	  be	  
involved	   in	  CBZ	  treatment	  failure	  by	   lowering	  the	  drug	  concentration	   in	  the	  brain,	  
particularly	   at	   the	   seizure	   focus	   (Aronica	   et	   al.	   2004,	   Dombrowski	   et	   al.	   2001,	  
Kubota	  et	  al.	  2006).	  So	  far,	  however,	  direct	  evidence	  for	  CBZ	  being	  a	  substrate	  for	  
ABCC2	  is	  lacking	  (Luna-­‐Tortos	  et	  al.	  2010).	  	  
A	   number	   of	   recently	   published	   clinical	   studies	   have	   suggested	   an	  
association	  between	  CBZ	  treatment	  response	  and	  ABCC2	  genetic	  variants.	  In	  a	  study	  
of	   Caucasian	   patients,	   a	   higher	   probability	   for	   CBZ	   treatment	   response	   was	  
observed	  for	  the	  c.1249G>A	  variant	   (Ufer	  et	  al.	  2011).	  The	  c.1249G>A	  variant	  was	  
also	  reported	  to	  be	  related	  to	  CBZ	  adverse	  neurological	  drug	  reactions	  in	  a	  Korean	  
case-­‐control	  study	  (Kim	  et	  al.	  2010).	  A	  recent	  study	  of	  Han	  Chinese	  epilepsy	  patients	  
reported	  an	  association	  between	   treatment	   resistance	  and	   the	  c.1249G>A	  variant	  
(Ma	  et	  al.	  2014).	  However,	  these	  results	  were	  only	  significant	  in	  a	  pooled	  analysis	  of	  
patients	  receiving	  multidrug	  therapy	  while	  a	  subgroup	  analysis	  of	  patients	  treated	  
with	  CBZ/oxcarbazepine	  monotherapy	  remained	  non-­‐significant	  (Ma	  et	  al.	  2014).	  In	  
an	   Indian	   population,	   seizure	   control	   in	  women	   treated	  with	   CBZ	  was	   associated	  
with	  the	  variants	  -­‐1549G>A	  and	  -­‐1019A>G	  in	  the	  ABCC2	  promoter	  region	  (Grover	  et	  
al.	   2012).	   Another	   variant	   within	   the	   ABCC2	   promoter	   region,	   -­‐24C>T,	   and	   the	  
synonymous	   variant	   c.3972C>T	   have	   been	   reported	   to	   be	   associated	   with	   AED	  
treatment	   resistance	   in	   a	   study	   with	   Chinese	   epilepsy	   patients	   (Qu	   et	   al.	   2012).	  
These	   results,	  however,	  have	  not	  been	   stratified	  according	   to	   the	  drug	   treatment	  
used	  as	  responses	  to	  different	  AEDs	  were	  pooled.	  Similarly,	  the	  -­‐24C>T	  variant	  has	  
been	   associated	  with	   AED	   treatment	   failure	   in	   a	   study	   conducted	  with	   Caucasian	  
epilepsy	  patients	  mainly	  treated	  with	  valproate	  (Ufer	  et	  al.	  2009).	  	  
A	  number	  of	  clinical	  studies,	  including	  a	  recently	  published	  meta-­‐analysis,	  
have	  also	  failed	  to	  detect	  an	  association	  between	  the	  most	  commonly	  investigated	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ABCC2	  single	  nucleotide	  polymorphisms	  (SNPs)	  -­‐24C>T,	  c.1249G>A,	  c.3972C>T	  and	  
AED	   treatment	   response	   (Grover	   et	   al.	   2013,	   Hilger	   et	   al.	   2012,	   Kim	   et	   al.	   2009,	  
Kwan	  et	  al.	  2011,	  Seo	  et	  al.	  2008,	  Sporis	  et	  al.	  2013).	  	  
A	  model	  of	   the	  ABCC2	  membrane	   topology	  highlighting	   the	   two	  coding-­‐
region	  polymorphisms	  c.1249G>A	  (valine	  substituted	  by	  isoleucine	  at	  position	  417)	  
and	  c.3972C>T	  (synonymous	  variant	  with	   isoleucine	  at	  position	  1324)	   is	   illustrated	  
in	  Figure	  2.1.	  
	  
Figure	  2.1:	  Predicted	  membrane	  topology	  of	  ABCC2	  
Membrane	   topology	   of	   ABCC2	   as	   predicted	   by	   TMHMM	   server	   v.	   2.0	  
(http://www.cbs.dtu.dk/services/TMHMM-­‐2.0)	   and	   plotted	   with	   TOPO2	  
(http://www.sacs.ucsf.edu/TOPO2).	   The	   corresponding	   amino	   acids	   from	   the	   coding	   genetic	  
polymorphisms	   c.1249G>A	   (valine	   substituted	   by	   isoleucine	   at	   position	   417)	   and	   c.3972C>T	  
(synonymous	  polymorphism	  with	  isoleucine	  at	  position	  1324)	  are	  highlighted	  in	  red 
Due	  to	  the	   inconclusive	  and	   largely	  conflicting	  studies	  regarding	  the	  role	  
of	   ABCC2	   in	   CBZ	   treatment	   response,	   a	   comprehensive	   two-­‐step	   analysis	   was	  
undertaken.	  First,	  sets	  of	  in	  vitro	  assays	  were	  carried	  out	  to	  investigate	  whether	  CBZ	  
was	   a	   substrate	   of	   ABCC2.	   Second,	   clinical	   and	   genetic	   data	   from	   the	   SANAD	  
Chapter	  2	  
	   73	  
(Standard	  and	  New	  Antiepileptic	  Drugs)	  study	   (Marson	  et	  al.	  2007)	  were	  analysed	  
focusing	  on	  three	  ABCC2	  gene	  polymorphisms,	  -­‐24C>T,	  c.1249G>A,	  and	  c.3972C>T,	  
and	  CBZ	  treatment	  response.	  
2.2. Materials	  and	  methods	  
2.2.1. Materials	  
Unless	   otherwise	   specified,	   all	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich,	  
Taufkirchen,	   Germany.	   Dulbecco’s	   modified	   eagle	   medium	   (DMEM),	   phosphate	  
buffered	   saline	   without	   calcium/magnesium	   (PBS),	   and	   0.05	   %	   trypsin	   with	  
ethylenediaminetetraacetic	  acid	  (EDTA)	  were	  obtained	  from	  Lonza	  GmbH,	  Cologne,	  
Germany.	  Hanks’	  balanced	  salt	  solution	  (HBSS),	  HEPES	  (1	  M)	  and	  fetal	  bovine	  serum	  
(FBS)	   gold	   came	   from	   PAA	   Laboratories	   GmbH,	   Pasching,	   Austria.	   0.25	   %	   trypsin	  
EDTA,	   MEM	   non-­‐essential	   amino	   acids	   (MEM	   NEAA),	   penicillin	   (10,000	   U)-­‐
streptomycin	   (10,000	   µg/ml),	   L-­‐glutamine	   (200	   mM),	   and	   CellTrackerTM	   Green	   5-­‐
chloromethylfluorescein	  diacetate	   (CMFDA)	  were	  obtained	   from	  Life	  Technologies	  
GmbH,	  Darmstadt,	  Germany.	  G418-­‐BC	  (30,000	  U/ml)	  was	  purchased	  from	  Biochrom	  
AG,	  Berlin,	  Germany,	  ZeocinTM	  (100	  mg/ml)	  from	  Cayla-­‐InvivoGen	  Europe,	  Toulouse,	  
France,	  and	  Aquasafe	  300	  Plus	  scintillation	  cocktail	  from	  Zinsser	  Analytic,	  Frankfurt,	  
Germany.	  Tritium-­‐labelled	  CBZ	  ([3H]-­‐CBZ,	  1	  mCi/ml,	  specific	  activity	  10.0	  Ci/mmol),	  
tritium-­‐labelled	   LTG	   ([3H]-­‐LTG,	   1	   mCi/ml,	   specific	   activity	   5.0	   Ci/mmol),	   tritium-­‐
labelled	   TPM	   ([3H]-­‐TPM,	   1	   mCi/ml,	   specific	   activity	   8.0	   Ci/mmol),	   and	   tritium-­‐
labelled	  LEV	  ([3H]-­‐LEV,	  1	  mCi/ml,	  specific	  activity	  5.0	  Ci/mmol)	  were	  purchased	  from	  
American	  Radiolabeled	  Chemicals	  Inc.,	  St.	  Louis,	  MO,	  USA.	  For	  Western	  Blot,	  mouse	  
anti-­‐ABCC2	   monoclonal	   antibody	   M2III-­‐6	   and	   anti-­‐mouse	   IgG	   (whole	   molecule)–
peroxidase	   antibody	   produced	   in	   rabbit	   were	   purchased	   from	   Abcam	   plc,	  
Cambridge,	  UK,	  and	  Sigma-­‐Aldrich,	  Taufkirchen,	  Germany,	  respectively.	  Super	  Signal	  
West	   Dura	   Extended	   Duration	   Substrate	   came	   from	   Thermo	   Fisher	   Scientific,	  
Rockford,	  IL,	  USA.	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2.2.2. Cell	  lines	  and	  culture	  conditions	  
2.2.2.1. Rht14-­‐10	  /	  Rht14-­‐10	  ABCC2(WT)-­‐EGFP	  cell	  lines	  
Rht14-­‐10	  cells	  were	  derived	  from	  the	  human	  fibrosarcoma	  cell	  line	  HT1080	  utilising	  
a	  "screen	  and	  insert"	  strategy	  (Brough	  et	  al.	  2007).	  The	  cells	  were	  stably	  transfected	  
with	   a	   single	   insertion	   of	   the	   tetracycline-­‐regulated	   d2EGFP	   reporter	   and	   the	  
tetracycline	   transactivator	   protein.	   Cre-­‐mediated	   recombination	   allowed	   site-­‐
specific	   insertion	  of	   a	   vector	   coding	   for	  ABCC2	   (MRP2)	   tagged	   to	  enhanced	  green	  
fluorescent	   protein	   (ABCC2-­‐EGFP.pEGFP-­‐N1)	   (Arlanov	   et	   al.	   2012).	   Cells	   were	  
cultured	  in	  DMEM	  supplemented	  with	  10	  %	  FBS	  (v/v),	  0.4	  %	  penicillin-­‐streptomycin	  
(v/v),	   2	  mM	  L-­‐glutamine,	   4	  %	  MEM	  NEAA	   (v/v),	   and	  0.2	  %	  Zeocin	   (v/v).	   Rht14-­‐10	  
ABCC2(WT)-­‐EGFP	  cells	  were	  further	  supplemented	  with	  0.8	  %	  G418-­‐BC	  (v/v).	  Both	  
cell	  lines	  were	  cultured	  at	  37	  °C	  and	  5	  %	  CO2.	  
2.2.2.2. MDCKII	  /	  MDCKII	  ABCC2	  cell	  lines	  
Madin	  Darby	  canine	  kidney	  cells	  II	  (MDCKII)	  were	  used	  as	  parental	  cell	  line	  or	  stably	  
transfected	  with	  ABCC2	  by	  means	  of	  retroviral	  transduction	  (kind	  gift	  from	  Prof.	  Dr.	  
P.	  Borst,	  Netherland	  Cancer	  Institute,	  Amsterdam,	  NL)	  (Evers	  et	  al.	  1998).	  Cells	  were	  
cultured	   in	   DMEM	   supplemented	   with	   10	   %	   FBS	   (v/v)	   and	   1	   %	   penicillin-­‐
streptomycin	  (v/v)	  at	  37	  °C	  and	  5	  %	  CO2.	  
2.2.3. Efflux	  assays	  
Cellular	   efflux	   assays	   were	   carried	   out	   as	   described	   previously	   with	   minor	  
modifications	  (Arlanov	  et	  al.	  2012).	  200,000	  cells/well	  were	  seeded	  onto	  NuncTM	  6-­‐
well	  plates	  (Fisher	  Scientific	  GmbH,	  Schwerte,	  Germany)	  and	  cultured	  for	  3	  days	  to	  
obtain	  80-­‐90	  %	  confluence.	  Cells	  were	  pre-­‐incubated	  for	  1	  hour	  at	  4	  °C	  with	  either	  	  
5	  µM	  CMFDA	  or	  5	  µM	  [3H]-­‐CBZ	  (2.4	  µCi/ml)	  in	  transport	  buffer	  (HBSS	  supplemented	  
with	  10	  mM	  HEPES,	  adjusted	  to	  pH	  7.4).	  CMFDA,	  a	  non-­‐fluorescent	  and	  membrane	  
permeable	   chemical,	   was	   utilised	   as	   the	   positive	   control	   for	   ABCC2-­‐mediated	  
transport.	  Upon	  uptake	   into	  cells,	  CMFDA	   is	  hydrolysed	  by	   intra-­‐cellular	  esterases	  
and	   glutathione	   S-­‐transferase	   into	   the	   non-­‐membrane	   permeable,	   fluorescent	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ABCC2	   (MRP2)	  substrate	  glutathione-­‐methylfluorescein	   (GS-­‐MF)	   (Pratt	  et	  al.	  2006,	  
Roelofsen	  et	  al.	  1997).	  
Radioassays	   with	   [3H]-­‐CBZ	   (2.4	   µCi/ml)	   were	   supplemented	   with	   non-­‐
radiolabelled	   drug	   to	   a	   final	   concentration	   of	   5	  µM.	   For	   analysis,	   100	  µl	   samples	  
were	  taken	  immediately	  (referred	  to	  as	  time	  point	  0)	  and	  subsequently	  at	  different	  
time	   points.	   Fluorescence	   emitted	   from	   the	   ABCC2	   substrate	   GS-­‐MF	   was	  
determined	  with	   an	   excitation	   and	   emission	  wavelength	   of	   485	   nm	   and	   535	   nm,	  
respectively	   (1420	   Victor2	   multilabel	   plate	   counter,	   Wallac,	   Turku,	   Finland).	  
Radioactivity	  was	  determined	  by	   adding	  5	  ml	   scintillation	   cocktail	   to	   each	   sample	  
with	   scintillation	   counting	   performed	   to	   detect	   radionuclide	   disintegrations	   per	  
minute	   (HIDEX	   300	   SL	   Liquid	   Scintillation	   Counter,	   FCI	   Frenzel	   Consulting	   &	  
Instruments,	  Straubenhardt,	  Germany).	  	  
2.2.4. Vesicle	  preparation	  
Plasma	   membrane	   vesicles	   were	   prepared	   from	   Rht14-­‐10	   and	   Rht14-­‐10	  
ABCC2(WT)-­‐EGFP	   cells	   based	   on	   a	   previously	   published	   protocol	   (Keppler	   et	   al.	  
1998)	  and	   is	  outlined	  below.	  Cells	   from	  each	  cell	   line	  were	  seeded	  on	  cell	   culture	  
dishes	  of	  size	  150	  x	  20	  mm	  (Sarstedt	  AG	  &	  Co.,	  Nümbrecht,	  Germany)	  with	  15	  ml	  
medium	  per	  plate	  and	  incubated	  for	  three	  days	  to	  reach	  80-­‐90	  %	  confluence.	  
2.2.4.1. Washing	  of	  cells	  
On	  the	  day	  of	  vesicle	  preparation,	  cells	  were	  scraped	  off	  the	  cell	  culture	  dishes	  to	  
give	  about	  400	  ml	  cell	  suspension	  per	  cell	  line.	  Cell	  suspensions	  were	  centrifuged	  at	  
3,000	   rpm	   for	   10	  minutes	   at	   4	   °C	   (Sorvall	   superspeed	   RC2-­‐B	   centrifuge	  with	  GSA	  
rotor,	   Fisher	   Scientific	  GmbH,	   Schwerte,	  Germany)	   and	   resuspended	   in	  50	  ml	   ice-­‐
cold	   PBS.	   The	   suspension	   was	   centrifuged	   at	   1,500	   rpm	   for	   10	   minutes	   at	   4	   °C	  
(Universal	   centrifuge	   320	   R	  with	   swing-­‐out	   rotor	   1324,	   Andreas	   Hettich	   GmbH	  &	  
Co.KG,	   Tuttlingen,	  Germany),	   again	   resuspended	   in	   50	  ml	   PBS	   and	   centrifuged	   as	  
before.	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2.2.4.2. Hypotonic	  cell	  lysis	  
The	   washed	   cell	   pellets	   were	   lysed	   in	   95	   ml	   hypotonic	   buffer	   (0.5	   mM	   sodium	  
phosphate,	  pH	  7.4)	  containing	  the	  protease	  inhibitors	  phenylmethylsulfonyl	  fluoride	  
(100	  µM),	  aprotinin	  (0.3	  µM),	  and	  leupeptin	  (1	  µM).	  Cells	  were	  lysed	  for	  1.5	  hours	  
under	  stirring	  (250	  rpm)	  at	  4	  °C	  and	  the	  lysate	  subsequently	  centrifuged	  at	  35,000	  
rpm	  for	  45	  minutes	  at	  4	  °C	  (OptimaTM	  L-­‐100	  XP	  ultracentrifuge	  with	  type	  70	  Ti	  rotor,	  
Beckman	  Coulter	  GmbH,	  Krefeld,	  Germany).	  
2.2.4.3. Plasma	  membrane	  isolation	  
Each	  cell	  pellet	  was	  resuspended	  in	  10	  ml	  hypotonic	  buffer	  and	  homogenised	  with	  
30	   strokes	   at	   500	   rpm	   and	   4	   °C	   using	   an	   electric	   Potter-­‐Elvehjem	   homogeniser	  
model	   S	   (Sartorius	   AG,	   Göttingen,	   Germany).	   The	   homogenised	   cell	   lysates	   were	  
centrifuged	   at	   10,000	   rpm	   for	   10	   minutes	   at	   4	   °C	   (Sorvall	   superspeed	   RC2-­‐B	  
centrifuge	   with	   SS34	   rotor,	   Fisher	   Scientific	   GmbH,	   Schwerte,	   Germany)	   and	   the	  
supernatant	  stored	  on	  ice.	  The	  pellets	  were	  resuspended	  in	  7.5	  ml	  incubation	  buffer	  
(0.25	   M	   sucrose,	   10	   mM	   Tris-­‐HCl,	   pH	   7.4)	   with	   protease	   inhibitors	   and	   again	  
homogenised	   (20	   strokes)	   and	   centrifuged	   as	   before.	   Supernatants	   from	   both	  
postnuclear	   homogenisation	   steps	   were	   finally	   combined	   and	   centrifuged	   at	  	  
35,000	  rpm	  for	  45	  minutes	  at	  4	  °C	  (ultracentrifuge	  as	  in	  2.2.4.2).	  
2.2.4.4. Plasma	  membrane	  purification	  and	  vesicle	  preparation	  
The	   resulting	   cell	   pellets	   from	   the	   plasma	   membrane	   isolation	   step	   were	  
resuspended	   in	   15	   ml	   incubation	   buffer	   with	   protease	   inhibitors	   followed	   by	   a	  
manual	   homogenisation	   step	  with	   50	   strokes	   on	   ice	   using	   a	   Dounce	   type	   Potter-­‐
Elvehjem	  hand	  homogeniser	  (Sartorius	  AG,	  Göttingen,	  Germany).	  The	  homogenate	  
was	  carefully	  transferred	  on	  top	  of	  a	  38	  %	  (w/v)	  sucrose	  solution	  (in	  5	  mM	  HEPES-­‐
KOH,	  pH	  7.4)	  and	  centrifuged	  at	  40,000	  rpm	  for	  1.5	  hours	  at	  4	  °C	  (OptimaTM	  L-­‐100	  
XP	   ultracentrifuge	   with	   SW40	   swing	   rotor,	   Beckman	   Coulter	   GmbH,	   Krefeld,	  
Germany).	   The	   interphases	   (plasma	   membranes)	   and	   the	   pellets	   (endoplasmic	  
reticulum)	   were	   removed	   separately	   and	   diluted	   with	   ice-­‐cold	   incubation	   buffer	  
without	  protease	   inhibitors	   to	  give	  a	   final	  volume	  of	  10	  ml	  each.	  Another	  manual	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homogenisation	   step	   was	   carried	   out	   (20	   strokes)	   and	   the	   homogenates	  
subsequently	  centrifuged	  at	  35,000	  rpm	  for	  50	  minutes	  at	  4	  °C	  (OptimaTM	  L-­‐100	  XP	  
ultracentrifuge	  with	   type	  70	  Ti	   rotor,	  Beckman	  Coulter	  GmbH,	  Krefeld,	  Germany).	  
Each	   cell	   pellet	   was	   resuspended	   in	   200	   µl	   ice-­‐cold	   incubation	   buffer	   without	  
protease	   inhibitors.	   To	   generate	   vesicles,	   the	   suspensions	  were	   passed	   through	   a	  
27-­‐gauge	   needle	   (20	   times)	   (B.	   Braun	  Melsungen	   AG,	  Melsungen,	   Germany)	   and	  	  
20	   µl	   aliquots	   were	   frozen	   in	   liquid	   nitrogen	   until	   needed.	   The	   protein	  
concentration	  was	  determined	  according	   to	   the	  Smith	  method	   (Smith	  et	  al.	  1985)	  
and	  a	  confirmatory	  immunoblot	  carried	  out	  as	  described	  by	  Arlanov	  et	  al.	  (2012).	  
2.2.5. 	  Vesicle	  uptake	  assays	  
Vesicle	  uptake	  assays	  were	  performed	  based	  on	  the	  rapid	  filtration	  method	  (Leier	  et	  
al.	   1994).	   Frozen	  vesicles	  were	   thawed	  at	  37	   °C	  and	   immediately	  used	   for	  uptake	  
assays.	  Each	  reaction	  consisted	  of	  vesicles	  with	  30	  µg	  protein,	  4	  mM	  ATP	  or	  4	  mM	  
AMP,	   20	   mM	   MgCl2,	   50	   µM	   5-­‐(and-­‐6)-­‐carboxy-­‐2',7'-­‐dichlorofluorescein	   diacetate	  
mixed	   isomers	   (CDCF)	  as	  positive	  control	  or	  5	  µM	  [3H]-­‐CBZ,	  5	  µM	  [3H]-­‐LTG,	  5	  µM	  
[3H]-­‐TPM,	   5	   µM	   [3H]-­‐LEV	   (0.6	   µCi/ml)	   in	   transport	   buffer	   (250	   mM	   sucrose,	  	  
10	  mM	   Tris-­‐HCl,	   pH	   7.4).	   Radioassays	  were	   supplemented	  with	   non-­‐radiolabelled	  
drug	  to	  give	  the	  final	  concentration	  of	  5	  µM.	  	  
Reactions	  were	   incubated	   at	   37	   °C	   in	   a	  water	   bath	   for	   20	  minutes	   and	  
subsequently	  stopped	  by	  adding	  1	  ml	  ice-­‐cold	  transport	  buffer.	  Reactions	  were	  then	  
transferred	   and	   passed	   under	   vacuum	   (0.2	   bar)	   through	   pre-­‐wetted	   Millipore	  
Durapore®	  membrane	  filters	  (pore	  size	  0.22	  µm)	  on	  a	  Millipore	  Sampling	  Manifold	  
(Merck	  KGaA,	  Darmstadt,	  Germany).	  Filters	  were	  washed	  three	  times	  with	  ice-­‐cold	  
transport	   buffer	   and	   membrane	   vesicles	   finally	   lysed	   with	   1	   ml	   sodium	   dodecyl	  
sulfate	  (SDS)-­‐HEPES	  buffer	  (1	  %	  SDS,	  7.5	  mM	  HEPES,	  pH	  7.4)	  for	  30	  minutes	  at	  room	  
temperature.	  200	  µl	  aliquots	  were	  taken	  and	  fluorescence	  determined	  (see	  2.2.3).	  
Filters	   with	   vesicles	   containing	   radiolabelled	   AEDs	   were	   transferred	   into	   a	  
scintillation	  tube	  and	  incubated	  with	  5	  ml	  scintillation	  cocktail	  for	  30	  minutes	  before	  
radioactivity	  was	  determined	  (see	  2.2.3).	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2.2.6. SANAD	  study	  details	  
The	  SANAD	  study	  was	  an	  unblinded	  randomised	  controlled	  clinical	   trial	  conducted	  
in	  the	  UK	  between	  1999	  and	  2005	  (International	  Standard	  Randomised	  Controlled	  
Trial	   number	   ISRCTN38354748).	   1721	   patients	   with	   partial	   epilepsy	   were	  
randomised	   in	   arm	  A	   to	   CBZ,	   gabapentin,	   LTG,	   oxcarbazepine,	   or	   TPM,	   aiming	   to	  
compare	   the	   long-­‐term	   efficacy	   of	   the	   drugs.	   Details	   of	   the	   study	   have	   been	  
described	  elsewhere	  (Marson	  et	  al.	  2007).	  All	  patients	  gave	  their	  written	  informed	  
consent	   to	  be	   included	   into	   the	   SANAD	   study	  and	   the	   study	   received	  all	   required	  
approvals	   from	   ethics	   and	   research	   committees.	   Patients	   were	   followed	   for	   a	  
minimum	   of	   12	  months	   and	   seizure	   outcomes	   included	   time	   to	   first	   seizure	   and	  
time	  to	  12-­‐month	  seizure	  remission.	  
2.2.7. Genotyping	  
Genotyping	   was	   performed	   on	   Illumina	   660	   and	   received	   all	   required	   ethical	  
approvals.	  All	  patients	  gave	  their	  written	  informed	  consent	  to	  be	  included	  into	  the	  
study	  (Speed	  et	  al.	  2013).	  
2.2.8. Patient	  selection	  
Patient	  selection	  from	  the	  SANAD	  study	  arm	  A	  was	  carried	  out	   in	  two	  steps.	  First,	  
only	   patients	   with	   available	   genotyping	   data	   (678	   patients)	   were	   selected.	   In	   a	  
second	   step,	  patients	   from	   this	   group	  were	  eligible	   for	   inclusion	   if	   they	  had	  been	  
treated	  with	   CBZ	  monotherapy	   for	   any	   time	   throughout	   the	   study.	   This	   included	  
patients	   not	   necessarily	   initially	   randomised	   to	   CBZ.	   A	   transition	   period	   with	  
overlapping	   treatments	   was	   considered	   acceptable	   when	   followed	   by	   CBZ	  
monotherapy	   (tapering	  of	  previous	  medication).	  Three	  patients	  with	  an	  exception	  
made	   from	   above	   criteria	   have	   been	   included.	   These	   patients	   were	   on	   CBZ	  
monotherapy	   for	   1737	   days,	   1967	   days,	   and	   1299	   days,	   respectively.	  Within	   this	  
period,	   records	   indicated	  additional	  TPM	  intake	  between	  two	  subsequent	  visits	  of	  
77	   days,	   103	   days,	   and	   273	   days,	   respectively.	   The	   intake	   of	   CBZ	   remained	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unchanged	  for	  the	  whole	  period.	  After	  the	  selection	  process,	  a	  total	  of	  229	  patients	  
were	  eligible	  for	  statistical	  analysis.	  
2.2.9. Statistical	  analysis	  
Survival	  analysis	  was	  undertaken	  utilising	  the	  'survival'	  package	  in	  R	  (version	  3.0.0).	  
Polymorphisms	   rs717620	   (-­‐24G>A),	   rs2273697	   (c.1249G>A),	   and	   rs3740067	  
(c.3843+124C>G)	  were	  analysed	  for	  two	  outcomes,	  time	  to	  first	  seizure	  and	  time	  to	  
12-­‐month	  remission.	  All	  three	  polymorphisms	  were	  found	  to	  be	  in	  Hardy-­‐Weinberg	  
equilibrium.	  Data	  from	  patients	  without	  the	  outcome	  event	  having	  occurred	  before	  
a	   stop	   date	   were	   included	   as	   right-­‐censored	   data.	   A	   stop	   date	   was	   defined	   as	  
addition	  of	   another	  AED	   to	  CBZ	  monotherapy	   treatment,	   non-­‐compliance,	   loss	   to	  
follow-­‐up,	  withdrawn	   consent,	   and	   end	   of	   study.	   The	   three	   polymorphisms	  were	  
stratified	   according	   to	   genotype	   but	  minor	   allele	   homozygotes	  were	   pooled	  with	  
heterozygotes	  because	  of	  their	  low	  frequency.	  
Kaplan-­‐Meier	  survival	  probabilities	  were	  calculated	  and	  curves	  plotted	  for	  
each	   condition	   (stepped	   curves).	   In	   addition,	   parametric	   regression	  models	   were	  
fitted	   to	   the	   data.	   Parametric	   survival	  models	   describe	   the	   outcomes	   based	   on	   a	  
known	   distribution	   and	   therefore	   are	   smooth	   curves	   rather	   than	   stepped	   curves	  
(Kleinbaum	   et	   al.	   2012).	   Curves	   derived	   from	   a	   parametric	   survival	   distribution	  
approach	   zero	   for	   an	   infinite	   time	   while	   Kaplan-­‐Meier	   curves	   may	   not,	   due	   to	  
patients	  still	  at	  risk	  at	  the	  end	  of	  the	  study	  (Kleinbaum	  et	  al.	  2012).	  Three	  commonly	  
used	  distributions,	   exponential,	  Weibull,	   and	   log-­‐logistic,	  were	  evaluated	   for	   their	  
appropriateness	   of	   fit	   to	   the	   survival	   data.	   Holding	   of	   model	   assumptions	   was	  
explored	  graphically	  by	  transforming	  each	  parametric	  survival	  function	  and	  plotting	  
the	   transformed	   Kaplan-­‐Meier	   estimates	   against	   time	   or	   natural	   logarithm	   (ln)	   of	  
time	   (Kleinbaum	   et	   al.	   2012).	   A	   linear	   relationship	   with	   parallel	   lines	   indicated	  
holding	  of	  model	  assumptions.	  For	   the	   final	  model	  selection,	  Akaike´s	   information	  
criterion	  was	   calculated	   as	   a	  measure	   of	   the	   goodness	   of	   fit.	   The	   lowest	   number	  
indicated	   the	  best	   fit.	  A	  p-­‐value	  was	  obtained	   for	   the	   regression	   coefficients	  with	  	  
p	  <	  0.05	  considered	  statistically	  significant.	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In	   vitro	   efflux	   assays	   were	   carried	   out	   three	   independent	   times	   in	  
triplicate.	  Data	  are	  presented	  as	  means	  ±	  standard	  deviation	  (SD).	  An	  independent	  
two-­‐tailed	  t-­‐test	  was	  applied	  for	  statistical	  analysis	  of	  each	  time	  point	  (ABCC2	  over-­‐
expressing	   vs.	   control	   cell	   lines).	   In	   vitro	   vesicle	   uptake	   experiments	  were	   carried	  
out	   once	   in	   triplicate.	   Data	   are	   presented	   as	  means	   ±	   SD.	   A	   one-­‐way	   analysis	   of	  
variance	   (ANOVA)	   was	   performed	   for	   statistical	   analysis	   followed	   by	   a	   Dunnett’s	  
post-­‐hoc	   test	   for	   significant	   results	   with	   p<0.05.	   Significant	   results	   are	   indicated	  
with	  *	  for	  p<0.05,	  **	  for	  p<0.01,	  and	  ***	  for	  p<0.001.	  Analysis	  was	  performed	  with	  
SPSS®	  Statistics	  version	  20	  (IBM	  United	  Kingdom	  Ltd.,	  Hampshire,	  UK).	  
2.3. Results	  
2.3.1. In	  vitro	  cell	  efflux	  assays	  
In	  initial	  experiments,	  time-­‐course	  cell	  efflux	  assays	  were	  undertaken	  to	  study	  CBZ	  
as	  a	  potential	  substrate	  for	  ABCC2	  (MRP2).	  CMFDA	  served	  as	  a	  positive	  control	  pro-­‐
drug	  and	  confirmed	  ABCC2	  activity	  in	  both	  transfected	  cell	  lines	  (Figure	  2.2	  A+B).	  No	  
increased	  CBZ	   efflux	  was	   observed	   from	  ABCC2-­‐transfected	  Rht14-­‐10	   and	  MDCKII	  
cells	  as	  compared	  to	  controls	  (Figure	  2.2	  C+D).	  	  
As	   CBZ	   has	   previously	   been	   reported	   to	   inhibit	   ABCC2-­‐mediated	   GS-­‐MF	  
efflux	   (Kim	   et	  al.	   2010),	   the	   same	  assay	  was	   repeated	   in	   the	  presence	  of	  100	  µM	  
CBZ	  or	  vehicle.	  No	  difference	  in	  GS-­‐MF	  efflux	  was	  observed	  between	  CBZ	  or	  vehicle-­‐
only	  treated	  cells	  (Figure	  2.3).	  
2.3.2. In	  vitro	  vesicle	  uptake	  assays	  
To	   further	   validate	   the	   results	   obtained	   from	   cell	   efflux	   assays,	   inside-­‐out	   plasma	  
membrane	  vesicles	  were	  prepared	   from	  Rht14-­‐10	  and	  Rht14-­‐10	  ABCC2(WT)-­‐EGFP	  
cells.	   An	   immunoblot	   confirmed	   the	   presence	   and	   absence	   of	   ABCC2-­‐EGFP,	  
respectively	  (Figure	  2.4).	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Figure	  2.2:	  Cell	  efflux	  assays	  to	  investigate	  whether	  carbamazepine	  is	  an	  ABCC2	  substrate	  
Time-­‐course	   efflux	   assays	   from	  human	   fibrosarcoma	   (Rht14-­‐10)	   and	  Madin	  Darby	   canine	   kidney	   II	  
(MDCKII)	  cell	   lines.	  Efflux	  was	  compared	  between	  cells	   stably	   transfected	  with	  ABCC2	  and	  controls	  
(Rht14-­‐10	   ABCC2(WT)-­‐EGFP	   vs.	   Rht14-­‐10	   and	   MDCKII	   ABCC2	   vs.	   MDCKII).	   A+B)	   Positive	   control	  
substrate	  glutathione-­‐methylfluorescein	  (GS-­‐MF);	  C+D)	  Carbamazepine	  (CBZ).	  Data	  are	  expressed	  as	  
means	   ±	   standard	   deviation	   (n	   =	   3	   independent	   experiments	   in	   triplicate).	   Significant	   results	   are	  
indicated	  with	  *	  for	  p<0.05	  and	  **	  for	  p<0.01	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Figure	   2.3:	   Cell	   efflux	   competition	   assays	   to	   investigate	   whether	   carbamazepine	   is	   an	   ABCC2	  
inhibitor	  
Time-­‐course	  efflux	  assays	  from	  A)	  human	  fibrosarcoma	  (Rht14-­‐10)	  and	  B)	  Madin	  Darby	  canine	  kidney	  
II	   (MDCKII)	   cell	   lines.	  Efflux	  of	  glutathione-­‐methylfluorescein	   (GS-­‐MF)	  was	  compared	  between	  cells	  
stably	   transfected	  with	  ABCC2	   and	   controls	   (Rht14-­‐10	   ABCC2(WT)-­‐EGFP	   vs.	   Rht14-­‐10	   and	  MDCKII	  
ABCC2	  vs.	  MDCKII)	  in	  the	  presence	  or	  absence	  of	  100	  µM	  carbamazepine	  (CBZ).	  Data	  are	  expressed	  
as	  means	  ±	  standard	  deviation	  (n	  =	  3	  independent	  experiments	  in	  triplicate)	  
	  
Figure	  2.4:	  ABCC2	  immunoblot	  of	  plasma	  membrane	  vesicle	  preparations	  
Immunoblot	  with	  monoclonal	   antibody	   against	  ABCC2	   (MRP2)	   indicating	   expression	  or	   absence	  of	  
ABCC2-­‐EGFP.	   Lane	   1:	   Rht14-­‐10	   plasma	   membrane	   vesicles;	   Lane	   2:	   Rht14-­‐10	   ABCC2(WT)-­‐EGFP	  
plasma	  membrane	  vesicles	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CDCF	  served	  as	  a	  positive	  control	   substrate	  and	   is	   closely	   related	   to	   the	  
CMFDA	  hydrolysis	  product	  GS-­‐MF	  (Pratt	  et	  al.	  2006).	  Drug	  uptake	  was	  determined	  
in	   the	   presence	   of	   either	   ATP	   or	   AMP.	   ABCC2	   (MRP2)	   over-­‐expressing	   vesicles	  
exhibited	  a	   significant	  94	  %	   reduction	  of	  CDCF	  uptake	  when	  ATP	  was	   replaced	  by	  
AMP	  (Figure	  2.5	  A).	  In	  addition,	  control	  vesicles	  accumulated	  26	  %	  less	  CDCF	  in	  the	  
presence	   of	   ATP	   as	   compared	   to	   ABCC2	   over-­‐expressing	   vesicles.	   These	   results	  
confirmed	  that	  vesicle	  preparations	  were	  functionally	  suitable	  to	  investigate	  CBZ	  as	  
a	   potential	   ABCC2	   substrate.	   In	   contrast	   to	   CDCF,	   CBZ	   uptake	   into	   control	   and	  
ABCC2-­‐EGFP	  over-­‐expressing	  vesicles	  was	  not	  different	  both	  in	  the	  presence	  of	  AMP	  
or	  ATP	  (Figure	  2.5	  B).	  
In	  addition	  to	  CBZ,	  the	  uptake	  of	  three	  other	  AEDs,	  namely	  LTG,	  TPM,	  and	  
LEV,	  was	   analysed	   but	   also	  with	   negative	   outcome	   (Figure	   2.5	   C-­‐E).	   Although	   the	  
focus	   of	   this	   research	   chapter	  was	   the	   analysis	   of	   CBZ,	   the	   additional	   three	  AEDs	  
were	  included	  because	  only	  limited	  transport	  studies	  on	  ABCC2	  have	  been	  done	  so	  
far	   (Baltes	   et	   al.	   2007,	   Luna-­‐Tortos	   et	   al.	   2010,	   Luna-­‐Tortos	   et	   al.	   2009).	   In	  
agreement	   with	   the	   negative	   results	   presented	   here,	   these	   studies	   also	   failed	   to	  
find	   any	   ABCC2-­‐mediated	   transport	   of	   LTG,	   TPM,	   and	   LEV	   and	   thus	   further	  
experiments	  were	  not	  pursued.	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Figure	   2.5:	   Vesicle	   uptake	   assays	   to	   investigate	   whether	   different	   antiepileptic	   drugs	   are	  
substrates	  of	  ABCC2	  
Uptake	   assays	   into	   inside-­‐out	   vesicles	   derived	   from	   human	   fibrosarcoma	   cell	   lines	   stably	   over-­‐
expressing	  ABCC2-­‐EGFP	   (Rht14-­‐10	  ABCC2(WT)-­‐EGFP)	   and	   controls	   (Rht14-­‐10).	   Assays	  were	   carried	  
out	   in	   the	  presence	  of	   either	   4	  mM	  ATP	  or	   4	  mM	  AMP	  and	  uptake	  determined	  after	   20	  minutes;	  
A)	   Positive	   control	   substrate	   50	   µM	   5-­‐(and-­‐6)-­‐carboxy-­‐2',7'-­‐dichlorofluorescein	   diacetate	   mixed	  
isomers	   (CDCF);	   B)	   5	   µM	   carbamazepine	   (CBZ);	   C)	   5	   µM	   lamotrigine	   (LTG);	   D)	   5	   µM	   topiramate	  
(TPM);	   E)	   5	   µM	   levetiracetam	   (LEV).	   Data	   are	   expressed	   as	   means	   ±	   standard	   deviation	   (n	   =	   3).	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2.3.3. Clinical	  analysis	  
The	   clinical	   impact	   of	   three	   ABCC2	   polymorphisms	   on	   CBZ	   treatment	   outcomes	  
(time	  to	  first	  seizure	  and	  time	  to	  12-­‐month	  remission)	  was	  analysed	  using	  samples	  
from	  the	  SANAD	  study.	  229	  patients	  on	  CBZ	  monotherapy	  were	  eligible	  for	  analysis	  
of	  time	  to	  first	  seizure.	  Out	  of	  these,	  a	  subset	  of	  134	  patients	  received	  treatment	  for	  
at	   least	  365	  days	  and	  was	  eligible	  for	  analysis	  of	  time	  to	  12-­‐month	  remission.	  The	  
clinical	  and	  demographic	  data	  are	  summarised	  in	  Table	  2.1.	  
Table	  2.1:	  Baseline	  clinical	  and	  demographic	  characteristics	   for	  patients	  selected	  for	   time	  to	   first	  
seizure	  (n=229)	  and	  time	  to	  12-­‐month	  remission	  outcome	  analysis	  (n=134)	  
	   	  
Time	   to	   first	  
seizure	  (n=229)	  
Time	   to	   12-­‐month	  
remission	  (n=134)	  
Sex	   	   	   	  
	   Female	   113	  (49	  %)	   72	  (54	  %)	  
Treatment	  history	   	   	   	  
	   Untreated	   115	  (50	  %)	   74	  (55	  %)	  
History	   	   	   	  
	   Learning	  disability	   16	  (7	  %)	   8	  (6	  %)	  
	   Neurological	  deficit	   17	  (7	  %)	   8	  (6	  %)	  
Neurological	  disorder	   	   	   	  
	   Stroke/cerebrovascular	   19	  (8	  %)	   14	  (10	  %)	  
	   Intracranial	  surgery	   12	  (5	  %)	   7	  (5	  %)	  
	   Head	  injury	   9	  (4	  %)	   6	  (4	  %)	  
	   Meningitis/encephalitis	   5	  (2	  %)	   2	  (1	  %)	  
	   Other	   18	  (8	  %)	   12	  (9	  %)	  
Epilepsy	  syndrome	   	   	   	  
	   Partial	   215	  (94	  %)	   122	  (91	  %)	  
	   Generalised	   0	  (0	  %)	   0	  (0	  %)	  
	   Unclassified	   14	  (6	  %)	   12	  (9	  %)	  
Mean	  age	  in	  years	  at	  CBZ	  
treatment	  start	  (SD)	  
	   41	  (17)	   42	  (17)	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Genetic	   polymorphisms	   of	   interest	   included	   rs717620	   (-­‐24C>T),	  
rs2273697	  (c.1249G>A),	  and	  rs3740066	  (c.3972C>T).	  The	  Illumina	  chip	  covered	  the	  
first	   two	   variants	   but	   not	   the	   latter	   one.	   The	   closely	   located	   SNP	   rs3740067	  
(c.3843+124C>G),	   however,	   was	   included	   on	   the	   chip	   and	   is	   in	   perfect	   linkage	  
disequilibrium	   (LD)	   to	   rs3740066	   (r2=1,	   Figure	   2.6).	   It	   was	   therefore	   eligible	   as	   a	  
surrogate	  marker.	  Minor	  allele	  frequencies	  (MAFs)	  for	  all	  three	  polymorphisms	  are	  
summarised	  in	  Table	  2.2	  and	  correspond	  well	  to	  the	  MAFs	  extracted	  from	  HapMap.	  
All	   HapMap	   data	   used	   for	   analysis	   were	   from	   Utah	   residents	   with	   northern	   and	  
western	  European	  ancestry	  (CEU)	  from	  phase	  III	  release	  28.	  
	  
Figure	  2.6:	  Linkage	  disequilibrium	  plot	  for	  selected	  ABCC2	  genetic	  polymorphisms	  
Linkage	   disequilibrium	   (LD)	   plot	   for	   the	   genetic	   polymorphisms	   rs717620	   (-­‐24C>T),	   rs2273697	  
(c.1249G>A),	   rs3740066	   (c.3972C>T),	   and	   the	   surrogate	  marker	   rs3740067	   (c.3843+124C>G).	   LD	   is	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Table	  2.2:	  Minor	  allele	  frequencies	  for	  selected	  polymorphisms	  in	  ABCC2	  
rs717620	  (-­‐24G>A)	   rs2273697	  (c.1249G>A)	   rs3740067	  (c.3843+124C>G)	  
HapMap	  (CEU):	  0.21	   HapMap	  (CEU):	  0.24	   HapMap	  (CEU):	  0.35	  





















0.20	   0.18	   0.18	   0.19	   0.38	   0.35	  
	  
SNPs	   rs717620	   (-­‐24C>T)	   and	   rs2273697	   (c.1249G>A)	   were	   successfully	  
genotyped	   in	   all	   229	   patients.	   rs3740067	   (c.3843+124C>G)	   was	   successfully	  
genotyped	  in	  228	  out	  of	  229	  patients.	  For	  survival	  analysis,	  each	  polymorphism	  was	  
stratified	   against	   genotype	   and	   analysed	   for	   both	   outcomes,	   time	   to	   first	   seizure	  
and	   time	   to	   12-­‐month	   remission.	   Kaplan-­‐Meier	   curves	  were	  plotted	   from	  Kaplan-­‐
Meier	   estimates	   but	   frequently	   crossed	   each	   other	   indicating	   a	   violation	   of	   the	  
proportional	  hazards	  assumption	  underlying	  Cox	  regression	  modelling	  and	  the	  log-­‐
rank	   test.	   To	  obtain	   a	   reliable	  p-­‐value,	   additional	   parametric	   survival	   curves	  were	  
fitted	   to	   the	   Kaplan-­‐Meier	   estimates.	   Three	   commonly	   used	   distributions	   were	  
assessed	   for	   their	   appropriateness	   to	   fit	   the	   Kaplan-­‐Meier	   estimates,	   the	  
exponential,	   Weibull,	   and	   log-­‐logistic	   distribution.	   Holding	   of	   model	   assumptions	  
was	  verified	  graphically	  by	  transforming	  each	  survival	  function	  into	  a	  linear	  function	  
and	   plotting	   the	   transformed	   Kaplan-­‐Meier	   estimates	   against	   time	   or	   natural	  
logarithm	  (ln)	  of	  time	  (Table	  2.3).	  Reasonable	  linear	  and	  parallel	  lines	  were	  obtained	  
for	  the	  Weibull	  and	  log-­‐logistic	  distributions	  for	  both	  outcomes	  analysed	  (Figure	  2.7	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Table	  2.3:	  Parametric	  survival	  functions	  with	  linear	  transformations	  
Distribution	   Survival	  function	   Linear	  transformation	  of	  survival	  function	  
Exponential	  	   𝑆(𝑡) = exp  (−𝜆𝑡)	   −𝑙𝑛 𝑆(𝑡) = 𝜆𝑡	  
Weibull	  	   𝑆(𝑡) = exp  (−𝜆𝑡!)	   𝑙𝑛 −ln  (𝑆 𝑡 ) = ln 𝜆 + 𝑝 ∙ 𝑙𝑛(𝑡)	  
Log-­‐logistic	  	   𝑆(𝑡) = 11 + 𝜆𝑡!	   ln 1𝑆 𝑡 − 1 = 𝑝 ∙ ln  (𝜆) + 𝑝 ∙ ln  (𝑡)	  
	  
For	  final	  model	  selection,	  Akaike´s	  information	  criterion	  was	  calculated	  as	  
a	  measure	  of	  the	  goodness	  of	  fit.	  The	  log-­‐logistic	  distribution	  was	  found	  to	  describe	  
all	  analysed	  outcomes	  and	  genotypes	  best.	  With	  one	  exception,	  the	  p-­‐values	  of	  the	  
corresponding	   regression	   coefficients	   indicated	   no	   statistically	   significant	  
differences	  between	  genotypes	  and	  outcomes	  (Figure	  2.9).	  The	  time	  to	  first	  seizure	  
analysis	  for	  SNP	  rs717620	  (-­‐24C>T)	  was	  statistically	  significant	  with	  p=0.034	  but	  did	  
not	  withstand	  Bonferroni	  correction	  for	  multiple	  testing	  (pc	  =	  0.01).	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Figure	  2.7:	  Graphical	  analysis	  of	  parametric	  model	  assumptions	  for	  time	  to	  first	  seizure	  outcomes	  
Transformed	   Kaplan-­‐Meier	   estimates	   for	   genetic	   polymorphisms	   rs717620	   (-­‐24G>A),	   rs2273697	  
(c.1249G>A),	   and	   rs3740067	   (c.3843+124C>G)	   stratified	   according	   to	   genotype	   are	  plotted	   against	  
time	  or	  natural	  logarithm	  (ln)	  of	  time.	  Three	  commonly	  used	  distributions,	  exponential,	  Weibull,	  and	  
log-­‐logistic,	  were	  analysed	  for	  holding	  of	  model	  assumptions	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Figure	   2.8:	  Graphical	   analysis	   of	   parametric	  model	   assumptions	   for	   time	   to	   12-­‐month	   remission	  
outcomes	  
Transformed	   Kaplan-­‐Meier	   estimates	   for	   genetic	   polymorphisms	   rs717620	   (-­‐24G>A),	   rs2273697	  
(c.1249G>A),	   and	   rs3740067	   (c.3843+124C>G)	   stratified	   according	   to	   genotype	   are	  plotted	   against	  
time	  or	  natural	  logarithm	  (ln)	  of	  time.	  Three	  commonly	  used	  distributions,	  exponential,	  Weibull,	  and	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Figure	  2.9:	  Survival	  analysis	  for	  selected	  ABCC2	  genetic	  polymorphisms	  to	  investigate	  an	  impact	  on	  
carbamazepine	  treatment	  response	  
Survival	   analysis	   for	   genetic	   polymorphisms	   rs717620	   (-­‐24G>A),	   rs2273697	   (c.1249G>A),	   and	  
rs3740067	  (c.3843+124C>G)	  as	  a	  surrogate	  marker	  for	  rs3740066	  (c.3972C>T)	  stratified	  according	  to	  
genotype.	  Outcomes	  analysed	  were	  A)	  Time	  to	  first	  seizure	  and	  B)	  Time	  to	  12-­‐month	  remission.	  Step	  
curves	  were	  plotted	  from	  Kaplan-­‐Meier	  estimates	  with	  vertical	  tick-­‐marks	  indicating	  right	  censoring.	  
Smooth	   curves	  were	   derived	   from	   fitting	   a	   parametric	   log-­‐logistic	  model	   to	   the	   data.	   The	   p-­‐value	  
obtained	  from	  the	  log-­‐logistic	  regression	  coefficient	  is	  indicated.	  p<0.05	  was	  considered	  statistically	  
significant	  
2.4. Discussion	  
The	  study	  of	  ABCC2	  (MRP2)	  as	  a	  potential	  mechanism	  for	  CBZ	  pharmacoresistance	  
has	   become	   a	   highly	   active	   field	   of	   research	   but	   results	   from	   in	   vitro	   and	   clinical	  
studies	   have	   largely	   been	   conflicting.	   The	   present	   analysis	   attempted	   to	  
comprehensively	  investigate	  both	  aspects	  to	  gain	  more	  confidence	  in	  the	  potential	  
importance	  of	  ABCC2	  regarding	  CBZ	  treatment	  response	  in	  epilepsy.	  
Sets	   of	   highly	   sensitive	   in	   vitro	   assays	   were	   utilised	   to	   investigate	   the	  
direct	  transport	  of	  tritium-­‐labelled	  CBZ	  by	  ABCC2.	  CBZ	  was	  found	  to	  be	  negative	  in	  
time-­‐course	   cell	   efflux	   assays	   from	   two	   different	   ABCC2	   transfected	   cell	   lines	  
(human	  Rht14-­‐10	  and	  canine	  MDCKII,	  Figure	  2.2).	   In	  addition,	  100	  µM	  CBZ	  had	  no	  
effect	  on	  ABCC2-­‐mediated	  GS-­‐MF	  efflux	  (Figure	  2.3).	  	  
Efflux	  assays	  from	  cells	  can	  be	  limited	  by	  the	  initial	  uptake	  of	  the	  drug	  into	  
the	   cells.	   To	   circumvent	   any	   potential	   uptake	   issues	   and	   metabolism	   with	   living	  
cells,	   inside-­‐out	   plasma	   membrane	   vesicles	   were	   prepared	   from	   Rht14-­‐10	   and	  
Rht14-­‐10	  ABCC2(WT)-­‐EGFP	  cell	   lines.	  The	  EGFP-­‐tag	  has	  previously	  been	  shown	  not	  
to	   affect	   ABCC2	   function	   using	   two	   model	   substrates	   (Arlanov	   et	   al.	   2012)	   and	  
allows	   a	   visual	   control	   of	   protein	   expression	   throughout	   cell	   passaging.	   CDCF	   is	   a	  
well-­‐established	  control	  substrate	  for	  vesicular	  uptake	  assays	  with	  ABCC2	  (Colombo	  
et	  al.	  2013,	  Heredi-­‐Szabo	  et	  al.	  2008,	  Kidron	  et	  al.	  2012,	  Lechner	  et	  al.	  2010)	  and	  
mimics	  GS-­‐MF,	  the	  hydrolysis	  and	  conjugation	  product	  of	  CMFDA	  used	  for	  cell	  efflux	  
assays.	   Uptake	   of	   CDCF	   into	   ABCC2	   over-­‐expressing	   vesicles	   markedly	   dropped	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when	   ATP	  was	   replaced	   by	   AMP	   (Figure	   2.5	   A).	   Also,	   control	   vesicles	   exhibited	   a	  
reduced	   accumulation	   in	   the	   presence	   of	   ATP	   as	   compared	   to	   ABCC2	   over-­‐
expressing	  vesicles.	  The	  remaining	  accumulation	  might	  be	  a	  result	  of	  compensatory	  
effects	   by	   other,	   endogenous	   ABC	   transporters	   recognising	   that	   CDCF	   is	   a	   rather	  
unspecific	   substrate	   (Lehmann	   et	   al.	   2001,	   Pratt	   et	   al.	   2006).	   The	   ABCC2	   model	  
substrates	   leukotriene	   C4	   or	   estradiol-­‐17β-­‐D-­‐glucuronide	   (E217βG)	   are	   not	  
considered	  promising	  alternatives	   to	  CDCF,	  as	  both	  are	  also	  known	  substrates	   for	  
other	   ABC	   transporters	   (see	   chapter	   1	   section	   1.2.2).	   However,	   given	   that	   CDCF-­‐
uptake	  was	  strongly	  ATP-­‐dependent	  but	  CBZ	  was	  not,	  CBZ	  does	  not	  seem	  to	  be	  a	  
substrate	  for	  any	  of	  the	  expressed	  ABC	  transporters,	  including	  ABCC2	  (Figure	  2.5	  B).	  
Together,	  the	  presented	  negative	  cell-­‐efflux	  and	  vesicle-­‐uptake	  experiments	  do	  not	  
suggest	  a	  role	  for	  ABCC2	  in	  CBZ	  efflux.	  	  
The	  presented	  in	  vitro	  data	  confirm	  previously	  published	  results	  indicating	  
no	  direct	  transport	  of	  CBZ	  by	  ABCC2	  (Luna-­‐Tortos	  et	  al.	  2010)	  but	  conflict	  with	  the	  
conclusions	  drawn	  by	  Kim	  et	  al.	   (2010)	  who	  performed	   indirect	   functional	   studies	  
with	   human	   embryonic	   kidney	   cells	   (HEK293)	   over-­‐expressing	  ABCC2	  WT	   and	   the	  
c.1249G>A	   variant	   (valine	   substituted	   by	   isoleucine	   at	   position	   417).	   They	   found	  
that	  CBZ	  can	  inhibit	  efflux	  of	  the	  ABCC2	  substrate	  5,6-­‐carboxyfluorescein	  diacetate	  
in	  ABCC2	  WT	  but	  only	  weakly	  in	  ABCC2	  V417I	  transfected	  cells	  (Kim	  et	  al.	  2010).	  In	  
addition,	  ATPase	  activities	  in	  membrane	  vesicles	  obtained	  from	  the	  same	  cell	   lines	  
were	   compared	   regarding	   their	   response	   to	   CBZ	   treatment.	   With	   increasing	   CBZ	  
concentrations,	   ABCC2	   WT	   vesicles	   exhibited	   substantial	   ATPase	   activity.	   In	  
contrast,	  the	  variant	  only	  showed	  about	  15	  %	  of	  the	  maximum	  ABCC2	  WT	  ATPase	  
activity	   concluding	   that	   CBZ	   is	   a	   substrate	   of	   ABCC2	   with	   impaired	   transporter	  
activity	   in	   the	   variant	   (Kim	   et	   al.	   2010).	   These	   data	   have	   to	   be	   interpreted	   with	  
caution	  however,	   since	  neither	   assay	  measures	   the	   transport	  of	  CBZ	  directly.	   It	   is	  
well	   established	   that	   drugs	   with	   inhibitory	   potencies	   may	   not	   necessarily	   be	  
substrates	  themselves	  and	  ABCC2	  has	  been	  suggested	  to	  have	  at	  least	  two	  binding	  
sites	  with	  one	  modulatory	  and	  one	  transport	  binding	  site	  (Bodo	  et	  al.	  2003,	  Zelcer	  
et	   al.	   2003).	   Furthermore,	   ATPase	   assays	   only	   measure	   the	   release	   of	   inorganic	  
phosphate	   after	   stimulation	   of	   any	   ATPase	   activity	   but	   again	   are	   not	   a	   direct	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transport	  measure.	   It	   is	   unclear	  why	   the	  CBZ-­‐mediated	   inhibition	  of	  GS-­‐MF	  efflux	  
seen	  by	  Kim	  et	  al.	  could	  not	  be	  reproduced	  (Figure	  2.3).	  However,	  consistent	  with	  
the	   data	   presented	   here	   it	   has	   been	   reported	   that	   CBZ	   is	   not	   an	   inhibitor	   of	   the	  
ABCC2	  model	  substrate	  E217βG	  (Pedersen	  et	  al.	  2008).	  
Three	   ABCC2	   polymorphisms	   have	   been	   extensively	   studied	   regarding	  
their	   impact	   on	   CBZ	   or	   AED	   treatment	   response	   in	   epilepsy	   patients,	   namely	  
rs717620	  (-­‐24C>T),	  rs2273697	  (c.1249G>A),	  and	  rs3740066	  (c.3972C>T).	  To	  follow-­‐
up	  on	  the	  negative	  CBZ	  in	  vitro	  studies,	  the	  clinical	  influence	  of	  these	  three	  SNPs	  on	  
response	   to	   CBZ	   monotherapy	   was	   analysed	   using	   the	   well-­‐accepted	   clinical	  
outcome	   measures	   time	   to	   first	   seizure	   and	   time	   to	   12-­‐month	   remission.	   No	  
statistically	  significant	  differences	  were	   found	  between	  genotypes	  after	  correcting	  
for	  multiple	  testing	  (Figure	  2.9).	  
To	  our	  knowledge,	   this	   is	   the	   first	   study	  analysing	   time	  to	  event	  data	   to	  
explore	   the	   potential	   role	   of	   ABCC2	   polymorphisms	   on	   CBZ	   treatment	   efficacy.	  
Previously	   published	   studies	   tested	   for	   differences	   between	   the	   genotypes	   of	  
responders	   and	   non-­‐responders	   using	  𝜒! 	  or	   Fisher’s	   exact	   test	   and/or	   logistic	  
regression	   modelling.	   There	   are	   several	   advantages	   to	   survival	   analysis.	   First,	  
censored	   data	   can	   be	   included	   and	   provide	   a	   powerful	   tool	   to	   make	   use	   of	   all	  
available	   data	   whilst	   reducing	   any	   potential	   selection	   bias.	   Patients	   that	   do	   not	  
respond	  well	  to	  treatment	  might	  be	  at	  a	  higher	  risk	  of	  dropout	  and	  therefore	  are	  at	  
higher	  risk	  of	  being	  excluded	  from	  other	  methods	  compared	  with	  survival	  analysis.	  
Second,	  there	  is	  no	  need	  to	  define	  a	  specific	  time-­‐point	  in	  order	  to	  classify	  patients	  
as	   responders	   or	   non-­‐responders.	   Other	   advantages	   of	   the	   presented	   analysis	  
include	  the	  prospective	  nature	  of	  data	  collection	  over	  a	  long	  period	  of	  time	  (6	  years	  
maximum)	   in	   a	   well-­‐defined	   cohort	   of	   patients	   recruited	   into	   a	   randomised	  
controlled	  trial.	  All	  selected	  patients	  were	  treated	  with	  CBZ	  monotherapy	  and	  most	  
(>	  90	  %)	  had	  focal	  epilepsy.	  	  
This	   patient	   population	   does	   have	   some	   limitations,	   most	   notably	   the	  
sample	   size.	   As	   the	   number	   of	   patients	   at	   risk	   drop	   over	   time	   the	   cumulative	  
survival	  probabilities	  are	  not	  well	  described	  by	  Kaplan-­‐Meier	  curves	  and	  parametric	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models	   are	   difficult	   to	   fit.	   This	   is	   particularly	   an	   issue	   with	   the	   data	   after	  
approximately	   500	   days	   (Figure	   2.9).	   Up	   to	   500	   days,	   however,	   the	   survival	  
probabilities	   are	   described	   well	   by	   parametric	   models	   based	   on	   the	   log-­‐logistic	  
distribution.	  Another	   limitation	  of	   the	   study	  could	  have	  been	   the	  dosing	   that	  was	  
not	   dictated	   by	   the	   study	   protocol	   but	   rather	   was	   at	   the	   discretion	   of	   each	  
investigator	   according	   to	   clinical	   guidelines	   (Marson	   et	   al.	   2007).	   However,	   this	  
approach	  was	  considered	  closer	   to	  clinical	  practice.	  The	  ethnic	  background	  of	   the	  
patients	  was	  not	  taken	  into	  account	  for	  the	  analysis	  but	  the	  SANAD	  study	  was	  solely	  
conducted	   in	   the	  UK	  and	  MAFs	   from	  all	   included	  patients	   correspond	  well	   to	   the	  
MAFs	  obtained	  for	  Caucasians	  from	  HapMap	  (Table	  2.2).	  
Several	  factors	  can	  account	  for	  the	  conflicting	  results	  previously	  reported.	  
These	  include	  the	  sample	  size,	  definition	  of	  outcome,	  time	  of	  observation,	  epilepsy	  
phenotype,	   co-­‐treatment	   with	   other	   AEDs,	   prospective	   vs.	   retrospective	   studies,	  
and	   differences	   in	   the	   study	   population.	   The	   survival	   analysis	   presented	   here	   is	  
potentially	  the	  most	  unbiased	  study	  reported	  so	  far	  and	  is	  consistent	  with	  previous	  
studies	  that	  failed	  to	  find	  any	  association	  between	  the	  investigated	  polymorphisms	  
and	  CBZ	  treatment	  efficacy.	  
ABCC2,	   expressed	   in	   important	   biological	   barriers	   such	   as	   hepatocytes	  
and	  proximale	  tubule	  epithelial	  kidney	  cells,	   is	   involved	  in	  the	  excretion	  of	  various	  
conjugated	  endogenous	  and	  exogenous	  substrates	   (see	  chapter	  1	  section	  1.2.2.2).	  
Therefore,	  it	  is	  possible	  that	  a	  conjugated	  CBZ-­‐metabolite	  is	  recognised	  as	  an	  ABCC2	  
substrate	   rather	   than	   the	   parent	   drug.	   Based	  on	   the	   presented	   in	   vitro	   data,	   this	  
possibility	  cannot	  be	  excluded.	  The	  additional	  survival	  data,	  however,	  describe	  the	  
efficacy	   of	   CBZ	   treatment	   in	   vivo	   and	   therefore	   include	   potential	   clinical	   effects	  
derived	  from	  CBZ-­‐metabolites	  for	  the	  outcomes	  and	  genotypes	  measured.	  
In	  conclusion,	  CBZ	  is	  not	  actively	  transported	  by	  ABCC2	  in	  vitro.	  Clinically,	  
no	   association	   between	   ABCC2	   polymorphisms	   rs717620	   (-­‐24C>T),	   rs2273697	  
(c.1249G>A),	   rs3740066	   (c.3972C>T),	   and	   CBZ	   treatment	   response	   could	   be	  
observed	  in	  patients	  from	  the	  SANAD	  study.	  This	  comprehensive	  analysis	  does	  not	  
support	  a	  significant	  role	  for	  ABCC2	  in	  CBZ	  treatment	  efficacy.	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Membrane	  transporters	  are	  beginning	   to	  be	  recognised	  as	   important	  components	  
in	  drug	  ADME	  and	  the	  FDA	  recommends	  an	  increasing	  number	  of	  transporters	  to	  be	  
included	   in	  drug	   interaction	  studies	   in	  clinical	  development	   (see	  chapter	  1	  section	  
1.2).	  Despite	  their	  emerging	  role,	  drug	  transport	  processes	  have	  rarely	  been	  studied	  
for	   already	   licensed	   AEDs	   and	   the	   mechanism	   of	   BBB	   translocation	   is	   largely	  
unknown	   or	   considered	   to	   rely	   on	   passive	   diffusion.	   The	   available	   studies	   have	  
largely	   focused	   on	   ABCB1	   (MDR1,	   Pgp),	   ABCC1	   (MRP1),	   ABCC2	   (MRP2),	   ABCC5	  
(MRP5),	   and	   ABCG2	   (BCRP)	   as	   potential	   mediators	   for	   pharmacoresistance,	   but	  
results	  have	  mostly	  been	  conflicting	  or	  negative	   (see	  chapter	  1	  sections	  1.3.3	  and	  
1.4).	   In	   view	   of	   the	   fact	   that	   the	   human	   genome	   encodes	   for	   at	   least	   390	   SLC	  
transporters	   (see	  chapter	  1	   section	  1.2.1)	  and	  48	  ABC	   transporters	   (see	  chapter	  1	  
section	   1.2.2),	   more	   research	   is	   needed	   to	   clarify	   the	   potential	   role	   drug	  
transporters	  play	   in	   the	  uptake	  and	  efflux	  of	   established	  AEDs,	  particularly	   at	   the	  
BBB.	  
A	   better	   understanding	   of	   AED	   ADME	   will	   be	   important	   to	   make	   AED	  
treatment	   more	   effective	   and	   safer.	   To	   address	   this	   research	   need,	   a	   screening	  
approach	   was	   applied	   in	   order	   to	   find	   and	   characterise	   unknown	   transport	  
processes	   for	   six	   major	   AEDs,	   namely	   CBZ,	   LTG,	   TPM,	   LEV,	   VPA,	   and	   PHT	   (see	  
chapter	  1	  section	  1.3.3).	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3.2. Materials	  and	  methods	  
3.2.1. Materials	  
Unless	   otherwise	   specified,	   all	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich	  
Company	   Ltd.,	   Gillingham,	   UK.	   EBM-­‐2	   basal	   medium	   was	   obtained	   from	   Lonza	  
Group	   Ltd.,	   Basel,	   Switzerland.	   TaqMan®	   gene	   expression	   assays,	   TaqMan®	   gene	  
expression	  master	  mix,	  TaqMan®	  reverse	  transcription	  reagents,	  collagen	  I	  from	  rat	  
tail,	  fibroblast	  growth	  factor-­‐basic	  (amino	  acids	  1-­‐155)	  recombinant	  human	  protein	  
(bFGF),	  chemically	  defined	  lipid	  concentrate,	  and	  SLC7A5	  targeting/negative	  control	  
#1	   Silencer®	   Select	   siRNAs	   came	   from	  Life	   Technologies	   Ltd.,	   Paisley,	  UK.	   Tritium-­‐
labelled	   CBZ	   ([3H]-­‐CBZ,	   1	   mCi/ml,	   specific	   activity	   10.0	   Ci/mmol),	   tritium-­‐labelled	  
LTG	  ([3H]-­‐LTG,	  1	  mCi/ml,	  specific	  activity	  5.0	  Ci/mmol),	   tritium-­‐labelled	  TPM	  ([3H]-­‐
TPM,	   1	   mCi/ml,	   specific	   activity	   8.0	   Ci/mmol),	   tritium-­‐labelled	   LEV	   ([3H]-­‐LEV,	  	  
1	   mCi/ml,	   specific	   activity	   5.0	   Ci/mmol),	   and	   tritium-­‐labelled	   GBP	   ([3H]-­‐GBP,	  	  
1	   mCi/ml,	   specific	   activity	   1.0	   Ci/mmol)	   were	   purchased	   from	   American	  
Radiolabeled	   Chemicals	   Inc.,	   St.	   Louis,	   MO,	   USA.	   Tritium-­‐labelled	   VPA	   ([3H]-­‐VPA,	  	  
1	   mCi/ml,	   specific	   activity	   55.0	   Ci/mmol)	   and	   tritium-­‐labelled	   PHT	   ([3H]-­‐PHT,	  	  
1	  mCi/ml,	  specific	  activity	  1.1	  Ci/mmol)	  came	  from	  Moravek	  Biochemicals	  Inc.,	  Brea,	  
CA,	   USA	   and	   tritium-­‐labelled	   digoxin	   ([3H]-­‐digoxin,	   1	   mCi/ml,	   specific	   activity	  	  
40.0	  Ci/mmol)	  from	  PerkinElmer,	  Seer	  Green,	  UK.	  Gold	  Star	  scintillation	  cocktail	  was	  
purchased	   from	  Meridian	  Biotechnologies	  Ltd.,	  Epsom,	  UK,	  MK571,	  methotrexate,	  
and	   Ko143	   from	   Tocris	   Bioscience,	   Bristol,	   UK,	   and	   montelukast	   from	   Insight	  
Biotechnology	  Ltd.,	  Wembley,	  UK.	  DharmaFECT1	  transfection	  reagent,	  Dharmacon	  
targeting	  siGENOME	  siRNAs	  -­‐	  SMARTpool,	  and	  non-­‐targeting	  siGENOME	  siRNA	  pool	  
#2	  were	  obtained	   from	  Fermentas	  GmbH	  –	  Thermo	  Fisher	  Scientific,	  St.	  Leon-­‐Rot,	  
Germany.	   FlexiTube	  GeneSolution	   for	  human	  ABCC5	   and	  AllStars	  negative	   control	  
siRNA	  came	  from	  Qiagen	  Ltd.,	  Manchester,	  UK.	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3.2.2. Cell	  lines	  and	  culture	  conditions	  
3.2.2.1. hCMEC/D3	  cell	  line	  
The	  human	  microvascular	  brain	  endothelial	  cell	   line	  hCMEC/D3	   is	  an	   immortalised	  
cell	   clone	   derived	   from	   primary	   brain	   endothelial	   cells	   from	   a	   female	   epilepsy	  
patient	  who	  underwent	  temporal	  lobectomy	  (Weksler	  et	  al.	  2005).	  The	  primary	  cells	  
were	  immortalised	  using	  a	  lentiviral	  transduction	  approach	  with	  human	  telomerase	  
reverse	  transcriptase	  and	  the	  simian	  vacuolating	  virus	  40	   large	  T	  antigen	  (Weksler	  
et	  al.	  2005).	  hCMEC/D3	  cells	  were	  cultured	  at	  37	  °C	  and	  5	  %	  CO2	  in	  EBM-­‐2	  medium	  
supplemented	  with	  5	  %	  FBS	  (v/v),	  1	  %	  penicillin-­‐streptomycin	  (v/v),	  10	  mM	  HEPES,	  
1.4	   µM	   hydrocortisone,	   5	   µg/ml	   ascorbic	   acid,	   1	   %	   chemically	   defined	   lipid	  
concentrate	   (v/v),	   and	   1	   ng/ml	   bFGF.	   hCMEC/D3	   are	   adhesive	   cells	   and	   were	  
cultured	  on	   collagen-­‐coated	  plates	   or	   flasks.	   For	   collagen-­‐coating,	   collagen	   I	   from	  
rat	   tail	   was	   diluted	   with	   distilled	   water	   to	   give	   a	   final	   protein	   concentration	   of	  	  
60	  µg/ml.	  Plates/flasks	  were	  treated	  with	  the	  solution	  for	  1-­‐2	  hours	  at	  37	  °C.	  After	  
treatment,	  the	  collagen	  solution	  was	  removed	  and	  plates/flasks	  washed	  once	  with	  
HBSS.	  
3.2.3. Distribution	  coefficient	  (logD,	  pH	  7.4)	  
The	   distribution	   coefficient	   (logD,	   pH	   7.4)	   is	   a	   commonly	   used	   measure	   for	   the	  
lipophilicity	  of	  a	  drug.	  It	  is	  related	  to	  the	  partitioning	  coefficient	  (logP)	  and	  describes	  
the	  distribution	  of	  a	  drug	  in	  a	  biphasic	  system	  at	  equilibrium,	  usually	  1-­‐octanol	  and	  
water	   (Kenakin	   2012).	   While	   the	   logP	   does	   not	   take	   account	   of	   the	   potentially	  
ionised	  fraction	  of	  a	  drug,	  the	   logD	   is	  the	  distribution	  at	  a	  given	  pH	  and	  therefore	  
independent	  of	  the	  compounds	  net	  charge	  (Kenakin	  2012).	  
The	   logD	   was	   determined	   at	   a	   physiological	   pH	   of	   7.4	   using	   transport	  
buffer	  as	  aqueous	  phase	  (HBSS	  supplemented	  with	  25	  mM	  HEPES,	  adjusted	  to	  pH	  
7.4)	  and	  1-­‐octanol	  as	  organic	  phase	  (Davies	  et	  al.	  2009,	  Dickens	  et	  al.	  2013a,	  Yunger	  
et	   al.	   1981).	   0.64	  µl	   from	  a	  1/10	  dilution	  of	   tritium-­‐labelled	  drug	  was	  mixed	  with	  	  
4	  ml	  transport	  buffer	  and	  equally	  divided	  into	  4x1	  ml	  fractions,	  each	  supplemented	  
Chapter	  3	  
	  103	  
with	  1	  ml	  1-­‐octanol.	  The	  biphasic	  solutions	  were	  vigorously	  shaken	  for	  15	  minutes	  
and	   subsequently	   centrifuged	   at	   250	   g	   for	   5	   minutes	   at	   room	   temperature	  
(HeraeusTM	  MegafugeTM	   11R	   centrifuge	   with	   T41	   swing-­‐out	   rotor,	   Thermo	   Fisher	  
Scientific,	   Leicestershire,	   UK).	   500	   µl	   from	   both	   phases	   were	   transferred	   into	  
scintillation	  tubes	  containing	  4	  ml	  scintillation	  cocktail.	  Radioactivity	  was	  measured	  
by	   means	   of	   scintillation	   counting	   (1500	   Tri	   Carb	   LS	   Counter,	   Packard,	   now	  
PerkinElmer,	   Seer	   Green,	   UK)	   and	   results	   obtained	   as	   disintegrations	   per	   minute	  
(DPM).	   The	   logD	   was	   calculated	   as	   follows:	  	  𝑙𝑜𝑔𝐷  (𝑝𝐻  7.4) = log  ( !"#  (!!!"#$%!&  !!!"#)!"#  (!"#$%&'"!  !"##$%  !!!"#))	  
3.2.4. Drug	  accumulation	  assays	  
Accumulation	  assays	  were	  prepared	  by	  seeding	  300,000	  hCMEC/D3	  cells/well	  onto	  
NuncTM	  6-­‐well	  plates	  (Fisher	  Scientific	  UK	  Ltd.,	  Loughborough,	  UK)	  with	  culturing	  for	  
two	   days	   to	   reach	   confluence.	   Confluent	   cells	  were	   then	  washed	   two	   times	  with	  
pre-­‐warmed	  (37	  °C)	  HBSS	  and	  the	  assay	   initiated	  by	  adding	  1	  ml/well	  pre-­‐warmed	  
master	  mix.	  A	  separate	  master	  mix	  was	  prepared	  for	  each	  condition	  to	  be	  tested,	  
consisting	  of	  transport	  buffer	  (HBSS	  supplemented	  with	  25	  mM	  HEPES,	  adjusted	  to	  
pH	   7.4),	   0.6	   µCi/ml	   tritium-­‐labelled	   “hot”	   drug	   (except	   [3H]-­‐PHT	   which	   was	   0.3	  
µCi/ml),	   5	   µM	   non-­‐labelled	   corresponding	   “cold”	   drug,	   and,	   if	   applicable,	   the	  
inhibitor	  or	  vehicle	  only	  as	  control.	  The	  total	  vehicle	  concentration	  did	  not	  exceed	  
1.1	   %	   per	   reaction	   (dimethyl	   sulfoxide	   (DMSO)	   and	   methanol).	   The	   assay	   was	  
incubated	   at	   37	   °C	   or	   4	   °C	   for	   the	   desired	   time	   and	   subsequently	   washed	   with	  	  
1	  ml	  ice-­‐cold	  HEPES.	  Washing	  was	  repeated	  three	  times	  and	  the	  cells	  finally	  lysed	  in	  
400	  µl	  10	  %	  SDS.	  Each	  lysate	  was	  transferred	  into	  a	  scintillation	  tube	  containing	  4	  ml	  
scintillation	  cocktail	  and	  radioactivity	  determined	  by	  scintillation	  counting	  (1500	  Tri	  
Carb	  LS	  Counter,	  Packard,	  now	  PerkinElmer,	  Seer	  Green,	  UK).	  
3.2.5. siRNA	  transfection	  
Gene	   silencing	   or	   RNA	   interference	   (RNAi)	   experiments	   by	   means	   of	   small	  
interfering	  RNA	  (siRNA)	  transfections	  were	  essentially	  carried	  out	  as	  recommended	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by	   the	   Dharmacon	   siGENOME	   siRNA	   manufacturer	   Fermentas	   GmbH	   –	   Thermo	  
Fisher	  Scientific,	  St.	  Leon-­‐Rot,	  Germany.	  The	  siRNAs	  for	  all	  genes	  to	  be	  investigated	  
were	  from	  the	  Dharmacon	  siGENOME	  SMARTpool	  product	  line	  from	  Thermo	  Fisher,	  
each	   with	   four	   different	   targeting	   sequences	   pooled	   for	   higher	   knockdown	  
efficiency.	   Transfection	   with	   the	   non-­‐targeting	   siGENOME	   siRNA	   pool	   #2	   was	  
utilised	   as	   negative	   control.	   The	   functional	   positive	   control	   targeting	   SLC7A5	   and	  
corresponding	  non-­‐targeting	  control	  #1	  were	  from	  the	  Silencer®	  Select	  product	  line	  
from	  Life	  Technologies	  with	  one	  siRNA	  sequence	  only.	  For	  ABCC5,	  an	  additional	  set	  
of	   four	  pooled	   siRNAs	  plus	   the	   corresponding	  non-­‐targeting	   control	   (AllStars)	  was	  
obtained	   from	   the	   FlexiTube	  GeneSolution	   line	   from	  Qiagen.	  All	   siRNA	   sequences	  
and	  corresponding	   identification	  numbers	  are	   listed	   in	   the	  appendix.	   Independent	  
from	  manufacturer,	  gene	  silencing	  assays	  were	  carried	  out	  using	  the	  same	  protocol	  
with	  DharmaFECT1	  as	  transfection	  reagent.	  
100,000	  hCMEC/D3	  cells/well	  (or	  as	  specified)	  were	  seeded	  onto	  collagen-­‐
coated	  NuncTM	  6-­‐well	  plates	  and	  incubated	  for	  24	  hours	  to	  allow	  attachment	  to	  the	  
surface.	   The	   growth	   medium	   (3.2.2.1)	   was	   slightly	   modified	   and	   did	   not	   contain	  
penicillin-­‐streptomycin	   throughout	   the	   experiments.	   For	   transfection,	   a	   10x	  
concentrated	   siRNA	   solution	   (1/10	   of	   final	   volume)	   and	   10x	   concentrated	  
DharmaFECT1	   solution	   (1/10	   of	   final	   volume)	   was	   prepared	   separately	   in	   serum-­‐
free	   EBM-­‐2	   medium	   (no	   supplements).	   After	   assay	   optimisation,	   the	   final	  
DharmaFECT1	   concentration	  used	  was	   0.2	  %	   (or	   as	   specified)	   and	   the	   final	   siRNA	  
concentrations	   25	   nM	   (or	   as	   specified).	   Both	   solutions	   were	   gently	   mixed	   and	  
incubated	   for	  5	  minutes	  at	   room	  temperature	  before	  they	  were	  combined,	  gently	  
mixed,	   and	   again	   incubated	   for	   20	   minutes	   at	   room	   temperature.	   Finally,	   the	  
combined	   DharmaFECT1/siRNA	   solutions	   were	   filled-­‐up	   with	   growth	   medium	   to	  
give	  the	  final	  volume	  of	  2	  ml/well	  on	  a	  6-­‐well	  plate	   (1.6	  ml	  culture	  medium	  to	  be	  
added).	  The	  old	  culture	  medium	  was	  replaced	  by	  the	  transfection	  solution	  and	  the	  
cells	   incubated	   at	   37	   °C	   for	   48	   hours.	   Downstream	   experiments	   included	   gene	  
expression	  (3.2.6)	  and	  drug	  accumulation	  assays	  (3.2.4).	  
Chapter	  3	  
	  105	  
3.2.6. Gene	  expression	  
3.2.6.1. RNA	  extraction	  
RNA	   extraction	   was	   carried	   out	   using	   a	   standard	   phenol-­‐chloroform	   extraction	  
method	  based	  on	  the	  TRIzol®	  Reagent	  protocol	  from	  Life	  Technologies	  Ltd.,	  Paisley,	  
UK.	  1	  ml/well	  Tri	  Reagent®	  was	  used	  for	  cell	  homogenisation	  on	  6-­‐well	  plates	  and	  
the	  homogenate	  incubated	  for	  5	  minutes	  at	  room	  temperature.	  0.2	  ml	  chloroform	  
was	   added	   to	   each	   sample,	   vigorously	   shaken	  by	   hand	   for	   15	   seconds,	   and	   again	  
incubated	  at	  room	  temperature	  for	  3	  minutes.	  Centrifugation	  (HeraeusTM	  FrescoTM	  
21	   centrifuge	  with	   24	   x	   1.5/2.0	  ml	   rotor,	   Thermo	   Fisher	   Scientific,	   Leicestershire,	  
UK)	   at	   12,000	   g	   for	   15	  minutes	   at	   4	   °C	   resulted	   in	   a	   phase	   separation	  with	   three	  
layers.	  The	  top	  layer	  with	  RNA	  was	  further	  processed	  and	  the	  RNA	  precipitated	  by	  
adding	   0.5	  ml	   100	   %	   isopropanol.	   Each	   sample	   was	   incubated	   for	   10	  minutes	   at	  
room	   temperature	   and	   centrifuged	   at	   12,000	   g	   at	   4	   °C	   for	   another	   10	   minutes	  
(HeraeusTM	   FrescoTM	   21	   centrifuge	   with	   24	   x	   1.5/2.0	   ml	   rotor,	   Thermo	   Fisher	  
Scientific,	   Leicestershire,	  UK).	   The	   supernatant	  was	   removed	  and	   the	  precipitated	  
RNA	   washed	   with	   1	   ml	   70	   %	   ethanol.	   A	   final	   centrifugation	   step	   at	   7,500	   g	   for	  	  
5	  minutes	   at	   4	   °C	   (HeraeusTM	   FrescoTM	   21	   centrifuge	   with	   24	   x	   1.5/2.0	  ml	   rotor,	  
Thermo	   Fisher	   Scientific,	   Leicestershire,	   UK)	   allowed	   the	   ethanol	   to	   be	   removed.	  
The	  RNA	  pellet	  was	  dried	  for	  10	  minutes	  at	  room	  temperature	  and	  resuspended	  in	  
RNAse-­‐free,	   molecular	   biology-­‐grade	   water.	   RNA	   concentrations	   and	   purity	   were	  
analysed	   on	   a	   NanoDropTM	   8000	   spectrophotometer	   (Fisher	   Scientific	   UK	   Ltd.,	  
Loughborough,	  UK).	  
3.2.6.2. RT-­‐PCR	  
To	  analyse	  gene	  expression,	  messenger	  RNA	   (mRNA)	  was	   first	   reverse-­‐transcribed	  
into	  copy	  DNA	  (cDNA)	  using	  the	  TaqMan®	  reverse	  transcription	  reagents	  for	  reverse	  
transcriptase	  (RT)-­‐polymerase	  chain	  reaction	  (PCR)	  according	  to	  the	  manufacturer.	  
Each	   reaction	  mix	  contained	  1	  µl	  10x	  TaqMan®	  RT	  buffer	   (1x	   final),	  2.2	  µl	  25	  mM	  
MgCl2	   (5.5	   mM	   final),	   2	   µl	   2.5	   mM	   deoxyribonucleoside	   triphosphates	   (dNTPs)	  
mixture	   (500	   µM	   final),	   0.5	   µl	   50	   µM	   random	   hexamers	   (2.5	   µM	   final),	   0.2	   µl	   of	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20	   U/µl	   RNAse	   inhibitor	   (0.4	   U/µl	   final),	   0.35	   µl	   of	   50	   U/µl	   MultiScribe	   reverse	  
transcriptase	  (1.25	  U/µl	  final),	  0.4	  µg	  RNA,	  and	  RNAse-­‐free,	  molecular	  biology-­‐grade	  
water	  to	  give	  a	  final	  volume	  of	  10	  µl.	  The	  reaction	  mix	  was	  incubated	  in	  a	  Veriti®	  96-­‐
well	   thermal	   cycler	   (Life	   Technologies	   Ltd.,	   Paisley,	   UK)	   running	   the	   following	  
programme:	  
1. 25	  °C	  for	  10	  minutes	  
2. 48	  °C	  for	  30	  minutes	  
3. 95	  °C	  for	  5	  minutes	  
4. Hold	  4	  °C	  
Single-­‐stranded	   cDNA	   concentrations	   and	   purity	   were	   analysed	   on	   a	  
NanoDropTM	  8000	  spectrophotometer	  (Fisher	  Scientific	  UK	  Ltd.,	  Loughborough,	  UK)	  
and	  each	   sample	  diluted	   to	   a	   concentration	  of	   50	  ng/µl.	   The	   cDNA	  was	   stored	  at	  	  
-­‐20	  °C	  until	  needed.	  
3.2.6.3. Real-­‐time	  PCR	  
The	  relative	  gene	  expression	   (delta	   threshold	  cycle	   (∆Ct)	  method)	  was	  determined	  
on	  an	  Applied	  Biosystems®	  7900HT	  fast	  real-­‐time	  PCR	  system	  using	  a	  384-­‐well	  block	  
(Life	  Technologies	  Ltd.,	  Paisley,	  UK).	  TaqMan®	  gene	  expression	  assays	  were	  ordered	  
for	   each	   gene	   of	   interest	   (GoI),	   consisting	   of	   two	   unlabelled	   primers	   and	   a	   gene-­‐
specific	   probe	   that	   is	   covalently	   attached	   to	   the	   fluorescent	   reporter	   dye	   FAMTM.	  
Gene	  expression	  was	  normalised	  to	  the	  human	  housekeeping	  gene	  glyceraldehyde-­‐
3-­‐phosphate	  dehydrogenase	  (GAPDH)	  by	  subtracting	  the	  Ct	  of	  each	  gene	  from	  the	  Ct	  
obtained	   for	   GAPDH	   expression	   (∆Ct).	   The	   software	   calculated	   the	   optimal	  
threshold	  and	  baseline	  levels	  automatically.	  In	  contrast	  to	  FAMTM-­‐labelled	  GoI	  gene	  
expression	   assays,	   the	  GAPDH	   gene	   expression	   assay	   consisted	   of	   a	   VIC®-­‐labelled	  
reporter	   dye	   and	   was	   primer	   limited,	   allowing	   multiplex	   reactions.	   Multiplex	  
reactions	  reduce	  the	  number	  of	  required	  assays	  and	  give	  more	  robust	  results	  due	  to	  
the	  minimised	   influence	  of	   other	   factors	   such	   as	   pipetting.	   TaqMan®	  assay	  probe	  
sequences	   and	   identification	   numbers	   are	   listed	   in	   the	   appendix.	   Each	   multiplex	  
reaction	   consisted	   of	   10	   µl	   2x	   TaqMan®	  master	  mix	   (1x	   final),	   1	   µl	  GoI	   TaqMan®	  
gene	   expression	   assay,	   1	   µl	  GAPDH	   TaqMan®	   gene	   expression	   assay,	   2	   µl	   cDNA	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(50	  ng/µl),	  and	  6	  µl	  molecular	  biology-­‐grade	  water.	  The	  following	  program	  was	  used	  
for	  real-­‐time	  amplification:	  
1. 95	  °C	  for	  15	  minutes	  
2. 95	  °C	  for	  15	  seconds	  
3. 60	  °C	  for	  60	  seconds	  
4. Repeat	  cycles	  2	  and	  3,	  50x	  
3.2.7. 	  Statistical	  analysis	  
All	  data	  are	  presented	  as	  means	  ±	  SD.	  A	  one-­‐way	  ANOVA	  followed	  by	  a	  Dunnett’s	  
post-­‐hoc	  test	  was	  carried	  out	  for	  statistical	  analysis	  of	  all	  experiments	  with	  multiple	  
comparisons.	   Single	   comparisons	  were	   analysed	   by	   an	   independent,	   two-­‐tailed	   t-­‐
test.	  Significant	  results	  are	   indicated	  with	  *	  for	  p<0.05,	  **	  for	  p<0.01,	  and	  ***	  for	  
p<0.001.	   Analysis	   was	   performed	   with	   SPSS®	   Statistics	   version	   20	   (IBM	   United	  




3.3.1. Lipophilicity	  and	  cellular	  accumulation	  of	  AEDs	  
Brain	   uptake	   of	   AEDs	   could,	   theoretically,	   solely	   or	   dominantly	   occur	   by	   passive-­‐
transcellular	   diffusion	   across	   the	   BBB.	   The	   lipophilicity	   of	   a	   drug	   is	   a	   strong	   and	  
important	  predictor	  for	  passive	  diffusion	  (see	  chapter	  1	  section	  1.1.2)	  and	  the	  logD	  
of	  six	  major	  AEDs,	  namely	  CBZ,	  LTG,	  TPM,	  LEV,	  VPA,	  and	  PHT,	  was	  determined	  at	  a	  
physiological	   pH	   of	   7.4	   (Table	   3.1).	   In	   addition,	   the	   predicted	   logD	   (pH	   7.4)	   was	  
derived	  from	  www.chemspider.com	  using	  the	  ACD	  labs	  algorithm	  and	  compared	  to	  
the	  experimentally	  obtained	  logD	  (pH	  7.4).	  
Except	  for	  TPM,	  the	  predicted	  and	  experimentally	  derived	  logDs	  (pH	  7.4)	  
were	   of	   similar	   order	   of	   magnitude	   and	   resulted	   in	   the	   same	   drug	   rank	   order	  	  
(Table	   3.1).	   A	   huge	   discrepancy	   was	   observed	   for	   TPM	   with	   a	   predicted	   logD	  	  
(pH	   7.4)	   of	   2.97	   and	   an	   experimentally	   derived	   logD	   (pH	   7.4)	   of	   -­‐0.64.	   In	   the	  
literature,	   an	   experimental	   logD	   (pH	   7.4)	   of	   0.51	   was	   reported	   (Maryanoff	   et	   al.	  
1998).	   Given	   that	   TPM	   is	   a	   sulfamate-­‐substituted	   monosaccharide	   (Janssen	  
Pharmaceuticals	   Inc.	   2012)	  with	   a	   predicted	   high	   polar	   surface	   area	   of	   123.92	   Å2	  
(van	   de	   Waterbeemd	   et	   al.	   1998)	   (www.chemspider.com),	   the	   predicted	   logD	  	  
(pH	   7.4)	   of	   2.97	   seems	   very	   unlikely	   and	   the	   results	   presented	   here	   and	   by	  
Maryanoff	  et	  al.	  are	  substantially	  lower.	  
To	   correlate	   the	   lipophilicity	   of	   each	   drug	   to	   cellular	   uptake,	   drug	  
accumulation	   was	   assessed	   in	   the	   hCMEC/D3	   cell	   line	   as	   a	   BBB	   model	   after	  	  
30	   minutes	   at	   37	   °C	   (Figure	   3.1	   A)	   and	   compared	   to	   the	   experimentally	   derived	  
logDs	   (pH	   7.4).	   No	   notable	   correlation	   could	   be	   observed	   and	   linear	   regression	  
yielded	  an	  R2	  of	  only	  0.02	  with	  a	  p-­‐value	  of	  0.81	  (Figure	  3.1	  B).	  The	  null	  hypothesis	  
was	  that	  the	  slope	  of	  the	  regression	  line	  is	  equal	  to	  zero.	  Due	  to	  the	  fact	  that	  LTG	  is	  
a	  known	  substrate	  of	  SLC22A1	  (OCT1)	  (Dickens	  et	  al.	  2012),	  the	  same	  analysis	  was	  
repeated	  but	  excluding	  LTG.	  The	  linear	  correlation	  markedly	  improved	  from	  an	  R2	  of	  
0.02	  to	  0.3	  (Figure	  3.1	  C),	  showing	  the	  substantial	  influence	  of	  drug	  transporters	  on	  
this	  analysis.	  However,	  the	  p-­‐value	  remained	  non-­‐significant	  on	  the	  5	  %	  level	  with	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p	   =	   0.37,	   suggesting	   that	   additional	   drug	   transporters	   may	   be	   involved	   in	   AED	  
accumulation.	  
This	   comparison	   can	   only	   be	   considered	   as	   a	   first	   step	   and	   has	   to	   be	  
interpreted	  with	   care	   since	   intracellular	   accumulation	  was	   only	  measured	   at	   one	  
time	  point	  using	  a	  single	  concentration.	  Other	   factors	  such	  as	   intracellular	  protein	  
binding	   might	   have	   affected	   total	   drug	   uptake	   in	   addition	   to	   lipophilicity	   and	  
transporters.	   However,	   because	   passive	   diffusion	   is	   a	   strong	   predictor	   for	   drug	  
uptake	   in	  the	  absence	  of	  transporters,	  a	  stronger	  and	  significant	   linear	  correlation	  
would	  have	  been	  expected.	  
Table	  3.1:	  Lipophilicity	  of	  six	  antiepileptic	  drugs	  
	   Predictive	  logD	  (pH	  7.4)	   Experimental	  logD	  (pH	  7.4)	  
Phenytoin	   2.49	   1.95±0.02	  
Carbamazepine	   1.90	   1.60±0.01	  
Valproate	   0.16	   0.04±0.05	  
Lamotrigine	   -­‐0.19	   0.00±0.01	  
Levetiracetam	   -­‐0.67	   -­‐0.60±0.01	  
Topiramate	   2.97	   -­‐0.64±0.01	  




Figure	  3.1:	  Accumulation	  of	  six	  AEDs	  in	  the	  hCMEC/D3	  cell	  line	  and	  correlation	  with	  lipophilicity	  
A)	  Accumulation	  of	  six	  antiepileptic	  drugs	  (AEDs,	  10	  µM	  each)	  in	  hCMEC/D3	  cells	  after	  30	  minutes	  at	  
37	   °C.	   Data	   are	   expressed	   as	   means	   ±	   standard	   deviation	   (n	   =	   3	   independent	   experiments	   in	  
triplicate);	   B)	   Lipophilicity	   of	   six	   AEDs,	   given	   as	   logD	   at	   pH	   7.4,	   plotted	   against	   the	   mean	  
accumulation	  in	  hCMEC/D3	  cells	  as	  indicated	  in	  A;	  C)	  Lipophilicity	  of	  five	  AEDs	  (without	  LTG),	  given	  as	  
logD	   at	   pH	   7.4,	   plotted	   against	   the	   mean	   accumulation	   in	   hCMEC/D3	   cells	   as	   indicated	   in	   A;	  	  
LTG	  =	  lamotrigine,	  PHT	  =	  phenytoin,	  TPM	  =	  topiramate,	  LEV	  =	  levetiracetam,	  CBZ	  =	  carbamazepine,	  




















































































































3.3.2. Initial	   screening	  of	  antiepileptic	  drug	  transport	   in	  the	  
hCMEC/D3	   cell	   line	   using	   low	   molecular	   weight	  
inhibitors	  
Drug	  accumulation	  in	  the	  hCMEC/D3	  cell	  line	  and	  the	  logD	  (pH	  7.4)	  did	  not	  correlate	  
to	   a	   statistically	   significant	   degree.	   Therefore,	   other	   mechanisms	   such	   as	   drug	  
transporters	  may	   be	   involved	   in	   AED	   uptake	   and/or	   efflux.	   A	   screening	   approach	  
utilising	   known	   chemical	   drug	   transporter	   inhibitors	   (including	   substrates	   as	  
competitive	  inhibitors)	  was	  applied	  to	  obtain	  information	  about	  potentially	  involved	  
drug	  transporters.	  
The	  selected	  compounds	  are	  listed	  in	  Table	  3.2	  with	  corresponding	  typical	  
and	   important	   drug	   transporter	   classes	   affected.	   The	   term	   “class”	   shall	   denote	   a	  
drug	   transporter	   family,	   subfamily,	   or	   further	   sub-­‐divisions	   such	   as	   the	   OATs	   or	  
OCTs	   within	   the	   SLC22A	   subfamily	   (see	   chapter	   1	   section	   1.2.1.3).	   Chemical	  
inhibitors	   can	   never	   be	   considered	   as	   absolutely	   specific	   and	   thus	   a	   transporter	  
class	   was	   regarded	   as	   being	   affected	  when	   one	   or	  more	   transporters	   have	   been	  
shown	  to	  interact	  with	  the	  designated	  compound.	  This	  should	  not	  imply,	  however,	  
that	   every	  member	   from	  within	   these	   transporter	   classes	   is	   necessarily	   affected.	  
The	   accumulation	   of	   all	   six	   AEDs	   was	   determined	   in	   hCMEC/D3	   cells	   after	   30	  
minutes	  at	  37	  °C	  in	  the	  presence	  of	  various	  chemical	  inhibitors	  and	  compared	  to	  the	  
control	  accumulation	  with	  solvent	  only	  (Figure	  3.2).	  
Overall,	   most	   of	   the	   inhibitors	   tested	   did	   not	   result	   in	   an	   altered	   AED	  
accumulation,	  except	  for	  PHT.	  	  PHT	  showed	  a	  significantly	  reduced	  accumulation	  in	  
the	   presence	   of	   several	   inhibitors,	   namely	   MK571,	   verapamil,	   phloretin,	   and	  
naringenin,	  suggesting	  one	  or	  more	  transporters	  being	  involved	  in	  PHT	  uptake.	  VPA	  
accumulation,	  by	  contrast,	  was	  not	  affected	  by	  any	  inhibitor	  and	  notably	  very	  close	  
to	   background	   level.	   CBZ	   accumulation	   was	   also	   not	   affected	   by	   any	   of	   the	  
inhibitors	   tested.	   LTG	   accumulation	   was	   lower	   in	   the	   presence	   of	   verapamil,	  
consistent	   with	   the	   results	   obtained	   by	   Dickens	   et	   al.	   showing	   that	   LTG	   is	   a	  
substrate	   for	   SLC22A1	   (OCT1)	   (Dickens	   et	   al.	   2012).	   Except	   for	   a	   slightly	   reduced	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accumulation	   in	   the	   presence	   of	   phloretin,	   possibly	   also	   a	   result	   of	   SLC22A1	  
inhibition,	   no	   other	   inhibitor	   tested	   had	   an	   effect	   on	   LTG	   accumulation.	  
Interestingly,	   the	  accumulation	  of	  TPM	  and	  LEV	  was	  enhanced	   in	   the	  presence	  of	  
MK571,	   a	   leukotriene	   D4	   receptor	   antagonist	   and	   prototypical	   ABCC	   transporter	  
inhibitor.	   On	   average,	   TPM	   accumulation	   was	   enhanced	   by	   53	   %	   and	   LEV	  
accumulation	  by	  23	  %.	  None	  of	  the	  other	  tested	  inhibitors	  had	  an	  effect.	  
Table	  3.2:	  Selected	   low	  molecular	  weight	  chemical	  drug	  transporter	   inhibitors/substrates	   for	  the	  









MK571	   50	  µM	   ABCCs,	  OATPs	  
(Keppler	   2011,	   Letschert	   et	   al.	  
2005)	  
Probenecid	   500	  µM	   OATs	   (Burckhardt	  et	  al.	  2011)	  
Verapamil	   100	  µM	   ABCBs,	  ABCGs,	  OCTs,	  OCTNs	  	  
(Giacomini	   et	   al.	   2010,	   Matsson	  
et	   al.	   2009,	   Nies	   et	   al.	   2011,	  
Ohashi	  et	  al.	  1999,	  Yabuuchi	  et	  al.	  
1999)	  
Methotrexate	   100	  µM	   OATPs,	  OATs,	  ABCCs,	  ABCGs	  
(Badagnani	   et	   al.	   2006,	  
Burckhardt	   et	   al.	   2011,	   Chen	   et	  
al.	  2003,	  Keppler	  2011)	  
Phloretin	   55	  µM	   ABCGs,	  ABCBs	  	  
(Zhang	   et	   al.	   2003,	   Zhang	   et	   al.	  
2004)	  
Naringenin	   100	  µM	   ABCGs,	  ABCBs,	  (OATPs)	  
(Bailey	   et	   al.	   2007,	  Dresser	   et	   al.	  
2002,	   Shirasaka	   et	   al.	   2009,	  
Zhang	  et	  al.	  2004)	  
The	   flavonoid	   naringenin	   has	   been	   suggested	   to	   act	   as	   inhibitor	   of	   OATP	   transporters	   but	   direct	  
evidence	  for	  human	  OATPs	  is	  currently	  lacking	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Figure	   3.2:	   Initial	   screening	   of	   antiepileptic	   drug	   transport	   in	   the	   hCMEC/D3	   cell	   line	   using	   low	  
molecular	  weight	  inhibitors	  
Accumulation	   of	   six	   antiepileptic	   drugs	   in	   the	   presence	   of	   different	   known	   drug	   transporter	  
inhibitors	   in	   the	   hCMEC/D3	   cell	   line	   after	   30	   minutes	   at	   37	   °C.	   Data	   are	   expressed	   as	   means	  	  
±	   standard	   deviation	   (n	   =	   3-­‐12	   independent	   experiments	   in	   triplicate).	   Significant	   results	   are	  
indicated	   with	   *	   for	   p<0.05,	   **	   for	   p<0.01	   and	   ***	   for	   p<0.001.	   CBZ	   =	   carbamazepine,	  	  






































































































































































































































































































































































































































































































































































3.3.3. Second	   inhibitor	   screening	   to	   further	   assess	  
topiramate	  and	  phenytoin	  transport	  in	  the	  hCMEC/D3	  
cell	  line	  
The	  results	   from	  the	   initial	  screening	  approach	   indicate	  TPM	  and	  PHT	  as	  the	  most	  
promising	  AEDs	  to	  be	  further	  investigated	  as	  potential	  drug	  transporter	  substrates	  
in	  the	  hCMEC/D3	  cell	   line.	  An	  unrecognised	  efflux	  transporter	  or	  transporters	  may	  
be	  involved	  in	  TPM	  transport	  while	  an	  uptake	  transporter	  or	  transporters	  seem	  to	  
mediate	  PHT	  uptake.	  
To	   gain	   additional	   information	   about	   the	   potentially	   involved	   drug	  
transporter	  classes,	  a	  second	  screening	  was	  applied	  for	  these	  two	  drugs	  utilising	  a	  
different	  set	  of	  chemical	   inhibitors.	  Because	  TPM	  accumulation	  is	  enhanced	  in	  the	  
presence	   of	   the	   prototypical	   ABCC	   transporter	   inhibitor	   MK571,	   additional	   ABCC	  
transporter	   inhibitors	   were	   included	   into	   this	   set.	   As	   for	   the	   first	   screening	  
approach,	   the	   selected	   inhibitors	   are	   summarised	   in	   Table	   3.3	   with	   the	  
corresponding	  typical	  and	  important	  drug	  transporter	  classes	  affected.	  MK571	  and	  
phloretin	  were	  included	  as	  positive	  controls,	  respectively.	  
The	   second	   screening	   resulted	   in	   two	   additional	   positive	   hits	   affecting	  
TPM	   accumulation,	   montelukast	   and	   prazosin	   (Figure	   3.3).	   Montelukast,	   another	  
leukotriene	  D4	  receptor	  antagonist,	   is	  a	  typical	  ABCC	  transporter	   inhibitor	  showing	  
the	  same	  enhanced	  TPM	  uptake	  as	  was	  observed	  with	  MK571.	  Prazosin	  resulted	  in	  
a	  decrease	  in	  accumulation,	  suggesting	  that	  in	  addition	  to	  efflux,	  TPM	  influx	  might	  
also	   be	   carrier-­‐mediated.	   For	   PHT,	   additional	   positive	   results	  were	   obtained	  with	  
montelukast,	   prazosin,	   and	   quercetin,	   all	   lowering	   PHT	   cell	   accumulation	   (Figure	  
3.3).	   In	  conclusion	  from	  both	  screenings,	  TPM	  could	  potentially	  be	  a	  substrate	   for	  
an	  efflux	  transporter	  from	  the	  ABCC	  subfamily.	  Given	  that	  all	  the	  tested	  flavonoids	  
(naringenin,	  phloretin,	  quercetin)	  and	  leukotriene	  D4	  receptor	  antagonists	  (MK571,	  
montelukast)	   resulted	   in	   reduced	   PHT	   accumulation,	   a	   SLCO	   (OATP)	   transporter	  




Table	   3.3:	   Selected	   chemical	   drug	   transporter	   inhibitors	   for	   second	   screening	   to	   further	   assess	  









Montelukast	   50	  µM	   ABCCs,	  OATPs	  
(Letschert	  et	  al.	  2006,	  Roy	  et	  
al.	  2009)	  
Diclofenac	   50	  µM	  
ABCCs,	   OATs,	   OATPs,	   OCTs,	  
ABCGs	  
(Burckhardt	   et	   al.	   2011,	  
Khamdang	  et	  al.	  2002,	  Kindla	  
et	  al.	  2011,	  Lagas	  et	  al.	  2009,	  
Reid	  et	  al.	  2003)	  
Indomethacin	   100	  µM	   ABCCs,	  OATs,	  OCTs	  
(Burckhardt	   et	   al.	   2011,	  
Khamdang	   et	   al.	   2002,	   Reid	  
et	  al.	  2003)	  
Prazosin	   100	  µM	   OCTs,	  ABCGs	  
(Matsson	   et	   al.	   2007,	  
Matsson	   et	   al.	   2009,	  Nies	   et	  
al.	  2011)	  
Ko143	   1	  µM	   ABCGs	   (Allen	  et	  al.	  2002)	  
Quercetin	   50	  µM	   OATPs,	  ABCGs,	  ABCBs,	  ABCCs	  
(Mandery	   et	   al.	   2010,	  
Matsson	   et	   al.	   2009,	   Wu	   et	  
al.	  2012,	  Zhang	  et	  al.	  2004)	  
Mycophenolic	  Acid	   50	  µM	   OATs	  
(Uwai	  et	  al.	  2007,	  Wolff	  et	  al.	  
2007)	  





Figure	  3.3:	  Second	  inhibitor	  screening	  to	  further	  assess	  topiramate	  and	  phenytoin	  transport	  in	  the	  
hCMEC/D3	  cell	  line	  
Accumulation	  of	  topiramate	  and	  phenytoin	  in	  the	  presence	  of	  various	  drug	  transporter	  inhibitors	  in	  
the	  hCMEC/D3	  cell	  line	  after	  30	  minutes	  at	  37	  °C.	  Data	  are	  expressed	  as	  means	  ±	  standard	  deviation	  
(n	  =	  4	  independent	  experiments	  in	  triplicate).	  Significant	  results	  are	  indicated	  with	  **	  for	  p<0.01	  and	  
***	  for	  p<0.001.	  TPM	  =	  topiramate,	  PHT	  =	  phenytoin	  
TPM	   has	   previously	   been	   described	   as	   a	   weak	   substrate	   for	   ABCB1	  
(MDR1,	   Pgp)	   (Luna-­‐Tortos	   et	   al.	   2009)	   and	   although	   the	   typical	   ABCB1	   inhibitor	  
verapamil	   had	   no	   effect	   on	   TPM	   accumulation,	   ABCB1	   transport	   cannot	   be	   fully	  
excluded	  as	  the	  underlying	  reason	  for	  the	  results	  obtained.	  To	  gain	  more	  confidence	  
that	   impaired	   ABCB1	   transport	   is	   not	   involved	   in	   the	   observed	   increase	   in	   TPM	  
accumulation,	  an	  additional	  experiment	  was	  carried	  out	  with	  the	  ABCB1	  substrate	  
digoxin	  as	  a	  positive	  control	  (Giacomini	  et	  al.	  2010).	  The	  accumulation	  of	  5	  µM	  TPM	  
and	   5	   µM	   digoxin	   was	   determined	   after	   30	   minutes	   in	   hCMEC/D3	   cells	   in	   the	  
presence	   of	   two	   relatively	   specific	   ABCB1	   inhibitors,	   tariquidar	   and	   PSC-­‐833	  
(Dickens	   et	   al.	   2013b),	   as	   well	   as	   the	   typical	   ABCC	   inhibitor	   MK571.	   While	   the	  
accumulation	   of	   digoxin	   increased	   in	   the	   presence	   of	   all	   three	   inhibitors	   tested,	  






















































































































































































































































considered	  a	  prototypical	  ABCC	  transporter	  inhibitor	  but	  has	  also	  been	  reported	  to	  
inhibit	  ABCB1,	  explaining	  the	  positive	  results	  obtained	  with	  digoxin	  (Matsson	  et	  al.	  
2009).	  These	  results	  demonstrate	  that	  the	  enhanced	  TPM	  accumulation	  observed	  in	  
the	  presence	  of	  MK571	  is	  not	  a	  result	  of	  an	  impaired	  ABCB1	  transport	  but	  other,	  so	  
far	  unknown,	  transport	  process.	  
Figure	  3.4:	  Investigation	  of	  ABCB1	  (MDR1,	  Pgp)	  activity	  on	  topiramate	  accumulation	  
The	  accumulation	  of	  topiramate	  and	  digoxin	  (positive	  control)	  was	  tested	  in	  the	  presence	  of	  the	  two	  
ABCB1	  inhibitors	  tariquidar	  and	  PSC-­‐833	  plus	  the	  ABCC	  inhibitor	  MK571.	  The	  accumulation	  of	  both	  
drugs	   was	   analysed	   in	   hCMEC/D3	   cells	   after	   30	   minutes	   at	   37	   °C.	   Data	   are	   expressed	   as	   means	  	  
±	  standard	  deviation	  (n	  =	  3	   independent	  experiments	   in	  triplicate).	  Significant	  results	  are	   indicated	  
with	  ***	  for	  p<0.001	  
To	   further	   characterise	   the	  unknown	  TPM	  and	  PHT	   transport	  processes,	  
the	   effect	   of	   temperature	  was	   analysed	   as	   shown	   in	   Figure	   3.5	  A+B.	   An	   opposite	  
effect	   as	   with	   chemical	   inhibitors	   was	   observed	   when	   temperature	   was	   lowered	  
from	  37	  °C	  to	  4	  °C,	  with	  reduced	  TPM	  accumulation	  and	  elevated	  PHT	  accumulation.	  
These	   results	   indicate	   that	  more	   than	  one	   transport	  process	  might	  be	   involved	   in	  
TPM	   and	   PHT	   accumulation	   and	   both,	   uptake	   and	   efflux,	   are	   important	   in	  






































































the	  underlying	  transport	  kinetics,	  the	  accumulation	  of	  both	  drugs	  was	  determined	  
at	  different	  time	  points,	  0.25,	  0.5,	  1,	  2,	  5,	  10,	  20,	  and	  30	  minutes	  (Figure	  3.5	  C+D).	  
While	   TPM	   exhibited	   typical	   transporter	   kinetics	   starting	   with	   a	   linear	   phase	   of	  
uptake	  and	  followed	  by	  a	  saturation	  process	  (Figure	  3.5	  C),	  PHT	  uptake	  was	  much	  








Figure	  3.5:	  Effect	  of	  temperature	  and	  time	  on	  topiramate	  and	  phenytoin	  accumulation	  
Accumulation	   of	   A)	   topiramate	   (TPM)	   and	   B)	   phenytoin	   (PHT)	   in	   the	   hCMEC/D3	   cell	   line	   after	   30	  
minutes	  at	   37	   °C	  and	  4	   °C,	   respectively.	  Data	  are	  expressed	  as	  means	  ±	   standard	  deviation	   (n	  =	  4	  
independent	  experiments	  in	  triplicate).	  Significant	  results	  are	  indicated	  with	  *	  for	  p<0.05	  and	  **	  for	  
p<0.01.	  Time	  course	  of	  C)	  topiramate	  and	  D)	  phenytoin	  accumulation	  in	  the	  hCMEC/D3	  cell	  line	  at	  37	  
























































































































3.3.4. Gene	   expression	   of	   ABCC	   transporters	   in	   the	  
hCMEC/D3	  cell	  line	  
Based	  on	  the	  results	  from	  both	  screening	  approaches	  and	  clinical	  aspects,	  TPM	  was	  
considered	   the	   most	   promising	   and	   more	   important	   AED	   candidate	   for	   further	  
investigation.	  First,	  the	  transporter	  involved	  in	  TPM	  efflux	  appears	  to	  be	  a	  member	  
of	  the	  ABCC	  transporter	  subfamily	  while	  the	  transporter	   involved	   in	  PHT	  uptake	   is	  
less	  conclusive,	  possibly	  a	  member	   from	  the	  SLCO	  (OATP)	  superfamily.	  TPM	  efflux	  
across	   the	   BBB	   is	   important	   to	   study	   further	   as	   it	   is	   a	   potential	   mechanism	   or	  
contributing	   factor	   for	  TPM	  treatment	  resistance.	  Second,	  while	  PHT	  used	  to	  be	  a	  
very	  important	  drug	  for	  the	  management	  of	  epilepsy,	  it	  is	  no	  longer	  recommended	  
as	   first-­‐line	  or	  second-­‐line	  treatment	   for	  any	  epilepsy	  syndrome	  or	  seizure	  type	   in	  
the	   UK	   (except	   as	   second-­‐line	   treatment	   for	   status	   epilepticus),	   and	   hence	   is	  
clinically	   less	   important	   than	   TPM	   (National	   Institute	   for	   Health	   and	   Clinical	  
Excellence	  2012).	  
Assuming	   that	   an	   ABCC	   transporter	   is	   involved	   in	   TPM	   efflux	   in	   the	  
hCMEC/D3	   cell	   line,	   a	   functional	   siRNA	   screening	   approach	   was	   considered	   a	  
promising	   strategy	   to	   determine	   the	   exact	   transporter(s)	   for	   further	  
characterisation.	   To	   reduce	   the	  number	   of	   transporters	   to	   be	   screened,	   the	   gene	  
expression	  of	  all	  twelve	  known	  ABCC	  transporter	  genes	  (excluding	  one	  pseudogene)	  
was	   determined	   in	   the	   hCMEC/D3	   cell	   line	   using	   highly	   specific	   and	   sensitive	  
TaqMan®	   gene	   expression	   assays	   with	   100	   ng	   cDNA	   per	   reaction.	   ABCC	   gene	  
expression	  was	  normalised	  to	  GAPDH	  and	  plotted	  as	   reciprocal	  ∆Ct	   (Figure	  3.6).	  A	  
lower	  1/∆Ct	  indicates	   lower	  gene	  expression.	  ABCC2	  showed	  borderline	  expression	  
with	  a	  1/∆Ct	  of	  0.06	   (ABCC2	  Ct	  was	  39).	  No	  gene	  expression	  could	  be	  detected	   for	  
ABCC7,	  ABCC8,	  ABCC9,	  ABCC11,	  and	  ABCC12.	  
Chapter	  3	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Figure	  3.6:	  Gene	  expression	  of	  ABCC	  transporters	  in	  the	  hCMEC/D3	  cell	  line	  normalised	  to	  GAPDH	  
Gene	   expression	   of	   all	   known	   human	   ABCC	   transporters	   (excluding	   pseudogene	   ABCC13)	   in	   the	  
hCMEC/D3	  cell	  line	  normalised	  to	  human	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  (GAPDH).	  The	  
normalised	  gene	  expression	  is	  given	  as	  the	  reciprocal	  delta	  of	  both	  threshold	  cycles	  (1/∆Ct).	  Empty	  
fields	   indicate	   non-­‐detectable	   ABCC	   gene	   expression.	   Data	   are	   expressed	   as	   means	   ±	   standard	  
deviation	  and	  were	  derived	  from	  1	  experiment	  analysed	  in	  quadruplicate	  
3.3.5. siRNA	  assay	  optimisation	  
siRNA	  pools	  containing	  four	  targeting	  sequences	  were	  ordered	  for	  each	  expressed	  
ABCC	  gene	  based	  on	  the	  results	  obtained	  in	  3.3.4.	  Before	  screening,	  the	  assay	  had	  
to	  be	  optimised	   for	  every	  gene	   to	  obtain	   the	  best	  possible	   knockdown	  efficiency.	  
Knockdown	  efficiency	  is	  defined	  as	  the	  relative	  gene	  expression	  in	  cells	  transfected	  
with	   targeting	   siRNAs	   as	   compared	   to	   cells	   transfected	   with	   non-­‐targeting,	  
scrambled	   siRNAs	   and	   calculated	   by	   subtracting	   both	   ∆Ct	   values	   (∆∆Ct).	   A	  
knockdown	   efficiency	   with	   a	   remaining	   relative	   gene	   expression	   of	   ≤	   25	   %	   was	  
considered	  optimal.	  Initially,	  the	  siRNA	  delivery	  into	  hCMEC/D3	  cells	  was	  optimised	  
using	   ABCC4	   targeting	   siRNAs.	   siRNA	   delivery	   is	   particularly	   dependent	   on	   cell	  
density	   as	   well	   as	   the	   amount	   of	   transfection	   reagent.	   All	   siRNA	   screening	  
experiments	   were	   carried	   out	   on	   6-­‐well	   plates.	   Seeding	   of	   two	   different	   cell	  
quantities,	  0.1	  million	  and	  0.25	  million,	  respectively,	  was	  analysed	  with	  regards	  to	  
knockdown	   efficiency	   using	   10	   nM,	   25	   nM,	   and	   50	   nM	   of	   ABCC4	   targeting	   and	  





























































effect	  on	  knockdown	  efficiency	  for	  this	  particular	  gene,	  a	  lower	  cell	  quantity	  of	  only	  
0.1	  million	  cells	  per	  well	  resulted	  in	  a	  considerably	  higher	  knockdown	  efficiency.	  For	  
one	   condition	   (0.25	   million	   cells,	   10	   nM	   siRNA)	   the	   RNA	   pellet	   was	   lost	   during	  
extraction	   and	   the	   relative	   gene	   expression	   could	   not	   be	   determined.	   This	   does,	  
however,	  not	  affect	  the	  conclusions	  drawn.	  	  
According	   to	   the	   manufacturer,	   a	   final	   transfection	   reagent	  
(DharmaFECT1)	  concentration	  between	  0.05-­‐0.5	  %	  (v/v)	  is	  recommended	  for	  6-­‐well	  
plates,	  depending	  on	  the	  cell	  line.	  For	  the	  initial	  experiment	  shown	  in	  Figure	  3.7	  A,	  
0.2	   %	   (v/v)	   transfection	   reagent	   was	   chosen	   as	   a	   starting	   concentration.	   Using	  	  
0.1	  million	  cells	  for	  plating	  and	  varying	  DharmaFECT1	  concentrations	  between	  0.05-­‐
0.4	   %	   (v/v),	   the	   initially	   chosen	   concentration	   of	   0.2	   %	   (v/v)	   turned	   out	   to	   be	  
optimal	  (Figure	  3.7	  B).	  After	  optimising	  the	  siRNA	  delivery	  into	  hCMEC/D3	  cells,	  the	  
ideal	   siRNA	   concentrations	  were	  determined	   for	   each	  particular	  GoI.	   Three	   siRNA	  
concentrations	   were	   chosen	   to	   be	   tested,	   10	   nM,	   25	   nM,	   and	   50	   nM,	   and	   the	  
knockdown	   efficiencies	   analysed	   (Figure	   3.7	   C).	   25	   nM	   siRNAs	   turned	   out	   to	   be	  
optimal	  for	  the	  knockdown	  of	  all	  ABCC	  genes	  tested.	  
For	   ABCC2,	   no	   accurate	   comparative	   gene	   expression	   could	   be	  
determined	  as	   the	  Ct	   values	  highly	   fluctuated	  around	  approximately	  40	  with	  both	  
positive	  and	  negative	  ∆∆Ct	  values.	  According	  to	  the	  manufacturer,	  a	  Ct	  above	  38	  is	  
considered	   as	   a	   “not	   detectable	   amplification	   signal”	   (Applied	   Biosystems	   by	   Life	  
Technologies	  2010).	  In	  addition,	  assuming	  very	  borderline	  ABCC2	  expression,	  such	  a	  
low	  copy	  number	  will	  require	  a	  much	  larger	  sample	  size	  to	  improve	  the	  reliability	  of	  
the	  results	  (Applied	  Biosystems	  by	  Life	  Technologies	  2011).	  Therefore,	  the	  potential	  
role	  of	  ABCC2	  (MRP2)	  for	  TPM	  efflux	  can	  be	  considered	  negligible	  and	  results	  from	  
chapter	   2	   of	   this	   thesis	   confirm	   that	   ABCC2	   is	   not	   involved	   in	   TPM	   uptake	   into	  
ABCC2	  overexpressing	  plasma	  membrane	  vesicles	  (see	  chapter	  2	  section	  2.3.2).	  The	  
missing	  information	  for	  ABCC1	  knockdown	  efficiency	  using	  50	  nM	  siRNAs	  is	  due	  to	  a	  
lost	   RNA	  pellet	   during	   RNA	   extraction.	  However,	   25	   nM	   siRNAs	   already	   yielded	   a	  
high	  knockdown	  efficiency	  with	  only	  12	  %	  relative	  remaining	  gene	  expression	  and	  




Figure	  3.7:	  Optimisation	  of	  siRNA	  screening	  conditions	  for	  the	  hCMEC/D3	  cell	  line	  
A)	  Knockdown	  efficiency	  utilising	   three	   concentrations	   of	  ABCC4	   targeting	   siRNAs	   (10	  nM,	   25	  nM,	  	  
50	   nM,	   respectively)	   and	   two	   different	   cell	   quantities	   (0.1	  million	   and	   0.25	  million,	   respectively);	  
B)	   Knockdown	   efficiency	   of	  ABCC4	   targeting	   siRNAs	   (10	   nM)	   utilising	   varying	   transfection	   reagent	  
concentrations.	   0.1	  million	   cells	  were	   plated	   as	   assessed	   in	   A;	   C)	   Knockdown	   efficiency	   of	   various	  
ABCC	  genes	  under	  optimised	  delivery	  conditions	  (0.1	  million	  plated	  cells,	  0.2	  %	  transfection	  reagent)	  
using	  three	  siRNA	  concentrations,	  10	  nM,	  25	  nM,	  and	  50	  nM,	  respectively.	  Knockdown	  efficiency	  is	  
plotted	   as	   the	   remaining	   relative	   gene	   expression	   in	   %	   as	   compared	   to	   negative	   control	   siRNA	  
transfected	  cells.	  Analysis	  of	  ABCC2	  failed	  due	  to	  the	  borderline	  gene	  expression.	  Data	  are	  expressed	  



















































































































































3.3.6. siRNA	  screening	  
TPM	  accumulation	  was	  assessed	  in	  the	  hCMEC/D3	  cell	  line	  after	  30	  minutes	  at	  37	  °C	  
utilising	   a	   siRNA	   screening	   approach	   under	   optimised	   conditions	   (3.3.5).	   No	  
enhanced	   TPM	   accumulation	   could	   be	   observed	   after	   knockdown	   of	   any	   of	   the	  
expressed	   ABCC	   transporter	   genes	   as	   compared	   to	   control	   (Figure	   3.8	   A).	  
Gabapentin	  (GBP)	  has	  recently	  been	  demonstrated	  to	  be	  a	  substrate	  of	  the	  L-­‐	  alpha	  
amino	  acid	  transporter	  1	  (SLC7A5,	  LAT1)	  utilising	  a	  similar	  screening	  approach	  and	  
was	  included	  as	  a	  functional	  positive	  control	  (Dickens	  et	  al.	  2013a).	  Knockdown	  of	  
SLC7A5	  resulted	  in	  a	  significantly	  reduced	  accumulation	  of	  GBP	  and	  confirmed	  the	  
functionality	  of	  the	  assay	  (Figure	  3.8	  B).	  
The	  average	  knockdown	  efficiency	  was	  determined	  by	  real-­‐time	  PCR	  and	  
good	   efficiencies	   obtained	   for	   most	   genes	   tested	   (Figure	   3.8	   C).	   The	   average	  
knockdown	  efficiency	  for	  ABCC10	  was	  32	  %	  remaining	  relative	  gene	  expression	  and	  
therefore	  slightly	  higher	  than	  the	  threshold	  of	  25	  %.	  However,	  an	  average	  of	  32	  %	  
was	  still	  considered	  acceptable	  as	  25	  %	  is	  a	  rather	  strict	  threshold	  and	  others	  have	  
commonly	  used	  30	  %	  (Krueger	  et	  al.	  2007).	   It	   is	  unlikely	  that	  7	  %	  or	  2	  %	  (25	  %	  or	  	  
30	  %	  threshold)	  would	  change	  the	  interpretation	  of	  the	  results	  as	  no	  tendency	  for	  
an	   increased	  TPM	  accumulation	  could	  be	  observed	   in	   the	   functional	  assay.	  ABCC5	  
knockdown,	   in	   contrast,	   was	   clearly	   insufficient	   with	   a	   high	   intra-­‐experimental	  
fluctuation	  (Figure	  3.8	  C).	  In	  addition,	  the	  functional	  assay	  resulted	  in	  a	  significantly	  
decreased	  accumulation	  of	  TPM	  (Figure	  3.8	  A),	  possibly	  a	  siRNA	  off-­‐target	  effect.	  It	  
is	   unlikely	   that	   an	   increase	   in	   siRNA	   concentration	   will	   improve	   the	   knockdown	  
efficiency	   without	   increasing	   the	   possible	   off-­‐target	   effect.	   Therefore,	   a	   different	  
pool	   of	   four	   ABCC5	   targeting	   siRNAs	   and	   corresponding	   negative	   control	   was	  
ordered	   from	   a	   different	  manufacturer	   (Qiagen).	   Transfection	   of	   hCMEC/D3	   cells	  
using	   the	   same	   optimised	   conditions	   as	   before	   resulted	   in	   no	   measurable	  
knockdown	  using	   10	   nM	  or	   25	   nM	   siRNAs.	   In	   conclusion,	  ABCC5	   gene	   expression	  
seems	   to	   be	   difficult	   to	   target	   and	   further	   siRNA	   approaches	   are	   thus	   not	  
considered	  promising.	  However,	  in	  a	  previous	  study	  using	  stably	  ABCC5-­‐transfected	  
cells	  it	  was	  demonstrated	  that	  TPM	  is	  not	  a	  substrate	  for	  this	  particular	  transporter	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(Luna-­‐Tortos	  et	  al.	  2009).	  As	  before	  with	  the	  optimisation	  experiments,	  ABCC2	  gene	  
expression	   is,	   at	   best,	   borderline	   and	   no	   accurate	   comparative	   gene	   expression	  
could	   be	   determined	   (see	   for	   3.3.5	   discussion).	   Nevertheless,	   the	   functional	  
screening	   with	   ABCC2	   targeting	   siRNAs	   was	   included	   as	   an	   additional	   negative	  
control.	  
	  
Figure	  3.8:	  Functional	  siRNA	  screening	  of	  ABCC	  transporters	  in	  the	  hCMEC/D3	  cell	  line	  
A)	  Accumulation	  of	  topiramate	  (TPM)	  in	  hCMEC/D3	  cells	  after	  30	  minutes	  at	  37	  °C	  utilising	  a	  siRNA	  
screening	  approach.	  Cells	  were	  transfected	  either	  with	  negative	  control	  siRNAs	  or	  ABCC	  transporter-­‐
targeting	   siRNAs;	   B)	   Functional	   positive	   control	   assay.	   The	   accumulation	   of	   gabapentin	   (GBP)	   in	  
hCMEC/D3	   cells	   transfected	   with	   control	   siRNA	   or	   SLC7A5-­‐targeting	   siRNA	   was	   assessed	   after	  	  
30	  minutes	  at	  37	   °C;	  C)	  Relative	   remaining	  gene	  expression	  as	  compared	   to	  negative	  control	   in	  %.	  
The	  analysis	  of	  ABCC2	   failed	  due	   to	   the	  borderline	  gene	  expression.	  Data	  are	  expressed	  as	  means	  	  
±	   standard	  deviation	   (n=	  4	   independent	  experiments	  each	   in	   triplicate	   (A+B)	  or	  quadruplicate	   (C)).	  

































































































































A	  screening	  approach	  by	  means	  of	  chemical	  transporter	  inhibitors	  and	  siRNAs	  was	  
applied	   to	   identify	   unknown	   transport	   processes	   for	   already	   licensed	   AEDs.	  
Although	   a	   variety	   of	   known	   chemical	   transporter	   inhibitors	   were	   chosen,	   the	  
overall	  effect	  on	  drug	  accumulation	  was	  surprisingly	  modest	  and	  no	  effect	  could	  be	  
observed	  for	  CBZ	  and	  VPA.	  Interestingly,	  VPA	  uptake	  into	  hCMEC/D3	  cells	  was	  very	  
low	   and	   detection	   close	   to	   background	   levels.	   In	   vivo,	   however,	   VPA	   is	   known	   to	  
cross	   the	   BBB	   and	   is	   a	   very	   effective	   drug,	   particularly	   for	   the	   treatment	   of	  
generalised	  seizures	  (see	  chapter	  1	  section	  1.3.3.5).	  These	  results	  demonstrate	  that,	  
as	  with	  every	   in	  vitro	  model,	  differences	  to	  the	   in	  vivo	  situation	  exist.	  However,	   in	  
vitro	  models	  are	  useful	  tools	  for	  the	  initial	  identification	  of	  potential	  clinical	  effects	  
(Giacomini	  et	  al.	  2010),	  the	  main	  target	  for	  this	  research	  chapter.	  
Chemical	  inhibitors	  can	  never	  be	  considered	  absolutely	  specific	  and	  most	  
of	  those	  tested	  have	  been	  demonstrated	  before	  to	  affect	  multiple	  drug	  transporter	  
classes	  (3.3.2	  and	  3.3.3).	  While	  this	   is	  an	  issue	  for	  the	  identification	  of	  a	  particular	  
transporter,	   it	   increases	   the	   probability	   of	   obtaining	   positive	   results.	   The	   overall	  
accumulation	   profile	   may	   then	   help	   to	   identify	   the	   potentially	   involved	   group	   of	  
transporters	   before	   more	   elaborate	   and	   expensive	   methods	   are	   considered.	  
However,	   it	   appears	   that	   none	   of	   these	   groups	   is	   heavily	   involved	   in	   the	  
accumulation	  of	   the	   six	  AEDs	   tested	   in	   vitro	   by	  using	   the	  hCMEC/D3	  cell	   line	  as	  a	  
BBB	  model.	  An	  exception	  was	  PHT	  with	  a	  reduced	  accumulation	  in	  the	  presence	  of	  
several	   inhibitors	   tested.	   Also,	   TPM	   exhibited	   an	   interesting	   increase	   in	  
accumulation	   in	   the	   presence	   of	   the	   prototypical	   ABCC	   transporter	   inhibitors	  
MK571	   and	   montelukast.	   Based	   on	   the	   inhibitor	   profile	   and	   clinical	   aspects	  
(discussed	  in	  section	  3.3.3),	  TPM	  was	  considered	  the	  most	  promising	  candidate	  AED	  
to	   be	   further	   investigated	   as	   a	   potential	   substrate	   for	   one	   or	   more	   ABCC	  
transporter(s).	  
RNAi	  is	  a	  useful	  method	  to	  screen	  the	  transporter-­‐specific	  effect	  on	  drug	  
accumulation	   for	   several	   drug	   transporters	   in	   parallel	   by	   means	   of	   siRNA	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transfection	  (Dickens	  et	  al.	  2013a).	  This	  method	  was	  applied	  on	  all	  expressed	  ABCC	  
transporter	  genes	  but	  no	   increased	  TPM	  accumulation	  could	  be	  observed.	  Several	  
reasons	  might	  have	  led	  to	  these	  negative	  results.	  First,	  the	  transporter	  affected	  by	  
MK571	  and	  montelukast	  could	  be	  from	  a	  different	  ABC	  subfamily.	  Also,	  an	  uptake	  
transporter	   from	   the	   SLC	   superfamily	   might	   be	   involved	   and	   an	   allosteric	   rather	  
than	   an	   inhibitory	   effect	   responsible	   for	   the	   increased	   TPM	   accumulation	   in	   the	  
presence	   of	   MK571	   and	   montelukast,	   respectively	   (Kindla	   et	   al.	   2011).	   Second,	  
although	  siRNA	   transfections	   substantially	   lowered	   the	  expression	  of	   the	   targeted	  
transporter	  gene,	  the	  remaining	  expressed	  protein	  might	  still	  have	  enough	  capacity	  
in	   the	   functional	   assay.	   In	   addition,	   functional	   redundancy	   could	  mask	   increased	  
accumulation	   if	   the	   expression	   of	   only	   one	   transporter	   is	   impaired.	   For	   example,	  
ABCC3	   is	   well	   known	   to	   compensate	   for	   the	   impaired	   conjugated-­‐bilirubin	   efflux	  
from	  hepatocytes	  in	  patients	  with	  Dubin-­‐Johnson	  syndrome	  (see	  chapter	  1	  section	  
1.2.2.2).	  
In	   conclusion,	   an	   interesting	   enhanced	   accumulation	   of	   TPM	   in	   the	  
presence	  of	  MK571	  and	  montelukast	  was	  observed	  in	  the	  hCMEC/D3	  cell	  line	  as	  an	  
in	  vitro	  model	  of	  the	  BBB.	  A	  subsequent	  siRNA	  screening,	  however,	  failed	  to	  identify	  
the	   exact	   transporter(s)	   involved	   in	   TPM	   efflux	   and	   it	   remains	   unclear	   if	   it/they	  
belong(s)	   to	   the	   ABCC	   subfamily	   as	   hypothesised	   from	   the	   inhibitor	   screening.	  
Assays	  with	  transient	  transfections	  of	  every	  expressed	  ABCC	   transporter	  may	  be	  a	  
strategy	  to	  overcome	  the	   limitations	  of	  RNAi.	  However,	  these	  assays	  will	  also	  give	  
negative	  results	  if	  the	  involved	  transporter(s)	  is/are	  from	  a	  different	  ABC	  subfamily	  
or	   even	   from	   the	   SLC	   superfamily.	   A	   large-­‐scale	   siRNA	   library	   screening	   approach	  
targeting	  all	  expressed	  ABC	  transporters	  could	  be	  an	  alternative	  but	  with	  the	  same	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LTG	  transport	  by	  SLC22A1	  (OCT1)	  has	  recently	  been	  demonstrated	   in	  vitro	  utilising	  
an	   SLC22A1-­‐transfected	   chronic	   myeloid	   leukemia	   cell	   line	   (KCL22)	   and	   the	  
hCMEC/D3	  cell	  line	  as	  a	  BBB	  model	  (Dickens	  et	  al.	  2012).	  A	  large	  number	  of	  drugs,	  
particularly	   organic	   cations	   or	   drugs	   that	   display	   a	   positive	   net	   charge	   at	  
physiological	   pH,	   have	   been	   demonstrated	   to	   act	   as	   inhibitors	   of	   SLC22A1	   (see	  
chapter	  1	  section	  1.2.1.3).	  Therefore,	  the	  potential	  for	  SLC22A1-­‐mediated	  drug-­‐drug	  
interactions	  with	  LTG	   is	  high.	  Two	  clinically	   relevant	   interactions	  were	  noted	  from	  
the	  literature	  and	  analysed	  in	  this	  research	  chapter.	  
In	   a	   study	   with	   healthy	   volunteers,	   LTG	   serum	   levels	   were	   significantly	  
changed	   in	   subjects	   co-­‐treated	  with	   lopinavir/ritonavir	   as	   compared	   to	   treatment	  
with	   LTG	   only	   (van	   der	   Lee	   et	   al.	   2006).	   The	   area	   under	   the	   curve	   (AUC)	   was	  
reduced	   by	   50	   %	   and	   twice	   the	   LTG	   dose	   was	   required	   to	   achieve	   serum	   levels	  
comparable	  to	  LTG	  monotherapy	  (van	  der	  Lee	  et	  al.	  2006).	  Lopinavir/ritonavir	  is	  an	  
antiretroviral	  protease	   inhibitor	  combination	   indicated	  for	  the	  treatment	  of	  HIV-­‐1.	  
In	  the	  US	  and	  European	  Economic	  Area	   it	   is	  marketed	  by	  AbbVie	  under	  the	  brand	  
name	   Kaletra®	   (AbbVie	   Inc.	   2013).	  While	   the	   antiretroviral	   activity	   of	   Kaletra®	   is	  
mediated	   by	   lopinavir,	   ritonavir	   is	   co-­‐formulated	   to	   boost	   the	   plasma	   levels	   of	  
lopinavir	  by	  means	  of	  CYP3A	  enzyme	  inhibition	  (AbbVie	  Inc.	  2013).	  
So	   far,	   no	   data	   for	   a	   potential	   lopinavir	   and	   SLC22A1	   interaction	   have	  
been	  published,	  but	  two	  in	  vitro	  studies	  reported	  an	  inhibitory	  effect	  of	  ritonavir	  on	  
the	   uptake	   of	   two	   SLC22A1	   model	   substrates,	   tetraethylammonium	   (TEA+)	   and	  
MPP+	  (Jung	  et	  al.	  2008,	  Jung	  et	  al.	  2012,	  Zhang	  et	  al.	  2000).	  Individuals	  infected	  with	  
HIV	   often	   experience	   seizure	   disorders	   with	   an	   incidence	   of	   11	   %	   (Birbeck	   et	   al.	  
2012).	   Interactions	   between	   AEDs	   and	   antiretroviral	   drugs	   are	   thus	   important	   to	  
understand,	  particularly	  with	  LTG	  as	  a	  first-­‐line	  treatment	  option	  for	  focal	  seizures	  
and	   important	   alternative	   to	   VPA	   for	   generalised	   seizures	   (National	   Institute	   for	  
Health	   and	   Clinical	   Excellence	   2012).	   The	   decreased	   LTG	   serum	   levels	   in	   the	  
presence	   of	   lopinavir/ritonavir	   have	   been	   linked	   to	   an	   enhanced	   LTG	  metabolism	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with	  elevated	  2N-­‐glucuronide	  concentrations	  (AbbVie	  Inc.	  2013,	  Burger	  et	  al.	  2008,	  
GlaxoSmithKline	   Inc.	   2012,	   van	   der	   Lee	   et	   al.	   2006).	   However,	   an	   impaired	   LTG	  
uptake	   by	   SLC22A1	   could	   be	   an	   additional	   factor	   leading	   to	   the	   observed	  
alterations.	  
The	   atypical	   antipsychotic	   clozapine	   (CLP)	   (introduced	   in	  more	   detail	   in	  
chapter	   5)	   is	   indicated	   as	   a	   last-­‐resort	   treatment	   option	   for	   otherwise	   refractory	  
schizophrenia	   (Novartis	   Pharmaceuticals	   Corporation	   2013).	   Despite	   this	   option,	  
there	  is	  still	  a	  large	  proportion	  of	  patients	  that	  also	  fail	  to	  respond	  to	  CLP	  (Chakos	  et	  
al.	  2001,	  Kane	  et	  al.	  1988,	  Lieberman	  et	  al.	  1994).	  To	  improve	  treatment	  response,	  
different	  CLP	  augmentation	  strategies	  have	  been	  reported,	  including	  the	  AED	  LTG.	  A	  
meta-­‐analysis	   from	   2009	   (Tiihonen	   et	   al.	   2009)	   that	   analysed	   five	   clinical	   studies	  
(Goff	  et	  al.	  2007,	  Kremer	  et	  al.	  2004,	  Tiihonen	  et	  al.	  2003,	  Zoccali	  et	  al.	  2007)	  found	  
a	   significant	   superiority	  of	   LTG	  augmentation	   in	   comparison	   to	  placebo.	  Recently,	  
another	  meta-­‐analysis	   from	   the	   same	   five	   studies	   reported	   contradictory	   findings	  
(Sommer	  et	  al.	  2012).	  By	  analysing	  the	  effect	  size	  of	  each	  study,	  one	  (Zoccali	  et	  al.	  
2007)	  was	   identified	  as	  an	  outlier	  of	  more	  than	  two	  SDs	  from	  the	  mean	  weighted	  
effect	  size	  and	  excluded	  from	  further	  analysis	  (Sommer	  et	  al.	  2012).	  The	  remaining	  
studies	  did	  not	  show	  superiority	  of	  LTG	  over	  placebo	  augmentation.	  However,	  if	  the	  
largest	  and	  longest	  randomised	  controlled	  trial	  from	  the	  entire	  group	  is	  excluded	  as	  
a	  statistical	  outlier,	  this	  could	  bias	  the	  results.	  Another	  meta-­‐analysis	  on	  a	  subset	  of	  
these	  studies	  (Goff	  et	  al.	  2007,	  Tiihonen	  et	  al.	  2003)	  did	  not	  find	  superiority	  of	  LTG	  
augmentation	  as	  compared	  to	  placebo	  (Porcelli	  et	  al.	  2012).	  	  
In	   conclusion,	   LTG	   may	   be	   beneficial	   as	   an	   augmentation	   strategy	   to	  
overcome	  CLP	  resistance,	  at	  least	  for	  a	  subset	  of	  patients,	  but	  more	  clinical	  studies	  
are	   needed.	   Assuming	   there	   is	   a	   positive	   effect,	   the	   underlying	  molecular	   reason	  
would	   be	   important	   to	   understand.	   LTG	   is	   a	   substrate	   of	   SLC22A1	   and	   another	  
atypical	  antipsychotic	  drug,	  quetiapine,	  has	  been	  characterised	  as	  a	  potent	  inhibitor	  
of	  this	  particular	  transport	  (Dickens	  et	  al.	  2012).	  Thus,	  an	  interaction	  between	  LTG	  
and	  CLP	  on	   the	  drug	   transporter	   level	   is	  hypothesised	   to	   contribute	   to	  an	  altered	  
CLP	  treatment	  efficacy.	  Notably,	  a	  clinical	   interaction	  between	  quetiapine	  and	  LTG	  
has	  also	  been	  reported	  (Andersson	  et	  al.	  2011,	  Castberg	  et	  al.	  2007).	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4.2. Materials	  and	  methods	  
4.2.1. Materials	  
Unless	   otherwise	   specified,	   all	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich	  
Company	   Ltd.,	  Gillingham,	  UK,	  or	   listed	   in	   the	   corresponding	   section	  of	   chapter	  3	  
(3.2.1).	  Tritium-­‐labelled	  CLP	  ([3H]-­‐CLP,	  1	  mCi/ml,	  specific	  activity	  80.0	  Ci/mmol)	  and	  
carbon-­‐14-­‐labelled	   TEA+	   ([14C]-­‐TEA,	   0.1	   mCi/ml,	   specific	   activity	   55.0	   mCi/mmol)	  
were	   obtained	   from	   American	   Radiolabeled	   Chemicals	   Inc.,	   St.	   Louis,	   MO,	   USA.	  
Lopinavir,	  ritonavir,	  lamivudine,	  and	  abacavir	  came	  from	  Insight	  Biotechnology	  Ltd.,	  
Wembley,	  UK,	  L-­‐glutamine	  (200	  mM)	  from	  Life	  Technologies	  Ltd.,	  Paisley,	  UK,	  and	  
BD	  MatrigelTM	  Basement	  Membrane	  Matrix	  from	  BD	  Biosciences,	  Oxford,	  UK.	  
4.2.2. Cell	  lines	  and	  culture	  conditions	  
4.2.2.1. hCMEC/D3	  cell	  line	  
Please	  refer	  to	  chapter	  3	  section	  3.2.2.1.	  
4.2.2.2. KCL22	  cell	  lines	  
The	  human	  chronic	  myeloid	   leukaemia	  cell	   line	  KCL22	  was	  stably	   transfected	  with	  
an	   empty	   vector	   (control)	   or	   a	   vector	   encoding	   for	   SLC22A1	   (OCT1)	   by	  means	   of	  
electroporation	  (Giannoudis	  et	  al.	  2008).	  Both	  non-­‐adherent	  cell	   lines	  were	  a	  kind	  
gift	   from	   Dr	   Athina	   Giannoudis	   (Department	   of	   Haematology,	   University	   of	  
Liverpool,	   UK)	   and	   cultured	   in	   RPMI-­‐1640	  medium	   supplemented	   with	   10	   %	   FBS	  
(v/v)	  and	  1	  %	  penicillin-­‐streptomycin	  (v/v)	  at	  37	  °C	  and	  5	  %	  CO2.	  
4.2.2.3. Primary	  human	  hepatocytes	  
Primary	  human	  hepatocytes	  were	  derived	  from	  patients	  that	  underwent	  surgery	  for	  
resectable	   primary	   hepatocellular	   carcinoma	   or	   colorectal	   liver	   metastases.	   All	  
patients	  gave	  their	  written	  informed	  consent	  to	  the	  use	  of	  their	  resected	  tissue	  for	  
experimental	  purposes	  and	  the	  Liverpool	  Central	  Research	  Ethics	  Committee	  gave	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ethical	   approval.	  Hepatocytes	  were	  extracted	  with	   kind	  help	  of	  Dr	  Rowena	  Sison-­‐
Young	  and	  James	  Heslop.	  
Excess	   healthy	   liver	   parenchyma	   was	   resected	   as	   part	   of	   the	   regular	  
procedure	  and	  immediately	  stored	  in	  ice-­‐cold	  HEPES	  buffer	  (10	  mM	  HEPES,	  136	  mM	  
NaCl,	  5	  mM	  KCl,	  0.5	  %	  glucose,	  pH	  7.6)	  on	  ice.	  Within	  30	  minutes	  of	  removal	  from	  
the	  patient,	  the	  extraction	  process	  for	  primary	  human	  hepatocytes	  was	  initiated	  by	  
perfusion	  of	  accessible	  circulatory	  vessels	  to	  wash	  the	  tissue.	  Perfusion	  was	  carried	  
out	   at	   a	   flow	   rate	   of	   50	   ml/min	   using	   1-­‐2	   l	   warm	   (37	   °C)	   HEPES	   buffer.	   After	  
washing,	  the	  perfusion	  continued	  for	  up	  to	  20	  minutes	  with	  the	  addition	  of	  700	  µM	  
CaCl2	  and	  0.5	  mg/ml	  collagenase	  to	  digest	  the	  connective	  tissue.	  The	  digested	  tissue	  
was	   then	   carefully	   disrupted	  using	   forceps	   and	  blunt-­‐ended	   scissors	   and	   the	   cells	  
disassociated	  with	  ice-­‐cold	  Williams’	  medium	  E	  without	  L-­‐glutamine.	  The	  cells	  were	  
poured	   through	   a	   nylon	   mesh	   and	   centrifuged	   at	   80	   g	   for	   5	   minutes	   at	   4	   °C	  
(Megafuge	   11R	   centrifuge	   with	   T41	   swing-­‐out	   rotor,	   Thermo	   Fisher	   Scientific,	  
Leicestershire,	  UK).	   The	   resulting	   cell	   pellet	  was	   carefully	   resuspended	   in	   ice-­‐cold	  
William´s	  medium	  E	  without	  L-­‐glutamine	  by	  gently	  rocking	  back	  and	  forth.	  Finally,	  
the	   cells	  were	   centrifuged	   as	   before	   and	   resuspended	   in	   full	  William´s	  medium	  E	  
(supplemented	  with	   1	   %	   penicillin-­‐streptomycin	   (v/v),	   2	  mM	   L-­‐glutamine,	   1	   %	   of	  
100x	   insulin-­‐transferrin-­‐selenium	   (ITS)	   liquid	   media	   supplement	   (v/v),	   100	   nM	  
dexamethasone).	  Cell	  viability	  and	  concentration	  was	  determined	  using	  a	  Countess®	  
Automated	   Cell	   Counter	   (Life	   Technologies	   Ltd.,	   Paisley,	   UK)	   after	   staining	   with	  
trypan	  blue.	  A	  cell	  viability	  of	  ≥	  85	  %	  was	  required	  for	  further	  experimentation.	  
Initially,	   500,000	   cells	   were	   seeded	   into	   each	   well	   of	   ready	   to	   use	  
collagen-­‐coated	   (collagen	   I	   from	   rat	   tail)	   24-­‐well	   plates	   (Life	   Technologies	   Ltd.,	  
Paisley,	   UK)	   and	   incubated	   at	   37	   °C	   and	   5	   %	   CO2	   for	   3	   hours.	   The	   medium	   was	  
removed,	   cells	   washed	   once	   with	  WiIlliam´s	   medium	   E	   without	   L-­‐glutamine,	   and	  
hepatocytes	   finally	   incubated	   for	   12	   hours	   at	   37	   °C	   and	   5	  %	  CO2	   in	   full	  William´s	  
medium	  E	  (supplemented	  with	  1	  %	  penicillin-­‐streptomycin	  (v/v),	  2	  mM	  L-­‐glutamine,	  
1	  %	  of	  100x	  ITS	  liquid	  media	  supplement	  (v/v),	  100	  nM	  dexamethasone).	  
Chapter	  4	  
	  135	  
4.2.2.4. Primary	  rat	  hepatocytes	  
Primary	   rat	   hepatocytes	   (kindly	   provided	  by	  Dr	   Sophie	  Regan)	  were	  derived	   from	  
adult	   male	   Wistar	   rats	   (175	   –	   300	   g)	   obtained	   from	   Charles	   River	   Laboratories	  
(Margate,	   Kent,	   UK).	   All	   experiments	   involving	   live	   animals	   were	   carried	   out	  
according	   to	   criteria	   outlined	   in	   a	   license	   that	   was	   granted	   under	   the	   Animals	  
(Scientific	  Procedures)	  Act	  1986	  and	  approved	  by	   the	  Animal	  Ethics	  Committee	  of	  
the	  University	  of	  Liverpool.	  
For	   hepatocyte	   extraction,	   animals	   were	   anaesthetised	   with	   sodium	  
pentobarbital	  (1	  μl/g)	  and	  the	  liver	  perfused	  with	  warm	  (37	  °C)	  HEPES	  buffer	  (HBSS	  
without	  Ca+	  supplemented	  with	  5.8	  mM	  HEPES	  and	  4.5	  mM	  NaHCO3)	  at	  a	  flow	  rate	  
of	  40	  ml/min	  for	  9	  minutes.	  After	  this	  initial	  washing	  step,	  perfusion	  was	  continued	  
as	  before	  but	  in	  the	  presence	  of	  0.05	  %	  collagenase	  (w/v),	  0.0068	  %	  trypsin	  inhibitor	  
(w/v),	   and	   5	   mM	   CaCl2	   until	   sufficiently	   digested.	   Subsequently,	   the	   liver	   was	  
removed	  from	  the	  animal	  and	  rinsed	  in	  HEPES	  buffer	  containing	  0.1	  mg/ml	  DNAse	  I	  
(w/v).	  The	  cells	  were	  disassociated	  from	  connective	  tissue	  by	  careful	  combing	  with	  
sharp	   forceps	   and	  poured	   through	  a	  nylon	  mesh	  before	   they	  were	   centrifuged	  at	  	  
50	  g	   for	  2	  minutes	  at	  4	   °C	   (HeraeusTM	  MegafugeTM	  11R	  centrifuge	  with	  T41	   rotor,	  
Thermo	   Fisher	   Scientific,	   Leicestershire,	  UK).	   The	   resulting	   cell	   pellet	  was	  washed	  
twice	   with	   ice-­‐cold	   HEPES	   buffer	   containing	   0.1	   mg/ml	   DNAse	   I.	   Cells	   were	  
centrifuged	  between	  and	  after	   the	  washing	  steps	  as	  described	  before.	  Finally,	   the	  
washed	  cell	  pellet	  was	  resuspended	  in	  full	  William´s	  medium	  E	  (supplemented	  with	  
1	  %	  penicillin-­‐streptomycin	  (v/v),	  2	  mM	  L-­‐glutamine,	  1.25	  %	  of	  100x	  ITS	  liquid	  media	  
supplement	   (v/v),	   25	   nM	   dexamethasone,	   and	   5	   %	   FBS	   (v/v)).	   Cell	   viability	   and	  
concentration	   was	   determined	   using	   a	   Countess®	   Automated	   Cell	   Counter	   (Life	  
Technologies	   Ltd.,	   Paisley,	   UK)	   after	   staining	   with	   trypan	   blue.	   A	   cell	   viability	   of	  	  
≥	  85	  %	  was	  required	  for	  further	  experimentation..	  
Initially,	   300,000	   cells	   were	   seeded	   into	   each	   well	   of	   ready	   to	   use	  
collagen-­‐coated	   (collagen	   I	   from	   rat	   tail)	   24-­‐well	   plates	   (Life	   Technologies	   Ltd.,	  
Paisley,	   UK)	   and	   incubated	   at	   37	   °C	   and	   5	   %	   CO2	   for	   3	   hours.	   The	   medium	   was	  
removed,	   cells	   washed	   once	   with	  WiIlliam´s	   medium	   E	   without	   L-­‐glutamine,	   and	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hepatocytes	   finally	   incubated	   for	   12	   hours	   at	   37	   °C	   and	   5	  %	  CO2	   in	   full	  William´s	  
medium	  E	  (supplemented	  with	  1	  %	  penicillin-­‐streptomycin	  (v/v),	  2	  mM	  L-­‐glutamine,	  
1.25	  %	  of	  100x	  ITS	  liquid	  media	  supplement	  (v/v),	  25	  nM	  dexamethasone,	  and	  5	  %	  
FBS	  (v/v))	  including	  0.5	  mg/ml	  BD	  MatrigelTM	  Basement	  Membrane	  Matrix.	  
4.2.3. Drug	  accumulation	  assays	  
4.2.3.1. Non-­‐adherent	  cells	  
As	   preparation	   for	   accumulation	   assays	   with	   the	   non-­‐adherent	   KCL22	   cell	   lines,	  
each	   cell	   incubation	   was	   initially	   centrifuged	   at	   250	   g	   for	   5	   minutes	   at	   room	  
temperature	   (HeraeusTM	   MegafugeTM	   11R	   centrifuge	   with	   T41	   swing-­‐out	   rotor,	  
Thermo	   Fisher	   Scientific,	   Leicestershire,	   UK).	   The	   culture	   medium	   was	   discarded	  
and	  the	  cell	  pellets	  resuspended	   in	  pre-­‐warmed	  (37	  °C)	  HBSS	  followed	  by	  another	  
centrifugation	   step.	   Washed	   cells	   were	   resuspended	   in	   pre-­‐warmed	   (37	   °C)	  
transport	  buffer	  (HBSS	  supplemented	  with	  25	  mM	  HEPES,	  adjusted	  to	  pH	  7.4)	  and	  
the	   viability	   and	   concentration	   determined	   using	   a	   Countess®	   Automated	   Cell	  
Counter	  (Life	  Technologies	  Ltd.,	  Paisley,	  UK)	  after	  staining	  with	  trypan	  blue.	  A	  250	  µl	  
cell	  suspension	  (adjusted	  to	  8.0	  million	  cells	  per	  ml)	  was	  used	  for	  each	  reaction	  and	  
transferred	   into	  a	  1.5	  ml	  microcentrifuge	  tube	  (Starlab	  Ltd.,	  Milton	  Keynes,	  UK)	  to	  
give	  a	  final	  quantity	  of	  2.0	  million	  cells	  per	  reaction.	  
A	   double-­‐concentrated	   master	   mix	   was	   prepared	   separately	   for	   each	  
condition	   to	  be	   tested,	   consisting	  of	   transport	  buffer	  with	  0.11	   -­‐	  0.3	  µCi/ml	   [14C]-­‐	  
TEA+	   or	   0.3	   µCi/ml	   [3H]-­‐LTG,	   non-­‐labelled	   corresponding	   “cold”	   drug	   to	   give	  	  
5.46	   µM	   TEA+	   or	   10	   µM	   LTG,	   CLP	   as	   inhibitor	   from	   1000x	   concentrated	   stock	  
solutions,	  and	  0.2	  %	  bovine	  serum	  albumin	  (BSA)	  (w/v).	  The	  vehicle	  concentration	  
did	  not	  exceed	  1.1	  %	  per	  reaction	  (ethanol	  and/or	  DMSO).	  The	  assay	  was	  initiated	  
by	  adding	  250	  µl	  corresponding	  master	  mix	  to	  each	  tube	  containing	  250	  µl	  empty	  
vector-­‐transfected	   or	   SLC22A1-­‐transfected	   KCL22	   cells.	   Reactions	   were	   gently	  
mixed,	   incubated	   for	   30	   minutes	   at	   37	   °C,	   and	   subsequently	   stored	   on	   ice	   for	  
another	   10	   minutes.	   To	   remove	   excess	   radioactive	   drug,	   each	   reaction	   mix	   was	  
washed	  three	  times	  with	  1	  ml	  ice-­‐cold	  HBSS.	  Samples	  were	  centrifuged	  at	  250	  g	  for	  
Chapter	  4	  
	  137	  
5	  minutes	  at	  4	  °C	  between	  and	  after	  the	  washing	  steps	   (Megafuge	  11R	  centrifuge	  
with	  T41	  swing-­‐out	  rotor,	  Thermo	  Fisher	  Scientific,	  Leicestershire,	  UK).	  Finally,	   the	  
cells	   were	   lysed	   in	   400	   µl	   10	   %	   SDS	   and	   transferred	   into	   scintillation	   tubes	  
containing	  4	  ml	   scintillation	   cocktail.	   Radioactivity	  was	  determined	  by	   scintillation	  
counting	  (1500	  Tri	  Carb	  LS	  Counter,	  Packard,	  now	  PerkinElmer,	  Seer	  Green,	  UK).	  
4.2.3.2. Adherent	  cells	  
Cell	   accumulation	   assays	   for	   adherent	   cells,	   namely	   hCMEC/D3,	   primary	   human	  
hepatocytes,	  and	  primary	  rat	  hepatocytes	  were	  carried	  out	  as	  described	  in	  chapter	  
3	  section	  3.2.4.	  The	  master	  mix	  consisted	  of	  transport	  buffer	  (HBSS	  supplemented	  
with	  25	  mM	  HEPES,	  adjusted	  to	  pH	  7.4)	  with	  0.3	  µCi/ml	  [3H]-­‐LTG	  or	  0.1	  µCi/ml	  [3H]-­‐
CLP,	   non-­‐labelled	   corresponding	   “cold”	   drug	   to	   give	   5	   µM	   LTG	   or	   1	   µM	   CLP,	  
corresponding	   CLP	   or	   LTG	   as	   inhibitor,	   and	   0.1	   %	   BSA	   (w/v).	   The	   vehicle	  
concentration	  did	  not	  exceed	  1.1	  %	  per	  reaction	  (DMSO).	  
4.2.3.3. Poly-­‐L-­‐lysine-­‐attached	  non-­‐adherent	  cells	  
For	   time-­‐course	   assays,	   quick	   washing	   of	   the	   cells	   is	   essential	   in	   order	   to	   obtain	  
accurate	  data	  for	  shorter	  incubation	  times.	  To	  conduct	  time-­‐course	  assays	  with	  the	  
non-­‐adherent	  KCL22	  cell	  lines,	  cells	  were	  first	  attached	  to	  the	  surface	  of	  NuncTM	  6-­‐
well	  plates	  (Fisher	  Scientific	  UK	  Ltd.,	  Loughborough,	  UK)	  by	  means	  of	  poly-­‐L-­‐lysine.	  
A	  1/20	  dilution	  from	  a	  0.01	  %	  poly-­‐L-­‐lysine	  stock	  solution	  (w/v)	  was	  prepared	  and	  
each	  well	   incubated	  with	  1	  ml	   for	  10	  minutes	  at	   room	   temperature.	   The	   solution	  
was	  removed	  and	  plates	   left	  to	  air-­‐dry.	   In	  the	  meantime,	  KCL22	  cell	  cultures	  were	  
prepared	   and	   initially	   centrifuged	   at	   250	   g	   for	   5	   minutes	   at	   room	   temperature	  
(Megafuge	   11R	   centrifuge	   with	   T41	   swing-­‐out	   rotor,	   Thermo	   Fisher	   Scientific,	  
Leicestershire,	   UK).	   The	   culture	   medium	   was	   discarded	   and	   the	   cell	   pellets	  
resuspended	  in	  pre-­‐warmed	  (37	  °C)	  HBSS	  followed	  by	  another	  centrifugation	  step.	  
Washed	  cells	  were	  again	  resuspended	  in	  pre-­‐warmed	  HBSS	  (37	  °C)	  and	  the	  viability	  
and	   concentration	   determined	   using	   a	   Countess®	   Automated	   Cell	   Counter	   (Life	  
Technologies	   Ltd.,	   Paisley,	   UK)	   after	   staining	  with	   trypan	   blue.	   The	   concentration	  
was	   adjusted	   to	   2	   million	   cells	   per	   ml.	   1	   ml	   of	   the	   cell	   suspension	   was	   finally	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transferred	   onto	   each	   well	   of	   air-­‐dried	   poly-­‐L-­‐lysine-­‐coated	   6-­‐well	   plates	   and	  
incubated	  at	  37	  °C	  for	  30	  to	  60	  minutes	  to	  allow	  attachment	  of	  the	  cells.	  
The	  assay	  was	   initiated	  by	   replacing	  HBSS	  with	  master	  mix	   consisting	  of	  
transport	  buffer	  (HBSS	  supplemented	  with	  25	  mM	  HEPES,	  adjusted	  to	  pH	  7.4)	  with	  
0.05	  µCi/ml	  [3H]-­‐CLP,	  non-­‐labelled	  “cold”	  CLP	  to	  give	  a	  final	  concentration	  of	  1	  µM	  
drug,	   and	   0.1	   %	   BSA	   (w/v).	   The	   vehicle	   concentration	   did	   not	   exceed	   1.1	   %	   per	  
reaction	   (DMSO).	   Cells	   were	   incubated	   for	   the	   desired	   time	   at	   37	   °C	   and	  
subsequently	  washed	  with	  1	  ml	   ice-­‐cold	  HBSS.	  Washing	  was	  repeated	  three	  times	  
and	   the	   cells	   finally	   lysed	   in	   400	   µl	   10	  %	   SDS.	   Each	   lysate	  was	   transferred	   into	   a	  
scintillation	  tube	  containing	  4	  ml	  scintillation	  cocktail	  and	  radioactivity	  determined	  
by	  scintillation	  counting	  (1500	  Tri	  Carb	  LS	  Counter,	  Packard,	  now	  PerkinElmer,	  Seer	  
Green,	  UK).	  
4.2.4. Gene	  expression	  
RNA	  extraction,	  RT-­‐PCR,	  and	  real-­‐time	  PCR	  were	  carried	  out	  as	  described	  in	  chapter	  
3	   section	   3.2.6.	   TaqMan®	   assay	   probe	   sequences	   and	   identification	   numbers	   are	  
listed	   in	   the	   appendix.	   The	   human	   beta-­‐actin	   (ACTB)	   gene	   expression	   assay	   was	  
FAMTM-­‐labelled	  and	  therefore	  used	  in	  singleplex	  reactions.	  Each	  singleplex	  reaction	  
consisted	   of	   10	  µl	   2x	   concentrated	   TaqMan®	  master	  mix	   (1x	   final	   concentration),	  	  
1	  µl	  GoI	  TaqMan®	  gene	  expression	  assay,	  2	  µl	  cDNA	  (50	  ng/µl),	  and	  7	  µl	  molecular	  
biology-­‐grade	  water.	  
4.2.5. Statistical	  analysis	  
All	   data	   are	   presented	   as	  means	   ±	   SD.	   The	   inhibitor	   concentration	   that	   achieved	  
half-­‐maximum	  inhibition	  (IC50)	  of	  substrate	  accumulation	  was	  determined	  by	  fitting	  
a	   non-­‐linear	   regression	   curve	   with	   variable	   slope	   to	   the	   data	   using	   Prism	   6	  




4.3.1. Interactions	   between	   lamotrigine	   and	   antiretrovirals	  
mediated	  by	  SLC22A1	  (OCT1)	  
The	  effect	  of	   lopinavir	  and	  ritonavir	  on	  SLC22A1	  (OCT1)-­‐mediated	  LTG	  uptake	  was	  
analysed	  in	  vitro	  utilising	  SLC22A1-­‐transfected	  and	  empty	  vector-­‐transfected	  KCL22	  
cell	   lines.	   Two	   additional	   antiretroviral	   drugs,	   lamivudine	   and	   abacavir,	   were	  
included	  as	  both	  have	  previously	  been	  shown	  to	  potently	  inhibit	  SLC22A1-­‐mediated	  
transport	  of	  MPP+,	  an	  OCT	  model	  substrate	  (Jung	  et	  al.	  2008,	  Minuesa	  et	  al.	  2009).	  
At	   a	   fixed	   concentration	   of	   10	   µM,	   lamivudine	   and	   abacavir	   had	   no	   effect	   on	  
SLC22A1-­‐mediated	   LTG	   uptake	   after	   30	   minutes	   at	   37	   °C	   (Figure	   4.1	   A).	   In	   the	  
presence	   of	   10	   µM	   lopinavir	   and	   ritonavir,	   in	   contrast,	   a	   statistically	   significant	  
decrease	  in	  LTG	  accumulation	  was	  observed	  as	  compared	  to	  control.	  Ritonavir	  was	  
more	  potent	  than	  lopinavir	  with	  56	  %	  and	  39	  %	  reduction,	  respectively	  (Figure	  4.1	  
A).	  
Clinically,	  lopinavir	  and	  ritonavir	  are	  used	  in	  combination	  with	  ritonavir	  as	  
a	   pharmacokinetic	   booster	   for	   lopinavir	   plasma	   levels	   (Kaletra®).	   Following	   twice-­‐
daily	   dosing	  with	   400/100	  mg	   Kaletra®,	   the	  mean	   peak	   plasma	   concentrations	   of	  
lopinavir	   and	   ritonavir	   reach	   about	   13.5	   µM	   and	   0.8	   µM	   at	   steady-­‐state,	  
respectively	   (AbbVie	   Inc.	   2013).	   Thus,	   the	   ritonavir	   concentrations	   achieved	   in	  
patients	   are	  much	   lower	   than	  10	  µM	  and	   an	   additional	   accumulation	   experiment	  
was	  carried	  out	   in	  the	  presence	  of	  13.5	  µM	  lopinavir	  and	  0.8	  µM	  ritonavir	   (Figure	  
4.1	   A).	   The	   same	   effect	   as	   with	   lopinavir	   alone	   (both	   resulted	   in	   a	   statistically	  
significant	   39	   %	   reduction	   of	   LTG	   accumulation	   as	   compared	   to	   control)	   was	  
observed,	  indicating	  that	  lopinavir	  is	  an	  inhibitor	  of	  SLC22A1-­‐mediated	  LTG	  uptake	  
at	   clinically	   relevant	   concentrations.	   To	   further	   characterise	   this	   effect,	   the	  
SLC22A1-­‐mediated	   uptake	   of	   LTG	   was	   determined	   in	   the	   presence	   of	   increasing	  
lopinavir	   concentrations	   ranging	   from	   0.1	   –	   100	   µM	   (Figure	   4.1	   B).	   While	   the	  
inhibitory	  effect	  seen	  before	  was	  confirmed,	  an	  IC50	  could	  not	  be	  determined	  due	  to	  
the	  high	  SD	  for	  some	  data	  points	  combined	  with	  a	  slowly	  decreasing	  accumulation	  
Chapter	  4	  
	  140	  
over	  the	  lopinavir	  concentration	  range	  used.	  In	  addition,	  the	  curve	  appears	  to	  reach	  
a	  plateau	  and	  exhibit	  a	  biphasic	  dose	  response,	  although	  this	  observation	  has	  to	  be	  
taken	  with	  care	  and	  may	  result	  from	  the	  high	  SD	  of	  some	  data	  points.	  
	  
Figure	  4.1:	  Interactions	  between	  lamotrigine	  and	  antiretrovirals	  mediated	  by	  SLC22A1	  (OCT1)	  
A)	  The	  uptake	  of	  5	  µM	  lamotrigine	  (LTG)	  into	  KCL22	  cells	  transfected	  with	  empty	  vector	  or	  SLC22A1	  
was	  determined	  after	  30	  minutes	  at	  37	  °C	   in	  the	  presence	  of	  different	  antiretroviral	  drugs,	  namely	  
lopinavir,	   ritonavir,	   lamivudine,	   and	   abacavir;	   B)	   The	   uptake	   of	   5	   µM	   lamotrigine	   into	   KCL22	   cells	  
transfected	  with	  empty	  vector	  or	  SLC22A1	  was	  determined	  after	  30	  minutes	  at	  37	  °C	  in	  the	  presence	  
of	   increasing	   lopinavir	   concentrations	   (0.1	   –	   100	   µM).	   SLC22A1	   (OCT1)-­‐mediated	   uptake	   was	  
determined	   by	   subtracting	   the	   data	   of	   empty	   vector-­‐transfected	   from	   SLC22A1-­‐transfected	   KCL22	  
cells.	   Results	   are	   expressed	   as	   means	   ±	   standard	   deviation	   (n	   =	   3	   independent	   experiments	   in	  
triplicate).	  Significant	  results	  are	  indicated	  with	  **	  for	  p<0.01	  and	  ***	  for	  p<0.001	  
4.3.2. Analysis	   of	   clozapine	   as	   a	   potential	   SLC22A1	   (OCT1)	  
substrate	  
To	   test	   the	   hypothesis	   that	   LTG	   enhances	   CLP	   effectiveness	   by	   means	   of	   an	  
interaction	   with	   SLC22A1	   (OCT1),	   CLP	   was	   initially	   investigated	   as	   a	   potential	  
substrate	   for	   SLC22A1	   in	   a	   time	   course	   assay	   utilising	   SLC22A1-­‐transfected	   and	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empty	   vector-­‐transfected	   KCL22	   cell	   lines.	   A	   CLP	   concentration	   as	   low	   as	   1	   µM	  
(range	  from	  0.3	  –	  2.4	  µM)	  has	  been	  reported	  as	  average	  peak	  plasma	  concentration	  
at	   steady-­‐state	   following	   twice-­‐daily	   doses	   of	   100	   mg	   (Novartis	   Pharmaceuticals	  
Corporation	  2013).	   This	   concentration	  was	   chosen	   for	   all	   assays	  presented	   in	   this	  
research	  chapter.	  A	  time-­‐course	  accumulation	  assay	  over	  30	  minutes	  at	  37	  °C	  with	  
data	   obtained	   at	   0.25,	   0.5,	   1,	   2,	   5,	   10,	   20,	   and	   30	   minutes	   did	   not	   show	   any	  
significant	   difference	   between	   empty	   vector-­‐transfected	   and	   SLC22A1-­‐transfected	  
KCL22	  cell	   lines	   (Figure	  4.2	  A).	  A	  positive	   control	  utilising	  5	  µM	  LTG	  as	  a	  SLC22A1	  
substrate	   (30	  minutes	   time	  point)	  confirmed	  the	   functionality	  of	   the	  assay	   (Figure	  
4.2	  B).	  These	   results	  demonstrate	   that	  CLP	   is	  not	  a	   substrate	   for	  SLC22A1	   in	  vitro	  
using	   clinically	   relevant	   concentrations.	   Therefore,	   the	   hypothesis	   that	   CLP	  
effectiveness	   is	   enhanced	   in	   the	   presence	   of	   LTG	   by	   means	   of	   an	   SLC22A1	  
interaction	  has	  to	  be	  rejected.	  	  
A	   transporter	   other	   than	   SLC22A1,	   however,	  may	   still	   affect	   CLP	  uptake	  
into	  the	  brain.	  Therefore,	  the	  accumulation	  of	  CLP	  was	  assessed	  in	  the	  hCMEC/D3	  
cell	  line	  as	  an	  in	  vitro	  model	  of	  the	  BBB	  after	  30	  minutes	  at	  37	  °C	  in	  the	  presence	  of	  
increasing	  LTG	  concentrations	  ranging	  from	  1	  –	  1000	  µM.	  An	   inhibitory	  effect	  was	  
observed	  with	  LTG	  concentrations	  ≥	  100	  µM,	  but	  not	  within	  therapeutic	  range.	  The	  
manufacturer's	   product	   monograph	   specifies	   that	   LTG	   peak	   plasma	   levels	   range	  
between	  2	  –	  18	  µM	  following	  single	  LTG	  doses	  of	  50	  –	  400	  mg	  (GlaxoSmithKline	  Inc.	  
2012).	  A	  peak	  plasma	  concentration	  up	  to	  47	  µM	  has	  been	  reported	  in	  a	  study	  that	  
assessed	   individual	   therapeutic	   thresholds	   in	   epilepsy	   patients	   with	   doses	   up	   to	  
1,200	  mg	  (Sondergaard	  Khinchi	  et	  al.	  2008).	  This	  value	  represents	  an	  extreme	  and	  is	  





Figure	   4.2:	   Analysis	   of	   clozapine	   as	   a	   potential	   SLC22A1	   (OCT1)	   substrate	   and	   interactions	  with	  
lamotrigine	  
A)	  Time-­‐course	  of	  clozapine	  (CLP)	  uptake	  into	  KCL22	  cells	  transfected	  with	  empty	  vector	  or	  SLC22A1	  
at	  37	  °C;	  B)	  Positive	  control	  with	  uptake	  of	  lamotrigine	  (LTG)	  into	  KCL22	  cells	  transfected	  with	  empty	  
vector	  or	  SLC22A1	  after	  30	  minutes	  at	  37	  °C;	  C)	  Accumulation	  of	  CLP	  in	  the	  hCMEC/D3	  cell	  line	  after	  
30	   minutes	   at	   37	   °C	   in	   the	   presence	   of	   increasing	   LTG	   concentrations	   (1	   –	   1000	   µM).	   The	  
therapeutically	  relevant	  maximum	  LTG	  concentration	  of	  47	  µM	  is	  indicated	  by	  a	  dotted	  line;	  Data	  are	  
expressed	  as	  means	  ±	  standard	  deviation	   (n	  =	  3	   independent	  experiments	   in	   triplicate).	  Significant	  
results	  are	  indicated	  with	  **	  for	  p<0.01	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4.3.3. Interactions	   between	   lamotrigine	   and	   clozapine	  
mediated	  by	  SLC22A1	  (OCT1)	  
Based	  on	  the	  results	  obtained	  in	  section	  4.3.2,	  the	  hypothesis	  that	  CLP	  effectiveness	  
is	  enhanced	  in	  the	  presence	  of	  LTG	  by	  means	  of	  an	  SLC22A1	  (OCT1)	  interaction	  had	  
to	  be	  rejected.	  Unrelated	  to	  this	  hypothesis,	  however,	  CLP	  exhibits	  typical	  SLC22A1	  
inhibitor	   characteristics	   with	   a	   positive	   net	   charge	   at	   physiological	   pH	   and	   high	  
lipophilicity	   (Ahlin	   et	   al.	   2008).	   In	   addition,	   CLP	   has	   been	   reported	   to	   inhibit	   the	  
SLC22A1-­‐mediated	   uptake	   of	   4-­‐(4-­‐(dimethylamino)styryl)-­‐N-­‐methylpyridinium	  
(ASP+)	  by	  47.5	  %	  (Ahlin	  et	  al.	  2008).	  
To	  test	  the	  effect	  of	  CLP	  on	  LTG	  transport,	  KCL22	  cells,	  either	  transfected	  
with	  empty	  vector	  or	  SLC22A1,	  were	   incubated	  with	  5	  µM	  LTG	  and	  2.73	  µM	  TEA+,	  
respectively,	   in	   the	   presence	   of	   increasing	   CLP	   concentrations	   ranging	   from	  0.1	   –	  
100	  µM	  (Figure	  4.3	  A+B).	  TEA+	  is	  a	  SLC22A1	  model	  substrate	  and	  served	  as	  positive	  
control.	   A	   dose-­‐response	   was	   observed	   for	   increasing	   CLP	   concentrations	   and	  
curve-­‐fitting	   yielded	   IC50	   values	   of	   1.8	   µM	   (LTG	   as	   a	   substrate)	   and	  	  
5.7	   µM	   (TEA+	   as	   a	   substrate),	   respectively.	   The	   analysis	   was	   extended	   to	   the	  
hCMEC/D3	   cell	   line,	   again	   with	   5	   µM	   LTG	   as	   a	   substrate	   and	   increasing	   CLP	  
concentrations	   ranging	   from	   0.1	   –	   100	   µM	   (Figure	   4.3	   C).	   As	   before,	   a	   dose-­‐
response	  was	  observed	  and	  curve-­‐fitting	  resulted	  in	  a	  similar	  IC50	  of	  2.0	  µM.	  These	  
in	   vitro	   results	   indicate	   that	   CLP	   can	   potently	   inhibit	   SLC22A1-­‐mediated	   LTG	  





Figure	  4.3:	  Drug-­‐drug	  interactions	  between	  lamotrigine	  and	  clozapine	  
Uptake	   of	   LTG	   (A)	   and	   TEA+	   (B)	   into	   KCL22	   cells	   transfected	   with	   empty	   vector	   or	   SLC22A1,	  
determined	  after	  30	  minutes	  at	  37	  °C	  in	  the	  presence	  of	   increasing	  clozapine	  concentrations	  (0.1	  –	  
100	   µM).	   SLC22A1	   (OCT1)-­‐mediated	   uptake	   was	   calculated	   by	   subtracting	   the	   data	   derived	   from	  
empty	   vector-­‐transfected	   from	   SLC22A1-­‐transfected	   KCL22	   cells;	   C)	   Accumulation	   of	   LTG	   in	   the	  
hCMEC/D3	  cell	  line	  after	  30	  minutes	  at	  37	  °C	  in	  the	  presence	  of	  increasing	  clozapine	  concentrations	  
(0.1	   –	   100	   µM);	   All	   results	   are	   expressed	   as	   means	   ±	   standard	   deviation	   (n	   =	   3	   independent	  
experiments	  in	  triplicate).	  LTG	  =	  lamotrigine,	  TEA+	  =	  tetraethylammonium	  
To	   further	   characterise	   the	   interaction	   between	   LTG	   and	   CLP	   and	   its	  
potential	   clinical	   relevance,	   additional	   assays	  were	   carried	  out	   as	  before	  but	  with	  
primary	  human	  and	  rat	  hepatocytes	  (Figure	  4.4).	  Primary	  human	  hepatocytes	  were	  
extracted	   from	   healthy	   liver	   tissue	   donated	   from	   two	   patients	   that	   underwent	  
surgery	   for	   easily	   resectable	   primary	   hepatocellular	   carcinoma	   or	   colorectal	   liver	  
metastases.	  The	  baseline	  clinical	  and	  demographic	  characteristics	  are	   summarised	  
in	   Table	   4.1.	   A	   dose-­‐response	  was	   observed	  with	   all	   three	   primary	   cell	   lines	   and	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curve-­‐fitting	  yielded	   IC50	  values	  of	  7.9	  µM	  for	  patient	  1,	  3.9	  µM	  for	  patient	  2,	  and	  
4.7	   µM	   for	   rat	   hepatocytes	   (Figure	   4.4).	   Cell	   viability	   after	   hepatocyte	   extraction	  
was	   79	   %	   for	   patient	   1,	   89	   %	   for	   patient	   2,	   and	   90	   %	   for	   rat.	   The	   viability	   of	  
hepatocytes	   derived	   from	  patient	   1	  was	   slightly	   below	   the	   threshold	  of	   85	  %	  but	  
considered	  acceptable	  because	  of	  the	  high	  value	  of	  these	  cells.	  
Table	  4.1:	  Baseline	  clinical	  and	  demographic	  characteristics	  for	  patients	  who	  donated	  hepatocytes	  
	   Patient	  1	   Patient	  2	  
Sex	   Male	   Male	  
Age	  (years)	   65	   75	  
Weight	  (kg)	   72	   67	  
Race	   Caucasian	   Caucasian	  
Smoking	  status	   Non-­‐smoker	   Non-­‐smoker	  
Alcohol	  consumption	   Zero	   Zero	  






Figure	  4.4:	  Drug-­‐drug	   interactions	  between	   lamotrigine	  and	   clozapine	   in	  primary	  human	  and	   rat	  
hepatocytes	  
Accumulation	  of	  lamotrigine	  (LTG)	  after	  30	  minutes	  at	  37	  °C	  in	  the	  presence	  of	  increasing	  clozapine	  
concentrations	   (0.1	   –	   100	  µM);	   A)	   Primary	   human	  hepatocytes	   from	  patient	   1;	   B)	   Primary	   human	  
hepatocytes	   from	   patient	   2;	   C)	   Primary	   rat	   hepatocytes;	   All	   results	   are	   expressed	   as	   means	  	  
±	  standard	  deviation	  (n	  =	  1	  experiment	  in	  triplicate)	  
SLC22A1	   gene	   expression	   levels	   in	   primary	   human	   hepatocytes	   and	   the	  
hCMEC/D3	  cell	   line	  were	  analysed	  by	  TaqMan®	  real-­‐time	  PCR	  using	  100	  ng	  cDNA.	  
Initially,	  GAPDH	  was	  utilised	  as	  the	  housekeeping	  gene	  for	  normalisation.	  However,	  
while	  the	  Ct	  for	  SLC22A1	  gene	  expression	  was	  29	  for	  both	  patients,	  the	  Ct	  obtained	  
for	  GAPDH	  gene	  expression	  was	  dramatically	  different	  with	  only	  36	  for	  patient	  2	  but	  
26	   for	  patient	  1.	  Assuming	  a	  primer	  efficacy	  of	  2,	   this	   corresponds	   to	  a	  1024-­‐fold	  
difference	  in	  GAPDH	  gene	  expression.	  The	  underlying	  reason	  for	  this	  observation	  is	  
unknown	  but	  might	  be	  linked	  to	  the	  cancer	  in	  the	  patient.	  In	  any	  case,	  GAPDH	  is	  not	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suitable	   for	   normalisation	   and	   the	   assay	  was	   therefore	   repeated	   using	   beta-­‐actin	  
(ACTB)	   as	  an	  alternative	  housekeeping	  gene.	   In	   contrast	   to	  GAPDH,	   the	  Ct	   for	   the	  
ACTB	  gene	  expression	  was	  26	  for	  both	  human	  hepatocyte	  batches.	  In	  addition,	  the	  
Ct	  for	  SLC22A1	  was	  30	  for	  both	  patients.	  Surprisingly,	  SLC22A1	  was	  only	  borderline	  
expressed	   in	   the	  hCMEC/D3	   cell	   line	  with	   a	  Ct	   of	   39.	   The	   relative	  SLC22A1	  mRNA	  
expression	  levels,	  normalised	  to	  ACTB,	  are	  summarised	  in	  Figure	  4.5	  and	  plotted	  as	  
fold	  difference	  to	  the	  expression	  in	  the	  hCMEC/D3	  cell	  line.	  Hepatocytes	  from	  both	  
patients	   displayed	   on	   average	   915-­‐fold	   higher	   SLC22A1	   mRNA	   expression	   than	  
hCMEC/D3	  cells.	  
Figure	   4.5:	   Relative	   gene	   expression	   of	   SLC22A1	   in	   primary	   human	   hepatocytes	   and	   hCMEC/D3	  
cells	  
Gene	  expression	  of	  SLC22A1	  in	  two	  batches	  of	  primary	  human	  hepatocytes	  relative	  to	  the	  expression	  
in	   hCMEC/D3	   cells	   normalised	   to	   beta-­‐actin	   (ACTB).	   The	   relative	   gene	   expression	   is	   given	   as	   fold	  




















































Numerous	   drugs	   are	   known	   to	   inhibit	   SLC22A1	   (OCT1)	   and	   the	   risk	   for	   drug-­‐drug	  
interactions	   with	   LTG	   as	   an	   SLC22A1	   substrate	   is	   high.	   From	   the	   literature,	   two	  
clinical	   interactions	  were	   noted	   and	   investigated	   in	   vitro,	   an	   interaction	   between	  
LTG	  and	  the	  HIV	  protease	  inhibitors	   lopinavir/ritonavir,	  and	  a	  potential	   interaction	  
between	  LTG	  and	  the	  antipsychotic	  clozapine.	  
Lopinavir/ritonavir	   have	   been	   reported	   to	   reduce	   LTG	   serum	   levels	   by	  
about	   50	  %.	   To	   analyse	   a	   potential	   interaction	   at	   the	   drug	   transporter	   level,	   the	  
accumulation	   of	   LTG	   was	   assessed	   in	   empty	   vector-­‐transfected	   and	   SLC22A1-­‐
transfected	   KCL22	   cells	   in	   the	   presence	   of	   several	   antiretroviral	   drugs.	   At	  
therapeutically	   relevant	   concentrations,	   a	   combination	   of	   lopinavir/ritonavir	  
significantly	  reduced	  the	  SLC22A1-­‐mediated	  uptake	  of	  LTG	  by	  39	  %.	  The	  same	  39	  %	  
reduction	  was	  observed	  with	  lopinavir	  alone,	  suggesting	  that	  lopinavir,	  at	  clinically	  
relevant	  concentrations,	  is	  the	  dominant	  or	  sole	  inhibitor	  of	  SLC22A1-­‐mediated	  LTG	  
uptake.	  
Ritonavir	  has	  previously	  been	  described	  as	  an	  SLC22A1	   inhibitor	  utilising	  
the	  two	  model	  substrates	  TEA+	  and	  MPP+	  (Jung	  et	  al.	  2008,	  Jung	  et	  al.	  2012,	  Zhang	  
et	  al.	  2000).	  This	  observation	  could	  be	  confirmed	  for	  SLC22A1-­‐mediated	  LTG	  uptake	  
using	   ritonavir	   at	   a	   concentration	   of	   10	   µM.	   However,	   10	   µM	   is	   more	   than	   one	  
order	  of	  magnitude	  higher	  than	  relevant	  peak	  plasma	  levels	  when	  ritonavir	  is	  used	  
as	   a	   pharmacokinetic	   booster	   (AbbVie	   Inc.	   2013).	   The	   inhibitory	   characteristics	   of	  
lopinavir	  were	   further	   investigated	   utilising	   a	   range	   of	   concentrations	   from	   0.1	   –	  
100	   µM.	   A	   dose-­‐response	   curve	   was	   difficult	   to	   fit	   due	   to	   the	   slowly	   increasing	  
inhibitory	  potency	  combined	  with	  a	  high	  SD,	   likely	  a	  technical	  consequence	  of	  the	  
non-­‐adherent	  KCL22	  cell	   lines	   that	   required	  extensive	  washing	  with	  centrifugation	  
between	  each	  washing	  step.	  In	  addition,	  the	  curve	  appears	  to	  reach	  a	  plateau	  and	  
may	  thus	  describe	  a	  biphasic	  dose-­‐response.	  However,	  many	  more	  repeats	  and	  data	  
points	  with	  higher	  and	  lower	  concentrations	  would	  be	  required	  to	  gain	  confidence	  
in	  this	  hypothesis.	  Notably,	  a	  biphasic	  dose-­‐response	  has	  been	  described	  before	  for	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the	   inhibition	   of	   SLC22A1-­‐mediated	  MPP+	   uptake	   by	   lamivudine,	   concluding	   that	  
SLC22A1	  has	  a	  low-­‐affinity	  and	  high-­‐affinity	  binding	  site	  (Minuesa	  et	  al.	  2009).	  The	  
same	   study	   also	   found	   abacavir	   to	   be	   a	   very	   potent	   inhibitor	   of	   MPP+	   uptake.	  
Interestingly,	   lamivudine	   and	   abacavir	   both	   had	   no	   effect	   on	   LTG	   uptake	   as	  
presented	  here,	  suggesting	  that	  LTG	  may	  bind	  to	  different	  site(s)	  than	  MPP+	  within	  
the	  substrate-­‐binding	  cavity	  of	  SLC22A1.	  	  
In	   conclusion,	   this	   is	   the	   first	   study	   reporting	   an	   inhibition	   of	   SLC22A1-­‐
mediated	  LTG	  uptake	  by	  lopinavir	  at	  clinically	  relevant	  concentrations.	  Reduced	  LTG	  
serum	  levels	   in	  the	  presence	  of	   lopinavir/ritonavir	  have	  been	  reported	  before	  and	  
were	   correlated	   to	   an	   increased	   LTG	  metabolism	   (AbbVie	   Inc.	   2013,	   Burger	   et	   al.	  
2008,	  GlaxoSmithKline	  Inc.	  2012,	  van	  der	  Lee	  et	  al.	  2006).	  The	  data	  presented	  here	  
suggest	  an	  additional	  effect	  from	  an	  interaction	  with	  SLC22A1,	  for	  example	  through	  
reduced	  LTG	  uptake	  from	  the	  intestine	  (Han	  et	  al.	  2013).	  
LTG	   may	   be	   beneficial	   as	   an	   augmentation	   strategy	   to	   overcome	   CLP	  
resistance	  for	  the	  treatment	  of	  schizophrenia,	  but	  no	  mechanistic	  pharmacological	  
studies	   have	   been	   done	   so	   far.	   To	   analyse	   a	   potential	   interaction	   at	   the	   drug	  
transporter	   level,	   the	   accumulation	   of	   CLP	   was	   assessed	   in	   empty	   vector-­‐
transfected	   and	   SLC22A1-­‐transfected	   KCL22	   cells	   in	   a	   time-­‐course	   assay	   up	   to	   30	  
minutes.	   No	   difference	   was	   observed	   indicating	   that	   CLP	   is	   not	   a	   substrate	   for	  
SLC22A1.	  Thus,	  based	  on	  these	  data,	  the	  initial	  hypothesis	  had	  to	  be	  rejected.	  CLP,	  
however,	   may	   still	   act	   as	   an	   inhibitor	   of	   SLC22A1	   as	   it	   exhibits	   typical	   SLC22A1	  
inhibitor	   characteristics	   (Ahlin	   et	   al.	   2008).	   An	   impaired	   SLC22A1-­‐mediated	   LTG	  
uptake	   by	   means	   of	   CLP	   could	   be	   clinically	   important	   because	   CLP	   treatment	   is	  
associated	   with	   an	   elevated	   risk	   for	   seizures	   (boxed	   warning)	   (Novartis	  
Pharmaceuticals	   Corporation	   2013).	   The	  drug	  of	   choice	   for	   the	   treatment	   of	   CLP-­‐
induced	  seizures	  is	  VPA,	  but	  LTG	  is	  increasingly	  recognised	  as	  an	  alternative	  (Varma	  
et	  al.	  2011).	  	  
The	  accumulation	  of	  LTG	  was	  analysed	  in	  the	  presence	  of	   increasing	  CLP	  
concentrations	   utilising	   different	   cell	   lines.	   First,	   empty	   vector-­‐transfected	   and	  
SLC22A1-­‐transfected	   KCL22	   cells	   yielded	   an	   SLC22A1-­‐mediated	   inhibition	   with	   an	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IC50	  as	  low	  as	  1.8	  µM.	  A	  very	  similar	  effect	  was	  seen	  in	  the	  hCMEC/D3	  cell	  line	  as	  an	  
in	   vitro	   model	   of	   the	   BBB	   yielding	   an	   IC50	   of	   2.0	   µM.	   These	   numbers	   are	   within	  
therapeutically	   relevant	   CLP	   concentration	   ranges	   of	   0.3	   µM	   to	   2.4	   µM	   (Novartis	  
Pharmaceuticals	   Corporation	   2013).	   Primary	   human	   and	   rat	   hepatocytes	   further	  
confirmed	   the	   observed	   interaction.	   Experiments	   with	   hepatocytes	   derived	   from	  
two	  patients	  yielded	  IC50	  values	  of	  7.9	  µM	  and	  3.9	  µM,	  respectively.	  The	  latter	  value	  
might	  be	  more	  reliable	  as	  the	  hepatocytes	  from	  patient	  1	  showed	  a	  viability	  of	  only	  
79	  %	  and	  the	  experimental	  data	  had	  larger	  SDs.	  In	  addition,	  the	  R2	  as	  a	  measure	  of	  
the	  goodness	  of	  fit	  was	  0.91	  (patient	  1)	  vs.	  0.99	  (patient	  2).	  Rat	  hepatocytes	  yielded	  
an	   IC50	   of	   4.7	   µM	   and	   R2	   of	   0.99.	   Overall,	   a	   strong	   inhibitory	   effect	   of	   CLP	   was	  
observed	  on	   the	   SLC22A1-­‐mediated	  uptake	  of	   LTG	   in	   different	   cell	   lines	   including	  
primary	   hepatocytes.	   The	   IC50	   values	   were	   close	   together	   in	   the	   low,	   single-­‐digit	  
micromolar	  range	  at	  therapeutically	  relevant	  concentrations.	  
SLC22A1	   is	  known	  to	  be	  most	  abundantly	  expressed	   in	   the	   liver	   (Nies	  et	  
al.	   2011)	   and	   hepatocytes	   derived	   from	   both	   patients	   showed	   strong	   and	  
comparable	  SLC22A1	  mRNA	  expression	  levels.	  Surprisingly,	  the	  hCMEC/D3	  cell	   line	  
only	  exhibited	  a	  very	  borderline	  SLC22A1	  mRNA	  expression.	  While	  this	  corresponds	  
to	  the	  lower	  effect	  size	  as	  compared	  to	  hepatocytes	  or	  SLC22A1-­‐transfected	  KCL22	  
cells,	  it	  remains	  possible	  that,	  in	  addition	  to	  SLC22A1,	  LTG	  is	  a	  substrate	  for	  another,	  
as	  yet	  unknown,	  drug	  transporter.	  
In	   conclusion,	   CLP	   potently	   inhibits	   SLC22A1-­‐mediated	   LTG	   transport	   at	  
therapeutically	   relevant	   concentrations.	   These	   in	   vitro	   observations	   might	   have	  
consequences	   for	   the	   safety	   and/or	   effectiveness	   of	   LTG	   when	   co-­‐administered	  
with	  CLP.	  At	  the	  BBB,	  LTG-­‐CLP	  interaction	  could	  impair	  the	  uptake	  of	  LTG	  and	  thus	  
affect	   the	   drug´s	   effectiveness	   in	   the	   treatment	   of	   epilepsy	   or	   bipolar	   I	   disorder	  	  
(Figure	  4.6	  C).	  In	  the	  liver,	  in	  contrast,	  an	  impaired	  LTG	  uptake	  into	  hepatocytes	  may	  
increase	   the	   plasma	   concentration	   of	   LTG	   with	   an	   increased	   risk	   of	   side	   effects	  
(Figure	  4.6	  B).	   In	  the	  intestine,	  a	  reduced	  LTG	  absorbance	  may	  result	   in	  lower	  oral	  
bioavailability	  and	  consequently	  reduced	  efficacy	   (Figure	  4.6	  A).	  Finally,	  a	   reduced	  
LTG	  reabsorption	  by	  tubule	  epithelial	  kidney	  cells	  may	  increase	  the	  drug´s	  clearance	  
(Figure	   4.6	   D).	   The	   results	   obtained	   from	   this	   chapter	   with	   primary	   human	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hepatocytes	   and	   the	   fact	   that	   SLC22A1	   is	  most	   abundantly	   expressed	   in	   the	   liver	  
suggests	   that	   impaired	   LTG	   uptake	   into	   hepatocytes	   may	   be	   of	   particular	  
importance.	   The	  beneficial	   effects	  observed	  with	   co-­‐treatment	  by	  CLP	  and	   LTG	   in	  
treatment	   resistant	   schizophrenia	   could	   result	   from	  a	  net	   increase	  of	   LTG	  plasma	  
levels.	   Rather	   than	   having	   a	   pharmacokinetic	   effect	   on	   CLP	   efficiency,	   LTG	   could	  
have	   a	   therapeutic	   role	   and	   elevated	   LTG	   plasma	   levels	   may	   be	   of	   critical	  
importance.	  It	  has	  been	  proposed	  before	  that	  LTG	  adds	  to	  or	  synergises	  the	  effect	  
of	   CLP	   in	   treatment	   resistant	   schizophrenia	   by	   modulating	   neuronal	   glutamate	  
transmission	   (Large	   et	   al.	   2005).	   The	   potential	   clinical	   consequences	   that	   derive	  
from	  the	  presented	  in	  vitro	  observations,	  however,	  require	  further	  research.	  
To	  assess	  whether	  a	  transporter	  other	  than	  SLC22A1	  (OCT1)	  is	  involved	  in	  
an	   interaction	   between	   CLP	   and	   LTG,	   the	   accumulation	   of	   CLP	   was	   studied	   in	  
hCMEC/D3	   cells	   in	   the	   presence	   of	   increasing	   LTG	   concentrations.	   No	   effect	   was	  
observed	  up	  to	  the	  maximum	  therapeutic	  LTG	  plasma	  levels	  of	  47	  µM.	  Interestingly,	  
a	  higher	  LTG	  concentration	  of	  ≥	  100	  µM	  resulted	  in	  a	  decreased	  CLP	  accumulation,	  
suggesting	   that	   an	   unknown	   transporter	   could	   be	   involved	   in	   CLP	   uptake.	   This	   is	  
further	   supported	   by	   the	   observation	   that	   the	   uptake	   of	   1	   µM	   CLP	   (about	  	  
400	  pmol/million	  cells	  after	  30	  minutes	  at	  37	  °C)	  is	  high	  when	  compared	  to	  all	  other	  
dugs	   studied	   in	   this	   thesis.	   CLP	   uptake	   by	   an	   unidentified	   transporter	  will	   be	   the	  




Figure	  4.6:	  Illustration	  of	  a	  potential	  contribution	  of	  SLC22A1	  (OCT1)	  to	  absorption,	  metabolism,	  distribution,	  and	  elimination	  (ADME)	  of	  lamotrigine	  
Simplified	  model	   illustrating	   the	   subcellular	   localisation	   of	   SLC22A1	   (OCT1)	   at	   four	   pharmacologically	   important	   barriers	   potentially	   involved	   in	   lamotrigine	   absorption	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The	   results	   from	   chapter	   4	   of	   this	   thesis	   suggest	   that	   an	   unidentified	   uptake	  
transporter	  may	  be	  involved	  in	  CLP	  accumulation	  in	  the	  hCMEC/D3	  cell	   line.	  CLP	  is	  
an	   important	   last-­‐resort	   treatment	   option	   for	   patients	   suffering	   from	   otherwise	  
treatment-­‐resistant	  schizophrenia	  (Novartis	  Pharmaceuticals	  Corporation	  2013).	  
Schizophrenia	  is	  a	  severe	  mental	  illness	  affecting	  about	  24	  million	  people	  
worldwide	   (World	   Health	   Organisation	   2014).	   It	   is	   characterised	   by	   symptoms	   of	  
altered	  perception,	  thought,	  affect,	  and	  behaviour	  (National	  Institute	  for	  Health	  and	  
Clinical	  Excellence	  2009).	  Schizophrenia	  can	  have	  a	  devastating	  effect	  on	  a	  patient’s	  
social	   life.	   The	  disease	   is	   accompanied	  by	   increased	  mortality,	   leading	   to	   reduced	  
life	  expectancy	  of	  12	  –	  15	  years	  as	   compared	   to	   the	  general	  population	   (National	  
Institute	  for	  Health	  and	  Clinical	  Excellence	  2009,	  van	  Os	  et	  al.	  2009).	  
Pathophysiologically,	  schizophrenia	  is	  associated	  with	  elevated	  dopamine	  
synthesis,	  release,	  and	  elevated	  synaptic	  concentrations	  at	  resting-­‐state	  (van	  Os	  et	  
al.	   2009).	   Consequently,	   all	   currently	   approved	   treatments	   interfere	   with	   the	  
dopaminergic	  circuit	  and	  the	  dopamine	  D2	  receptor	  is	  regarded	  as	  the	  main	  target	  
(Kapur	   et	   al.	   2006,	   Miyamoto	   et	   al.	   2012,	   van	   Os	   et	   al.	   2009).	   However,	   most	  
antipsychotic	   drugs	   (APDs)	   also	   affect	   other	   neurotransmitter	   receptors	   such	   as	  
serotonergic,	   adrenergic,	   and/or	   muscarinic	   receptors.	   In	   addition,	   monoamine	  
transporters	  from	  the	  SLC6A	  family	  are	  frequently	  affected	  (Miyamoto	  et	  al.	  2012).	  
The	   action	   on	   multiple	   but	   still	   distinct	   targets	   is	   assumed	   to	   define	   the	   overall	  
therapeutic	  and	  side	  effect	  profile	  of	  each	  APD	  (Miyamoto	  et	  al.	  2012).	  
APDs	   are	   classified	   as	   first-­‐generation	   APDs	   (FGD)	   or	   second-­‐generation	  
APDs	   (SGD).	   SGDs,	   with	   its	   prototypical	   drug	   clozapine,	   are	   also	   referred	   to	   as	  
atypical	   APDs	   (Miyamoto	   et	   al.	   2012).	   The	   term	   “atypical”	   derives	   from	   the	  
observation	   that	   treatment	   with	   SGDs	   is	   associated	   with	   reduced	   occurrence	   of	  
extrapyramidal	  side	  effects,	  a	  common	  problem	  with	  FGDs	  that	  has	  been	  linked	  to	  
the	   high	   D2	   receptor	   occupancy	   (Miyamoto	   et	   al.	   2012).	   High	   affinity	   for	   the	  
serotonin	  receptor	  5-­‐HT2A	  in	  combination	  with	  reduced,	  but	  still	  present,	  occupancy	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of	   D2	   is	   thought	   to	   be	   the	   underlying	  molecular	   reason	   leading	   to	   the	   “atypical”	  
behaviour	  of	  SGDs	  (Meltzer	  et	  al.	  1989,	  Miyamoto	  et	  al.	  2012).	  
Pharmacological	   treatment	   is	   of	   fundamental	   importance	   to	   cope	   with	  
the	   symptoms	   of	   schizophrenia.	   However,	   about	   one	   third	   of	   all	   patients	   do	   not	  
respond	  adequately	  to	  standard	  treatment	  options	  and	  remain	  refractory	  (van	  Os	  et	  
al.	  2009).	  In	  the	  UK,	  a	  patient	  is	  classified	  as	  refractory	  if	  treatment	  with	  at	  least	  two	  
APDs,	   including	  one	  SGD	  (except	  CLP),	  has	  failed	  (National	  Institute	  for	  Health	  and	  
Clinical	   Excellence	   2009).	   CLP	   is	   approved	   for	   the	   treatment	   of	   schizophrenia	   in	  
otherwise	   refractory	   patients	   and	   has	   demonstrated	   clear	   superiority	   to	  
chlorpromazine	  with	   a	   response	   rate	   of	   30	  %	   vs.	   4	  %	   (Kane	   et	   al.	   1988,	  Novartis	  
Pharmaceuticals	   Corporation	   2013).	   Based	   on	   this	   study,	   Novartis	   received	   FDA	  
marketing	  authorisation	  for	  CLP	  in	  1989.	  	  
CLP	  is	  about	  97	  %	  serum-­‐protein	  bound	  and	  reaches	  average	  steady-­‐state	  
peak	   plasma	   concentrations	   of	   about	   1	   µM	   (range	   from	   0.3	   –	   2.4	   µM)	   following	  
twice-­‐daily	  doses	  of	  100	  mg	  (Novartis	  Pharmaceuticals	  Corporation	  2013).	  The	  drug	  
is	   extensively	   and	   almost	   completely	   metabolised	   to	   three	   principal	   CLP	  
metabolites,	   namely	   desmethylclozapine	   (norclozapine),	   clozapine	   N-­‐oxide,	   and	  
hydroxyclozapine	  (Novartis	  Pharmaceuticals	  Corporation	  2013).	  While	  norclozapine	  
has	  been	  reported	  to	  show	  some	  limited	  pharmacological	  activity,	  the	  latter	  two	  are	  
inactive	   (Novartis	  Pharmaceuticals	  Corporation	  2013).	  The	  main	  enzymes	   involved	  
in	  CLP	  metabolism	  are	  CYP1A2	  and	  CYP3A4,	  which	  does	   lead	   to	   critical	  drug-­‐drug	  
interactions	  (Eiermann	  et	  al.	  1997,	  Pirmohamed	  et	  al.	  1995).	  
As	   yet,	   CLP	   has	   not	   been	   demonstrated	   to	   be	   a	   substrate	   for	   any	  
particular	   human	   drug	   transporter	   using	   direct	   approaches.	   The	   transepithelial	  
transport	   of	   tritium-­‐labelled	   CLP	   across	   a	   human	  ABCB1-­‐transfected	   pig	   epithelial	  
kidney	  cell	  line	  was	  negative	  (Schinkel	  et	  al.	  1996).	  In	  contrast,	  several	  studies	  have	  
found	  an	  inhibitory	  effect	  on	  the	  uptake	  or	  efflux	  of	  model	  substrates	  for	  SLC22A1	  
(OCT1),	   SLC22A2	   (OCT2),	   SLC22A3	   (OCT3),	   SLC29A4	   (ENT4),	   ABCB1	   (MDR1,	   Pgp),	  
and	  ABCG2	  (BCRP)	  using	  overexpressing	  cell	  lines	  (Ahlin	  et	  al.	  2008,	  Haenisch	  et	  al.	  
2010,	  Haenisch	  et	  al.	  2012,	  Schmitt	  et	  al.	  2012,	  Wang	  et	  al.	  2006,	  Wang	  et	  al.	  2008).	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However,	  most	   of	   the	   reported	   IC50	   values	  were	   considerably	   above	   average	   CLP	  
peak	   plasma	   levels	   of	   1	   µM.	   Interestingly,	   the	   lowest	   IC50	   value	   of	   6.65	   µM	  was	  
reported	  for	  SLC22A1	  using	  15	  nM	  MPP+	  as	  a	  model	  substrate	  (Haenisch	  et	  al.	  2012)	  
(see	  also	  chapter	  4).	   In	  vivo,	   the	  mouse	  Abcb1a/Abcb1b	   (-­‐/-­‐)	  knockout	  model	  was	  
used	   to	  elicit	   a	  potential	   effect	  on	  CLP	  brain	   to	   serum/plasma	  AUC	  concentration	  
ratios.	  While	  one	   study	   reported	  no	  effect	   (Schmitt	   et	   al.	   2012),	   another	   found	  a	  
minor	  difference	  as	  compared	  to	  WT	  animals	  with	  a	  brain	   to	  plasma	  AUC	  ratio	  of	  
6.6	  vs.	  4.1	  (Doran	  et	  al.	  2005).	  
The	   reason	   for	  CLP	  only	  being	   licensed	  as	   a	   reserve	   treatment	  option	   is	  
the	   substantially	   increased	   risk	   for	   agranulocytosis	   and	   seizures	   (boxed	  warnings)	  
(Novartis	  Pharmaceuticals	  Corporation	  2013).	  Due	  to	  the	  risk	  for	  agranulocytosis,	  an	  
extensive	  blood	  monitoring	   (weekly	   for	   the	   first	   six	  months)	   is	   required	   for	   every	  
patient	   treated	   with	   the	   drug.	   Other	   boxed	   warnings	   include	   myocarditis,	  
cardiomyopathy,	   orthostatic	   hypotension,	   bradycardia,	   syncope,	   and	   an	   increased	  
mortality	   in	   elderly	   patients	   with	   dementia-­‐related	   psychosis	   (Novartis	  
Pharmaceuticals	  Corporation	  2013).	  
In	   view	   of	   these	   severe	   adverse	   effects	   with	   unknown	   aetiology,	  
transporter-­‐mediated	   cellular	   uptake	   of	   CLP	   could	   be	   a	   critical	   component.	  
Additional	  evidence	  for	  this	  hypothesis	  is	  present	  in	  the	  literature	  with	  two	  studies	  
of	   particular	   note.	   First,	   likely	   transporter-­‐mediated,	   active	   CLP	   uptake	   into	   the	  
promyelocytic	   leukemia	   cell	   line	  HL-­‐60	   has	   been	   described	   (Henning	   et	   al.	   2002).	  
The	   second	   study	   reported	   eight	   times	   higher	   CLP	   concentrations	   in	   leukocytes	  
derived	   from	   a	   patient	   with	   CLP-­‐induced	   agranulocytosis	   compared	   with	   ten	  
patients	   treated	   with	   CLP	   but	   no	   evidence	   of	   agranulocytosis	   (Bergemann	   et	   al.	  
2007).	  After	  correcting	  for	  CLP	  plasma	  levels	  a	  difference	  of	  about	  six	  was	  noted.	  	  
Theoretically,	  variants	  or	  differences	  in	  expression	  levels	  of	  this	  unknown	  
transporter	   might	   predict	   the	   effectiveness	   (e.g.	   uptake	   into	   the	   brain)	   and/or	  
adverse	   effects	   (e.g.	   uptake	   into	   leukocytes,	   cardiomyocytes,	   or	   brain)	   of	   CLP,	  
allowing	  personalised	  prescription.	  The	  aim	  of	  this	  research	  chapter	  was	  therefore	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to	   identify	  and	  characterise	   the	  unknown	  CLP	  uptake	   transporter	  as	  hypothesised	  
based	  on	  data	  from	  chapter	  4	  and	  the	  literature.	  
5.2. Materials	  and	  methods	  
5.2.1. Materials	  
Unless	   otherwise	   specified,	   all	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich	  
Company	  Ltd.,	  Gillingham,	  UK,	  or	   listed	  in	  the	  corresponding	  sections	  of	  chapter	  3	  
and	   4	   (3.2.1	   and	   4.2.1).	   Carbon-­‐14-­‐labelled	   TEA+	   ([14C]-­‐TEA+,	   0.1	   mCi/ml,	   specific	  
activity	  3.5	  mCi/mmol)	  was	  obtained	  from	  PerkinElmer,	  Seer	  Green,	  UK.	  
5.2.2. Cell	  lines	  and	  culture	  conditions	  
5.2.2.1. hCMEC/D3	  cell	  line	  
Please	  refer	  to	  chapter	  3	  section	  3.2.2.1.	  
5.2.2.2. KCL22	  cell	  line	  
The	  human	  chronic	  myeloid	   leukaemia	  cell	   line	  KCL22	  was	  stably	   transfected	  with	  
an	  empty	  vector	   (control)	  or	  a	  vector	  encoding	   for	  SLC22A4	  (OCTN1)	  by	  means	  of	  
electroporation.	   Both	   non-­‐adherent	   cell	   lines	   were	   a	   kind	   gift	   from	   Dr	   Athina	  
Giannoudis	  (Department	  of	  Haematology,	  University	  of	  Liverpool,	  UK)	  and	  cultured	  
in	   RPMI-­‐1640	   medium	   supplemented	   with	   10	   %	   FBS	   (v/v)	   and	   1	   %	   penicillin-­‐
streptomycin	  (v/v)	  at	  37	  °C	  and	  5	  %	  CO2	  (Dickens	  et	  al.	  2013a).	  
5.2.3. Distribution	  coefficient	  (logD,	  pH	  7.4)	  




5.2.4. Drug	  accumulation	  assays	  
5.2.4.1. Non-­‐adherent	  cells	  
Cell	  accumulation	  assays	  with	  non-­‐adherent	  KCL22	  cells,	  stably	  transfected	  with	  an	  
empty	   vector	   or	   SLC22A4,	   were	   carried	   out	   as	   described	   in	   chapter	   4	   section	  
4.2.3.1.	   The	   double-­‐concentrated	  master	  mix	   consisted	   of	   transport	   buffer	   (HBSS	  
supplemented	  with	  25	  mM	  HEPES,	  adjusted	  to	  pH	  7.4)	  with	  1.2	  µCi/ml	  [14C]-­‐TEA+	  or	  
0.2	  µCi/ml	  [3H]-­‐CLP,	  non-­‐labelled	  corresponding	  “cold”	  CLP	  to	  give	  2	  µM,	  and	  0.2	  %	  
BSA	   (w/v).	   The	   final	   vehicle	   concentration	   did	   not	   exceed	   0.6	   %	   per	   reaction	  
(Ethanol	   and/or	   DMSO).	   The	   positive	   control	   with	   [14C]-­‐TEA+	   did	   not	   contain	   any	  
additional	  “cold”	  drug	  and	  resulted	  in	  a	  final	  concentration	  of	  171.42	  µM	  TEA+.	  
5.2.4.2. Adherent	  cells	  
Cell	   accumulation	   assays	   with	   adherent	   hCMEC/D3	   cells	   were	   carried	   out	   as	  
described	  in	  chapter	  3	  section	  3.2.4.	  
The	  master	  mix	  for	  CLP	  time-­‐course	  assays,	  siRNA	  screenings,	  and	  assays	  
to	   determine	   the	   effect	   of	   temperature	   consisted	   of	   transport	   buffer	   (HBSS	  
supplemented	  with	   25	  mM	  HEPES,	   adjusted	   to	   pH	   7.4)	  with	   0.1	   µCi/ml	   [3H]-­‐CLP,	  
non-­‐labelled	   corresponding	   “cold”	   CLP	   to	   give	   a	   final	   concentration	  of	   1	  µM,	   and	  	  
0.1	   %	   BSA	   (w/v).	   The	   vehicle	   concentration	   did	   not	   exceed	   0.2	   %	   per	   reaction	  
(DMSO).	  
The	  master	  mix	  for	  inhibitor	  screenings	  consisted	  of	  transport	  buffer	  with	  
0.1	   µCi/ml	   [3H]-­‐CLP,	   non-­‐labelled	   corresponding	   “cold”	   CLP	   to	   give	   a	   final	  
concentration	  of	  1	  µM,	  the	  inhibitor	  or	  vehicle	  only	  as	  control,	  and	  0.1	  %	  BSA	  (w/v).	  
The	   vehicle	   concentration	   did	   not	   exceed	   0.6	   %	   per	   reaction	   (DMSO	   and	   HCl).	  
Norepinephrine	  was	  dissolved	   in	  1	  M	  HCl	  with	  no	  effect	  on	   the	  pH	  of	   the	  master	  
mix.	  
The	  master	  mix	   to	  determine	  CLP	  uptake	  kinetics	   consisted	  of	   transport	  
buffer	  with	  0.05	  µCi/ml	  [3H]-­‐CLP,	  non-­‐labelled	  corresponding	  “cold”	  CLP	  to	  give	  final	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concentrations	   ranging	   from	   0.1	   –	   300	   µM,	   and	   0.1	   %	   BSA	   (w/v).	   The	   vehicle	  
concentration	  did	  not	  exceed	  0.4	  %	  per	  reaction	  (DMSO).	  
5.2.5. siRNA	  transfection	  
RNAi	  experiments	  were	  carried	  out	  as	  outlined	  in	  chapter	  3	  section	  3.2.5.	  All	  siRNA	  
sequences	  and	  corresponding	  identification	  numbers	  are	  listed	  in	  the	  appendix.	  
5.2.6. Gene	  expression	  
RNA	  extraction,	  RT-­‐PCR,	  and	  real-­‐time	  PCR	  were	  carried	  out	  as	  described	  in	  chapter	  
3	   section	   3.2.6.	   TaqMan®	   assay	   probe	   sequences	   and	   identification	   numbers	   are	  
listed	  in	  the	  appendix.	  
5.2.7. Statistical	  analysis	  
All	  data	  are	  presented	  as	  means	  ±	  SD.	  One-­‐way	  ANOVA	  followed	  by	  Dunnett’s	  post-­‐
hoc	   test	   was	   carried	   out	   for	   statistical	   analysis	   of	   all	   experiments	   with	   multiple	  
comparisons.	   Single	   comparisons	  were	   analysed	   by	   an	   independent,	   two-­‐tailed	   t-­‐
test.	  Significant	  results	  are	   indicated	  with	  *	  for	  p<0.05,	  **	  for	  p<0.01,	  and	  ***	  for	  
p<0.001.	   Analysis	   was	   performed	   with	   SPSS®	   Statistics	   version	   20	   (IBM	   United	  
Kingdom	   Ltd.,	   Hampshire,	   UK).	   Kinetic	   parameters	   were	   calculated	   with	   Prism	   6	  
(GraphPad	  Software	  Inc.,	  La	  Jolla,	  CA,	  USA)	  by	  fitting	  a	  non-­‐linear	  Michaelis-­‐Menten	  




5.3.1. Lipophilicity	  of	  clozapine	  
CLP	  is	  a	  lipophilic	  drug	  with	  a	  predicted	  logD	  (pH	  7.4)	  of	  1.95	  (ACD	  labs	  algorithm	  on	  
www.chemspider.com).	  Here,	  a	  slightly	  lower	  experimental	  logD	  (pH	  7.4)	  of	  1.36	  ±	  
0.01	  was	  obtained.	   Sugano	  et	  al.	   referred	   to	  drugs	  with	   a	   logD	  between	  0	  –	  2	   as	  
having	  moderate	  lipophilicity	  (Sugano	  et	  al.	  2010).	  A	  previous	  study	  using	  a	  similar	  
experimental	   approach	   reported	   a	   logD	   (pH	   7.4)	   of	   2.7	   (Hartter	   et	   al.	   2003).	  
However,	   despite	   some	   differences	   between	   the	   absolute	   numbers,	   all	   three	  
predicted	  and	  experimentally	  derived	  logDs	  (pH	  7.4)	  were	  within	  the	  range	  of	  1	  –	  4,	  
an	  area	  that	  has	  been	  described	  as	  optimal	  for	  passive	  diffusion	  across	  the	  BBB	  (van	  
de	  Waterbeemd	   et	  al.	  1998).	  Therefore,	  an	  active	  uptake	  of	  CLP	  has	  not	   received	  
much	   attention	   but	   there	   is	   growing	   evidence,	   including	   data	   from	   this	   thesis	  
(chapter	  4),	  that	  CLP	  could	  be	  a	  substrate	  for	  an	  unidentified	  uptake	  transporter.	  
5.3.2. Time-­‐course	   of	   clozapine	   uptake	   into	   the	   hCMEC/D3	  
cell	  line	  and	  the	  effect	  of	  temperature	  
To	   investigate	  potential	  carrier-­‐mediated	  CLP	  uptake	   into	  hCMEC/D3	  cells,	  a	  time-­‐
course	   assay	  was	   carried	   out	   (data	   obtained	   at	   0.15,	   0.5,	   1,	   2,	   5,	   10,	   20,	   and	   30	  
minutes)	   and	   the	   effect	   of	   temperature	   was	   investigated.	   CLP	   uptake	   into	  
hCMEC/D3	  cells	  exhibited	  typical	  transporter	  kinetics	  with	  a	  linear	  phase	  of	  uptake	  
(about	   two	  minutes)	   that	   was	   saturable	   (Figure	   5.1	   A).	   In	   addition,	   lowering	   the	  
temperature	  to	  4	  °C	  was	  accompanied	  by	  significantly	  decreased	  CLP	  accumulation	  
after	  30	  minutes	   (Figure	  5.1	  B).	  Both	  results	  support	   the	   involvement	  of	  an	  active	  




Figure	  5.1:	  Time-­‐course	  of	  clozapine	  uptake	  and	  the	  effect	  of	  temperature	  
A)	   Time-­‐course	   accumulation	   assay	   of	   clozapine	   (CLP)	   in	   hCMEC/D3	   cells	   at	   37	   °C.	   Data	   were	  
obtained	  at	  0.15,	  0.5,	  1,	  2,	  5,	  10,	  20,	  and	  30	  minutes,	  respectively;	  B)	  Accumulation	  of	  clozapine	  in	  
hCMEC/D3	  cells	   after	  30	  minutes	  at	  37	   °C	  and	  4	   °C,	   respectively;	  All	  data	  are	  expressed	  as	  means	  	  
±	  standard	  deviation	  (n	  =	  3	   independent	  experiments	   in	  triplicate).	  Significant	  results	  are	   indicated	  
with	  *	  for	  p<0.05	  
5.3.3. Initial	  chemical	  inhibitor	  screening	  to	  characterise	  the	  
uptake	  of	  clozapine	  into	  the	  hCMEC/D3	  cell	  line	  
Chemical	   inhibitor	  screening	  was	  applied	  as	  a	   first	  step	  to	   identify	  the	  transporter	  
class	   potentially	   responsible	   for	   CLP	   uptake	   into	   hCMEC/D3	   cells.	   The	   selected	  
compounds	   (including	   substrates	   as	   competitive	   inhibitors)	   are	   listed	   in	   Table	   5.1	  
with	   corresponding	   typical	   and	   important	   drug	   transporter	   classes	   affected.	   The	  
term	   “class”	   shall	   denote	   a	   drug	   transporter	   family,	   subfamily,	   or	   further	   sub-­‐
divisions	  such	  as	  the	  OATs	  or	  OCTs	  within	  the	  SLC22A	  subfamily	  (chapter	  1	  section	  
1.2.1.3).	  Chemical	  inhibitors	  can	  never	  be	  considered	  as	  absolutely	  specific	  and	  thus	  
a	  transporter	  class	  was	  regarded	  as	  affected	  when	  one	  or	  more	  transporters	  have	  
been	   shown	   to	   interact	   with	   the	   designated	   compound.	   This	   should	   not	   imply,	  
however,	   that	   every	  member	   from	  within	   these	   transporter	   classes	   is	   necessarily	  
affected.	   In	   chapter	   4	   section	   4.3.2	   LTG	   was	   shown	   to	   inhibit	   CLP	   uptake	   with	  
concentrations	  ≥	  100	  µM.	  This	  was	  included	  as	  a	  positive	  control.	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The	  accumulation	  of	  1	  µM	  CLP	  was	  determined	  separately	  in	  the	  presence	  
of	  all	  selected	  chemical	  inhibitors	  after	  30	  minutes	  at	  37	  °C	  (Figure	  5.2	  A).	  Prazosin	  
and	  verapamil	  were	  the	  most	  potent	  inhibitors,	  resulting	  in	  a	  reduced	  average	  CLP	  
accumulation	   of	   94	   %	   and	   83	   %,	   respectively.	   The	   presence	   of	   LTG	   resulted	   in	  
reduced	   average	   CLP	   accumulation	   of	   26	   %,	   expected	   based	   on	   the	   results	   from	  
chapter	  4	  showing	  that	  LTG	  has	  inhibitory	  potencies	  beginning	  at	  concentrations	  of	  
about	   100	   µM.	   Tariquidar	   exhibited	   a	   minor	   but	   significant	   effect	   on	   CLP	  
accumulation	  with	  an	  average	  15	  %	  reduction.	  
Table	   5.1:	   Selected	   chemical	   drug	   transporter	   inhibitors	   for	   initial	   screening	   to	   characterise	   the	  









Prazosin	   100	  µM	   OCTs,	  ABCGs	  
(Matsson	   et	   al.	   2007,	   Matsson	   et	  
al.	  2009,	  Nies	  et	  al.	  2011)	  
Verapamil	   100	  µM	  
ABCBs,	   ABCGs,	   OCTs,	  
OCTNs	  
(Giacomini	  et	  al.	  2010,	  Matsson	  et	  
al.	   2009,	   Nies	   et	   al.	   2011,	   Ohashi	  
et	  al.	  1999,	  Yabuuchi	  et	  al.	  1999)	  
Lamotrigine	   100	  µM	   OCTs	   (Dickens	  et	  al.	  2012)	  
Tariquidar	   1	  µM	   ABCBs,	  ABCCs,	  ABCGs	  
(Dickens	  et	  al.	  2013b,	  Kannan	  et	  al.	  
2011,	  Mistry	  et	  al.	  2001,	  Sun	  et	  al.	  
2013)	  
PSC-­‐833	   10	  µM	   ABCBs	  
(Boesch	   et	   al.	   1991,	  Dickens	   et	   al.	  
2013b)	  
Ko143	   1	  µM	   ABCGs	   (Allen	  et	  al.	  2002)	  
MK571	   50	  µM	   ABCCs,	  OATPs	  
(Keppler	   2011,	   Letschert	   et	   al.	  
2005)	  
Indomethacin	   100	  µM	   ABCCs,	  OATs,	  OCTs	  
(Burckhardt	  et	  al.	  2011,	  Khamdang	  
et	  al.	  2002,	  Reid	  et	  al.	  2003)	  
Methotrexate	   100	  µM	  
OATPs,	   OATs,	   ABCCs,	  
ABCGs	  
(Badagnani	  et	  al.	  2006,	  Burckhardt	  




Figure	   5.2:	   Initial	   chemical	   inhibitor	   screening	   to	   characterise	   the	   uptake	   of	   clozapine	   into	   the	  
hCMEC/D3	  cell	  line	  
Accumulation	   of	   clozapine	   (CLP)	   in	   the	   hCMEC/D3	   cell	   line	   in	   the	   presence	   of	   various	   drug	  
transporter	  inhibitors	  after	  30	  minutes	  at	  37	  °C.	  Data	  are	  expressed	  as	  means	  ±	  standard	  deviation	  	  
(n	  =	  3	  independent	  experiments	  in	  triplicate).	  Significant	  results	  are	  indicated	  with	  *	  for	  p<0.05	  and	  
***	  for	  p<0.001	  
5.3.4. Kinetics	   of	   clozapine	   uptake	   into	   the	   hCMEC/D3	   cell	  
line	  
The	   results	   from	   the	   initial	   inhibitor	   screening	   suggested	   that	   a	   strong	   uptake	  
process	   was	   responsible	   for	   CLP	   accumulation	   in	   the	   hCMEC/D3	   cell	   line.	   The	  
kinetics	  were	  determined	  at	  37	  °C	  in	  the	  linear	  phase	  of	  uptake	  at	  a	  fixed	  time-­‐point	  
of	  one	  minute	  with	  increasing	  CLP	  concentrations	  ranging	  from	  0.1	  –	  300	  µM.	  CLP	  
uptake	  followed	  nearly	  perfect	  Michaelis-­‐Menten	  kinetics	  and	  curve	  fitting	  yielded	  
an	   R2	   of	   0.99,	   Vmax	   of	   3299	   pmol/million	   cells,	   and	   Km	   of	   35.93	   µM	   (Figure	   5.3).	  
Considering	  that	  average	  CLP	  peak	  plasma	  concentrations	  are	  around	  1	  µM,	  a	  Km	  of	  
35.93	   µM	   indicates	   a	   high-­‐capacity	   CLP	   uptake	   transporter	   at	   therapeutically	  
relevant	  concentrations.	  






































































































Figure	  5.3:	  Michaelis-­‐Menten	  kinetics	  of	  clozapine	  uptake	  into	  the	  hCMEC/D3	  cell	  line	  
Clozapine	   uptake	   into	   hCMEC/D3	   cells	   was	   determined	   after	   1	   minute	   at	   37	   °C	   with	   clozapine	  
concentrations	   ranging	   from	  0.1	  –	  300	  µM.	  A	  Michaelis-­‐Menten	  regression	  curve	  was	   fitted	  to	   the	  
data	   and	   kinetic	   parameters	   Vmax	   and	   Km	   calculated.	   Data	   are	   expressed	   as	   means	   ±	   standard	  
deviation	  (n	  =	  6	  independent	  experiments	  in	  triplicate)	  
5.3.5. Second	   chemical	   inhibitor	   screening	   to	   investigate	  
SLC22A3	  (OCT3)	  as	  a	  potential	  clozapine	  transporter	  
In	   chapter	   4	   section	   4.3.3	   CLP	   was	   shown	   to	   be	   a	   potent	   inhibitor	   of	   SLC22A1	  
(OCT1)-­‐mediated	   LTG	  and	  TEA+	   transport.	   In	  addition,	  CLP	   is	  positively	   charged	  at	  
physiological	   pH	   (Ahlin	   et	   al.	   2008)	   and	   the	   inhibitor	   profile	   from	   the	   initial	  
screening	  experiment	  further	  suggests	  that	  an	  organic	  cation	  transporter	  from	  the	  
SLC22A	  transporter	  family	  may	  be	  involved	  in	  CLP	  uptake.	  SLC22A1,	  however,	  was	  
excluded	   as	   a	   potential	   CLP	   uptake	   transporter	   in	   chapter	   4	   (section	   4.3.2).	  
Additionally,	   SLC22A2	   mRNA	   levels	   are	   not	   detectable	   in	   the	   hCMEC/D3	   cell	   line	  
(Carl	   et	   al.	   2010,	   Dickens	   et	   al.	   2012).	   However,	   the	   same	   two	   studies	   reported	  
detectable	   SLC22A3	   mRNA	   levels	   encoding	   for	   the	   extraneuronal	   monoamine	  
transporter	  SLC22A3	  (OCT3).	  























Vmax = 3299 pmol/million cells




Monoamines	   are	   a	   class	   of	   molecules	   that	   include	   important	  
neurotransmitters	   such	   as	   dopamine,	   serotonin,	   and	   norepinephrine.	   Two	  
monoamine	  transporter	  systems	  are	  distinguished	  in	  the	  literature	  and	  referred	  to	  
as	   uptake1	   and	   uptake2.	   Uptake1	   consists	   of	   high-­‐affinity	   neuronal	   monoamine	  
transporters,	  mainly	  SLC6A2-­‐4	  (NET,	  DAT,	  and	  SERT),	  while	  uptake2	  consists	  of	  high-­‐
capacity	  extraneuronal	  monoamine	  transporters,	  particularly	  SLC22A3	  and	  SLC29A4	  
(ENT4)	   (Duan	   et	   al.	   2010).	   At	   this	   stage,	   SLC22A3	   was	   considered	   the	   most	  
promising	   transporter	   candidate	   for	   CLP	   and	   could	   explain	   the	   observed	   high-­‐
capacity	  uptake.	  Additional	  screening	  was	  thus	  applied	  with	  several	  known	  SLC22A3	  
inhibitors	   to	   gain	  more	   confidence	   in	   this	   hypothesis.	   The	   selected	   inhibitors	   are	  
listed	  in	  Table	  5.2	  and	  verapamil	  was	  included	  as	  a	  positive	  control.	  While	  verapamil	  
again	  potently	  inhibited	  CLP	  uptake,	  none	  of	  the	  other	  inhibitors	  had	  an	  effect	  after	  
30	  minutes	  at	  37	  °C	  (Figure	  5.4).	  
Table	   5.2:	   Selected	   chemical	   drug	   transporter	   inhibitors	   for	   second	   screening	   to	   investigate	  









Abacavir	   10	  µM	   OCT1,	  OCT2,	  OCT3	   (Minuesa	  et	  al.	  2009)	  
Phenytoin	   10	  µM	   OCT3	  
(Ahlin	   et	   al.	   2008,	   Hasannejad	  
et	  al.	  2004)	  
Corticosterone	   10	  µM	   OCT3	   (Hayer-­‐Zillgen	  et	  al.	  2002)	  
Corticosterone	   100	  µM	   OCT1,	  OCT2,	  OCT3	  
(Ahlin	  et	  al.	  2008,	  Hayer-­‐Zillgen	  




Figure	   5.4:	   Second	   chemical	   inhibitor	   screening	   to	   investigate	   SLC22A3	   (OCT3)	   as	   a	   potential	  
clozapine	  transporter	  
Accumulation	   of	   clozapine	   (CLP)	   in	   the	   hCMEC/D3	   cell	   line	   in	   the	   presence	   of	   different	   drug	  
transporter	  inhibitors	  after	  30	  minutes	  at	  37	  °C.	  Data	  are	  expressed	  as	  means	  ±	  standard	  deviation	  	  
(n	  =	  3	  independent	  experiments	  in	  triplicate).	  Significant	  results	  are	  indicated	  with	  ***	  for	  p<0.001	  
5.3.6. Investigation	   of	   potential	   clozapine	   transport	   by	  
SLC22A4	  (OCTN1)	  and	  SLC22A5	  (OCTN2)	  
The	   remaining,	   well-­‐characterised	   OCT	   transporter	   candidates	   from	   within	   the	  
SLC22A	   family	   are	   SLC22A4	   (OCTN1)	   and	   SLC22A5	   (OCTN2).	   A	   KCL22	   cell	   line	  
transfected	  with	  empty	  vector	  or	  SLC22A4	  was	  available	  and	  CLP	  investigated	  as	  a	  
potential	  substrate	   for	   this	  particular	   transporter	  after	  5	  and	  30	  minutes	  at	  37	  °C,	  
respectively.	  The	  model	  substrate	  TEA+	  was	  utilised	  as	  a	  positive	  control	  (Dickens	  et	  
al.	  2013a).	  While	  no	  difference	   in	  CLP	  uptake	  could	  be	  observed	  between	  control	  
and	   SLC22A4-­‐transfected	   cells	   (Figure	   5.5	   A),	   TEA+	   accumulation	  was	   significantly	  
increased	  in	  SLC22A4-­‐transfected	  cells	  at	  both	  time-­‐points,	  showing	  functionality	  of	  
the	  assay	  (Figure	  5.5	  B).	  These	  results	  suggest	  that	  SLC22A4	  does	  not	  mediate	  CLP	  
uptake	  into	  hCMEC/D3	  cells.	  














































































Figure	  5.5:	  Clozapine	  uptake	  into	  SLC22A4-­‐transfected	  KCL22	  cells	  
Clozapine	   (A)	   and	   TEA+	   (B)	   uptake	   into	   empty	   vector-­‐transfected	   and	   SLC22A4-­‐transfected	   KCL22	  
cells	  was	  determined	  after	  5	  and	  30	  minutes	  at	  37	  °C,	  respectively.	  All	  data	  are	  expressed	  as	  means	  	  
±	  standard	  deviation	  (n	  =	  3	   independent	  experiments	   in	  triplicate).	  Significant	  results	  are	   indicated	  
with	  *	  for	  p<0.05	  and	  ***	  for	  p<0.001.	  CLP	  =	  clozapine,	  TEA+	  =	  tetraethylammonium	  
A	  transfected	  cell	  line	  was	  not	  available	  to	  study	  CLP	  uptake	  by	  SLC22A5.	  
However,	  gene	  silencing	  by	  means	  of	  siRNA	  transfection	  had	  been	  optimised	  for	  the	  
hCMEC/D3	   cell	   line	   in	   chapter	   3	   and	  was	   thus	   used	   to	   investigate	   the	   impact	   of	  
SLC22A5	  gene	  expression	  on	  CLP	  accumulation.	   In	  addition,	  SLC22A3	  was	   included	  
into	   the	  analysis	   although	   the	   results	  presented	   in	   Figure	  5.4	  did	  not	   support	   the	  
involvement	  of	  SLC22A3	  (OCT3).	  The	  optimal	  siRNA	  transfection	  concentrations	  had	  
to	  be	  determined	   first.	   Surprisingly	  and	   in	  contrast	   to	  previous	   studies	   (Carl	   et	  al.	  
2010,	  Dickens	  et	  al.	  2012),	  SLC22A3	  mRNA	  was	  not	  detectable	  using	  100	  ng	  cDNA	  as	  
a	   template	   (Figure	   5.6	   A).	   Therefore,	   SLC22A3	   can	   be	   excluded	   as	   the	   underlying	  
reason	   for	   the	   observed	   CLP	   uptake.	   A	   strong	   gene	   silencing	   effect	  was	   obtained	  
with	   all	   three	   analysed	   SLC22A5-­‐targeting	   siRNA	   concentrations	   (10	   nM,	   25	   nM,	  	  
50	   nM)	   (Figure	   5.6	   A).	   For	   comparison,	   25	   nM	   siRNAs	   were	   chosen	   as	  
concentrations	  for	  the	  functional	  assays	  and	  the	  uptake	  of	  CLP	  determined	  after	  1	  
and	   30	  minutes	   at	   37	   °C,	   respectively.	   No	   difference	   was	   observed	   at	   both	   time	  
points	   comparing	   CLP	   uptake	   into	   SLC22A5-­‐targeting	   and	   negative	   control	   siRNA	  
transfected	  cells	  (Figure	  5.6	  B+C).	  The	  remaining	  relative	  SLC22A5	  gene	  expression	  
was	   10	   %	   on	   average	   in	   functional	   assays	   using	   25	   nM	   siRNAs	   for	   transfection	  
(Figure	  5.6	  D).	  







































































Figure	   5.6:	   Optimisation	   and	   functional	   siRNA	   screening	   of	   a	   potential	   clozapine	   uptake	   by	  
SLC22A3	  and	  SLC22A5	  
A)	  Optimisation	   of	   siRNA	   concentrations	   (10	   nM,	   25	   nM,	   50	   nM)	   targeting	   SLC22A3	   and	   SLC22A5	  
under	  optimised	  delivery	  conditions.	  The	  knockdown	  efficiency	   is	  plotted	  as	  the	  remaining	  relative	  
gene	  expression	   in	  %	  as	  compared	  to	  negative	  control	  siRNA	  transfected	  cells.	  No	  gene	  expression	  
was	  detectable	   for	  SLC22A3.	  Data	  are	  expressed	  as	  means	  ±	   standard	  deviation	  and	  were	  derived	  
from	  1	  experiment	  analysed	  in	  quadruplicate;	  B)	  Accumulation	  of	  clozapine	  (CLP)	  in	  hCMEC/D3	  cells	  
after	   1	   minute	   at	   37	   °C	   utilising	   a	   siRNA	   screening	   approach.	   Cells	   were	   transfected	   either	   with	  
negative	   control	   siRNAs	   or	   SLC22A5	   targeting	   siRNAs;	   C)	   Accumulation	   of	   CLP	   in	   hCMEC/D3	   cells	  
after	   30	  minutes	   at	   37	   °C	  utilising	   a	   siRNA	   screening	   approach.	   Cells	  were	   transfected	   either	  with	  
negative	   control	   siRNAs	   or	   SLC22A5	   targeting	   siRNAs;	   D)	   Relative	   remaining	   gene	   expression	   in	  
functional	  experiments	  as	  compared	  to	  negative	  control	  in	  %;	  Data	  in	  B,	  C,	  D	  are	  expressed	  as	  means	  
±	  standard	  deviation	  (n=	  4	  independent	  experiments	  each	  in	  triplicate	  (B+C)	  or	  quadruplicate	  (D)	  

































































































































5.3.7. Selection	  of	  additional	  SLC	  transporter	  candidates	  
CLP	   has	   so	   far	   been	   analysed	   as	   a	   potential	   substrate	   for	   all	   functionally	  
characterised	   organic	   cation	   transporters	   from	   the	   SLC22A	   family	   that	   are	  
expressed	   in	   the	   hCMEC/D3	   cell	   line.	   The	   results	   obtained,	   however,	   were	   all	  
negative	  and	  a	  broader	  screening	  approach	  was	  considered	  necessary.	  
As	  introduced	  in	  section	  5.3.5,	  SLC29A4	  (ENT4)	  is	  a	  particularly	  important	  
transporter	   within	   the	   uptake2	   system.	   Together	   with	   SLC22A3	   (OCT3),	   it	   is	  
recognised	   as	   a	   high-­‐capacity	   monoamine	   neurotransmitter	   transporter	   with	  
expression	  being	  detected	  in	  various	  brain	  regions	  (Engel	  et	  al.	  2004).	  Interestingly,	  
SLC29A4	  has	  also	  been	  demonstrated	  to	  exhibit	  similar,	  but	  still	  distinct,	  substrate	  
and	   inhibitor	   characteristics	  as	  organic	   cation	   transporters	   from	   the	  SLC22	   family,	  
particularly	   SLC22A3	   (Duan	   et	   al.	   2010,	   Engel	   et	   al.	   2005,	   Engel	   et	   al.	   2004).	  
Moreover,	   CLP	   has	   been	   found	   to	   act	   as	   a	   potent	   inhibitor	   of	   SLC29A4-­‐mediated	  
MPP+	   transport	   (Haenisch	   et	   al.	   2010).	   Corticosterone	   up	   to	   a	   concentration	   of	  	  
200	  µM,	  in	  contrast,	  had	  no	  inhibitory	  effect	  on	  the	  uptake	  of	  serotonin	  into	  stably	  
SLC29A4-­‐transfected	  MDCK	  cells,	  fitting	  with	  the	  data	  obtained	  for	  CLZ	  as	  described	  
in	   section	   5.3.5	   (Engel	   et	   al.	   2004).	   Therefore,	   SLC29A4	   was	   considered	   another	  
promising	  candidate	  transporter	  for	  the	  potential	  uptake	  of	  CLP	  into	  the	  hCMEC/D3	  
cell	  line.	  
Due	   to	   the	   fact	   that	   SLC22A3	   and	   SLC29A4	   both	   exhibit	   organic	   cation	  
transporter	   characteristics	   and	   mediate	   the	   translocation	   of	   monoamine	  
neurotransmitters,	  other	  monoamine	  transporters	  were	  also	  considered	  interesting	  
candidates.	   While	   SLC22A3	   and	   SLC29A4	   are	   important	   transporters	   within	   the	  
extraneuronal	   uptake2	   system,	   SLC6A2-­‐4	   (NET,	  DAT,	   SERT)	   are	   the	  main	   neuronal	  
monoamine	   transporters	   of	   uptake1.	   Although	   uptake1	   transporters	   are	   mostly	  
recognised	   as	   mediators	   for	   synaptic	   neurotransmitter	   re-­‐uptake,	   expression	   has	  
also	   been	   shown	   outside	   the	   brain.	   For	   example,	   SLC6A2	   has	   been	   detected	   in	  
capillary	  endothelial	  cells	  of	  the	  lung	  (Eisenhofer	  2001),	  SLC6A3	  in	  endothelial	  cells	  
of	  the	  pancreas	  (Eisenhofer	  2001),	  and	  SLC6A4	  in	  the	  plasma	  membrane	  of	  platelets	  
(Talvenheimo	   et	   al.	   1980).	   In	   addition,	   CLP	   is	   known	   to	   interact	   with	   many	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monoamine	   neurotransmitter	   receptors	   (Novartis	   Pharmaceuticals	   Corporation	  
2013)	   and	   thus	   there	  may	   be	   a	   link	   to	   potential	   transport	   by	   the	   corresponding	  
transporters,	  particularly	  SLC6A2-­‐4.	  
SLC29A4	  is	  only	  one	  out	  of	  four	  transporters	  classified	  within	  the	  SLC29A	  
subfamily.	  In	  addition,	  the	  SLC28A	  subfamily	  with	  three	  transporters	  is	  functionally	  
related	   to	   SLC29A	   and	   both	   subfamilies	   are	   particularly	   involved	   in	   nucleoside	  
transport.	   Thus,	   SLC6A2-­‐4,	   SLC28A1-­‐3	   (CNT1-­‐3),	   and	   SLC29A1-­‐4	   (ENT1-­‐4)	   are	   all	  
considered	  promising	   candidates	   for	   another	   functional	   screening	   approach	   using	  
RNAi.	  
As	  it	  is	  unlikely	  that	  all	  the	  selected	  transporters	  are	  indeed	  expressed	  in	  
the	   hCMEC/D3	   cell	   line,	   gene	   expression	   was	   initially	   determined	   using	   highly	  
specific	   and	   sensitive	   TaqMan®	   gene	   expression	   assays	   with	   100	   ng	   cDNA	   per	  
reaction.	  SLC22A2	   and	  SLC22A3	  were	   included	   to	   confirm	  non-­‐expression	  without	  
prior	  treatment	  with	  the	  transfection	  reagent.	  Gene	  expression	  was	  normalised	  to	  
GAPDH	   and	   plotted	   as	   reciprocal	   ∆Ct	   with	   lower	   1/∆Ct	   indicating	   lower	   gene	  
expression	  (Figure	  5.7).	  Non-­‐expression	  was	  confirmed	  for	  SLC22A2	  and	  SLC22A3.	  In	  
addition,	  SLC6A2,	   SLC6A3,	  SLC28A1,	   and	  SLC28A2	  were	  undetectable.	  SLC6A4	  was	  
also	   considered	  not	  expressed	  as	   the	  Ct	   values	  were	  above	  41.	   The	  manufacturer	  
defines	  a	  Ct	  above	  38	  as	  a	  “not	  detectable	  amplification	  signal”	  (Applied	  Biosystems	  
by	  Life	  Technologies	  2010).	  SLC28A3	  showed	  borderline	  expression	  with	  an	  average	  
Ct	   of	   38.	   Interestingly,	   all	   SLC29A	   transporter	   genes	   were	   found	   to	   be	   robustly	  




Figure	   5.7:	   Gene	   expression	   of	   selected	   SLC	   transporter	   genes	   in	   the	   hCMEC/D3	   cell	   line	  
normalised	  to	  GAPDH	  
Gene	   expression	   of	   SLC22A2-­‐3,	   SLC6A2-­‐4,	   SLC28A1-­‐3,	   and	   SLC29A1-­‐4	   in	   the	   hCMEC/D3	   cell	   line	  
normalised	   to	   human	   glyceraldehyde-­‐3-­‐phosphate	   dehydrogenase	   (GAPDH).	   The	   normalised	   gene	  
expression	  is	  given	  as	  the	  reciprocal	  delta	  of	  both	  threshold	  cycles	  (1/∆Ct).	  Empty	  fields	  indicate	  non-­‐
detectable	   gene	   expression.	   Data	   are	   expressed	   as	  means	   ±	   standard	   deviation	   and	  were	   derived	  
from	  1	  experiment	  analysed	  in	  quadruplicate	  	  
5.3.8. siRNA	  screening	  
For	   the	   delivery	   of	   siRNAs	   into	   the	   hCMEC/D3	   cell	   line	   the	   best	   results	   were	  
obtained	  by	  plating	  0.1	  million	  cells	  and	  transfecting	  with	  0.2	  %	  transfection	  reagent	  
(see	  chapter	  3	  section	  3.3.5).	  siRNA	  concentrations,	  however,	  were	  optimised	  on	  a	  
gene-­‐specific	   level.	   Therefore,	   the	   knockdown	   efficiencies	   for	   SLC28A3	   and	  
SLC29A1-­‐4	   were	   determined	   using	   10	   nM,	   25	   nM,	   and	   50	   nM	   siRNAs	   for	  
transfection,	  respectively	  (Figure	  5.8).	  No	  major	  differences	  could	  be	  observed	  and	  
the	  knockdown	  efficiency	  was	  sufficient	  for	  all	  five	  genes	  tested.	  To	  keep	  the	  assay	  
as	   consistent	   as	   possible,	   25	   nM	   siRNAs	   were	   chosen	   for	   transfection	   for	   the	  
functional	   assays.	  No	  accurate	   comparative	  gene	  expression	   could	  be	  determined	  
for	   SLC28A3	   as	   the	   Ct	   values	   fluctuated	   around	   approximately	   39,	   giving	   both	  
positive	  and	  negative	  ∆∆Ct	  values.	  As	  discussed	  before,	  however,	  a	  Ct	  above	  38	  was	  
considered	  to	  be	  not	  detectable	  (Applied	  Biosystems	  by	  Life	  Technologies	  2011).	  In	  







































































size	   of	   the	   observed	   CLP	   uptake.	   Still,	   the	   functional	   screening	   with	   SLC28A3-­‐
targeting	  siRNAs	  was	   included	  as	  an	  additional	  negative	  control	  and	  the	  uptake	  of	  
CLP	   determined	   for	   all	   five	   genes	   after	   1	   and	   30	   minutes	   at	   37	   °C,	   respectively	  
(Figure	   5.9	   A+B).	   No	   differences	  were	   observed	   as	   compared	   to	   negative	   control	  
siRNA	   transfected	   cells,	   indicating	   that	   SLC29A1-­‐4	   (ENT1-­‐4)	   do	   not	   mediate	   the	  
observed	   CLP	   uptake	   into	   hCMEC/D3	   cells.	   The	   average	   knockdown	   efficiencies	  
were	  adequate	  for	  all	  four	  genes	  tested	  (Figure	  5.9	  C).	  
Figure	  5.8:	  Optimisation	  of	  siRNA	  concentrations	  for	  gene	  silencing	  of	  selected	  SLC	  transporters	  in	  
the	  hCMEC/D3	  cell	  line	  
Knockdown	   efficiencies	   for	   SLC28A3,	   SLC29A1,	   SLC29A2,	   SLC29A3,	   and	   SLC29A4	   genes	   under	  
optimised	   delivery	   conditions	   using	   three	   siRNA	   concentrations,	   10	   nM,	   25	   nM,	   and	   50	   nM,	  
respectively.	   Knockdown	   efficiency	   is	   plotted	   as	   the	   remaining	   relative	   gene	   expression	   in	   %	   as	  
compared	   to	   negative	   control	   siRNA	   transfected	   cells.	   Analysis	   of	   SLC28A3	   failed	   due	   to	   the	  
borderline	   gene	   expression.	   Data	   are	   expressed	   as	  means	   ±	   standard	   deviation	   and	  were	   derived	  
















































Figure	  5.9:	  Functional	  siRNA	  screening	  of	  selected	  SLC	  transporters	  in	  the	  hCMEC/D3	  cell	  line	  
A)	   Accumulation	   of	   clozapine	   (CLP)	   in	   hCMEC/D3	   cells	   after	   1	   minute	   at	   37	   °C	   utilising	   a	   siRNA	  
screening	  approach.	  Cells	  were	  transfected	  either	  with	  negative	  control	  siRNAs	  or	  corresponding	  SLC	  
transporter	   targeting	   siRNAs;	  B)	  Accumulation	  of	  CLP	   in	  hCMEC/D3	  cells	  after	  30	  minutes	  at	  37	   °C	  
utilising	  a	  siRNA	  screening	  approach.	  Cells	  were	  transfected	  either	  with	  negative	  control	  siRNAs	  or	  
corresponding	  SLC	  transporter	  targeting	  siRNAs;	  C)	  Relative	  remaining	  gene	  expression	  as	  compared	  
to	  negative	  control	   in	  %.	  The	  analysis	  of	  SLC28A3	   failed	  due	  to	   the	  borderline	  gene	  expression.	  All	  
data	  are	  expressed	  as	  means	  ±	  standard	  deviation	  (n=	  4	  independent	  experiments	  each	  in	  triplicate	  
(A+B)	  or	  quadruplicate	  (C))	  










































































































































5.3.9. Receptor-­‐internalisation	  as	  a	  potential	  mechanism	  for	  
clozapine	  uptake	  into	  the	  hCMEC/D3	  cell	  line	  
At	   this	   stage	   it	   was	   difficult	   to	   identify	   any	   promising	   new	   drug	   transporter	  
candidates	  for	  analysis.	  The	  physicochemical	  properties	  of	  CLP	  and	  data	  from	  both	  
the	   literature	   and	   this	   thesis	   suggest	   an	  organic	   cation	   transporter	   as	  mechanism	  
for	  CLP	  uptake.	  However,	  all	  well-­‐characterised	  organic	  cation	  transporters	  that	  are	  
expressed	   in	   the	   hCMEC/D3	   cell	   line	   were	   tested	   but	   with	   negative	   outcome.	  
Theoretically,	  any	  expressed	  transporter	  from	  within	  the	  SLC	  superfamily	  could	  be	  
involved	  in	  CLP	  uptake	  and	  the	  lack	  of	  further	  evidence	  did	  not	  support	  additional	  
small-­‐scale	  screening	  approaches.	  
Although	  the	  observed	  CLP	  accumulation	  appeared	  to	  be	  mediated	  by	  an	  
organic	  cation	  transporter,	  other	  mechanisms	  such	  as	  receptor-­‐internalisation	  could	  
not	  be	  ruled	  out.	  CLP	   interacts	  with	  many	  neurotransmitter	  receptors,	  particularly	  
with	   dopamine	   and	   serotonin	   receptors	   (Meltzer	   et	   al.	   1989,	   Novartis	  
Pharmaceuticals	  Corporation	  2013).	  Most	  of	  these	  are	  G-­‐protein	  coupled	  receptors	  
and	  CLP-­‐induced	  receptor-­‐internalisation	  has	  been	  demonstrated	  for	  the	  serotonin	  
receptor	  2A	  (5-­‐HT2A)	  after	  stimulation	  for	  15	  and/or	  30	  minutes	  using	  100	  nM	  and	  	  
1	  µM	  CLP,	  respectively	  (Raote	  et	  al.	  2013,	  Willins	  et	  al.	  1999).	  Prazosin	  was	  the	  most	  
potent	   inhibitor	  of	  CLP	  accumulation	   in	   the	   initial	   screening	  assay	   (5.3.3)	   and	  not	  
only	   is	   it	   an	   OCT	   inhibitor	   but	   it	   is	   also	   an	   adrenergic	   α1-­‐receptor	   antagonist	  	  
(Forget	  et	  al.	  2010).	  	  
To	   investigate	   whether	   receptor-­‐internalisation	   was	   involved,	   a	   third	  
chemical	  inhibitor	  screening	  was	  undertaken.	  All	  selected	  inhibitors,	  listed	  in	  Table	  
5.3,	   interact	   with	   neurotransmitter	   receptors	   and	  might	   thus	   compete	   with	   CLP-­‐
induced	   internalisation.	   The	   accumulation	   of	   1	   µM	   CLP	   was	   determined	   after	   30	  
minutes	   at	   37	   °C	   in	   the	   presence	   of	   an	   excess	   quantity	   of	   inhibitor	   (20	   µM	   each	  
except	   for	   risperidone).	   Risperidone	   had	   to	   be	   used	   at	   a	   concentration	   of	   10	   µM	  
due	  to	  limited	  solubility.	  Prazosin	  and	  corticosterone	  were	  included	  as	  positive	  and	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negative	   controls,	   respectively,	   and	   prazosin	   concentration	   adjusted	   to	   20	   µM	   to	  
allow	  for	  a	  better	  comparison	  of	  the	  potential	  effect	  sizes.	  
Table	  5.3:	  Selected	  compounds	  for	  third	  inhibitor	  screening	  
Compound	   Receptors	   References	  
Norepinephrine	   Adrenergic	  (α	  and	  ß)	   (Kobilka	  2011)	  
Dopamine	   Dopamine	  (D)	   (Beaulieu	  et	  al.	  2011)	  
Serotonin	   Serotonin	  (5-­‐HT)	   (Meltzer	  et	  al.	  2003)	  
Risperidone	   Multiple	  
(Janssen	  Pharmaceuticals	   Inc.	  2012,	  Richelson	  et	  al.	  
2000)	  
Quetiapine	   Multiple	  
(AstraZeneca	  Pharmaceuticals	  LP	  2013,	  Richelson	  et	  
al.	  2000)	  
Doxazosin	   α1	   (Pfizer	  Inc.	  2013)	  
L-­‐741,626	   D2	   (Kulagowski	  et	  al.	  1996)	  
Propranolol	   ß	   (Hott	  et	  al.	  2012)	  
Phentolamine	   α	   (Hott	  et	  al.	  2012)	  
M100907	   5-­‐HT2A	   (Kehne	  et	  al.	  1996)	  
Sonepiprazole	   D4	   (Merchant	  et	  al.	  1996)	  
	  
A	   large	   number	   of	   positive	   results	   were	   obtained	   from	   this	   screening	  
approach	   (Figure	   5.10).	   While	   the	   natural	   monoamine	   receptor	   ligands	  
norepinephrine,	  dopamine,	  and	  serotonin	  did	  not	  affect	  CLP	  accumulation,	  all	  other	  
compounds,	   with	   the	   exception	   of	   phentolamine,	   showed	   varying	   degrees	   of	  
inhibition.	  Notably,	  the	  strongest	  inhibitory	  effect	  was	  observed	  with	  doxazosin,	  an	  
α1-­‐receptor	   blocker	   like	   prazosin.	   Prazosin	   at	   20	   µM	   showed	   considerably	   less	  
inhibitory	  potential	   (46	  %	  average	  reduction)	  compared	  with	  100	  µM	  used	  for	  the	  
initial	   screening	   (94	   %	   average	   reduction).	   Doxazosin	   was	   more	   potent	   with	   an	  
average	  reduction	  of	  81	  %	  when	  using	  20	  µM.	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Figure	   5.10:	   Third	   chemical	   inhibitor	   screening	   to	   investigate	   receptor-­‐internalisation	   as	   a	  
potential	  mechanism	  for	  clozapine	  uptake	  into	  the	  hCMEC/D3	  cell	  line	  
Accumulation	  of	  clozapine	  (CLP)	   in	  the	  hCMEC/D3	  cell	   line	  after	  30	  min	  at	  37	  °C	  in	  the	  presence	  of	  
monoamine	   neurotransmitter	   receptor	   agonists/antagonists.	   Data	   are	   expressed	   as	   means	  	  
±	  standard	  deviation	  (n	  =	  3	   independent	  experiments	   in	  triplicate).	  Significant	  results	  are	   indicated	  
with	  ***	  for	  p<0.001	  
Based	   on	   these	   results,	   it	   could	   be	   hypothesised	   that	   an	   α-­‐receptor	   is	  
involved	  in	  CLP-­‐internalisation.	  However,	  the	  negative	  results	  observed	  with	  the	  α-­‐
receptor	  antagonist	  phentolamine	  and	  the	  natural	   receptor	   ligand	  norepinephrine	  
do	  not	  fit	  with	  this	  hypothesis.	  Still,	  it	  remains	  possible	  that	  other	  receptor(s)	  is/are	  
involved	   in	   CLP-­‐internalisation.	   The	   inhibitor	   concentrations	   used	   were	   relatively	  
high	  and	  additional	  receptors	  might	  be	  affected.	  For	  example,	  L-­‐741,626,	  M100907,	  
and	  sonepiprazole	  are	  very	  selective	  for	  receptor	  subtypes	  in	  the	  nanomolar	  range	  
(Table	   5.3).	   None	   of	   them,	   however,	   is	   receptor-­‐specific	   at	   20	   µM	   (Kehne	   et	   al.	  
1996,	  Kulagowski	  et	  al.	  1996,	  Merchant	  et	  al.	  1996).	  

















































































































































The	   data	   suggest	   that	   CLP	   accumulation	   could	   indeed	   be	   a	   result	   from	  
receptor-­‐internalisation.	   In	   addition,	   however,	   the	   selected	   inhibitors	   may	   also	  
interact	   with	   an	   unidentified	   organic	   cation	   transporter.	   A	   larger	   functional	  
screening	   approach,	   ideally	   including	   all	   expressed	   SLC	   transporters	   and	  
neurotransmitter	   receptors,	   would	   be	   the	   most	   promising	   further	   strategy	   to	  
identify	  the	  underlying	  mechanism	  for	  CLP	  uptake.	  
5.4. Discussion	  
Evidence	  from	  the	  literature	  and	  chapter	  4	  suggested	  that	  cellular	  CLP	  accumulation	  
may	  be	  mediated	  by	  an	  unidentified	  uptake	  transporter.	  A	  screening	  approach	  was	  
applied	   to	   identify	  and	  characterise	   this	  process.	   Indeed,	  CLP	  accumulation	   in	   the	  
hCMEC/D3	  cell	  line	  could	  be	  inhibited	  by	  up	  to	  94	  %	  and	  the	  overall	  inhibitor	  profile	  
suggested	  that	  an	  organic	  cation	  transporter	  was	  involved.	  	  
The	   uptake	   of	   CLP	   was	   analysed	   in	   more	   detail	   and	   found	   to	   follow	  
classical	  Michaelis-­‐Menten	  kinetics	  with	  a	  Vmax	  of	  3299	  pmol/million	  cells	  and	  a	  Km	  
of	  35.93	  µM.	  Recently,	  the	  kinetics	  for	  LTG	  uptake	  has	  been	  described	  utilising	  the	  
same	  cell	   line.	   The	  SLC22A1	   (OCT1)-­‐mediated	  uptake	  of	   LTG	  was	   found	   to	  have	  a	  
Vmax	   of	   385	   pmol/million	   cells	   and	   a	   Km	   of	   62	   µM	   (Dickens	   et	   al.	   2012).	   A	   Km	   of	  	  
35.93	  µM	  for	  CLP	  uptake	   is	  notably	   lower	   than	   the	  Km	   for	  SLC22A1-­‐mediated	  LTG	  
uptake.	   Classically,	   this	  would	   imply	   a	   higher-­‐affinity	   but	   lower-­‐capacity	   transport	  
process	  for	  CLP	  relative	  to	  LTG.	  However,	  CLP	  peak	  plasma	  levels	  are	  around	  1	  µM	  
(Novartis	   Pharmaceuticals	   Corporation	   2013)	   and	   thus	   a	   Km	   of	   35.93	   µM	   still	  
indicates	  a	  high-­‐capacity	  transporter	  at	  clinically	  important	  concentrations.	  
The	  observed	  CLP	  uptake	  into	  hCMEC/D3	  cells	  was	  not	  corrected	  for	  any	  
background	   transport	   as	   has	   been	   done	   for	   LTG	   (Dickens	   et	   al.	   2012).	   However,	  
inhibition	   up	   to	   94	   %	   indicates	   that,	   despite	   the	   lipophilic	   characteristics,	   CLP	  
accumulation	  was	  primarily	  the	  result	  from	  an	  active	  uptake	  process.	  Interestingly,	  
a	  slightly	  lower	  but	  still	  similar	  Km	  of	  18.8	  µM	  has	  previously	  been	  observed	  for	  CLP	  
uptake	  into	  promyelocytic	  leukaemia	  HL-­‐60	  cells	  (Henning	  et	  al.	  2002).	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In	   an	   attempt	   to	   identify	   the	   unknown	   CLP	   transporter,	   the	   mRNA	  
expression	   levels	   of	   SLC22A2-­‐3,	   SLC22A5,	   SLC6A2-­‐4,	   SLC28A1-­‐3,	   and	   SLC29A1-­‐4	  
were	   analysed	   in	   the	   hCMEC/D3	   cell	   line,	   selected	   based	   on	   evidence	   from	   the	  
literature	  and	  results	  from	  the	  inhibitor	  screenings	  (see	  results	  section	  for	  details).	  
SLC22A5,	  SLC28A3,	  and	  SLC29A1-­‐4	  were	  found	  to	  be	  expressed	  and	  the	  transporters	  
functionally	   analysed	   using	   a	   siRNA	   screening	   approach.	   In	   addition,	   a	   potential	  
transport	   by	   SLC22A4	   (OCTN1)	   was	   analysed	   using	   transfected	   KCL22	   cell	   lines.	  
None	  of	  the	  transporters,	  however,	  had	  an	  impact	  on	  CLP	  accumulation.	  SLC22A1,	  
analysed	  in	  chapter	  4	  section	  4.3.2,	  was	  also	  negative.	  Surprisingly	  and	  in	  contrast	  
to	   previous	   reports	   (Carl	   et	   al.	   2010,	   Dickens	   et	   al.	   2012),	   SLC22A3	   was	   not	  
detectable	   in	   the	   hCMEC/D3	   cell	   line.	   The	   exact	   underlying	   reason	   for	   this	  
observation	   is	   unclear	   but	   chromosomal	   rearrangements	   have	   been	   reported	   for	  
the	   hCMEC/D3	   cell	   line	   that	   might	   explain	   the	   loss	   of	   SLC22A3	   expression	   as	  
compared	  to	  the	  cells	  used	  by	  Carl	  et	  al.	  and	  Dickens	  et	  al.	  (Mkrtchyan	  et	  al.	  2009).	  
CLP-­‐mediated	  receptor-­‐internalisation	  has	  previously	  been	  demonstrated	  
for	   the	   5-­‐HT2A	   receptor,	   providing	   an	   alternative	   hypothetical	  mechanism	   for	   the	  
observed	  CLP	  accumulation.	  Further	  screening	  was	  carried	  out	  to	  analyse	  the	  effect	  
of	   several	  monoamine	   receptor	   agonists/antagonists	   on	   CLP	   accumulation.	  While	  
most	   antagonists	   exhibited	   varying	   degrees	   of	   inhibition,	   all	   natural	   agonists,	  
namely	   norepinephrine,	   dopamine,	   and	   serotonin,	   had	   no	   effect	   on	   CLP	  
accumulation.	  It	  remains	  unclear	  if	  the	  observed	  inhibition	  is	  a	  result	  of	  an	  impaired	  
receptor-­‐internalisation,	   impaired	   transport	   by	   an	   unknown	   organic	   cation	  
transporter,	  or	  both.	  
The	   data	   does	   not	   support	   additional	   small-­‐scale	   screening	   approaches.	  
Instead,	  more	  extensive	  screening	  will	  be	  necessary,	  ideally	  including	  all	  expressed	  
SLC	   transporters	   and	  monoamine	   receptors.	   This	   screening	  would	   be	   approached	  
either	   clinically	   or	   functionally.	   Functionally,	   a	   siRNA	   library	   screening	   could	   be	   a	  
promising	   strategy	   as	   discussed	   for	   the	   unknown	   TPM	   efflux	   transporter	   (see	  
chapter	  3	  section	  3.4).	  However,	  this	  is	  an	  expensive	  and	  labour-­‐intensive	  approach.	  
In	   addition,	   siRNA	   screenings,	   including	   the	   ones	   discussed	   above,	   have	   some	  
limitations.	  First,	  siRNA	  transfections	  can	  substantially	   lower	  the	  expression	  of	  the	  
Chapter	  5	  
	  182	  
targeted	   transporter	   gene	   but	   the	   remaining	   expressed	   protein	   might	   still	   have	  
enough	  capacity	  to	  overcome	  this	  reduction.	  Second,	  functional	  redundancy	  could	  
mask	   impaired	  accumulation	   if	   the	  expression	  of	  only	  one	   transporter	   is	   reduced.	  
Third,	  and	  as	  seen	  in	  chapter	  3	  with	  ABCC5,	  it	  is	  likely	  that	  some	  transporters	  will	  be	  
difficult	  to	  target	  with	  siRNAs.	  
Clinically,	  a	  GWAS	  with	  samples	  from	  a	  CLP-­‐treated	  patient	  cohort	  may	  be	  
a	  promising	  strategy	  to	  identify	  variants	  of	  the	  unknown	  transporter	  that	  could	  be	  
associated	  with	   study	  outcomes	  such	  as	   treatment	   response	  or	   the	  occurrence	  of	  
adverse	  events.	  This	  transporter	  could	  then	  be	  further	  analysed	  and	  characterised	  
functionally.	  Such	  an	  approach	  has	  successfully	  been	  applied	  before.	  For	  example,	  
variants	   of	   SLCO1B1	   have	   been	   associated	   with	   statin-­‐induced	   myopathy	   and	  
variants	  of	  ABCG2	  with	  elevated	  urate	   levels	   (Dehghan	   et	   al.	   2008,	  Kottgen	   et	   al.	  
2013,	   Link	   et	   al.	   2008).	   However,	   there	   are	   some	   limitations	   to	   this	   approach	   as	  
well.	  Most	  importantly,	  a	  clinical	  study	  has	  to	  be	  undertaken	  first	  and	  DNA	  samples	  
from	  all	  patients	  collected.	  In	  addition,	  a	  critical	  number	  of	  patients	  will	  be	  required	  
to	   achieve	   enough	   power	   for	   statistical	   analysis.	   Finally,	   variants	   of	   the	   unknown	  
CLP	  transporter	  have	  to	  be	  associated	  with	  the	  study	  outcome(s)	  to	  be	  detectable.	  
In	   conclusion,	   a	   potent	   CLP	   uptake	   process	   has	   been	   identified	   and	  
characterised	   in	  the	  hCMEC/D3	  cell	   line	  as	  an	   in	  vitro	  model	  of	   the	  BBB.	  This	  may	  
critically	  affect	  CLP	  treatment	  efficacy	  in	  the	  brain.	  In	  addition,	  these	  results	  support	  
previous	   studies,	   which	   showed	   that	   a	   CLP	   transporter	   may	   also	   be	   involved	   in	  
severe	  side	  effects	  such	  as	  agranulocytosis	   (Bergemann	  et	  al.	  2007,	  Henning	  et	  al.	  
2002).	  A	  large-­‐scale	  functional	  or	  clinical	  screening	  will	  be	  necessary	  to	  identify	  the	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6.1. The	   emerging	   role	   of	   drug	   transporters	   in	  
pharmacokinetics	  
A	  large	  number	  of	  licensed	  drugs,	  particularly	  hydrophobic	  drugs,	  have	  to	  undergo	  
different	   biotransformation	   steps	   to	   be	   eliminated	   from	   the	   body.	   The	   enzymes	  
involved	   in	   drug	  metabolism	   are	   thus	   important	   components	   to	   be	   considered	   in	  
drug	  pharmacokinetics	  and	  have	  been	  studied	  for	  decades.	  In	  the	  middle	  of	  the	  20th	  
century,	   R.T.	   Williams	   first	   proposed	   that	   xenobiotic	   biotransformation	   can	  
essentially	  be	  classified	  into	  phase	  I	  and	  phase	  II	  reactions	  (Williams	  1959).	  Phase	  I	  
reactions	   were	   described	   as	   activation	   or	   inactivation	   steps	   through	   oxidation,	  
reduction,	   hydrolysis,	   or	   a	   combination	   of	   these.	   Phase	   II	   was	   referred	   to	   as	   the	  
synthesis	   step	   that	   is	   particularly	   characterised	   by	   conjugation	   reactions	   such	   as	  
glucuronidation,	   acetylation,	   or	   glutathione	   conjugation	   (Bachmann	   2009,	   David	  
Josephy	  et	  al.	  2005,	  Williams	  1959).	  Later,	  this	  classification	  was	  extended	  with	  the	  
introduction	   of	   the	   phase	   III	   and	   phase	   0	   systems	   to	   account	   for	   the	   uptake	   and	  
efflux	  of	  drugs	  and	  conjugates	  across	  plasma	  membranes	  (Doring	  et	  al.	  2014).	  Phase	  
0	   refers	   to	   the	   uptake	   of	   drugs	   by	   members	   of	   the	   SLC	   superfamily	   of	   drug	  
transporters,	  while	   phase	   III	   refers	   to	   efflux	   by	   transporters	   from	   the	   ABC	   family	  
(Doring	  et	  al.	  2014,	  Ishikawa	  1992,	  Petzinger	  et	  al.	  2006).	  
David	  Josephy	  et	  al.	  critically	  noted	  in	  2005	  that	  the	  terms	  phase	  I,	  phase	  
II,	  and	  phase	   III	  are	  misleading	  as	  they	   imply	  a	  sequential	  order	  that	   is	  not	  always	  
true	   (David	   Josephy	   et	   al.	   2005).	   In	   fact,	   drugs	   may	   only	   undergo	   phase	   II	  
metabolism	  without	  prior	  phase	  I	  (e.g.	  LTG,	  see	  chapter	  1	  section	  1.3.3.2)	  and	  drug	  
efflux	  is	  not	  restricted	  to	  conjugates	  and	  the	  final	  elimination	  step	  (David	  Josephy	  et	  
al.	   2005).	   Instead,	   the	   authors	   suggested	   classifying	   drug	   metabolism	   more	  
systematically	   according	   to	   the	   chemical	   reactions	   that	   occur,	   namely	   oxidation,	  
reduction,	   hydrolysis,	   and	   nucleophilic	   trapping	   reactions	   (David	   Josephy	   et	   al.	  
2005).	   However,	   the	   classification	   of	   chemical	   reactions	   and	   transport	   processes	  
into	  phases	  is	  still	  commonly	  used	  in	  the	  field	  of	  pharmacology.	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An	   estimated	   three-­‐fourths	   of	   all	   licensed	   drugs	   are	   subject	   to	  
metabolism	  by	  mixed-­‐function	  oxidases	  from	  the	  CYP	  family	  (Bachmann	  2009).	  CYP	  
enzymes	   have	   now	   been	   studied	   for	   decades	   and	   are	   recognised	   as	   major	  
determinants	  of	  a	  drug´s	  pharmacokinetic	  properties.	   In	  addition,	   they	  are	  known	  
to	   be	   of	   particular	   importance	   as	   mediators	   for	   pharmacokinetic	   drug-­‐drug	  
interactions	   if	   two	   co-­‐administered	   drugs	   are	   metabolised	   by	   the	   same	   CYP	  
enzyme(s)	  (Bachmann	  2009).	  For	  example,	  CYP3A4/5	  metabolise	  about	  50	  %	  of	  all	  
clinically	  used	  drugs	  and	  thus	  the	  risk	  for	  drug-­‐drug	  interactions	  is	  high	  (Bachmann	  
2009).	  
The	  metabolism	  by	  important	  CYP	  enzymes	  is	  now	  routinely	  evaluated	  in	  
the	  development	  of	  investigational	  new	  drugs	  (INDs).	  In	  their	  2012	  draft	  guideline,	  
the	   FDA	   recommends	   to	   begin	   with	   the	   in	   vitro	   analysis	   of	   CYP1A2,	   CYP2B6,	  
CYP2C8,	  CYP2C9,	  CYP2C19,	  CYP2D6,	  and	  CYP3A4.	  Depending	  on	   the	  outcome,	   the	  
analysis	  can	  then	  be	  extended	  to	   in	  vivo	   investigations	  and	  mechanistic	  modelling	  
(United	  States	  Food	  and	  Drug	  Administration	  2012).	  
In	   contrast	   to	   CYP	   enzymes,	   drug	   transporters	   have	   not	   received	  much	  
attention	   in	   drug	   development	   and	   recommendations	  were	   not	   available	   (except	  
for	   ABCB1)	   until	   2012	   (Giacomini	   et	   al.	   2010,	   United	   States	   Food	   and	   Drug	  
Administration	  2012).	  Based	  on	  the	  white	  paper	  published	  by	  the	  ITC	   in	  2010,	  the	  
FDA	   included	   a	   total	   of	   seven	   transporters	   into	   their	   latest	   (2012)	   draft	  
recommendations	   for	   the	   evaluation	   of	   potential	   drug-­‐drug	   interactions	   in	   IND	  
development,	   namely	   ABCB1	   (MDR1,	   Pgp),	   ABCG2	   (BCRP),	   SLC22A2	   (OCT2),	  
SLC22A6	   (OAT1),	   SLC22A8	   (OAT3),	   SLCO1B1	   (OATP1B1),	   and	   SLCO1B3	   (OATP1B3)	  
(Figure	  6.1).	  Recently,	  the	  ITC	  published	  a	  list	  of	  additional	  transporters	  (e.g.	  ABCC2	  
(MRP2))	   highlighting	   the	   discussions	   of	   the	   second	   ITC	   workshop	   held	   in	   2012	  
(Giacomini	   et	   al.	   2013).	   The	   publication	   of	   a	   series	   of	   additional	   white	   paper	  
recommendations	   was	   announced	   and	   it	   is	   likely	   that	   the	   FDA	   will	   follow	   these	  
recommendations	   in	   future	   guidelines.	   Overall,	   drug	   transporters	   are	   now	   being	  
recognised	  as	   important	   components	   in	  pharmacokinetics	  and	   in	  pharmacokinetic	  
drug-­‐drug	   interactions.	  As	   compared	   to	  CYP	  enzymes,	  however,	  drug	   transporters	  
are	  just	  beginning	  to	  be	  investigated	  more	  systematically	  and	  the	  large	  number	  of	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uncharacterised	  human	  SLC	  and	  ABC	  transporters	  make	  this	  an	  exciting	  and	  growing	  
field	  of	  research.	  
6.2. In	  vitro	  transporter	  assays	  
Drug	  transport	  across	  the	  BBB	  is	  of	  fundamental	  importance	  for	  the	  efficacy	  of	  CNS	  
targeting	  drugs.	   In	  addition,	  the	  restriction	  or	  uptake	  of	  drugs	  across	  the	  BBB	  may	  
determine	  the	  side	  effect	  profile	  of	  many	  non-­‐CNS	  targeting	  drugs.	  While	  INDs	  are	  
now	  increasingly	  characterised	  for	  their	  interaction	  with	  selected	  drug	  transporters	  
(United	   States	   Food	   and	   Drug	   Administration	   2012),	   data	   for	   currently	  marketed	  
drugs	  are	  very	  limited	  or	  absent.	  About	  30	  %	  of	  all	  epilepsy	  patients	  do	  not	  achieve	  
adequate	   seizure	   control	  with	   currently	   licensed	   AEDs	   (Brodie	   et	   al.	   2010,	  World	  
Health	  Organisation	  2009).	   In	   schizophrenia,	   CLP	   is	   a	   last-­‐resort	   treatment	  option	  
for	  otherwise	  refractory	  patients.	  However,	  about	  70	  %	  of	  these	  initially	  refractory	  
patients	  also	  fail	  to	  achieve	  adequate	  control	  over	  their	  symptoms	  with	  CLP	  (Chakos	  
et	  al.	  2001,	  Kane	  et	  al.	  1988,	  Lieberman	  et	  al.	  1994).	  	  
AEDs	   and	   APDs	   both	   target	   the	   CNS	   and	   thus	   have	   to	   cross	   the	   BBB	   in	  
order	   to	   become	   effective.	   Uptake	   and/or	   efflux	   transporters	   may	   be	   critical	  
components	   for	   the	   effectiveness	   of	   both	   classes	   of	   neurological	   treatments	   and	  
thus	   provide	   a	   pathophysiological	   basis	   explaining	   treatment	   failure	   in	   this	   large	  
proportion	   of	   patients.	   In	   addition,	   membrane	   transporters	   may	   be	   critical	  





Figure	   6.1:	   Membrane	   transporters	   currently	   recommended	   by	   the	   United	   States	   Food	   and	   Drug	   Administration	   (FDA)	   for	   the	   evaluation	   of	   potential	   drug-­‐drug	  
interactions	  in	  drug	  development	  	  
Simplified	  model	   illustrating	   the	   subcellular	   localisation	  of	   seven	   important	  membrane	   transporters	   at	   four	   pharmacologically	   important	   barriers,	   epithelial	   cells	   of	   the	  
intestine	  (A),	  liver	  hepatocytes	  (B),	  brain	  endothelial	  cells	  (C),	  and	  tubule	  epithelial	  kidney	  cells	  (D);	  Currently	  recommended	  efflux	  transporters	  include	  ABCB1	  (MDR1,	  Pgp)	  
and	  ABCG2	  (BCRP)	  while	  currently	  recommended	  uptake	  transporters	  include	  SLCO1B1	  (OATP1B1),	  SLCO1B3	  (OATP1B3),	  SLC22A2	  (OCT2),	  SLC22A6	  (OAT1),	  and	  SLC22A8	  
(OAT3).	  Model	  based	  on	  Giacomini	  et	  al.,	  2010 
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In	  chapters	  3	  and	  5	  of	  this	  thesis,	  the	  hCMEC/D3	  cell	   line	  (Weksler	  et	  al.	  
2005)	   was	   applied	   as	   an	   in	   vitro	   model	   of	   the	   BBB	   to	   investigate	   the	   effect	   of	  
various	   chemical	   drug	   transporter	   inhibitors	   on	   the	   accumulation	  of	   six	  AEDs	   and	  
the	   APD	   CLP.	   Increased	   accumulation	   of	   TPM	   was	   observed	   in	   the	   presence	   of	  
MK571	   and	   montelukast,	   suggesting	   an	   unidentified	   efflux	   transporter	   being	  
involved	   in	   TPM	   accumulation.	   The	   accumulation	   of	   CLP	   was	   reduced	   in	   the	  
presence	  of	  the	  typical	  organic	  cation	  transporter	  inhibitors	  prazosin	  and	  verapamil.	  
In	   addition,	  many	   neurotransmitter	   receptor-­‐targeting	   drugs	   significantly	   reduced	  
the	   accumulation	   of	   CLP.	   These	   data	   suggest	   an	   unidentified	   uptake	   transporter	  
and/or	   receptor-­‐internalisation	   being	   involved	   in	   CLP	   accumulation.	   Subsequent	  
investigations	   by	   means	   of	   siRNA	   transfections	   or	   stably	   transfected	   cell	   lines,	  
however,	  could	  not	  identify	  the	  exact	  transport	  processes	  involved	  in	  TPM	  and	  CLP	  
accumulation,	  although	  the	  assays	  were	  shown	  to	  be	  functional.	  	  
Due	  to	  the	  fact	  that	  the	  human	  genome	  encodes	  for	  about	  390	  SLC	  and	  48	  
ABC	   transporters	   (excluding	   pseudogenes),	   the	   overall	   fraction	   of	   tested	  
transporters	  is	  very	  small.	  The	  chemical	  inhibitors	  utilised	  cannot	  be	  considered	  as	  
absolutely	  specific	  and	  thus	  the	  impact	  of	  the	  majority	  of	  SLC	  and	  ABC	  transporters	  
on	   TPM	   and	   CLP	   accumulation	   remains	   unknown.	   Therefore	   and	   in	   addition	   to	  
potential	   issues	  with	  functional	  redundancy	  (see	  discussion	  sections	  3.4	  and	  5.4	  in	  
chapters	   3	   and	   5),	   the	   sought-­‐after	   transporters	   or	   receptors	   have	   likely	   been	  
missed.	  Due	  to	  the	  lack	  of	  further	  evidence	  from	  the	  literature,	  a	  broader	  screening	  
approach,	   ideally	   including	   all	   expressed	   SLC	   and	   ABC	   transporters	   as	   well	   as	  
neurotransmitter	  receptors,	  is	  necessary.	  	  
Functional	   siRNA	   library	  screenings	  could	  be	  a	  strategy	   to	  overcome	  the	  
limited	   number	   of	   transporters	   tested,	   but	   still	   carries	   the	   risks	   of	   functional	  
redundancy	   and	   insufficient	   knockdown	  efficiencies.	   A	  widely	   applied	  method	   for	  
the	   in	  vitro	   identification	  and	  characterisation	  of	  drug	  transporters	   is	  by	  means	  of	  
transporter	  assays	  utilising	  recombinant	  cell	  lines	  (Giacomini	  et	  al.	  2010).	  The	  value	  
of	   this	   method	   was	   demonstrated	   in	   chapters	   2	   and	   4	   to	   characterise	   CBZ	   as	   a	  
potential	  substrate	  of	  ABCC2	  (MRP2)	  and	  to	   investigate	  SLC22A1	  (OCT1)-­‐mediated	  
drug-­‐drug	   interactions	   with	   LTG.	   The	   same	   method,	   however,	   cannot	   readily	   be	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applied	  for	  a	  broader	  screening	  approach	  as	  would	  be	  required	  to	  follow	  up	  on	  the	  
results	   in	   chapters	  3	   and	  5	  with	  TPM	  and	  CLP,	   respectively.	   The	   large	  quantity	  of	  
encoded	   human	   SLC	   and	   ABC	   transporters	   and	   the	   simultaneous	   absence	   of	  
transfected	  cell	  lines	  for	  most	  of	  these	  transporters	  limits	  the	  applicability.	  
Currently,	   there	  are	  no	   reliable	  methods	  described	   that	  would	  allow	   for	  
large-­‐scale	   functional	   screenings.	   Lanthaler	  et	   al.	   recently	   reported	   the	   successful	  
implementation	   of	   a	   homozygous,	   diploid	   gene-­‐deletion	   collection	   of	  
Saccharomyces	  cerevisiae	  mutants	  to	  carry	  out	  cytotoxicity	  screenings	  as	  a	  measure	  
for	   unidentified	   drug	   transport	   processes	   (Giaever	   et	   al.	   2002,	   Lanthaler	   et	   al.	  
2011).	  Although	  this	  is	  an	  elegant	  method	  allowing	  high-­‐throughput	  screenings,	  the	  
indirect	   read-­‐out	  by	  means	  of	   cytotoxicity,	   the	   risk	  of	   functional	   redundancy,	   and	  
species-­‐differences,	  also	  limit	  the	  applicability	  of	  this	  approach.	  
While	  the	  hCMEC/D3	  cell	  line	  proved	  to	  be	  valuable	  for	  the	  identification	  
of	   TPM	   efflux	   and	   CLP	   uptake	   in	   the	   screening	   experiments,	   there	   are	   critical	  
limitations	   and	   drawbacks	   to	   this	   cell	   line	   being	   used	   in	   more	   systematic	   BBB	  
screenings,	   for	   example	   in	   pre-­‐clinical	   development.	   First,	   the	   absence	   and	   thus	  
missing	  interaction	  with	  other	  structures	  from	  the	  neurovascular	  unit	  may	  alter	  the	  
BBB	  characteristics	  of	  this	  isolated	  endothelial	  cell	  line,	  particularly	  with	  regards	  to	  
barrier	   properties	   (Lippmann	   et	   al.	   2012,	   Urich	   et	   al.	   2012).	   The	   transepithelial	  
resistance	   (TEER)	   of	   confluent	   hCMEC/D3	   cell	   monolayers	   is	   relatively	   low	   and	  
paracellular	  diffusion	  higher	  when	  compared	  to	  other	  reference	  BBB	  in	  vitro	  models	  
(bovine	   and	   porcine	   cerebral	   microvessel	   endothelial	   cells)	   for	   compounds	  	  
<	  4,000	  Da	  (Lippmann	  et	  al.	  2012,	  Poller	  et	  al.	  2008,	  Urich	  et	  al.	  2012,	  Weksler	  et	  al.	  
2013,	  Weksler	  et	  al.	  2005).	  Most	  drugs	  have	  a	  molecular	  weight	  far	  below	  4,000	  Da,	  
e.g.	  TPM	  is	  339	  Da	  and	  CLP	  is	  327	  Da,	  and	  thus	  bi-­‐directional	  transporter	  assays	  are	  
not	  suitable	  to	  investigate	  drug	  transport	  across	  a	  hCMEC/D3	  cell	  monolayer.	  
Recently,	  Ulrich	  et	  al.	   compared	   the	  global	  gene	  expression	  profile	   from	  
cultured	  hCMEC/D3	  cells,	  cultured	  primary	  human	  brain	  endothelial	  cells	  (cphBECs),	  
and	   freshly	   isolated	   mouse	   brain	   endothelial	   cells	   (fmBECs)	   on	   the	   mRNA	   level	  
(Urich	   et	   al.	   2012).	   While	   hCMEC/D3	   and	   cphBECS	   exhibited	   very	   similar	   overall	  
Chapter	  6	  
	  194	  
gene	  expression	  profiles,	  there	  were	  marked	  differences	  with	  fmBECs.	  In	  agreement	  
with	  the	  observed	  low	  TEER	  and	  poor	  paracellular	  restriction,	  substantially	  reduced	  
mRNA	  levels	  encoding	  for	  the	  important	  tight	  junction	  proteins	  claudin	  5,	  occludin,	  
and	  JAM	  2	  were	  noted	  in	  hCMEC/D3	  and	  cphBEC	  cells	  when	  compared	  with	  fmBECs	  
(Urich	  et	  al.	  2012).	  In	  addition,	  strongly	  reduced	  mRNA	  levels	  encoding	  for	  different	  
SLC	   and	   ABC	   transporters	   such	   as	   ABCB1	   (MDR1,	   Pgp),	   ABCG2	   (BCRP),	   SLC7A5	  
(LAT1),	  and	  SLC2A1	  (GLUT1)	  have	  been	  reported	  although	  the	  functional	  effect	  sizes	  
remain	  unknown	  and	   functionality	  of	  SLC7A5	  has	   recently	  been	  demonstrated	   for	  
the	   hCMEC/D3	   cell	   line	   (Dickens	   et	   al.	   2013,	   Urich	   et	   al.	   2012).	   The	   authors	  
concluded	   that	   primary	   or	   immortalised	   human	   brain	   endothelial	   cells	   both	   lose	  
some	  of	  their	  BBB	  specific	  features	  and	  exhibit	  an	  endothelial	  cell	  phenotype	  that	  is	  
more	  generic	   (Urich	  et	  al.	  2012).	  These	  cross-­‐species	  comparisons,	  however,	  have	  
to	   be	   taken	   with	   some	   care.	   For	   example,	   another	   study	   reported	   substantially	  
lower	  ABCG2	  mRNA	   levels	   in	   isolated	  human	  brain	  microvascular	  endothelial	   cells	  
(hBMECs)	   as	   compared	   to	   isolated	  BMECs	  derived	   from	  mouse,	   rat,	   cow,	   and	  pig	  
(Warren	  et	  al.	  2009).	  
A	  second	  limitation	  of	  the	  hCMEC/D3	  cell	  line	  is	  that	  it	  was	  isolated	  from	  
resected	  brain	  tissue	  derived	  from	  an	  epilepsy	  patient	  and	  the	  expression	  profile	  of	  
drug	  transporters	  may	  thus	  be	  altered	  as	  compared	  to	  healthy	  individuals	  (Weksler	  
et	  al.	   2005).	  Third	  and	  most	   critical	   for	   comparing	  data	  between	  different	   studies	  
using	  the	  hCMEC/D3	  cell	   line	   is	   that	  genetic	  shifts	  have	  been	  reported	   including	  a	  
complex	   karyotype	   and	   chromosomal	   rearrangements	   (Mkrtchyan	   et	   al.	   2009).	  
Evidence	  for	  this	  observation	  was	  obtained	   in	  chapter	  5	  where	  SLC22A3	  mRNA,	   in	  
contrast	   to	   previous	   studies	   (Carl	   et	   al.	   2010,	   Dickens	   et	   al.	   2012),	   was	   not	  
detectable	  using	  a	  large	  quantity	  (100	  ng)	  of	  cDNA	  template.	  
Taken	   together,	   the	   hCMEC/D3	   cell	   line	   is	   a	   suitable	  model	   cell	   line	   for	  
initial	  screening	  of	  drug	  transport	   into	  the	  human	  brain	  as	  has	  been	  performed	   in	  
chapters	   3	   and	   5.	   For	   systematic	   screening	   in	   drug	   development,	   however,	   the	  
limitations	   discussed	   encourage	   the	   development	   of	   more	   robust	   models	   with	  
improved	  barrier	  properties	  to	  better	  mimic	  the	  situation	  in	  vivo.	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Recently,	   an	   interesting	   new	  method	  has	   been	  published	   that	   describes	  
the	  generation	  of	  brain	  hBMECs	  derived	  from	  human	  pluripotent	  stem	  cells	  (hPSCs)	  
(Lippmann	   et	   al.	   2012).	   Co-­‐differentiation	   with	   other	   neural	   cells,	   initially	   with	  
unconditioned	  medium	  followed	  by	  incubation	  in	  endothelial	  cell	  medium,	  yielded	  
high	   amounts	  of	   hBMECs	   that	  were	   then	   successfully	   isolated	   and	   subcultured	   to	  
obtain	   pure	   hBMEC	  monolayers	   (Lippmann	   et	   al.	   2012).	   The	   hBMEC	  monolayers	  
have	   been	   characterised	   and	   were	   found	   to	   exhibit	   many	   BBB	   characteristics,	  
particularly	  the	  presence	  of	  well-­‐organised	  tight	  junctions	  and	  the	  expression	  of	  SLC	  
and	   ABC	   transporters	   such	   as	   SLC2A1,	   SLC7A5,	   ABCB1,	   ABCG2,	   ABCC1,	   ABCC2,	  
ABCC4,	   and	   ABCC5	   (Lippmann	   et	   al.	   2012).	   Most	   notably,	   TEER	   values	   were	  
substantially	  higher	  than	  has	  been	  reported	  for	  the	  hCMEC/D3	  cell	   line	  (Forster	  et	  
al.	  2008,	  Hatherell	  et	  al.	  2011,	  Weksler	  et	  al.	  2005)	  and	  co-­‐culture	  with	  astrocytes	  
further	   increased	   TEER	   values	   to	   a	   level	   similar	   to	   that	   observed	   in	   vivo	   in	  
anaesthetised	  rats	  (Butt	  et	  al.	  1990).	  Astrocyte	  co-­‐culture	  has	  also	  been	  reported	  to	  
increase	   TEER	   values	   in	   monolayers	   of	   hCMEC/D3	   cells,	   but	   the	   values	   obtained	  
were	  still	   low	  (Hatherell	  et	  al.	  2011).	  Lippmann	  et	  al.	  concluded	  that	  hPSC-­‐derived	  
hBMECs	   should	   be	   a	   valuable	   tool	   in	   drug	   screening	   approaches	   as	   these	   cells	  
exhibit	   important	   BBB	   characteristics	   and	   unlimited	   self-­‐renewal	   capabilities	  
(Lippmann	   et	  al.	  2012).	  This	  method	  may	  also	  provide	  an	  exciting	  opportunity	   for	  
the	   study	   of	   patient-­‐specific	   hPSC-­‐derived	   hBMECs	   to	   analyse	   differences	   in	   drug	  
transport	  across	  the	  BBB	  in	  vitro.	  
6.3. Membrane	  transporter	  biomarkers	  
The	  clinical	  analysis	  of	  genetic	  biomarkers	  as	  predictors	  for	  treatment	  response	  or	  
side	   effects	   represents	   an	   important	   alternative	   and	   additional	   method	   for	   the	  
identification	   and	   clinical	   validation	   of	   membrane	   transporters	   involved	   in	   drug	  
ADME.	  As	  currently	  available	  in	  vitro	  methods	  proved	  to	  be	  insufficient	  to	  ultimately	  
identify	  the	  observed	  TPM	  efflux	  and	  CLP	  uptake	  processes	  observed	  in	  chapters	  3	  
and	  5,	  a	  clinical	  approach	  may	  be	  more	  successful.	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The	   SANAD	   study,	   analysed	   in	   chapter	   2	   for	   the	   association	   of	   three	  
ABCC2	  polymorphisms	  with	  CBZ	  treatment	  response,	  included	  an	  arm	  with	  patients	  
randomised	  to	  TPM	  (Marson	  et	  al.	  2007).	  The	  GWAS	  data	  obtained	  by	  Speed	  et	  al.	  
could	   thus	   be	   stratified	   for	   treatment	   response	   to	   TPM	   (Speed	   et	   al.	   2013).	   It	  
remains	   questionable,	   however,	   if	   the	   medium	   effect	   size	   observed	   in	   vitro	   in	  
chapter	  3	  will	  be	  sufficient	  to	  result	  in	  a	  statistically	  significant	  clinical	  effect	  due	  to	  
the	  limited	  number	  of	  patients	  that	  consented	  to	  genotyping.	  	  
Given	  the	  large	  effect	  size	  observed	  with	  CLP	   in	  vitro	   in	  chapter	  5,	  this	  is	  
potentially	  a	  more	  promising	  drug	  to	  be	  analysed	  clinically,	  particularly	  with	  regard	  
to	   efficacy	   and	   the	   severe	   side	   effects	   that	   are	   associated	   with	   CLP	   treatment	  
(Novartis	   Pharmaceuticals	   Corporation	   2013).	   A	   GWAS	  with	   samples	   from	   a	   CLP-­‐
treated	   patient	   cohort	  may	   be	   a	   promising	   strategy	   to	   identify	   the	   unknown	   CLP	  
uptake	  transporter.	  There	  are,	  however,	  limitations	  to	  the	  clinical	  approach	  as	  well.	  
As	   discussed	   in	   chapter	   2	   section	   2.4	   for	   the	   analysis	   of	   an	   association	   between	  
ABCC2	   genetic	   polymorphisms	   and	   CBZ	   treatment	   response,	   the	   sample	   size,	  
definition	   of	   outcome,	   time	   of	   observation,	   disease	   phenotype,	   co-­‐treatments,	  
prospective	   vs.	   retrospective	   studies,	   and	   the	   study	   population	   were	   particularly	  
critical	   components	   to	   be	   considered	   in	   the	   analysis.	   Also,	   a	   genetic	   association	  
needs	  to	  be	  present,	  an	  assumption	  that	  is	  not	  required	  for	  a	  drug	  to	  be	  a	  substrate	  
of	   a	   given	   transporter.	   For	   CLP,	   however,	   the	   large	   inter-­‐individual	   differences	   in	  
treatment	   response	   and	   occurrence	   of	   side	   effects	   indicate	   that	   genetic	  
polymorphisms	   of	   the	   unknown	   uptake	   transporter	   or	   receptor	   may	   indeed	   be	  
present.	  
Ideally,	   clinical	   analysis	   should	   be	   combined	   with	   in	   vitro	   analysis	   to	  
obtain	  the	  most	  comprehensive	  conclusion	  –	  this	  is	  shown	  by	  the	  data	  in	  chapter	  2	  
with	  ABCC2	  (MRP2)	  and	  CBZ.	  If	  a	  clinical	  approach	  is	  successful	  in	  identifying	  genetic	  
transporter	   or	   receptor	   biomarker(s)	   associated	   with	   CLP	   treatment	   response	  
and/or	   adverse	   effects,	   stably	   transfected	   cell	   lines	   with	   the	   identified	   gene(s)	  
should	  be	  generated.	  A	   cell	   line	  utilising	  a	   “screen	  and	   insert”	   strategy,	   similar	   to	  
the	  Rht14-­‐10	  cell	   line	  stably	  transfected	  with	  a	  vector	  coding	  for	  ABCC2	  tagged	  to	  
EGFP	  as	  used	  in	  chapter	  2	  (Arlanov	  et	  al.	  2012,	  Brough	  et	  al.	  2007),	  would	  provide	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the	  exciting	  opportunity	  not	  only	  to	  confirm	  drug	  transport	  but	  to	  also	  compare	  the	  
functional	  impact	  of	  genetic	  polymorphisms.	  
6.4. Conclusions	  
Membrane	  transporters	  are	  emerging	  as	  an	   important	  component	   in	   the	  complex	  
network	  that	  determines	  the	  pharmacokinetic	  properties	  of	  drugs.	  Moreover	  and	  of	  
particular	   importance,	   individual	   differences	   in	   drug	   transport,	   for	   example	   by	  
genetic	  polymorphisms,	  may	  predict	  efficacy	  and/or	  adverse	  effects	  associated	  with	  
treatment	  on	  a	  personalised	   level.	  Drug-­‐drug	   interactions	  can	  be	  a	  direct	  result	  of	  
two	   drugs	   competing	   with	   the	   same	   transporter,	   similar	   to	   that	   seen	   with	   CYP	  
enzymes,	  and	  are	  thus	  critical	  for	  drug	  safety.	  	  
CNS	  diseases	  represent	  a	  major	  burden	  to	  population	  health,	  and	  there	  is	  
a	   need	   for	   the	   development	   of	   drugs	   that	   will	   have	   to	   cross	   the	   BBB	   to	   act	   on	  
targets	  in	  the	  brain.	  It	  is	  thus	  important	  that	  the	  passage	  of	  such	  drugs	  is	  carefully	  
characterised	  –	  this	  will	  provide	  a	  more	  comprehensive	  picture	  of	  the	  potential	  of	  
the	  drugs	  to	  lead	  to	  variability	  in	  both	  drug	  efficacy	  and	  drug	  safety.	  
In	  conclusion,	  this	  thesis	  demonstrates	  that	  drug	  transporters	  can	  play	  a	  
critical	  role	  in	  the	  effectiveness	  and/or	  safety	  of	  neurological	  drugs.	  However,	  given	  
the	   large	   number	   of	   SLC	   and	   ABC	   transporters	   that	   have	   not	   been	   functionally	  
characterised	  yet,	  a	  lot	  of	  work	  is	  still	  to	  be	  done.	  Robust	  and	  large-­‐scale	  functional	  
screening	  methodologies	  are	  urgently	  needed	  for	  systematic	  and	  broader	  screening	  
approaches	  in	  drug	  development,	  aiming	  for	  a	  more	  comprehensive	  understanding	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Table	   1:	   TaqMan®	   gene	   expression	   assays	   supplied	   by	   Life	   Technologies	   Ltd.,	   Paisley,	   UK.	  	  
GAPDH	   =	   glyceraldehyde-­‐	   3-­‐phosphate	   dehydrogenase;	   MGBNFQ	   =	   Minor	   groove	   binder	  
nonfluorescent	  quencher	  
Gene	   Reporter	  dye	   Quencher	   Catalogue	  number,	  Assay	  ID	  
GAPDH	   VIC®	   TAMRATM	   4310884E	  
ß-­‐actin	  (ACTB)	   FAMTM	   MGBNFQ	   4352935E	  
ABCC1	   FAMTM	   MGBNFQ	   4331182,	  Hs00219905_m1	  
ABCC2	   FAMTM	   MGBNFQ	   4331182,	  Hs00166123_m1	  
ABCC3	   FAMTM	   MGBNFQ	   4331182, Hs00978473_m1	  
ABCC4	   FAMTM	   MGBNFQ	   4331182, Hs00988717_m1	  
ABCC5	   FAMTM	   MGBNFQ	   4331182,	  Hs00981087_m1	  
ABCC6	   FAMTM	   MGBNFQ	   4331182,	  Hs00184566_m1	  
ABCC7	   FAMTM	   MGBNFQ	   4331182,	  Hs00357011_m1	  
ABCC8	   FAMTM	   MGBNFQ	   4331182,	  Hs01093761_m1	  
ABCC9	   FAMTM	   MGBNFQ	   4331182,	  Hs00245832_m1	  
ABCC10	   FAMTM	   MGBNFQ	   4331182,	  Hs00375701_m1	  
ABCC11	   FAMTM	   MGBNFQ	   4331182,	  Hs01090768_m1	  
ABCC12	   FAMTM	   MGBNFQ	   4331182,	  Hs00264354_m1	  
SLC6A2	   FAMTM	   MGBNFQ	   4448892,	  Hs00426573_m1	  
SLC6A3	   FAMTM	   MGBNFQ	   4448892,	  Hs00997364_m1	  
SLC6A4	   FAMTM	   MGBNFQ	   4448892,	  Hs00984349_m1	  
SLC7A5	   FAMTM	   MGBNFQ	   4331182,	  Hs00185826_m1	  
SLC22A1	   FAMTM	   MGBNFQ	   4331182,	  Hs00427552_m1	  
SLC22A2	   FAMTM	   MGBNFQ	   4331182,	  Hs01010723_m1	  
SLC22A3	   FAMTM	   MGBNFQ	   4331182,	  Hs01009568_m1	  
SLC22A4	   FAMTM	   MGBNFQ	   4331182,	  Hs01548718_m1	  
SLC22A5	   FAMTM	   MGBNFQ	   4331182,	  Hs00929869_m1	  
SLC28A1	   FAMTM	   MGBNFQ	   4448892,	  Hs00984403_m1	  
SLC28A2	   FAMTM	   MGBNFQ	   4448892,	  Hs00188407_m1	  
SLC28A3	   FAMTM	   MGBNFQ	   4448892,	  Hs00910439_m1	  
SLC29A1	   FAMTM	   MGBNFQ	   4448892,	  Hs01085704_g1	  
SLC29A2	   FAMTM	   MGBNFQ	   4453320, Hs00155426_m1	  
SLC29A3	   FAMTM	   MGBNFQ	   4448892,	  Hs00217911_m1	  




Table	  2:	  Human	  siGENOME	  SMARTpool	  siRNAs	  and	  control,	  5	  nmol,	  supplied	  by	  Fermentas	  GmbH	  
–	  Thermo	  Fisher	  Scientific,	  St.	  Leon-­‐Rot,	  Germany 

















































	   	   	  
Appendix	  
	  203	  





































Non-­‐targeting	  siRNA	  pool	  #2	  
	  









Table	   3:	   FlexiTube	   GeneSolution	   siRNAs	   for	   human	   ABCC5	   and	   control,	   1	   nmol	   and	   5	   nmol,	  
respectively,	  supplied	  by	  Qiagen	  Ltd.,	  Manchester,	  UK	  







AllStars	  negative	  control	  siRNA	  
	  




Table	   4:	   Silencer®	   Select	   siRNA	   for	   human	   SLC7A5	   and	   control,	   5	   nmol,	   supplied	   by	   Life	  
Technologies	  Ltd.,	  Paisley,	  UK	  
Gene	   siRNA	  sequence	  sense	  strand	  5'	  -­‐>	  3'	   Catalogue	  number	  
SLC7A5	   UGUCCAAUCUAGAUCCCAAtt	   4392420,	  ID	  s15653	  
Negative	  control	  no.	  1	   Not	  disclosed	  by	  manufacturer	   4390843	  
	  
